

National Institute of Pharmaceutical Education and Research (NIPERs)

Research Compendium released on 28th February, 2023 on occasion of 1st NIPER Council Meeting

Department of Pharmaceuticals (DoP) Ministry of Chemicals and Fertilizers Govt. of India

National Institute of Pharmaceutical Education and Research (NIPERs)

Research Compendium released on 28th February, 2023 on occasion of 1st NIPER Council Meeting

Department of Pharmaceuticals (DoP) Ministry of Chemicals and Fertilizers Govt. of India



डॉ, मनसुख मांडविया DR. MANSUKH MANDAVIYA



मंत्री स्वास्थ्य एवं परिवार कल्याण व रसायन एवं उर्वरक भारत सरकार Minister Health & Family Welfare and Chemicals & Fertilizers Government of India

MESSAGE

I take this opportunity to express my appreciation for the exemplary work done by the seven National Institutes of Pharmaceutical Education and Research (NIPERs) functioning under the aegis of the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India.

Bench to bedside or lab to health care philosophy is ingrained in the pharmaceutical sciences. It provides the platform for the development of medicinal products and technologies for their delivery, while advanced pharmacy practices result in the delivery of the benefits of the pharmaceutical products to the patient.

NIPERs have been established with a clear vision for realizing this idea via producing quality manpower and creating an innovation rich translational research and entrepreneurship ecosystem in the country, with the goal of making India a global frontrunner in pharmaceuticals.

I am confident that NIPERs will lead and provide guidance in drug discovery and development in the country through education, research, innovation, and entrepreneurship. I have no doubt that with the talent, dedication and hard work of the students, faculty, and staff members of the NIPERs, this goal will be achieved.

Research & Development is one of the crucial pillars of a country's economy. Let us all work towards nation-building in line with Hon'ble Prime Minister Narendra Modi Ji's vision of 'Jai Jawan, Jai Kisan, Jai Vigyan and Jai Anusandhaan.' Research and Innovation are a necessity for the sustained growth of the pharmaceuticals sector. NIPERs are playing a crucial role in strengthening India's health & pharma sector.

I extend my warm greetings to the students, faculty, and staff members for their commendable initiative and wish them success in all their endeavours.



22 February 2022

कार्यालय: 348, ए-स्कंध, निर्माण भवन, नई दिल्ली - 110011 • Office: 348, A-Wing, Nirman Bhawan, New Delhi - 110011 Tele.: (O): +91-11-23061661, 23063513 • Telefax : 23062358 • E-mail : india-hfm@gov.in भगवंत खुबा ಭಗವಂತ ಖೂಬಾ BHAGWANTH KHUBA



Amrit Mahotsav

रसायन एवं उर्वरक एवं नवीन एवं नवीकरणीय ऊर्जा राज्य मंत्री भारत सरकार Minister of State for Chemicals & Fertilizers and New & Renewable Energy Government of India 23.02.2023.



MESSAGE

I congratulate NIPERs on this initiative of bringing together the research and development activities of all the institutes in one document.

I take this opportunity to extend my greetings to all the seven NIPERs, their students, faculty and staff members for their praiseworthy initiative and wish them grand success in all their endeavours.

NIPERs have been set up with a vision to produce skilled manpower to cater to the pharma industry of India and to create global innovation and entrepreneurship ecosystem in the country so as to make India a global leader in the field of Pharmaceuticals. The academia industry linkage established by NIPERs with leading pharma Industries is expected to play a critical role in pharma R & D.

In the coming days the government expects the NIPERs to provide leadership in Drug Discovery and development in the country through education, research, innovation and entrepreneurship.

(Bhagwanth Khuba)

Chemicals & Fertilizers : Room No. 315, 'A'-Wing Shastri Bhawan, New Delhi-110001 Tel : 011- 23382364, 23383686, 23381768 Fax : 011-23381713, E-mail : mos-mocf@nic.in New & Renewable Energy : Room No. 202, IInd Floor, 14 Block, CGO Complex, New Delhi - 110003, Tel. : 011-24360359 सुश्री एस. अपर्णा ^{सचिव} Ms. S. Aparna Secretary



भारत सरकार रसायन और उर्वरक मंत्रालय औषध विभाग Government of India Ministry of Chemicals & Fertilizers Department of Pharmaceuticals

23rd February, 2023

The Department of Pharmaceuticals presents the NIPER Research Compendium 2022, a compilation of research projects and associated publications, book chapters, and patents, generated by the even National Institutes of Pharmaceutical Education and Research (NIPERs), institutes of national importance under the aegis of the department.

This collection showcases the diverse range of scientific inquiry and innovation and represents a testament to the ground-breaking work being conducted by the researchers at NIPERs and their commitment to advancing the field of constantly evolving Pharmaceutical Sciences.

NIPERs are premier institutions dedicated for advancing the frontiers of knowledge in the field of pharmaceuticals and related disciplines. The collaboration of these institutions represents a major milestone in the progression of the field, and demonstrates the commitment of the NIPERs in promoting innovation and improving human health and wellness.

The projects featured in this compilation span a wide range of topics, from natural products to synthetic analogues, drug discovery to drug delivery, pharmacology to bioinformatics, animal studies to clinical research, traditional medicines to AI based medicines, exploration of the underlying mechanisms of disease to the optimization of existing treatments. The resulting publications, book chapters, and patents demonstrate the impact and reach of this research, and showcase the innovative thinking and collaboration that are at the heart of the NIPERs mission. The research ecosystem will be further strengthened by the specialized fields like bulk drugs, medical devices, anti-viral research and phytopharmaceuticals that the NIPERs have taken up for development of Centres of Excellence.

This compilation is a valuable resource for pharmaceutical industry and indeed anyone interested in the field of Pharmaceutical Sciences, providing a comprehensive overview of the cutting-edge research being carried out at NIPERs and the impact of that research on the wider community. The need for product-oriented translational research, especially in the wake of the recent pandemic, is critical and NIPERs are well-positioned to fill the gap between new products and their affordability to the masses. I have no doubt that it will serve as an inspiration to those seeking to contribute to the field and make a difference in the lives of people everywhere.

I express my appreciation to all of the researchers and faculty involved in compiling this Compendium and commend their efforts in promoting innovation that contributes to improve human health and wellbeing.

Aparna)

शास्त्री भवन, डॉ राजेन्द्र प्रसाद रोड़, नई दिल्ली - 110 001 Dr. Rajendra Prasad Road, Shastri Bhawan, New Delhi - 110 001 Tel. : 23381573 / Fax : 23070245 E-mail : secy-pharma@nic.in

CONTENTS

| S. No. | Particulars | | Page No. | |
|--------|---|-------------------------------|----------|--|
| | Executive Summary Compendium on ongoing Research Project, research papers/book chapters published and granted patents | | 1-2 | |
| | | | 3 | |
| 1. | NIPER Ahm | edabad | | |
| | i. | From the Director's Desk | 7-8 | |
| | ii. | Extra-Mural Research Projects | 9-12 | |
| | iii. | Research Publications | 12-21 | |
| | iv. | Book Chapters | 21-24 | |
| | v. | Patents | - | |
| 2. | NIPER Guw | ahati | | |
| | i. | From the Director's Desk | 27 | |
| | ii. | Extra-Mural Research Projects | 28-41 | |
| | iii. | Research Publications | 41-49 | |
| | iv. | Book Chapters | 49-50 | |
| | V. | Patents | 50 | |
| 3. | NIPER Hajij | pur | | |
| | i. | From the Director's Desk | 53 | |
| | ii. | Extra-Mural Research Projects | 54-56 | |
| | iii. | Research Publications | 56-60 | |
| | iv. | Book Chapters | 60 | |
| | v. | Patents | 60-61 | |
| 4. | NIPER Hyde | erabad | | |
| | i. | From the Director's Desk | 65-66 | |
| | ii. | Extra-Mural Research Projects | 67-85 | |
| | iii. | Research Publications | 85-99 | |
| | iv. | Book Chapters | 100-101 | |
| | v. | Patents | 101 | |
| 5. | NIPER Kolk | ata | | |
| | i. | From the Director's Desk | 105-106 | |
| | ii. | Extra-Mural Research Projects | 107-110 | |

| | iii. | Research Publications | 111-118 |
|----|--------------|-------------------------------|---------|
| | iv. | Book Chapters | 118-119 |
| | v. | Patents | 119 |
| 6. | NIPER Raeb | pareli | |
| | i. | From the Director's Desk | 123-124 |
| | ii. | Extra-Mural Research Projects | 125-129 |
| | iii. | Research Publications | 129-135 |
| | iv. | Book Chapters | 135-137 |
| | V. | Patents | 137 |
| 7. | NIPER S.A. S | S Nagar | |
| | i. | From the Director's Desk | 141-142 |
| | ii. | Extra-Mural Research Projects | 143-151 |
| | iii. | Research Publications | 152-163 |
| | iv. | Book Chapters | 163-164 |
| | V. | Patents | 164 |

Executive Summary

National Institute of Pharmaceutical Education and Research (NIPER) was established under the aegis of Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Govt of India. From the first institute at S A S Nagar Punjab, the institute has grown to a group of seven Institutes spread all over the India.Aimed at becoming world leader in providing quality education in Pharmaceutical field and generation of a specialized human resource be it pharmacists, researchers or academicians, NIPERs are fast becoming an integral part of both higher studies as well as Pharmaceutical industry in India and abroad.

This compendium of NIPERs is compilation of research activities being carried out at NIPERs (Ahmedabad, Guwahati, Hajipur, Hyderabad, Kolkata, Raebareli and S A S Nagar) and outputs indices like publications, Book chapters and Patents.Through varied interest in research domains, NIPERs have produced 694 research publications, 109 book chapters and 28 patents and have175 ongoing extramural/industry projects for the year 2022.

Starting with a nascent vision of becoming a global brand in the areas of pharmaceutical education and research to achieve a globally recognised status, NIPER has proven itself,evident from its alumni placed at prestigious positions, national and international organizations.

NIPERs are exploring different areas of pharmaceutical research and development ranging from drug discovery from natural products using HIT to LEAD development (HIT identification, validation, and optimization), new drug synthesis and drug delivery through modern technologies including advanced drug delivery system& pharmaceutical additive manufacturing/3D & 4D printing. Other areas of research include cell based therapy as biopharmaceuticals, API synthesis and formulation strategies, disease pathogenesis, drug mechanisms, target identification, and therapeutic intervention in chronic and complex diseases like cancer, diabetes, obesity, inflammation, and infectious diseases.

To cater the healthcare sector and to overcome hurdles in drug discovery and development for ever evolving disease scenario, identification of druggable targets using AI based technologies are being utilized along with computational biology and *in silico* drug design methodologies.

NIPERs are taking strides in conducting pilot scale studies in API and dosage forms to facilitate data packaging and to transfer the same to industry partner. These initiatives have fortified the industry academia partnership for drug discovery and development.

Synthesis and semi synthesis of new compounds using natural products scaffolds and evaluation of promising molecules are accomplished using various experimental models. NIPERs have undertaken advanced drug delivery research for improving biopharmaceutical profile, DMPK studies, pre-formulation profiling, scale-up of NCEs for pre-clinical efficacy studies to overcome challenges in drug development. With the growing impetus of biopharmaceuticals, NIPERs have initiated several programs using proteins, peptides, and nucleic acids based therapies for various diseases including rare diseases.

NIPERs have an important emphasis on technology commercialization in which NIPER S A S Nagar has commercialized 4 technologies including: compositions and methods for trapping and inactivating pathogenic microbes and spermatozoa Phexxi (by EvoFem Inc.) and quick disintegrating taste masked composition Zinc Sulphate Tablets (by IDPL). Further, licensed out technologies include: a novel one-step process for preparation of nanocrystalline solid dispersions (NanoCrySP technology) and Pharmaceutical Compositions for Enhancing Anticancer Efficacy of Tamoxifen. NIPER Hyderabad has commercialized an Improved Process for a Noble Effervescent Formulation of an Anti-Aging Agent (to LiveactivusPvt. Ltd. Hyderabad).

NIPERs are working in all frontiers of pharmaceutical sciences employing most advanced tools and technologies. The institutions represent the modern approach to discover and develop pharmaceutical product under one roof. The NIPERs are striving hard to become centers of excellence in niche areas and serve the mankind as a whole.

Compendium on Ongoing Research Project, Research Papers/ Book Chapters published and granted Patents for the year 2022

| Sr No. | NIPER | Projects | Research | Book | Patents |
|--------|-------------|----------|--------------|----------|---------|
| | | | Publications | Chapters | |
| 1. | Ahmedabad | 11 | 108 | 34 | - |
| 2. | Guwahati | 35 | 89 | 5 | 6 |
| 3. | Hajipur | 4 | 43 | 4 | 3 |
| 4. | Hyderabad | 58 | 158 | 17 | 6 |
| 5. | Kolkata | 7 | 81 | 11 | 1 |
| 6. | Raebareli | 12 | 81 | 25 | 4 |
| 7. | S A S Nagar | 48 | 134 | 13 | 8 |
| | TOTAL | 175 | 694 | 109 | 28 |



NIPER, AHMEDABAD



Contact Address Opposite Air force Station Palaj, Gandhinagar-382355, Gujarat, India. Phone: +91 79 66745555, +91 79 66745501 Fax: +91 79 66745560 Email: registrar@niperahm.ac.in Website: www.niperahm.ac.in

From the Director's Desk

It gives me immense pleasure to welcome you to NIPER-Ahmedabad (NIPER-A). The institute is in the second decade of establishment that comesunder the aegis of Department of Pharmaceuticals, Ministry of Chemicals Fertilizers. and Government of India to promote quality education and research in the field of Pharmaceutical Sciences and Management. The Institute has an outstanding track record of producing excellent leaders serving as pharmacists. researchers. and academicians. NIPER-A has been



Prof Shailendra Saraf

functioning independently through transient building of its own campus at Gandhinagar since 2016 and will be shifting to its main campus very soon. NIPER-A has a state of art research facilities including central instrumentation and other academic facilities, animal house and a canteen. Presently, NIPER-A offering Masters programme in eight streams viz. Biotechnology, Natural Products, Pharmaceutics, Pharmaceutical Analysis, Medicinal Chemistry, Pharmacology & Toxicology, Medical Devices and Pharmaceutical Management and PhD programme in all streams except Pharmaceutical Management. NIPER-Ahas introduced industry relevant course curriculum and academic programme. The admissions to NIPERs are being made through the national level Joint Entrance Examination for post graduate and doctoral courses.

The pharmaceutical education has played a vital role in human resource development, catalyzing the growth of life sciences and healthcare industry. Enthusiastic and entrepreneurial efforts have turned Gujarat into the hub of Pharma manufacturing, Research and Development activities. The innovative and translational approach of the Indian scientists resulted in the paradigm shift from the industrial age to knowledge enriched economy. To cater the requirements, NIPER-Ahmedabad has established a state-of-the-art facility for quality research and education with a goal of providing analytical and drug development related support to Industries, MSMEs, and start-ups. The major research domains for NIPER-A include Drug Discovery which is focused on the new drug synthesis and/or identifying from natural products in the disease area through modern technologies. The new chemical entities are evaluated through in-vitro and animal testing. NIPER-A is also focusing on cell therapy as biological drugs. The Drug Development team is working on API synthesis and formulation strategies. The API development is helping for identifying new synthetic routs for existing drugs, which will help to decrease the dependency of Indian manufacturers from other countries. NIPER-A is also working on development of platform technologies for drug delivery and complex generics. Medical Device Development is focusing on product development of orthopaedic implants, ocular devices and diagnostic devices and their testing facilities.

The interdisciplinary courses and cultural diversity at NIPER-A spark the spirit of innovative research and all-round development of its students. The location of the Institute ensures a symbiotic association with Pharmaceutical Industries, Medical centers, and technological universities. The institute has achieved ranking in top 10

pharmacy institutes of the country since last three years in the NIRF ranking of MHRD. In the recent release of ARIIA Ranking, NIPER-A was placed in Band A category of public funded Institutes. NIPER-A aspires to serve as a good launching platform to revamp the Pharmaceutical Education and Research and to initiate the new era of translation of Pharmaceutical and Biomedical Sciences.

FUNDED EXTRA-MURAL RESEARCH PROJECTS

| S.N | Project Title | Principal Investigators and Centre coordinator's | Funding Agency | Funding Amount | Duration | |
|-----|--|---|-------------------|-------------------|----------|--|
| 1. | Electro-conductive and Immunomodulatory Macroporous Hydrogel Conduit for Faster Spinal Cord Regeneration | Akshay Srivastava and Hemant Kumar | DST, SERB | 62 lakhs | 3 years | |
| | Faster Spinal Cord | | | | | |
| 2. | Characterization of transcriptional landscape and its functional role in Gingivo-Buccal oral squamous cell carcinoma (GB-OSCC) for targeted drug discovery. | Dr. Amit Mandoli | GSBTM | 78.25 Lakh | 3 years | |
| | Oral Cancer is the second leading cause of cancer-related mortality in India. Using next-generation omics assays and CRISPR-Cas9 gene editing tools this project aims to identify the biomarkers and targeted drugs for precision therapy, | | | | | |

| | and better management | nt of GB-OS | CC patien | ts. We will | perform a o | clinical trail |
|----|--|---|--|---|---|---|
| | with the outcome of the | | F | | Γ | |
| 3. | Slow | Giriraj | Sahu | SERB | 30.27 | 2 Years |
| | afterhyperpolarization | , | | | lakh | |
| | the mechanism that | | | | | |
| | determines the | | | | | |
| | differential excitability | | | | | |
| | pattern of dorsoventra | | | | | |
| | hippocampal neurons, | | | | | |
| | potential target for | | | | | |
| | temporal lobe epilepsy | | | | | |
| | Faculty with this Project | | PER-Ahm | edabad. | | |
| | | | | 1 | | |
| 4. | Formulation | Rakesh | Tekade | DST, | 30 Lakhs | 3 years |
| | development and | | | SERB | | |
| | evaluation of miRNA | | | | | |
| | nanoformulation for | | | | | |
| | obesity | | | | | |
| | The proposed project | | | | | |
| | application considering | | | | | |
| | in this work. The labs o | | | | | |
| | expertise have assimila | ited to execu | ite the cri | tical milesto | nes for this | project. The |
| | dendrimeric template | approach | as pate | nted by PI | Tekade La | ab; NIPER- |
| | Ahmedabad (Indian Pa | tent Appln | no. 2018 | 21043610; 2 | 2019210198 | 98) backed |
| | by the expertise of his lab in executing miRNA and gene delivery; Quality-by- | | | | | |
| | design (QbD), scale-up expertise liposome and obesity mouse model research | | | | | |
| | expertise available at | NIPER-Ahr | nedabad 1 | holds huge o | commitment | to execute |
| | the science required fo | r industrial | translatio | n of this wor | k. | |
| 5. | To investigate Green | Rakesh | Tekade | ICMR | 30 Lakhs | 3 years |
| | Photothermal | | | | | |
| | 1 HOLULIIEI IIIai | | | | | |
| | Nanomaterials for Lase | r- | | | | |
| | | | | | | |
| | Nanomaterials for Lase | | | | | |
| | Nanomaterials for Lase directed Diabetic Wour | nd | ovel alter | mative and | innovative l | aser-guided |
| | Nanomaterials for Lase directed Diabetic Wour Healing in Mice Model | nd develop a n | | | | 0 |
| | Nanomaterials for Lase directed Diabetic Wour Healing in Mice Model "This project aims to approach for diabetic | nd develop a n wound heal | ing appli | cations in di | abetic mice | Model. The |
| | Nanomaterials for Lase directed Diabetic Wour Healing in Mice Model "This project aims to approach for diabetic approach will confer | nd develop a n wound heal a drug-free | ing applie synergis | cations in di stic strategy | abetic mice for improv | Model. The ving wound |
| | Nanomaterials for Lase directed Diabetic Wour Healing in Mice Model "This project aims to approach for diabetic approach will confer healing efficacies with | nd develop a n wound heal a drug-free out using ar | ing applic synergis y harmfu | cations in di stic strategy l therapy (d | abetic mice for improv rugs, surger | Model. The ring wound y, etc.). The |
| | Nanomaterials for Lase directed Diabetic Wour Healing in Mice Model "This project aims to approach for diabetic approach will confer healing efficacies with project will develop a | nd develop a n wound heal a drug-free out using ar patentable o | ing applic synergis y harmfu | cations in di stic strategy l therapy (d | abetic mice for improv rugs, surger | Model. The ring wound y, etc.). The |
| | Nanomaterials for Lase directed Diabetic Wour Healing in Mice Model "This project aims to approach for diabetic approach will confer healing efficacies with | nd develop a n wound heal a drug-free out using ar patentable o es. | ing applic synergis y harmfu lrug-free | cations in di stic strategy l therapy (d wound care | abetic mice for improv rugs, surger products for | Model. The ring wound y, etc.). The r enhancing |
| | Nanomaterials for Lase directed Diabetic Wour Healing in Mice Model "This project aims to approach for diabetic approach will confer healing efficacies with project will develop a wound healing activitie The resultant product | develop a n wound heal a drug-free out using ar patentable c s. would be co | ing applic synergis y harmfu lrug-free st-effectiv | cations in di stic strategy l therapy (d wound care re and non-to | abetic mice for improv rugs, surger products for oxic that cou | Model. The ring wound y, etc.). The r enhancing ld be useful |
| | Nanomaterials for Lase directed Diabetic Wour Healing in Mice Model "This project aims to approach for diabetic approach will confer healing efficacies with project will develop a wound healing activitie The resultant product | develop a n wound heal a drug-free out using ar patentable co s. would be co nealth care s | ing applic synergis y harmfu lrug-free st-effectiv ystems. T | cations in di stic strategy l therapy (d wound care ye and non-to he developm | abetic mice for improv rugs, surger products for oxic that counter that counter | Model. The ving wound y, etc.). The r enhancing ld be useful d dressings |
| | Nanomaterials for Lase directed Diabetic Wour Healing in Mice Model "This project aims to approach for diabetic approach will confer healing efficacies with project will develop a wound healing activitie The resultant product for patients as well as h may be effective due to | develop a n wound heal a drug-free out using ar patentable o es. would be co health care s o the excelle | ing applic synergis y harmfu lrug-free st-effectiv ystems. T ent antimi | cations in di stic strategy l therapy (d wound care re and non-to he developm crobial and a | abetic mice for improv rugs, surger products for oxic that coun nent of woun antidiabetic | Model. The ring wound y, etc.). The r enhancing ld be useful d dressings activities of |
| | Nanomaterials for Lase directed Diabetic Wour Healing in Mice Model "This project aims to approach for diabetic approach will confer healing efficacies with project will develop a wound healing activitie The resultant product for patients as well as h may be effective due to the chosen nanomateri | hd develop a n wound heal a drug-free out using an patentable o es. would be co health care s o the excelle als as well a | ing applic synergis y harmfu drug-free st-effectiv ystems. T ent antimi as plant m | cations in di stic strategy l therapy (d wound care re and non-to he developm crobial and a laterials. In t | abetic mice for improv rugs, surger products for oxic that coun nent of woun antidiabetic he field of do | Model. The ving wound y, etc.). The r enhancing ld be useful d dressings activities of ermatology, |
| | Nanomaterials for Lase directed Diabetic Wour Healing in Mice Model "This project aims to approach for diabetic approach will confer healing efficacies with project will develop a wound healing activitie The resultant product for patients as well as h may be effective due to the chosen nanomateric especially for wound | develop a n wound heal a drug-free out using an patentable co sealth care so the excelle als as well a care, the co | ing applic synergis y harmfu drug-free st-effectiv ystems. T ent antimi as plant m leveloped | cations in di stic strategy l therapy (d wound care re and non-to he developm crobial and a aterials. In t approach o | abetic mice for improv rugs, surger products for oxic that coun nent of woun antidiabetic he field of do | Model. The ving wound y, etc.). The r enhancing ld be useful d dressings activities of ermatology, |
| 6 | Nanomaterials for Lase directed Diabetic Wour Healing in Mice Model "This project aims to approach for diabetic approach will confer healing efficacies with project will develop a wound healing activitie The resultant product for patients as well as h may be effective due to the chosen nanomateri especially for wound generation candidates | develop a n wound heal a drug-free out using ar patentable co s. would be co health care so the excelle als as well a care, the co for wound d | ing applic synergis y harmfu lrug-free st-effectiv ystems. T ent antimi as plant m leveloped <u>ressings a</u> | cations in di stic strategy l therapy (d wound care re and non-to he developm crobial and a aterials. In t approach o application. | abetic mice for improv rugs, surger products for oxic that coun ent of woun antidiabetic he field of de could serve | Model. The ving wound y, etc.). The r enhancing ld be useful d dressings activities of ermatology, as a next- |
| 6. | Nanomaterials for Lase directed Diabetic Wour Healing in Mice Model "This project aims to approach for diabetic approach will confer healing efficacies with project will develop a wound healing activitie The resultant product for patients as well as h may be effective due to the chosen nanomateri especially for wound generation candidates | develop a n wound heal a drug-free out using ar patentable o es. would be co health care s o the excelle als as well a care, the o for wound d GovindaKaj | ing applic synergis y harmfu lrug-free st-effectiv ystems. T ent antimi as plant m leveloped <u>ressings a</u> | cations in di stic strategy l therapy (d wound care re and non-to he developm crobial and a aterials. In t approach o | abetic mice for improv rugs, surger products for oxic that coun nent of woun antidiabetic he field of do | Model. The ving wound y, etc.). The r enhancing ld be useful d dressings activities of ermatology, |
| 6. | Nanomaterials for Lase directed Diabetic Wour Healing in Mice Model "This project aims to approach for diabetic approach will confer healing efficacies with project will develop a wound healing activitie The resultant product for patients as well as h may be effective due to the chosen nanomateri especially for wound generation candidates Fiber Reinforced Poly (l-lactic acid) | develop a n wound heal a drug-free out using an patentable co so the excelle als as well a care, the co for wound d GovindaKap and | ing applie synergis y harmfu drug-free st-effectiv ystems. T ent antimi as plant m leveloped <u>ressings a</u> pusetti | cations in di stic strategy l therapy (d wound care re and non-to he developm crobial and a aterials. In t approach o application. | abetic mice for improv rugs, surger products for oxic that coun ent of woun antidiabetic he field of de could serve | Model. The ving wound y, etc.). The r enhancing ld be useful d dressings activities of ermatology, as a next- |
| 6. | Nanomaterials for Lase directed Diabetic Wour Healing in Mice Model "This project aims to approach for diabetic approach will confer healing efficacies with project will develop a wound healing activitie The resultant product for patients as well as h may be effective due to the chosen nanomateri especially for wound generation candidates | develop a n wound heal a drug-free out using ar patentable o es. would be co health care s o the excelle als as well a care, the o for wound d GovindaKaj | ing applie synergis y harmfu drug-free st-effectiv ystems. T ent antimi as plant m leveloped <u>ressings a</u> pusetti | cations in di stic strategy l therapy (d wound care re and non-to he developm crobial and a aterials. In t approach o application. | abetic mice for improv rugs, surger products for oxic that coun ent of woun antidiabetic he field of de could serve | Model. The ving wound y, etc.). The r enhancing ld be useful d dressings activities of ermatology, as a next- |

| | Antibiotic Surgical Staples for Wound Closing | | | | | | |
|----|--|---|---|--|---|--|--|
| | Currently, thousands of every day; among the kind of wound closin options for wound clo staples(metal-based). associated, like second hospital visit for the r bio-absorbable polymorelated to current wou of the staples computa as per regulatory guid designed model offe strength with skin, commercial designs. secondary interventio coated with antibiotics | m, more than 80% of g set-up at the end osing include surgical All the options have dary infection, scar for removal of the wound eric staples can be a s and closing strategies. ationally validated thr delines. The prelimin rs stronger resistan- and uniform stress Moreover, the biodeg n to removal as in n | f the clinical of the inter sutures, glu re one or to mation, dela l closing sys tronger opti The unique ough Finite ary studies ce to crack distributio gradability o netallic stap | l operations vention. Thes, adhesive the other s ayed healing tem, etc. Th on to resolve architecture Element Ana are suggestic propagation of staples ne les. The stap | need some he available strips, and hortcoming , secondary e proposed e the issues and design alysis (FEA) ng that the on, holding e available ot required | | |
| 7. | Investigational study for the precipitate generation over stability in the formulation. | Ravi Shah and DerajramBenival | Virbac Animal Health India Pvt Ltd. | 3 lakh | 6 months | | |
| | It is an industry projec | | | 1 | | | |
| 8. | Killing two birds with one stone: dual blockade of tumor pyruvate kinase M2 and dihydrofolate reductase through hybrid molecule in oral cancer | Dr. Amit Shard | ICMR | 42 Lakh | 3 years | | |
| | Hybrid compounds are essence of medicinal chemistry. They may be potent enough against two or more targets. Here we have planned to snthesize hybrid molecules which may target two enzymes crucial of cancerous cell growth. One target is DHFR and another selected is pyruvate kinase M2. (Project has not started as funding is not received) | | | | | | |
| 9. | Targeting Sweet Spot in Oral Cancer: Development of Novel Project Title Quinazolinones for Electrophillic Modification of Tumor Pyruvate Kinase M2 | Dr. Amit Shard | Gujarat State Biotechno logy Mission | 48 Lakh | 3 years | | |
| | The project involves design and deveopment of novel molecules against oral | | | | | | |

| | cancer. The oral cancer is a burgeoning problem of Gujarat as well as India. The treatmnet options are limited and are flanked with problems of chemoresistance and adverse side effects. In this regard, the molecules will be aimed at tumor pyruvate kinase M2 a typical metabolic conduit in oral cancer. | | | | | |
|-----|---|------------------------|---|---------------|---------|--|
| 10. | Age-dependent development of progressive mouse model of Parkinson's disease by stereotaxic injection of rotenone in the olfactory bulb and its validation through diffusion kurtosis imaging | Amit Khairnar | ICMR | 47.76 Lakh | 3 years | |
| 11. | A industrial consultancy project on systematic analysis of stability studies and related impurities of biotin and pantothenic acid. | SiddheshwarChau the | Proctor and Gamble Healthcar e Limited, Mumbai | 1.8 Lakh | | |
| | Project completed, This is an industrial project, Details of the project could not be disclosed as per the CDA agreement with company. | | | | | |

PUBLICATIONS (RESEARCH/ REVIEW):

Pharmaceutical analysis

- 1. Pillai, Megha Sajakumar, Sree Teja Paritala, Ravi P. Shah, Nitish Sharma, and Pinaki Sengupta. "Cutting-edge strategies and critical advancements in characterization and quantification of metabolites concerning translational metabolomics." Drug Metabolism Reviews 54, no. 4 **(2022)**: 401-426.
- 2. Sahu, Amit Kumar, Tarang Jadav, Niraj Rajput, Manish Kumar Sharma, and Pinaki Sengupta. "Bioanalysis by LC-MS/MS and preclinical pharmacokinetic interaction study of ribociclib and oleanolic acid." Bioanalysis 14, no. 15 **(2022)**: 1051-1065.
- 3. Jogpethe, Ashish, Tarang Jadav, Niraj Rajput, Amit Kumar Sahu, Rudradip Das, Astha Gupta, Amit Shard, and Pinaki Sengupta. "LC/Q-TOF MS and LC/QQQ MS based bioanalysis of a new ferrocene derivative as a potential anticancer lead with promising drug-like characteristics." Journal of Chromatography B 1210 (2022): 123469.
- 4. Palshikar, Mrunal, Tarang Jadav, Niraj Rajput, Amit Kumar Sahu, and Pinaki Sengupta. "Surrogate peptide selection and internal standardization for accurate quantification of endogenous proteins." Bioanalysis 14, no. 13 **(2022)**: 949-961.
- 5. Rachmale, Megha, Niraj Rajput, Tarang Jadav, Amit Kumar Sahu, Satyasheel Sharma, and Pinaki Sengupta. "High resolution mass spectrometry-driven metabolite profiling of baricitinib to report its unknown metabolites and step-bystep reaction mechanism of metabolism." Rapid Communications in Mass Spectrometry 36, no. 22 **(2022)**: e9385.

- 6. Deore, Jayshri, Niraj Rajput, Tarang Jadav, Amit K. Sahu, and Pinaki Sengupta. "Hot Stage Microscopy-based Method for Determination of Particle Size in Reverse Engineering: Establishment of a Platform Technology Employing Carvedilol as a Model Drug." Current Analytical Chemistry 18, no. 10 **(2022)**: 1117-1130.
- 7. Gangakhedkar, Shriya, Harsh Thakkar, Ravi P. Shah. Hydrogen-Deuterium Exchange in LC-MS Simple & Powerful Tool for Differentiating Protein Conformers, SpincotechCuttingEdge. **(2022)**:16-18.
- 8. Sharma, Nitish, ShivrajGiri, Amit kumarSahu, Sidheshwari More, Pinaki Sengupta, and Ravi P. Shah. "LC-Q/TOF-HRMS and NMR based structural characterization of the major photodegradation impurity of difluprednate." Chromatographia 85, no. 7 (2022): 605-615.
- 9. Sharma, Nitish, DivyaKukreja, Tushar Giri, Sumit Kumar, and Ravi P. Shah. "Synthetic pharmaceutical peptides characterization by chromatography principles and method development." Journal of Separation Science 45, no. 13 (2022): 2200-2216.
- 10. Jogpethe, Ashish, Tarang Jadav, Niraj Rajput, Amit Kumar Sahu, Rakesh K. Tekade, and Pinaki Sengupta. "Critical strategies to pinpoint carryover problems in liquid chromatography-mass spectrometry: a systematic direction for their origin identification and mitigation." Microchemical Journal **(2022)**: 107464.
- 11. Jain, Sonali, ShivrajGiri, Nitish Sharma, and Ravi P. Shah. "LC and LC-HRMS studies on stability behavior of molnupiravir an anti-COVID 19 drug." Journal of Liquid Chromatography & Related Technologies 44, no. 15-16 (2021): 750-759.
- 12. Rajput, Niraj, Fatema Soni, Amit Kumar Sahu, Tarang Jadav, Satyasheel Sharma, and Pinaki Sengupta. "Degradation kinetics and characterization of major degradants of binimetinib employing liquid chromatography-high resolution mass spectrometry." Journal of Pharmaceutical and Biomedical Analysis 215 (2022): 114753.
- 13. Bhangare, Dhiraj, Niraj Rajput, Tarang Jadav, Amit Kumar Sahu, Rakesh K. Tekade, and Pinaki Sengupta. "Systematic strategies for degradation kinetic study of pharmaceuticals: an issue of utmost importance concerning current stability analysis practices." Journal of Analytical Science and Technology 13, no. 1 (2022): 7
- 14. Rachmale, Megha, Niraj Rajput, Tarang Jadav, Amit Kumar Sahu, Rakesh K. Tekade, and Pinaki Sengupta. "Implication of metabolomics and transporter modulation-based strategies to minimize multidrug resistance and enhance site-specific bioavailability: a needful consideration toward modern anticancer drug discovery." Drug Metabolism Reviews 54, no. 2 **(2022)**: 101-119.18.
- 15. Mishra, Sonam, Niraj Rajput, Tarang Jadav, Amit Kumar Sahu, Rakesh K. Tekade, and Pinaki Sengupta. "Advancement in Analytical Strategies for Quantification of Biomarkers with a Special Emphasis on Surrogate Approaches." Critical Reviews in Analytical Chemistry **(2022)**: 1-16.
- 16. Sonawane, Dipali, Amit Kumar Sahu, Tarang Jadav, and Pinaki Sengupta. "Establishment of a Rapid and Highly Sensitive Reverse-phase High-performance Liquid Chromatography Based Analytical Assay Method for Duvelisib." Indian Journal of Pharmaceutical Education And Research 56, no. 1 **(2022)**: 287-295.20.
- 17. Sonawane, Dipali, Amit Kumar Sahu, Tarang Jadav, and Pinaki Sengupta. "UHPLC– Q-TOF–MS/MS-based metabolite profiling of duvelisib and establishment of its metabolism mechanisms." Biomedical Chromatography 36, no. 4 **(2022)**: e5314.

Pharmaceutics

- 18. Janrao, Chetan, Shivani Khopade, AkshayBavaskar, Shyam Sudhakar Gomte, Tejas Girish Agnihotri, and Aakanchha Jain. "Recent Advances of Polymer Based Nanosystems in Cancer Management." *Journal of Biomaterials Science, Polymer Edition* just-accepted **(2022)**: 1-73.
- 19. Sisodia, Yashi, Komal Shah, Adil Ali Sayyed, Meenakshi Jain, Syed Ansar Ali, Piyush Gondaliya, Kiran Kalia, and Rakesh Kumar Tekade. "Lung-on-chip microdevices to foster pulmonary drug discovery." *Biomaterials Science* (2023).
- 20. Sharma, Monika, FehminaMushtaqueMalim, Ashutosh Goswami, Nishant Sharma, Sai Sowmya Juvvalapalli, Sayan Chatterjee, Abhijeet S. Kate, and Amit Khairnar. "Neuroprotective Effect of Swertiamarin in a Rotenone Model of Parkinson's Disease: Role of Neuroinflammation and Alpha-Synuclein Accumulation." *ACS Pharmacology & Translational Science* (2022).
- 21. Kalyane, Dnyaneshwar, Suryanarayana Polaka, Nupur Vasdev, and Rakesh Kumar Tekade. "CD44-Receptor Targeted Gold-Doxorubicin Nanocomposite for Pulsatile Chemo-Photothermal Therapy of Triple-Negative Breast Cancer Cells." *Pharmaceutics* 14, no. 12 **(2022)**: 2734.
- 22. Pawar, Bhakti, Nupur Vasdev, Tanisha Gupta, Mahi Mhatre, Anand More, Neelima Anup, and Rakesh Kumar Tekade. "Current Update on Transcellular Brain Drug Delivery." *Pharmaceutics* 14, no. 12 **(2022)**: 2719.
- 23. Agnihotri, Tejas Girish, Shyam Sudhakar Gomte, and Aakanchha Jain. "Emerging theranostics to combat cancer: a perspective on metal-based nanomaterials." *Drug Development and Industrial Pharmacy* 48, no. 11 **(2022)**: 585-601.
- 24. Kalyane, Dnyaneshwar, Suryanarayana Polaka, Nupur Vasdev, and Rakesh Kumar Tekade. "Cancer Cell-Specific and Laser-Activatable NanoSeeds for Targeted Photothermal Ablation of Triple-negative Breast Cancer." *Photochemistry and Photobiology* (2022).
- 25. Vasdev, Nupur, Nakshatra Chaudhari, Suryanarayana Polaka, Kuldeep Rajpoot, Piyush Gondaliya, Adil Ali Sayyed, Pinaki Sengupta, and Rakesh Kumar Tekade. "Current progress in preservative-free topical ophthalmic formulations." *Journal of Drug Delivery Science and Technology* **(2022)**: 103996.
- 26. Salave, Sagar, Dhwani Rana, Hemant Kumar, NagavendraKommineni, and DerajramBenival. "Anabolic Peptide-Enriched Stealth Nanoliposomes for Effective Anti-Osteoporotic Therapy." *Pharmaceutics* 14, no. 11 **(2022)**: 2417.
- 27. Kumar, Ashish, Neeraj Kumar, Zarna Pathak, and Hemant Kumar. "Extra cellular matrix remodeling: an adjunctive target for spinal cord injury and intervertebral disc degeneration." *Neurospine* 19, no. 3 **(2022)**: 632-645.
- 28. Longare, Suraj, Dhwani Rana, Sagar Salave, and DerajramBenival. "Current Indian Science."
- 29. Bhagwani, Ankita, Manjeet Chopra, and Hemant Kumar. "Spinal cord injury provoked neuropathic pain and spasticity, and their GABAergic connection." *Neurospine* 19, no. 3 **(2022)**: 646-668.
- 30. Rawat, Garima, Shital Kolhe, Dhwani Rana, Sagar Salave, and DerajramBenival. "Exploring the Therapeutic Potential of Cyclosporin for Ophthalmic Indications by virtue of Novel Carrier Systems." *Critical Reviews™ in Therapeutic Drug Carrier Systems*.

- 31. Parekh, Pathik, Nishant Sharma, Monika Sharma, Anagha Gadepalli, Adil Ali Sayyed, Sayan Chatterjee, Abhijeet Kate, and Amit Khairnar. "AMPK-dependent autophagy activation and alpha-Synuclein clearance: a putative mechanism behind alpha-mangostin's neuroprotection in a rotenone-induced mouse model of Parkinson's disease." *Metabolic Brain Disease* 37, no. 8 **(2022)**: 2853-2870.
- 32. Choudhari, Manisha, Kritika Nayak, Noriaki Nagai, Yosuke Nakazawa, DigneshKhunt, and Manju Misra. "Role of mucoadhesive agent in ocular delivery of ganciclovir microemulsion: cytotoxicity evaluation in vitro and ex vivo." *International Ophthalmology* **(2022)**: 1-15.
- 33. Das, Krishna Kumar, SmaranikaPattnaik, Santosh Kumar Behera. Conventional Antibiotics from Actinomycetes: A mini review, *International Journal for Research Trends* and *Innovation*. 7(9)**(2022)**: 487-495. http://www.ijrti.org/papers/IJRTI2209064.pdf
- Malik, Jonaid Ahmad, Sakeel Ahmed, Zahid Yaseen, MutebAlanazi, TareqNafeaAlharby, Hisham AbdulazizAlshammari, and Sirajudheen Anwar.
 "Association of SARS-CoV-2 and Polypharmacy with Gut–Lung Axis: From Pathogenesis to Treatment." *ACS omega* 7, no. 38 (2022): 33651-33665.
- 35. Salave, Sagar, Dhwani Rana, Amit Sharma, K. Bharathi, Raghav Gupta, ShubhangiKhode, DerajramBenival, and NagavendraKommineni. "Polysaccharide based implantable drug delivery: Development strategies, regulatory requirements, and future perspectives." *Polysaccharides* 3, no. 3 **(2022)**: 625-654.
- 36. Salave, Sagar, Dhwani Rana, and DerajramBenival. "Dual Targeting Anti-Osteoporotic Therapy through Potential Nanotherapeutic Approaches." *Pharmaceutical Nanotechnology* 10, no. 5 **(2022)**: 384-392.
- 37. Sharma, Nishant, RituSoni, Monika Sharma, Sayan Chatterjee, Nidhi Parihar, MohdMukarram, Ruhi Kale, Adil Ali Sayyed, Santosh Kumar Behera, and Amit Khairnar. "Chlorogenic Acid: A Polyphenol from Coffee Rendered Neuroprotection Against Rotenone-Induced Parkinson's Disease by GLP-1 Secretion." *Molecular Neurobiology* 59, no. 11 **(2022)**: 6834-6856.
- 38. Salave, Sagar, Dhwani Rana, and DerajramBenival. "Encapsulation of Anabolic Peptide in Lipid Nano Vesicles for Osteoporosis." *Current Protein and Peptide Science* 23, no. 7 **(2022)**: 495-503.
- 39. Todke, Pooja, Suryanarayana Polaka, Nidhi Raval, Piyush Gondaliya, VishakhaTambe, Rahul Maheshwari, Kiran Kalia, and Rakesh Kumar Tekade. "'Transfersome-embedded-gel'for dual-mechanistic delivery of anti-psoriatic drugs to dermal lymphocytes." *Journal of Microencapsulation* 39, no. 6 **(2022)**: 495-511.
- 40. Rajpoot, Kshipra, Shiv Kumar Prajapati, Akanksha Malaiya, Richa Jain, and Aakanchha Jain. "Meropenem-Loaded Nanostructured Lipid Carriers For Skin and Soft Tissue Infection Caused by Staphylococcus aureus: Formulation, Design, and Evaluation." *AAPS PharmSciTech* 23, no. 7 **(2022)**: 241.
- 41. Polaka, Suryanarayana, Pratik Katare, Bhakti Pawar, Nupur Vasdev, Tanisha Gupta, Kuldeep Rajpoot, Pinaki Sengupta, and Rakesh Kumar Tekade. "Emerging ROS-modulating technologies for augmentation of the wound healing process." *ACS omega* 7, no. 35 **(2022)**: 30657-30672.
- 42. Salave, Sagar, KedarPrayag, Dhwani Rana, Prakash Amate, Rupali Pardhe, Ajinkya Jadhav, Anil B. Jindal, and DerajramBenival. "Recent Progress in Hot Melt Extrusion Technology in Pharmaceutical Dosage Form Design." *Recent Advances*

in Drug Delivery and Formulation: Formerly Recent Patents on Drug Delivery & Formulation 16, no. 3 **(2022)**: 170-191.

- 43. Singhai, V. D., S. Sharma, S. Paliwal, and R. Maheshwari. "Scalable Design and Development of Modified Release Hydrochlorothiazide Formulation Employing Quality by Design Approach." *Indian Journal of Pharmaceutical Sciences* 84, no. 4 (2022): 910-928.
- 44. Salave, Sagar, Sonali Jain, Ravi Shah, and DerajramBenival. "Quantification of Anti-Osteoporotic Anabolic Peptide in Stealth Lipid Nanovesicles Through Validated RP-HPLC Method." *Journal of AOAC International* 106, no. 1 (2023): 40-48.
- 45. Chopra, Manjeet, Ankita Bhagwani, and Hemant Kumar. "The Provenance, Providence, and Position of Endothelial Cells in Injured Spinal Cord Vascular Pathology." *Cellular and Molecular Neurobiology* **(2022)**: 1-17.
- 46. Paradia, Pankaj Kumar, Rameshwar Bhavale, Tejas Agnihotri, and Aakanchha Jain. "A Review on Edible Vaccines and Biopharmaceutical Products from Plants." *Current Pharmaceutical Biotechnology* **(2022)**.
- 47. Patel, Roshni, Zarna Pathak, Shrikalp Deshpande, and Gaurang Shah. "Comparative Evaluation of Aldose Reductase Inhibition in Polycystic Ovarian Syndrome–Induced Rats." *Reproductive Sciences* **(2022)**: 1-11.
- 48. Rana, Dhwani, Sagar Salave, Garima Rawat, and DerajramBenival. "Recent Trends in Drug Delivery and Emerging Biomedical Applications of Gelatin for Ophthalmic Indications." *Macromolecular Research* 30, no. 10 **(2022)**: 687-702.
- 49. Rana, Dhwani, Sagar Salave, Sonali Jain, Ravi Shah, and DerajramBenival. "Systematic Development and Optimization of Teriparatide-Loaded Nanoliposomes Employing Quality by Design Approach for Osteoporosis." *Journal of Pharmaceutical Innovation* **(2022)**: 1-15.
- 50. Datta, Aishika, DeepaneetaSarmah, Harpreet Kaur, Antra Chaudhary, Namrata Vadak, Anupom Borah, Sudhir Shah, Xin Wang, and Pallab Bhattacharya. "Advancement in CRISPR/Cas9 Technology to Better Understand and Treat Neurological Disorders." *Cellular and Molecular Neurobiology* **(2022)**: 1-17.
- 51. Saxena, Sanjay, Biswajit Jena, Neha Gupta, Suchismita Das, DeepaneetaSarmah, Pallab Bhattacharya, Tanmay Nath et al. "Role of artificial intelligence in radiogenomics for cancers in the era of precision medicine." *Cancers* 14, no. 12 (2022): 2860.
- 52. Kalyane, Dnyaneshwar, Devendra Choudhary, Suryanarayana Polaka, HanmantGoykar, Tukaram Karanwad, Kuldeep Rajpoot, and Rakesh Kumar Tekade. "Reactive oxygen nano-generators for cancer therapy." *Progress in Materials Science* (2022): 100974.
- 53. Tambe, Vishakha, Sagarkumar Patel, Amit Shard, Santosh Kumar Behera, Suryanarayana Polaka, Neelima Anup, Anuradha Gadeval, Kiran Kalia, and Rakesh Kumar Tekade. "Dendronized Polymeric Biomaterial for Loading, Stabilization, and Targeted Cytosolic Delivery of microRNA in Cancer Cells." *ACS Applied Bio Materials* 5, no. 9 (2022): 4128-4153.
- 54. Kulkarni, Deepak, Fouad Damiri, Satish Rojekar, MehrukhZehravi, SarkerRamproshad, DipaliDhoke, Shubham Musale et al. "Recent advancements microneedle technology for multifaceted biomedical in applications." Pharmaceutics 14, no. 5 (2022): 1097.
- 55. Agnihotri, Tejas Girish, Govinda Shivaji Jadhav, BichismitaSahu, and Aakanchha Jain. "Recent trends of bioconjugated nanomedicines through nose-to-brain

delivery for neurological disorders." *Drug Delivery and Translational Research* 12, no. 12 **(2022)**: 3104-3120.

- 56. Salave, Sagar, Dhwani Rana, Rupali Pardhe, Prajakta Bule, and DerajramBenival. "Unravelling micro and nano vesicular system in intranasal drug delivery for epilepsy." *Pharmaceutical Nanotechnology* 10, no. 3 **(2022)**: 182-193.
- 57. Shah, Viral, Ekta Khambhla, Manish Nivsarkar, Riddhi Trivedi, and Rakesh K. Patel. "An Integrative QbD approach for the development and optimization of controlled release compressed coated formulation of water-soluble drugs." *AAPS PharmSciTech* 23, no. 5 (2022): 120.
- 58. Shete, Meghanath B., Tulshidas S. Patil, Ashwini S. Deshpande, Gaurav Saraogi, Nupur Vasdev, Mrudul Deshpande, Kuldeep Rajpoot, and Rakesh Kumar Tekade. "Current trends in theranostic nanomedicines." *Journal of Drug Delivery Science and Technology* **(2022)**: 103280.
- 59. Polaka, Suryanarayana, Vaishali Makwana, Nupur Vasdev, Anjani Sheth, Kuldeep Rajpoot, Pinaki Sengupta, and Rakesh Kumar Tekade. "Engineering immunity via skin-directed drug delivery devices." *Journal of Controlled Release* **(2022)**.
- 60. Rana, Dhwani, Sagar Salave, Akhil Perla, Akanksha Nadkarni, Shital Kolhe, Anil B. Jindal, Amit Mandoli, Pradeep Dwivedi, and DerajramBenival. "Bugs as Drugs: Understanding the Linkage between Gut Microbiota and Cancer Treatment." *Current Drug Targets* 23, no. 9 **(2022)**: 869-888.
- 61. Rajpoot, Kuldeep, MuktikaTekade, Mukesh Chandra Sharma, Basel Arafat, and Rakesh Kumar Tekade. "Principles and concepts in toxicokinetic." *Pharmacokinetics and toxicokinetic considerations* **(2022)**: 1-26.

Medical devices

- 62. Pramanik, Sheersha, Shubham Kharche, Namdev More, Deepak Ranglani, and GovindaKapusetti. "Natural Biopolymers for Bone Tissue Engineering: A Brief Review." *Engineered Regeneration* **(2022)**.
- 63. Agarwal, Pooja, Zahra Sebghatollahi, Mehnaz Kamal, Archana Dhyani, Alpana Shrivastava, Kiran Kumari Singh, Mukty Sinha, NeelimaMahato, Awdhesh Kumar Mishra, and Kwang-Hyun Baek. "Citrus Essential Oils in Aromatherapy: Therapeutic Effects and Mechanisms." *Antioxidants* 11, no. 12 **(2022)**: 2374.
- 64. Pulugu, Priyanka, Neha Arya, Prasoon Kumar, and Akshay Srivastava. "Polystyrene-Based Slippery Surfaces Enable the Generation and Easy Retrieval of Tumor Spheroids." *ACS Applied Bio Materials* 5, no. 12 **(2022)**: 5582-5594.
- 65. Patel, Mitkumar, Mayuri Agrawal, and Akshay Srivastava. "Signal amplification strategies in electrochemical biosensors via antibody immobilization and nanomaterial-based transducers." *Materials Advances* **(2022)**.
- 66. Ghosh, Sumanta, Namdev More, and GovindaKapusetti. "Surgical staples: Current state-of-the-art and future prospective." *Medicine in Novel Technology and Devices* **(2022)**: 100166.
- 67. Jariyal, Heena, Harsh Thakkar, Adarsh Suresh Kumar, Medha Bhattacharyya, Ravi P. Shah, and Akshay Srivastava. "Extrinsic hyaluronic acid induction differentially modulates intracellular glutamine metabolism in breast cancer stem cells." *International Journal of Biological Macromolecules* 218 **(2022)**: 679-689.

Natural products

- 68. Sindhe, Haritha, NehanazSaiyed, AkshayKamble, Malladi Mounika Reddy, Amardeep Singh, and Satyasheel Sharma. "Catalytic and Chemodivergent Synthesis of 1-Substituted 9 H-Pyrrolo [1, 2-a] indoles via Annulation of β-CF3 Enones with 3-Substituted Indoles." *The Journal of Organic Chemistry* (2022).
- 69. Chatterjee, Debanjan, NazminaVhora, Ashutosh Goswami, Aishwarya Hiray, Alok Jain, and Abhijeet S. Kate. "In-silico and in-vitro hybrid approach to identify glucagon-like peptide-1 receptor agonists from anti-diabetic natural products." *Natural Product Research* **(2022)**: 1-5.
- 70. Niguram, Prakash, and Abhijeet S. Kate. "Comprehensive metabolite identification study of arterolane using hydrophilic interaction liquid chromatography with quadrupole-time-of-flight mass spectrometry." *Rapid Communications in Mass Spectrometry* 36, no. 16 **(2022)**: e9335.
- 71. Weerasinghe, Ramani H., Chaitrali D. Shevkar, Kasun Maduranga, Komal H. Pandey, Renuka N. Attanayake, Abhijeet S. Kate, Gothamie Weerakoon, Santosh K. Behera, Kiran S. Kalia, and Priyani A. Paranagama. "Bioprospecting of an Endolichenic Fungus Phanerochaetesordida Isolated from Mangrove-Associated Lichen Bactrosporamyriadea." *Journal of Chemistry* 2022 **(2022)**.
- 72. Shevkar, Chaitrali, Pranali Pradhan, Ashwini Armarkar, Komal Pandey, Kiran Kalia, PriyaniParanagama, and Abhijeet S. Kate. "Exploration of Potent Cytotoxic Molecules from Fungi in Recent Past to Discover Plausible Anticancer Scaffolds." *Chemistry & Biodiversity* 19, no. 4 **(2022)**: e202100976.
- 73. Negi, Poonam, Surbhi Gautam, Aditi Sharma, Charul Rathore, Lalit Sharma, Navneet Upadhyay, Murtaza M. Tambuwala et al. "Gastric ulcer healing by chebulinic acid solid dispersion-loaded gastroretentive raft systems: preclinical evidence." *Therapeutic delivery* 13, no. 2 (2022): 81-93.
- 74. Shevkar, Chaitrali, Ashwini Armarkar, Ramani Weerasinghe, Kasun Maduranga, Komal Pandey, Santosh K. Behera, Kiran Kalia, PriyaniParanagama, and Abhijeet S. Kate. "Cytotoxic Bioxanthracene and Macrocyclic Polyester from Endolichenic Fungus Talaromycespinophilus: In-Vitro and In-Silico Analysis." *Indian Journal of Microbiology* (2022): 1-11.
- 75. Taunk, Khushman, Priscilla Porto-Figueira, Jorge AM Pereira, Ravindra Taware, NattaneLuíza da Costa, Rommel Barbosa, Srikanth Rapole, and José S. Câmara. "Urinary Volatomic Expression Pattern: Paving the Way for Identification of Potential Candidate Biosignatures for Lung Cancer." *Metabolites* 12, no. 1 (2022): 36.

Biotechnology

- 76. Tripathy, Chandra Sekhar, and Santosh Kumar Behera. "Molecular Screening, Docking and DFT Study of Phytochemicals from Sesbania grandiflora against HER 2 Protein of Oral Cancer." *Sch Int J Tradit Complement Med* 5, no. 10 (2022): 189-198.
- 77. Dasa, Krishna Kumar, SmaranikaPattnaik, and Santosh Kumar Beherab. "Identification and Genomic study of the biopotent actinomycetes species MicrobacteriumBarkeri (LMA4): a computational approach." **(2022)**.

- 78. Das, Krishna Kumar, SmaranikaPattnaik, Santosh Kumar Behera."Application Of Actinomycetes In Secondary Metabolites Production: An Overview", *International Journal of Emerging Technologies and Innovative Research*. 9(9)**(2022)**.
- 79. Aamna, Bari, Aritra Kumar Dan, RaghabaSahu, Santosh Kumar Behera, and Sagarika Parida. "Deciphering the signaling mechanisms of β-arrestin1 and βarrestin2 in regulation of cancer cell cycle and metastasis." *Journal of Cellular Physiology* 237, no. 10 (2022): 3717-3733.
- 80. Tripathy, Chandra Sekhar, Santosh Kumar Behera, Anil Kumar, Santosh Kumar Panda, India Dr GauravGiri, Assistant Drugs Controller, Muhammad Akram, Deepak Bhattacharya, At QC, and Sri Radha Krishna RaasMandir. "Colorectal Cancer Vrs Glycyrrhiza glabra-Computational Docking & DFT Analysis vis-à-vis TNIK Receptor Protein."
- 81. Tripathy, Chandra Sekhar. "DengueVrsEllagic Acid & Ferric Carboxymaltose: InSilico." *Saudi J Biomed Res* 7, no. 7 **(2022)**: 211-218.
- 82. De, Soumik, Bari Aamna, RaghabaSahu, Sagarika Parida, Santosh Kumar Behera, and Aritra Kumar Dan. "Seeking heterocyclic scaffolds as antivirals against dengue virus." *European Journal of Medicinal Chemistry* **(2022)**: 114576.
- 83. Tripathy, Chandra Sekhar, Anil Kumar, Santosh Kumar Panda, Santosh Kumar Behera, Gaurav Giri, AsadollahAsadi, Santanu Kumar Budhia et al. "Osteosarcoma's STAT-3 Vrs Kaempferia parviflora's Compounds: Possible Drug Candidates."*Research Journal of Pharmacology and Pharmacy*6, 15, (2022): 6
- 84. Mahata, Sutapa, Santosh Kumar Behera, Sunil Kumar, Pranab Kumar Sahoo, Sinjini Sarkar, Mobashar Hussain UrfTurabeFazil, and Vilas D. Nasare. "In-silico and in-vitro investigation of STAT3-PIM1 heterodimeric complex: Its mechanism and inhibition by curcumin for cancer therapeutics." *International Journal of Biological Macromolecules* 208 **(2022)**: 356-366.
- 85. Tripathy, Chandra Sekhar, Anil Kumar, Ghassem Habibi Bibalani, Santosh Kumar Behera, Santanu Kumar Budhia, P. K. Mohanta, Easter Khura et al. "Psoriasis Vrs Cassia Fistula: In-Silico Study." **(2022)**.
- 86. Gondaliya, Piyush, Adil Ali Sayyed, Palak Bhat, Mukund Mali, Neha Arya, Amit Khairnar, and Kiran Kalia. "Mesenchymal stem cell-derived exosomes loaded with miR-155 inhibitor ameliorate diabetic wound healing." *Molecular Pharmaceutics* 19, no. 5 (2022): 1294-1308.

MBA

87. Nadiminti, Rajesh Kumar, Khyati Lakhani, MounicaKodavalla, Pawan Sharma, and Sachin Wadekute. "Impact of the Internet on healthcare marketing." *International Journal of Emerging Trends in Science and Technology* 9, no. 11 **(2022)**: 01-07.

Medicinal chemistry

- 88. Chatterjee, Deep Rohan, Saumya Kapoor, Meenakshi Jain, Rudradip Das, Moumita Ghosh Chowdhury, and Amit Shard. "PROTACting the kinome with covalent warheads." *Drug Discovery Today* **(2022)**: 103417.
- 89. Chowdhury, Moumita Ghosh, Rudradip Das, Het Vyas, TejalSasane, Omprakash Mori, SayaliKamble, Sagarkumar Patel, and Amit Shard. "A Comprehensive Account of Synthesis and Biological Activities of α-lidene-Benzocycloalkanones and Benzoheterocycles." *ChemistrySelect* 7, no. 33 (2022): e202201468.

- 90. Shinde, Sangita Dattatray, Dinesh Parshuram Satpute, Santosh Kumar Behera, and Dinesh Kumar. "Computational Biology of BRCA2 in Male Breast Cancer, through Prediction of Probable nsSNPs, and Hit Identification." *ACS omega* 7, no. 34 (2022): 30447-30461.
- 91. Gupta, Astha, Rudradip Das, Ambika Chamoli, AsmitaChoithramani, Hansal Kumar, Sagarkumar Patel, Datta Khude et al. "A Series of Ferrocene-Containing Pyrazolo [1, 5-a] pyrimidines Induce a Strong Antiproliferative Effect against Oral Cancer Cells." *Organometallics* 41, no. 16 **(2022)**: 2365-2378.
- 92. NikhiláVaidya, Gargi, ShyamKumaráLokhande, Sangita DattatrayáShinde, and Dinesh ParshuramáSatpute. "Water enabled, nickel-catalyzed highly chemoselective C-allylation of (NH)-indoles employing alcohols." *Green Chemistry* 24, no. 12 **(2022)**: 4921-4927.
- 93. Vaidya, Gargi Nikhil, Ramesh Hiralal Choudhary, MithileshNagpure, Shyam Kumar Lokhande, Pooja Rana, and Dinesh Kumar. "'In-water', nickel-catalyzed mild preparation of allylic amines employing alcohols: application to 'all-water'synthesis of pharmaceuticals." *Green Chemistry* 24, no. 10 **(2022)**: 3977-3984.
- 94. Jadhav, Jyotika, Rudradip Das, SayaliKamble, Moumita Ghosh Chowdhury, Saumya Kapoor, Astha Gupta, Het Vyas, and Amit Shard. "Ferrocene-based modulators of cancer-associated tumor pyruvate kinase M2." *Journal of Organometallic Chemistry* 968 **(2022)**: 122338.
- 95. Das, Rudradip, Moumita Ghosh Chowdhury, SonalRaundal, Jyotika Jadhav, Navin Kumar, Sagarkumar Patel, and Amit Shard. "Objective assessment of adrenocortical carcinoma driver genes and their correlation with tumor pyruvate kinase M2." *Gene* 822 **(2022)**: 146354.
- 96. Sharma, Satyasheel, Haritha Sindhe, Bharatkumar Chaudhary, Neelanjan Chowdhury, AkshayKamble, Vivek Kumar, and Aishwarya Lad. "Recent Advances in the Transition-Metal Catalyzed Directed C–H Functionalization with Fluorinated Building Blocks." *Organic Chemistry Frontiers* **(2022)**.
- 97. Shinde, Suchita D., Kamya B. Rao, Santosh K. Behera, Neha Arya, and BichismitaSahu. "Epithelial cell adhesion molecule (EpCAM) binding short peptides derived from antibody MOC-31; De-novo design, synthesis and their invitro evaluation." *Biochemical and Biophysical Research Communications* 600 (2022): 1-5.

Pharmacology

- 98. Sarmah, Deepaneeta, Geetesh Verma, Aishika Datta, Namrata Vadak, Antra Chaudhary, Kiran Kalia, and Pallab Bhattacharya. "Phyllanthus emblica L. Regulates BDNF/PI3K Pathway to Modulate Glutathione for Mitoprotection and Neuroprotection in a Rodent Model of Ischemic Stroke." *Central Nervous System Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Central Nervous System Agents*) 22, no. 3 **(2022)**: 175-187.
- 99. Roy, Rubina, Pallab Bhattacharya, and Anupom Borah. "Targeting the Pathological Hallmarks of Alzheimer's Disease Through Nanovesicleaided Drug Delivery Approach." *Current Drug Metabolism* 23, no. 9 **(2022)**: 693-707.
- 100. Dutta, Ankumoni, BanashreeChetiaPhukan, Rubina Roy, Muhammed KhairujjamanMazumder, Rajib Paul, Amarendranath Choudhury, Diwakar Kumar et al. "Garcinia morella extract confers dopaminergic neuroprotection by

mitigating mitochondrial dysfunctions and inflammation in mouse model of Parkinson's disease." *Metabolic Brain Disease* 37, no. 6 **(2022)**: 1887-1900.

- 101. Nalla, Lakshmi Vineela, Piyush Gondaliya, Kiran Kalia, and Amit Khairnar. "Targeting specificity protein 1 with miR-128-3p overcomes TGF-β1 mediated epithelial-mesenchymal transition in breast cancer: An in vitro study." *Molecular Biology Reports* 49, no. 7 (2022): 6987-6996.
- 102. Kulkarni, Riya, Akshata Thakur, and Hemant Kumar. "Microtubule Dynamics Following Central and Peripheral Nervous System Axotomy." *ACS Chemical Neuroscience* 13, no. 9 (2022): 1358-1369.
- 103. Datta, Aishika, DeepaneetaSarmah, Harpreet Kaur, Antra Chaudhary, Kamisetty Leela Mounica, Kiran Kalia, Anupom Borah, Dileep R. Yavagal, and Pallab Bhattacharya. "Post-stroke impairment of the blood-brain barrier and perifocal vasogenic edema is alleviated by endovascular mesenchymal stem cell administration: modulation of the PKCδ/MMP9/AQP4-mediated pathway." *Molecular neurobiology* 59, no. 5 **(2022)**: 2758-2775.
- 104. Albanghali, Mohammad, Saleh Alghamdi, Mohammed Alzahrani, Bassant Barakat, Abdul Haseeb, Jonaid Ahmad Malik, Sakeel Ahmed, and Sirajudheen Anwar. "Clinical characteristics and treatment outcomes of mild to moderate COVID-19 patients at tertiary care hospital, al baha, Saudi Arabia: a single centre study." *Journal of Infection and Public Health* 15, no. 3 **(2022)**: 331-337.
- 105. Sarmah, Deepaneeta, Aishika Datta, Harpreet Kaur, Kiran Kalia, Anupom Borah, Anne Marie Rodriguez, Dileep R. Yavagal, and Pallab Bhattacharya. "Sirtuin-1mediated NF-κB pathway modulation to mitigate inflammasome signaling and cellular apoptosis is one of the neuroprotective effects of intra-arterial mesenchymal stem cell therapy following ischemic stroke." *Stem cell reviews and reports* 18, no. 2 **(2022)**: 821-838.
- 106. Dolma, Sonam, Kirti Adhikari, Teena Mamidi, Abhishek Roy, Zarna Pathak, and Hemant Kumar. "Ethamsylate attenuates mutilated secondary pathogenesis and exhibits a neuroprotective role in experimental model of spinal cord injury." *Neuroscience* 484 **(2022)**: 26-37.
- 107. Bender, O., S. Anwar, S. Ahmed, M. Shinde, A. Mir, J. A. Malik, M. Ansari, and F. Alshammari. "The SARS-CoV-2 mutations versus vaccine effectiveness: New opportunities to new challenges." **(2022)**.
- 108. Rihan, Mohd, Lakshmi Vineela Nalla, Anil Dharavath, Sagarkumar Patel, Amit Shard, and Amit Khairnar. "Boronic acid derivative activates pyruvate kinase M2 indispensable for redox metabolism in oral cancer cells." *Bioorganic & Medicinal Chemistry Letters* 59 **(2022)**: 128539.

BOOK CHAPTERS:

- 1. Sengupta, Pinaki, Bappaditya Chatterjee, and Rakesh Kumar Tekade. "Drug toxicity and forensic pharmacokinetics." In Pharmacokinetics and Toxicokinetic Considerations, pp. 425-486. Academic Press, 2022.Rakesh Tekade (Ed.), Elsevier Academic Press (2022), pp. 425-486. doi.org/10.1016/B978-0-323-98367-9.00021-4
- Gupta, Rachna, Kuldeep Rajpoot, MuktikaTekade, Mukesh Chandra Sharma, MalihehSafavi, and Rakesh Kumar Tekade. "Factors influencing drug toxicity." In *Pharmacokinetics and Toxicokinetic Considerations*, pp. 27-50. Academic Press, (2022)..

- 3. Polaka, Suryanarayana, Hari Priya Koppisetti, RutujaSatvase, Aparna Lakshmi Manchikalapudi, MuktikaTekade, Mukesh Chandra Sharma, and Rakesh Kumar Tekade. "Molecular biology of apoptotic, necrotic, and necroptotic cell death." In *Pharmacokinetics and Toxicokinetic Considerations*, pp. 51-72. Academic Press, (2022).
- 4. Polaka, Suryanarayana, Nupur Vasdev, Sivaroopa Raji, Vaishali Makwana, Amarjitsing Rajput, Madhur Kulkarni, MuktikaTekade, Prashant Pingale, Mukesh Chandra Sharma, and Rakesh Kumar Tekade. "Toxicogenomics in drug safety assessment." *Pharmacokinetics and Toxicokinetic Considerations* **(2022)**: 73-98.
- 5. Tekade, Muktika, HariPriyaKoppisetti, Mukesh Chandra Sharma, Kuldeep Rajpoot, Pinaki Sengupta, Manoj Kumar, and Rakesh Kumar Tekade. "Understanding the concept of signal toxicity and its implications on human health." In *Pharmacokinetics and Toxicokinetic Considerations*, pp. 99-116. Academic Press, (**2022**)..
- 6. Gupta, Rachna, Suryanarayana Polaka, Kuldeep Rajpoot, MuktikaTekade, Mukesh Chandra Sharma, and Rakesh Kumar Tekade. "Importance of toxicity testing in drug discovery and research." In *Pharmacokinetics and Toxicokinetic Considerations*, pp. 117-144. Academic Press, (**2022**)..
- 7. Gupta, Rachna, Kuldeep Rajpoot, MuktikaTekade, Mukesh Chandra Sharma, and Rakesh Kumar Tekade. "Methods and models for in vitro toxicity." In *Pharmacokinetics and Toxicokinetic Considerations*, pp. 145-174. Academic Press, 2022.
- 8. Tekade, Rakesh Kumar, ed. *Pharmacokinetics and Toxicokinetic Considerations-Vol II*. Academic Press, (**2022**)..
- 9. Polaka, Suryanarayana, HariPriyaKoppisetti, Shreya Pande, MuktikaTekade, Mukesh Chandra Sharma, and Rakesh Kumar Tekade. "Zebrafish models for toxicological screening." In *Pharmacokinetics and Toxicokinetic Considerations*, pp. 221-240. Academic Press, (**2022**)..
- 10. Polaka, Suryanarayana, Jai DivyaTella, MuktikaTekade, Mukesh Chandra Sharma, and Rakesh Kumar Tekade. "Impact of ageing on the pharmacokinetics and pharmacodynamics of the drugs." In *Pharmacokinetics and Toxicokinetic Considerations*, pp. 241-261. Academic Press, (**2022**)..
- 11. Polaka, Suryanarayana, Kuldeep Rajpoot, MuktikaTekade, Mukesh Chandra Sharma, and Rakesh Kumar Tekade. "Food–drug interactions and their implications on oral drug bioavailability." In *Pharmacokinetics and Toxicokinetic Considerations*, pp. 263-289. Academic Press, (**2022**)..
- 12. Polaka, Suryanarayana, Hari Priya Koppisetti, MuktikaTekade, Mukesh Chandra Sharma, Pinaki Sengupta, and Rakesh Kumar Tekade. "Drug-drug interactions and their implications on the pharmacokinetics of the drugs." In *Pharmacokinetics and Toxicokinetic Considerations*, pp. 291-322. Academic Press, (**2022**)..
- 13. Polaka, Suryanarayana, Sayali Chaudhari, MuktikaTekade, Mukesh Chandra Sharma, Neelesh Malviya, Sapna Malviya, and Rakesh Kumar Tekade. "clinical importance of herb-drug interaction." In *Pharmacokinetics and Toxicokinetic Considerations*, pp. 323-356. Academic Press, (**2022**)..
- 14. Rajpoot, Kuldeep, Nimeet Desai, HariPriyaKoppisetti, MuktikaTekade, Mukesh Chandra Sharma, Santosh Kumar Behera, and Rakesh Kumar Tekade. "In silico methods for the prediction of drug toxicity." In *Pharmacokinetics and Toxicokinetic Considerations*, pp. 357-383. Academic Press, (**2022)**..

- 15. Polaka, Suryanarayana, Priyanka Pulugu, MuktikaTekade, Mukesh Chandra Sharma, and Rakesh Kumar Tekade. "Organ-on-chip for assessing environmental toxicants." In *Pharmacokinetics and Toxicokinetic Considerations*, pp. 385-400. Academic Press, (**2022**)..
- 16. Asati, Saket, Vikas Pandey, Vishal Gour, Rahul Tiwari, Vandana Soni, Kuldeep Rajpoot, MuktikaTekade, Mukesh Chandra Sharma, and Rakesh Kumar Tekade. "Toxicity and toxicokinetic considerations in product development and drug research." In *Pharmacokinetics and Toxicokinetic Considerations*, pp. 401-424. Academic Press, (**2022**).
- 17. Pandey, Vikas, Suryanarayana Polaka, Lakshmi Vineela Nalla, MuktikaTekade, Mukesh Chandra Sharma, and Rakesh Kumar Tekade. "Excipient toxicity and safety." In *Pharmacokinetics and Toxicokinetic Considerations*, pp. 487-511. Academic Press, (**2022**)..
- 18. Polaka, Suryanarayana, Shyam Sudhakar Gomte, Vikas Pandey, Jai DivyaTella, MuktikaTekade, Mukesh Chandra Sharma, NagashekharaMolugulu, and Rakesh Kumar Tekade. "Pharmaceutical excipients: special focus on adverse interactions." In *Pharmacokinetics and Toxicokinetic Considerations*, pp. 513-542. Academic Press, (**2022**)..
- 19. Polaka, Suryanarayana, Bhakti Pawar, MuktikaTekade, RutujaSatvase, Aparna Lakshmi Manchikalapudi, Mukesh Chandra Sharma, Vikas Pandey, Aditya Narayan Jhariya, and Rakesh Kumar Tekade. "Emerging role of novel excipients in drug product development and their safety concerns." In *Pharmacokinetics and Toxicokinetic Considerations*, pp. 543-567. Academic Press, (**2022)**..
- 20. Tiwari, Akhilesh, Megha Joshi, Neelima Salvi, Deepak Gupta, Sanyam Gandhi, Kuldeep Rajpoot, and Rakesh Kumar Tekade. "Toxicity of pharmaceutical azo dyes." In *Pharmacokinetics and toxicokinetic considerations*, pp. 569-603. Academic Press, (**2022**)..
- 21. Parikh, Kinjal J., Jenee R. Christian, Kuldeep Rajpoot, and Rakesh Kumar Tekade. "Environmental and safety aspects of bionanotechnology." In *Pharmacokinetics and Toxicokinetic Considerations*, pp. 605-650. Academic Press, (**2022)**..
- 22. Pramanik, Sheersha, Aditi Petwal, Vignesh Muthuvijayan, and Rakesh Kumar Tekade. "Toxicological assessment of risk of medical devices." In *Pharmacokinetics and Toxicokinetic Considerations*, pp. 651-684. Academic Press, (**2022**)..
- 23. Rajani, Chitra, Pooja Borisa, Swati Bagul, Kajal Shukla, VishakhaTambe, Nimeet Desai, and Rakesh Kumar Tekade. "Developmental toxicity of nanomaterials used in drug delivery: Understanding molecular biomechanics and potential remedial measures." In *Pharmacokinetics and Toxicokinetic Considerations*, pp. 685-725. Academic Press, (**2022**)..
- 24. Lingayat, Isha, Pranali Mishra, Nupur Vasdev, Suryanarayana Polaka, Ankit Mishra, and Rakesh Kumar Tekade. "Ethical defilements in clinical research and potential roles of institutional review board." In *Pharmacokinetics and Toxicokinetic Considerations*, pp. 727-750. Academic Press, (**2022)**..
- 25. Rajpoot, Kuldeep, Pratik Katare, MuktikaTekade, Mukesh Chandra Sharma, Survanaravana Polaka, Pinaki Sengupta, and Rakesh Kumar Tekade. "Toxicokinetic and toxicodynamic considerations in drug research." In Pharmacokinetics and Toxicokinetic Considerations, pp. 751-776. Academic Press, (2022) ...

- 26. Das, Rudradip, Hansal Kumar, AsmitaChoithramani, GouravBothra, and Amit Shard. "Polymeric Nanoparticles to Entrap Natural Drugs for Cancer Therapy." *Polymeric nanoparticles for the treatment of solid tumors* **(2022)**: 167-211.
- 27. Shinde, Suchita Dattatray, BichismitaSahu, Ambika Chamoli, Amit Mandoli, Kiran Kalia, and Santosh Kumar Behera. "Tyrosine kinases: their role in hepatocellular carcinoma." In *Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 2*, pp. 133-148. Academic Press, (**2022**)..
- 28. Shinde, Suchita Dattatray, Neeraj Kulkarni, BichismitaSahu, Kiran Kalia, and Santosh Kumar Behera. "Role of transcription factors in hepatocellular carcinoma." In *Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 2*, pp. 149-163. Academic Press, (**2022**)..
- 29. Pattnaik, Smaranika, Santosh Kumar Behera, and Niranjan Behera. "Molecular docking studies between components of eucalyptus essential oil and homologically modeled target protein." In *Contemporary Medical Biotechnology Research for Human Health*, pp. 169-176. Academic Press, (**2022**).
- 30. Khan, Raju, Arpana Parihar, Ajeet Kumar Kaushik, and Ashok Kumar, eds. *Advanced Biosensors for Virus Detection: Smart Diagnostics to Combat SARS-CoV-2*. Academic Press, (**2022**).
- 31. Hiray, Aishwarya Rajaram, Namdev More, and GovindaKapusetti. "Invertebratederived bioceramics: An effective alternative source for biomedical applications." In *Advanced Ceramics for Versatile Interdisciplinary Applications*, pp. 279-311. Elsevier, (**2022**).
- 32. More, Namdev, Deepak Ranglani, Aishwarya Rajaram Hiray, and GovindaKapusetti. "Piezoelectric ceramics as stimulatory modulators for regenerative medicine." In *Advanced Ceramics for Versatile Interdisciplinary Applications*, pp. 313-338. Elsevier, (**2022**).
- 33. Roy, Rubina, Rajib Paul, Pallab Bhattacharya, and Anupom Borah. "Assessment of Mitochondrial Complex II and III Activity in Brain Sections: A Histoenzymological Technique." In *Mitochondria: Methods and Protocols*, pp. 73-81. New York, NY: Springer US, (**2022**).
- 34. Mahanta, Sailendra Kumar, and Hemant Kumar Sharma. "Recent Advances in the Development of Synthetic Pro-oxidants: Implications for ROS based Cancer Therapeutics: Implications for ROS Based Cancer Therapeutics." *Handbook of Oxidative Stress in Cancer: Therapeutic Aspects* (2022): 1-9.




NIPER, GUWAHATI



Contact Address Sila Katamur (Halugurisuk), P.O.: Changsari, Dist: Kamrup, Assam, Pin: 781101, Assam, India Email: registrar@niperguwahati.ac.in; admin@niperguwahati.in Website: https://niperguwahati.ac.in/contact.html

From the Director's Desk

National Institute of Pharmaceutical Education & Research (NIPER) Guwahati is currently running with eight important Pharmacology departments viz, and Biotechnology, Toxicology, Pharmacv Practice, Pharmaceutics, Pharmaceutical Analysis, Medicinal Chemistry, Pharmaceutical Technology (Formulations) and Medical Devices. Department Pharmacology of and Toxicology emphasizing an integrated view experimental pathology. of pharmacology, and physiology, to work towards a better understanding of how the human body functions and to alleviate human diseases including the efficacy.



Prof USN Murty

safety, toxicity, and pharmacokinetic parameters. Department of Pharmacy Practice has been actively involved in patient care management by collaborating with other healthcare professionals in Govt. and Private Hospitals in and around Guwahati. This department also plays an active role in uplifting the health and wellness of the North-East population by conducting health screening and awareness programs. Biotechnology department is dedicated to understanding disease pathogenesis, drug mechanisms, target identification, and therapeutic intervention in chronic and complex diseases like cancer, diabetes, NAFLD, and cardiovascular diseases. Department of Pharmaceutics research interest on translational cutting-edge advanced pharmaceutical research in the field of micro/nano emulsions, meso-porous silica nanoparticles, nanomedicines & pharmaceutical additive manufacturing/3D & printing. Department 4D of Pharmaceutical analysis is dealing with various aspects of drug development viz to identifying drug targets, uncovering the mechanism of action of drugs, and assessing (or infer) their side effects by different omics approaches, drug degradation, and impurity profiling, toxicological evaluation, bioanalytical chemistry, drug metabolism studies. Identification of druggable targets, target validation, rational drug design, structural biology, computer-aided drug design, HIT to LEAD development (HIT identification, validation, and optimization), method development (chemical, biochemical, and computational), modelling reaction mechanism, extraction, and isolation of bioactive natural product compounds, molecular characteristics of drug action, establishing the relationship of chemical structure to the drug action and effects of metabolism on the drug structure, etc. are in the scope of research under medicinal chemistry department. Preformulation studies, solid state pharmaceutics, and development of an appropriate formulations are the purview of department of Pharmaceutical Technology (Formulations). Finally, recent department of Medical Devices involves in mechanical characterization of hypodermic needles, Single use syringes, catheters and Class A, & B Medical Devices, etc.

FUNDED EXTRA-MURAL RESEARCH PROJECTS

| S.N | Project Title | Principal Investigators and Centre coordinator' S | Funding Agency | Funding Amount | Duration |
|-----|--|--|--|---|---|
| 1. | Exploration of drug development for psychological stress mediated IBD from the Indigenous medicinal plants of NE- India. | Dr. USN Murty and Dr. VGM Naidu | DRDO | 41.65 Lakh | 2018-22 |
| | Explored the medicin aggravated intestinal alcoholic extracts of activity and also de pharmacological app publications were pub | inflammation two medicinal veloped polyher roaches to the | in pre-clinical m plants (Litsea and rbal formulation Ayurveda concep | odels and l Mesua) sh by integrati ot. Three ir | found that owed good ing reverse iternational |
| 2. | Development of novel liquid- retentive and reconstitutable solid-dry powder topical formulations containing oil-in- water nanosized cationic emulsions loaded with or without cyclosporine A to manage the moderate to severe dry eye syndrome. | Dr. S. Tamilvanan | DBT | 34.38 Lakh | 2018 - 22 |
| | In the new fashioned to use of computers a in front of modern us etc.) causes an ocular kerotoconjunctivitis s will feel a gritty sand watering eyes. Conv frequent instillation in acceptable to patient drops into eyes. The molecules to make p project. | nd mobile phone er friendly elect disease condition icca (KCS). In ge y sensation in the entional contriv- nto eyes to corre- due to visual dispersing the | es. The prolonged ronic gadgets (con on termed as Dry eneral, the people neir eyes and even yed solutions (tea ct or treat DES. Oil disturbance follow oil in water with | or extended nputers, mol Eye Syndron suffering fro seemingly ar substitute y eye drops ving instillat the help of | time spent bile phones, ne (DES) or m dry eyes paradoxical es) require are also not tion of oily f emulsifier |
| 3. | Hit to lead optimization of | Dr. VGM Naidu | DBT | 57.23 Lakh | 2018-22 |

| | Namel Train-in a | | | | |
|----|---------------------------------------|-----------------|-------------------|---------------------------------------|-------------|
| | Novel Triazine | | | | |
| | analogues as | | | | |
| | potential autophagy | | | | |
| | modulators for the | | | | |
| | prevention of | | | | |
| | cancer. | | | | 1. 1 |
| | Delineated the role of | | | | |
| | the ligands (IITZ01, | | , 0 | | |
| | showed potential an | • | · | | |
| | combination with exis | _ | | - | - |
| | autophagy mechanism | | | Publication | s are under |
| | progress as an outcom | | | 50 | 2010.22 |
| 4. | Systematic and | Dr. USN | NER | 50 | 2018-22 |
| | Scientific | Murty | Programme, | Lakh | |
| | investigation of | and | DBT | | |
| | selected medicinal | Dr. VGM | | | |
| | plants from north | Naidu | | | |
| | eastern part of India | | | | |
| | for rheumatoid | | | | |
| | arthritis and | | | | |
| | derivation of | | | | |
| | mechanism of action | | | | |
| | using bioguided | | | | |
| | fractionation | | | | |
| | methods besides identification and | | | | |
| | characterization of | | | | |
| | lead molecules using | | | | |
| | U U | | | | |
| | liquid-liquid separation | | | | |
| | technique. | | | | |
| | Explored the medicir | al plants and a | nia to NE India f | For their off | oct on ECA |
| | induced arthritis in p | • | | | |
| | medicinal plants (Li | | | | |
| | formulation studies a | | , 0 | | |
| | products. Three interr | | | | |
| L | * | | | · · · · · · · · · · · · · · · · · · · | |
| 5. | Medicated skin | Dr.Subham | Assam S&T | 2.9 Lakh | 2019-22 |
| | patch to mitigate | Banerjee | EnvironCouncil | | |
| | destructive | | (ASTEC), Govt. | | |
| | pulmonary | | of Assam | | |
| | tuberculosis in six | | | | |
| | districts of Assam. | | | | |
| | Quercetin in combina | | | | |
| | the spreading of nec | | | | |
| | Therefore, we hypoth | | | | |
| | with a quercetin-PVP | | | | |
| | drug concentration | | | - | |
| | quercetin-PVP 40 ext | ruded-filaments | by hot-melt extr | usion (HME |) technique |

| | along with Eudragit® RSPO and tri-ethyl citrate and further printed it to make medicated skin patches using fused deposition modeling (FDM) based 3D Printing technology. Various characterizations were performed to optimize the 3D-printed patch formulation. One granted patent & one international publications were published from this project. | | | | | | |
|----|--|---|--|--|--|--|--|
| 6. | Development of Targeted Gut Lymph angiogenesis nanomedicine for treatment of Liver Cirrhosis. | Dr.Subham Banerjee | DST | 50.25 Lakh | 2019-23 | | |
| | Runt-related transcri alcoholic steatohepati RUNX1 gene in live antibody tagged imm siRNA) in murine mo NASH. MCD mice giv vehicle, and mice w publications were pub | tis (NASH). We p r sinusoidal en- unonano-lipocar odels of methion ven nanolipocar with standard | berformed in vivo dothelial cells (L riers encapsulated ine choline deficie riers-encapsulated diet were contro | targeted sile SECs) by us l RUNX1 siR ent (MCD) d l negative s | ncing of the sing vegfr3 NA (RUNX1 liet-induced siRNA were | | |
| 7. | Integrated information system to interpret, integrate and mitigation of cardio metabolic health care in North East tribes of Assam and Mizoram. | Dr. USN Murty Dr.Ramu Adela | ICMR | 70 Lakh | 2019-23 | | |
| 8. | We are collecting clin cardio metabolic risk Pharmacoengineere d lipid core-shell nanoarchitectonics to enhance macrophages uptake for potential translational therapeutic outcome. | | | ibes and ide 34.70 Lakh | 2019-23 | | |
| | | | | | | | |

| | peer-reviewed publication | ations were made | e through this proi | ect | |
|----------|--|-------------------|---------------------|---------------|------------|
| 9. | Developing a public | Dr. USN | DST | 175 Lakh | 2019-23 |
| <i>.</i> | health informatics | Murty | 001 | 175 Lakii | 2017 25 |
| | platform in India for | Multy | | | |
| | a systems view of | | | | |
| | health & diseases | | | | |
| | under epidemiology | | | | |
| | data analytics (EDA) | | | | |
| | of interdisciplinary | | | | |
| | cyber physical | | | | |
| | systems (ICPS) | | | | |
| | programme. | | | | |
| | A public health inform | natics platform w | vac dovolopod in I | ndia for a su | stome view |
| | | | idemiology data | | |
| | | • | | • | (EDA) of |
| 10. | interdisciplinary cybe | Dr.Purusotta | DBT | 113.6 | 2020-25 |
| 10. | Development of | | DDI | | 2020-25 |
| | WNT-Signaling Based Anti- | m Mahapatra | | Lakh | |
| | Evolution and Anti- | | | | |
| | Metastatic | | | | |
| | | | | | |
| | Therapies Against Resistant Cancers | | | | |
| | | | | | |
| | (Under Ramalingacuami | | | | |
| | Ramalingaswami Re-entry | | | | |
| | Fellowship). | | | | |
| | The link between t | umor botorogor | oitu concor coll | clonal ava | lution and |
| | metastasis is still not | 0 | | | |
| | cancer diagnosis and | | - | | |
| | these above-mentione | | | | - |
| | interested to underst | - | | - | • |
| | chemotherapy-induce | | | | |
| | different molecular re | | | - | |
| | with the process of | | | | |
| | understanding will sh | | | | |
| | clonal evolution whic | _ | - | | |
| | novel diagnostic and t | | | • | - |
| 11. | Identify the DNA | Dr. Roshan | SERB, DST | 37.36 | 2020-24 |
| | adduct and | Borkar | _ , | Lakh | |
| | associated | | | | |
| | metabolic alteration | | | | |
| | in upper | | | | |
| | aerodigestive tract | | | | |
| | cancer with | | | | |
| | smokeless tobacco | | | | |
| | chewers in the | | | | |
| | Northeast Region of | | | | |
| | India: A | | | | |
| | Metabolomics | | | | |

| | Approach. | | | | | | | |
|----------|--|----------------------|---------------------|---------------|--------------|--|--|--|
| | In the northeast reg | ion of India (N | ERI), upper aero | digestive tra | act (UADT) | | | |
| | cancers account for a | | | | | | | |
| | cancers are very com | | | | | | | |
| | nut or areca nut is ve | | | | | | | |
| | with a different lifestyle, food habits and chewing tobacco with betel nuts is a | | | | | | | |
| | customary habit in the different socio-cultural and ethnic groups in NERI. | | | | | | | |
| | Presently, potential bi | | | | | | | |
| | early detection and ris | | | | | | | |
| | chromatography tand | | | | | | | |
| | bioinformatic approa | _ | | | | | | |
| | integrate state-of-the- | | | | | | | |
| | non-invasive panel o | | | - | - | | | |
| | detection and stratific | | | | | | | |
| | of developing UADT | cancer. This will | be the first study | y using a me | etabolomics | | | |
| | approach to describ | oe a strong co | nnection between | n altered n | nethylation, | | | |
| | perturbed xenobiotio | c metabolism, a | and UADT cance | r in conne | ction with | | | |
| | smokeless tobacco w | ith betel nuts. Fu | urthermore, devel | oping smoke | e-associated | | | |
| | perturbed metabolic | pathways specifi | c to UADT cancer | could be fur | ther bound | | | |
| | to develop better tr | eatment strateg | gies or combinate | orial therap | y with the | | | |
| | existing drugs to over | come tobacco-in | duced chemo-resis | tance. | | | | |
| 12. | Generation of 3D | Dr.Subham | ICMR | 24.27 | 2020-22 | | | |
| | printed multi | Banerjee | | Lakh | | | | |
| | functional | | | | | | | |
| | customized drug | | | | | | | |
| | delivery systems: in | | | | | | | |
| | vitro and in vivo | | | | | | | |
| | evaluation. | | | | | | | |
| | Field of pharmacolog | | _ | | | | | |
| | delivery systems des | | | | | | | |
| | patients. Three-dime | | | | - | | | |
| | personalized drug del | | | • • | 0 | | | |
| | patient needs. Norflo | | | | | | | |
| | and filled inside a st | | | | | | | |
| | hollow capsular devic | | | | · · · | | | |
| | 3D-printed hollow cap were characterized in | | • | | | | | |
| | papers are obtained th | | | means. One | | | | |
| 13. | Synthesis and | Dr. USN | NDTL | 110 Lakh | 2020-23 | | | |
| 15. | characterization of | Murty | | | 2020-23 | | | |
| | standards of certain | murty | | | | | | |
| | drugs and their | | | | | | | |
| | metabolites. | | | | | | | |
| | Six reference standar | l ds were made ui | nder this project & | handed-ov | er to NDTL | | | |
| | New Delhi to regain | | | | | | | |
| | Agency (WADA) | | | | inter doping | | | |
| 14. | Understanding the | Dr. S. | ICMR | 18.89 | 2020-23 | | | |
| <u> </u> | relationship | Sudhagar | 101/11 | Lakh | | | | |
| 1 | P | | | | | | | |

| | between metabolic | | | | |
|-----|--------------------------------------|---------------------------|----------------------|----------------|--------------|
| | stress and acquired | | | | |
| | tamoxifin resistance | | | | |
| | in breast cancer | | | | |
| | cells. | | | _ | |
| | The proposed work fo | | | | |
| | mitochondrial dynam | _ | | | |
| | tumor microenvironn | | | | |
| | explore the functio | | | | |
| | dynamics in response | | - | - | |
| | and to establish its lin | | | | |
| | The knowledge acqui | | | | |
| | targets and the deve | - | - | which could | i overcome |
| | acquired resistance ar | | | 10451 | 2024 24 |
| 15. | Exploiting the | Dr. Vaibhav A. | National | 19.17Lak | 2021-24 |
| | electron transfer | Dixit | Supercomputin | hs | |
| | parameters for the | | g Mission | | |
| | prediction of | | (NSM), DST | | |
| | selectivities in | | | | |
| | Cytochrome P450 | | | | |
| | catalyzed bio- transformations of | | | | |
| | industrial | | | | |
| | importance. | | | | |
| | Directed evolution of | Cutochromo P4 | 50 (CVP450) muta | nts ofton on | ables nevel |
| | reactions of industrial | | | | |
| | However, reliable an | | | | |
| | Directed evolution, of | _ | | - | |
| | are often outside the | | | | |
| | offer retrospective ra | - | | | |
| | with this approach. A | | | | |
| | transfer (ET) paramet | | | | |
| | determine the reactio | | | | |
| | mutants requires qua | ntum chemical a | nd molecular dyna | mics simula | tions which |
| | are penta and exascal | e computations. | This project, aims | to demonst | rate a HPC- |
| | application called "CY | YPWare" for the | estimation of ET | parameters | to unravel |
| | factors that drive | reaction selecti | ivities. After init | tial develop | ment, and |
| | validations CYPWare | will be utilized fo | or predictions of no | ovel activitie | s which will |
| | be tested in the PI and | <u>l co-PI laboratori</u> | es. | | |
| 16. | Deep Learning | Dr.Ramu | ICMR | 45.00 | 2021-24 |
| | assessment for | Adela | | Lakh | |
| | identification of | | | | |
| | novel diagnostic and | | | | |
| | prognostic | | | | |
| | biomarkers for | | | | |
| | prediction of | | | | |
| | diabetic retinopathy | | | | |
| | in north east | | | | |
| 1 | population. | | | | |

| | We are identifying bio imaging of diabetic re | | | | | | |
|-----|--|---|---|---|--|--|--|
| 17. | Bioactive reprogrammed nano-herbal formulation for photothermal therapy-based cancer theranostics. | Dr. Deepak Bharadwaj PVP | BIRAC, DBT | 25 Lakhs | 2021-23 | | |
| | According to 'cancer will be diagnosed in climb by 12% in the n times that of the 2 prevalently superficia develop a Nano herb anticancer agent CfA targeted approach of management of super issue, the use of a m evolve as an effective GlaxoSmithKline GSK herbal-based produc availability of this kin tumors will be a sol cancers. | India each year. ext five years, at 240,000 instance al cancers. Consid- al gel which is ac and light-base can be targete ficial tumors, es ultifunctional Na marketable proc and Abbott have ts. In countries d of product for t | Cancer incidence any one time, the es (www.ncdiring dering the current having both the sed thermal ther d, sustainable an pecially in our con ano-herbal product luct. Pharmaceutic started venturing s like India, the the non-invasive th | in India is o load is likely dia.org). Th t situation w beneficial pr apy. This n nd affordab untry. To en et has a bett cal corporation into the development herapy and t | expected to to be three is includes re intend to roperties of on-invasive le for the counter the er scope to ons, such as elopment of ent of and reatment of | | |
| 18. | Deciphering pharmacodynamics of Ayurvedic formulations used in the treatment of neurodegerative diseases by integrating reverse | Dr. VGM Naidu | Ministry of Ayush | 1.48 Crores | 2021-23 | | |
| | pharmacological approaches.Image: Constraint of the second secon | | | | | | |
| 19. | Evaluating the therapeutic effect of <i>Musa</i> <i>balbisiana</i> fruit powder on non- alcoholic fatty liver disease in rats. | Dr. Sanjay K Banerjee | ICMR | 20 Lakhs | 2021-23 | | |
| | Non-Alcoholic Fatty L healthcare system al western diet and oth | l over the worl | d. Due to moder | n lifestyle c | hanges, the | | |

| | There is no FDA approved drug is available in the market that can treat the chronic stage of fatty liver disease. Alternatively, researchers are looking into plant- derived extract to treat the metabolic disorders. According to mythological facts and traditional culture of medicine Musa balbisiana has been reported potentially therapeutic effects on different types of metabolic disorders such as Diabetes Mellitus and inflammatory diseases. Therefore, we are exploring Musa balbisiana that could be a potential pharmacological approach to treat the fatty liver disease. So in this research study we were focussed on the pathophysiology of Non-Alcoholic Fatty Liver Disease (NAFLD) further progression of the disease without any treatment leads to NASH and liver cirrhosis condition. There are certain mechanism are unclear till now we focussed on certain parameters such as fatty acid transporter protein (FATP1, FATP2, FATP3, FATP4, FATP5), lipid droplets associated proteins specially perilipins, Comparative gene identification 58 (CGI58), Fat specific protein 27 (FSP27), and PPAR- alpha regulated genes such as Carnitine Palmitoyl Transferase (CPT-1) and Forkhead box protein 01 (FOX01, which play a major role in fat deposition in hepatocytes. Furthermore, we are also trying to elucidate the possible pharmacological activity of Musa balbisiana on these targets which mention above. | | | | | | |
|-----|--|-------------------|--------------------|----------------|-------------|--|--|
| 20. | Investigating the | Dr.Bidya Dhar | SERB, DST | 31.47 | 2021-23 | | |
| | interplay of Kidney- | Sahu | - , - | Lakhs | | | |
| | Heart inflammatory | | | | | | |
| | axis and the role of | | | | | | |
| | histone deacetylase | | | | | | |
| | 6 (HDAC 6) | | | | | | |
| | signaling in chronic | | | | | | |
| | kidney disease. | diama an lan diaa | ace (CVD) in shree | ia hida ar dia | | | |
| | The prevalence of care patients is nearly 70% | | | - | | | |
| | CKD population, and r | | | | | | |
| | die of heart disease. | | | - | - | | |
| | cardio-renal syndrom | | | | | | |
| | renin- angiotensin sys | | | | - | | |
| | ineffective. Also, there | | - | | | | |
| | understanding of the p | | | | | | |
| | to address the dire ne | | | | | | |
| 0.1 | is to target renal inflar | | | | | | |
| 21. | Ultrathin 2D Nanomaterials | Dr. Saurabh | DST | 17.04 | 2021-23 | | |
| | Based Biosensor for | Kumar | | Lakh | | | |
| | multiplexed | | | | | | |
| | detection of breast | | | | | | |
| | cancer biomarkers. | | | | | | |
| | Breast cancer is the | most common | invasive cancer | in females | worldwide. | | |
| | Currently employed | | | | | | |
| | histopathology, ELIS. | | | | - | | |
| | personnel to operate | | | - | | | |
| | consuming and poor | sensitivity and | limited early dise | ase diagnosi | s notential | | |

consuming and poor sensitivity, and limited early disease diagnosis potential. Although the electrochemical biosensing protocols are available in breast cancer

| | detection, all of them are limited to single biomarker detection, which is not sufficient to predict breast cancer. There is a panel of biomarkers that should be studied for proper disease diagnosis. Every individual diagnosed with breast cancer has to go through a triple marker test (ER, PR, and HER2). Early detection of these biomarkers helps in early diagnosis, monitoring, and treatment strategies (Endocrine or Trastuzumab therapy). Addressing this issue, Efforts are being made to realize the automation and simultaneous detection of these biomarkers in a single chip that extend immunocapture beyond single marker | | | | | | |
|-----|---|---------------|----------|----------------|----------------|--|--|
| 22. | recognition. Enhancement of the | Dr. VGM | ICMR | 4.00 | 2021-23 | | |
| | chemotherapeutic potential of anticancer drug: Biothiol-stimulated | Naidu | TOWIK | Lakhs | 2021 23 | | |
| | fluorogenic | | | | | | |
| | strategies for | | | | | | |
| | adjuvant delivery of | | | | | | |
| | anticancer drug and | | | | | | |
| | GSTP1 inhibitor. | | | | | | |
| | This project is under the development of bi | | | | | | |
| | characterisation of mo | _ | | i activity. Sy | intilesis allu | | |
| 23. | Pre formulation, | Dr. Naveen | ICMR | 19.90 | 2021-23 | | |
| 20. | formulation | Chella | IGINI | Lakhs | 2021 20 | | |
| | characterization and | | | | | | |
| | preclinical study of | | | | | | |
| | Dillenia indica linn | | | | | | |
| | extract against | | | | | | |
| | diabetes and | | | | | | |
| | diabetic | | | | | | |
| | complications. | | h | .1 | N | | |
| | Dillenia indica Linn. India and other Asian | | • • • | | | | |
| | plethora of pharmaco | | • • | • | | | |
| | possess activity again | 0 | | | - | | |
| | about its physicocher | | ▲ | | | | |
| | dosage forms and fu | | | | | | |
| | from the natural s | | | | | | |
| | permeability, and st | | | - | - | | |
| | effectiveness of any r | - | | | | | |
| | due to their poor phy Hence, for the first t | · • | • | - | | | |
| | formulation developm | | | | - | | |
| | fraction of hydroalcol | | | | | | |
| | against diabetes and i | | | -0 1 -01 | | | |
| 24. | Exploration of | Dr.Bidya Dhar | ICMR | 19.95Lak | 2021-23 | | |
| | coumarin- | Sahu | | hs | | | |
| | derivatives in | | | | | | |
| | treating diabetic | | | | | | |

| | nephropathy. | | | | | | |
|-----|---|-------------------|------------------------|----------------|--------------|--|--|
| | Nephropathy is an | important cor | nnlication of dia | hetes mell | itus which | | |
| | | _ | - | | | | |
| | accelerates the progression to end-stage renal disease. Diabetic nephropathy represents a major cause of morbidity and mortality, occurring in between 30 | | | | | | |
| | | | | 0 | | | |
| | and 47% of patients | | | - | | | |
| | nephropathy are limi | | | | | | |
| | death, or renal disord | | - | - | | | |
| | provides new hope fo | | - | | - | | |
| | the dire need for new | • | • | | | | |
| | pharmacological activ | | • | • | • | | |
| | alternative medicines | | | | | | |
| | whether natural occu | _ | | | - | | |
| | protects diabetic neg | phropathy in m | ice, and identify | its possible | molecular | | |
| | mechanisms. | | I | I | | | |
| 25. | Finding the | Dr. Sanjay K | ICMR | 8.31 | 2021-22 | | |
| | mechanistic link | Banerjee | | Lakhs | | | |
| | between the | | | | | | |
| | progression of Non- | | | | | | |
| | alcoholic fatty liver | | | | | | |
| | disease and cardiac | | | | | | |
| | complication. | | | | | | |
| | NAFLD is a spectrum | of liver disease | which is characte | rized by inci | eased lipid | | |
| | accumulation, inflamm | nation and fibros | sis of the liver. This | s proposal is | focusing on | | |
| | to develop NAFLD in | SD rats. Choline | e- deficient diet h | as been use | d to induce | | |
| | moderate to severe | NAFLD in rat m | odel. We are goi | ng to evalua | ate NAFLD- | | |
| | induced insulin resist | ance and cardiac | phenotype during | NAFLD prog | gression. As | | |
| | there is close associa | ation among NA | FLD, insulin resis | tance and e | ctopic lipid | | |
| | accumulation, insulin | resistance may | lead to myocardia | l structure a | bnormality | | |
| | and cardiac dysfunct | ion by altering | metabolic pathwa | iy in the he | art. NAFLD | | |
| | often associated with | n ectopic fat acc | cumulation in oth | er sites sucl | h as in the | | |
| | epicardium. This ac | cumulation may | v result from an | alteration | in uptake, | | |
| | synthesis and oxidat | ion of fatty aci | ds. Also, these ec | topic fat de | pots might | | |
| | release various pro- | inflammatory m | ediators and could | ld cause stru | uctural and | | |
| | functional derangem | ents of the m | yocardium. Lipid | omic study | has been | | |
| | performed to explore | e the alteration | in homeostasis o | of cardiac lip | oids during | | |
| | progression of NAFL | D. The study wi | ll elucidate the m | iolecular me | chanism of | | |
| | NAFLD-induced met | abolic disorder | and find targe | et to preve | nt cardiac | | |
| | complication. | 1 | 1 | 1 | | | |
| 26. | Therapeutic | Dr.Purusotta | SERB, DST | 60.01 | 2022-25 | | |
| | Significance of | m Mohapatra | | Lakhs | | | |
| | MARCKS signalling | | | | | | |
| | Axis in ovarian | | | | | | |
| | cancer Metastasis: A | | | | | | |
| | precision Anti- | | | | | | |
| | Metastatic Therapy | | | | | | |
| | approach. | | | | | | |
| | The metastatic signal | ling in ovarian | cancer is not stud | lied properl | y in Indian | | |
| | patient samples and p | - | | | | | |
| | molecules available to | - | | | - | | |
| • | · | | | * | ÷ / | | |

| 27. | proposal, we aim to cancer by using a mod Our results will shed development of novel inhibit ovarian cancer Evaluating role of SERCA activation in febrile seizure and | lified MARCKS pl l light on the m anti-metastatic | hosphorylation-sp echanism of MAR | ecific peptide CKS activati | e candidate. on and the | | | |
|-----|--|---|--------------------------------------|--------------------------------|----------------------------|--|--|--|
| | its relation-ship with proinflammatory cytokine release | | | | | | | |
| | This study is proposed to investigate the effect of heat stress on the expression of calcium release- related proteins, to understand the relationship between febrile seizures, and expression of SERCA in different brain regions (thalamus, cortex, and hippocampus), and the effect of SERCA modulation in febrile seizures. This study will also establish a link between proinflammatory cytokines and SERCA expression in different brain regions (particularly, thalamus, cortex, and hippocampus) and will improve our understanding about febrile seizures. | | | | | | | |
| 28. | Development of laser scribed graphene based biomedical device for multiplex | Dr. Saurabh Kumar | SERB- DST | 31.87 Lakh | 2021-24 | | | |
| | For the development of biomedical devices, a rational design and fabrication process play a key role. Multiple detection of cancer biomarkers steps involve in device fabrication and the use of the additive in printing material compromised device performance. Moreover, during device fabrication, functional structures (e.g., electrodes) are co-planar, although these are good electronic conductors but limited ionic property, which limits the efficacy of the electrochemical devices. This proposal demonstrates a scalable, fast, and direct writing approach that provides versatile device design, ease of pattern, and excellent electrochemical properties. The so-called "on-chip printed electrodes" possess excellent electronic and ionic charge carriers. Further, this versatility will be used for the fabrication of electro-chemical devices for multiplexed detection of cancer biomarkers | | | | | | | |
| 29. | Synthesis and Evaluation of the Anti-metastatic Properties of Novel HuR (ELAVLI)- inhibitors Against Metastatic Breast | Dr. Kalyan Kumar Sethi | DST- SERB | 28.58 Lakh | 2022-24 | | | |

| | Cancers. | | | | | | | |
|-----|--|-----------------------|------------------------------|---------------|---------|--|--|--|
| | The objective of the pr HuR inhibitors. Evalua effects of the HuR inhi | ation of cellular t | oxicity, activity, an | d anti-metas | | | | |
| 30. | Low-cost scalable process optimization for the development of ginger oleoresin, high pure gingerols, and shogaols from Assam-based ginger variety | Dr. Pramod Kumar | BIONEST NIPER Guwahati | 1 lakh | 2023 | | | |
| | Gingerols and shogaol are being isolated from the root of Zingiber Officinalis which is locally known as ginger (Adrak). Two major gingerols and shogaols are widely available in local ginger, which is 6,8,10 gingerol and 6,8,10 shogaol, and are reported to be used for the management of various diseases antinausea, antiemetic, anti-inflammatory, antioxidant, anti-tumor, and anticancer effects. Gingerols and shogaols are widely used in the food, cosmetic, and pharmaceutical industries. The global ginger market size attained a value of USD 2.48 billion in 2021. Active pharmaceutical compounds that are highly pure and certified as reference material are quite expensive. The Indian Pharmacopoeia Commission, which is part of the ministry of family and health welfare, is actively creating herbal reference materials in India, although these materials for gingerols and shogaols are not yet available. These plant-based markers have high commercial potential as APIs as well as reference material for routine QAQC for herbal industries that are actively involved in the production of ginger extract and ginger-based finished products. Therefore, it is proposed to establish a lab-scale model for ginger oleoresins, pure gingerols, and shogaols with | | | | | | | |
| 31. | maximum purity. Bioengineered bilayer 3D printlets for segregated compartmental delivery of fixed dose ATDs combinations. | Dr.Subham Banerjee | NECBH DBT | 11.90 Lakh | 2019-21 | | | |
| | World Health Organization (WHO) recommends the use of first-line anti- tuberculosis drugs, that is, rifampicin (RIF) and isoniazid (INH) fixed-dose combination (FDC) therapies in tuberculosis (TB) disease. The absorption of RIF from an FDC incorporates INH, and it is significantly compromised due to its reaction with INH, resulting in a severe loss of RIF under gastric stomach pH condition. Such reduction in the dose of both drugs from FDC formulations has been alleged to be one of the chief obstacles in effective TB treatment. This emphasizes a need to develop suitable cutting-edge advanced bioengineered | | | | | | | |

| 32. | delivery devices that obstacle. Therefore, w 3D printed housing de strategy for segregate publication were obta 3D-printed microneedles for improving antibiotic treatment adherence. | ve designed, protection evices in the form d compartmenta | totyped, and chara n of printed tablet l delivery. A grant | acterized bio s adopting p | engineered rint and fill |
|-----|--|--|---|--|--|
| 33. | A 3D printed assembl reservoir void, was stereolithography (SI HMNs array was util antibiotics, i.e., rifan chemical instability, morphology was des needle tip to improve One ational publicatio Responsive Self- folding Feedstock for Pharmaceutical 4D Printing | as designed A) technology ized for transde npicin (Mw 822 low bioavailab igned with sub- its mechanical s | and additively utilizing a proprie ermal delivery of .94 g/mol), which ility, and severe apical holes prese strength and integ | manufactur etary class-I high molecu h suffers fr hepatotoxic ent in a qua rity of the H | red using resin. The llar weight om gastric city. HMNs rter of the |
| 34. | Applications. In this study, we synt 4-acryloyloxy benzop self-folding shape-men The lower critical so 4ABP) was determin determine the effect of transform infrared reversibility of the sh swelling study in diffe encapsulate the drug n memory behaviour of into p(NIPAM-4ABP) f Two Publications are of Prototyping of Transdermal Patches | whenone) i.e., p(mory polymer w lution temperate ned using dyna of the addition of spectroscopy (ape-memory me erent solvents wa nolecules into p(this synthesized feedstock to value | NIPAM-4ABP) ba ith an excellent sh ure (LCST) of the mic light scatter f 4-ABP to the pN FT-IR) was use echanism of the s as performed as a NIPAM-4ABP) net polymer was esta date the excellent | sed thermo- ape-memory synthesised ing (DLS) a IIPAM netwo d to under ynthesised fe driving force twork. Finally ablished via c shape memo | Presponsive behaviour. p(NIPAM- analysis to ork. Fourier cstand the eedstock. A e to further 7, the shape onverted it |
| | by Innovative 3D Printing Platform Technology. The drug-loaded pol extrusion-based inno delivery systems coul | vative 3D prin | ting techniques | proved that | the drug |

stability of the incorporated drug, even if the drug was subjected to high temperatures during the manufacturing process. We hypothesize that a 3Dprinted transdermal patches containing a drug could be easily manufactured through innovative powder extrusion process as feedstock through innovative technology mediated deliver platform, and can easily be applied to the skin surface via reducing the extreme hazards associated with extensive fast-pass metabolic effect of drug through oral delivery. In addition, it's believed to be non-invasive, needle free, painless with high treatment adherence.

| | non invasive, needre n'ee, panness with ingit treatment auterenee. | | | | | |
|-----|---|-----------|-------|---------|---------|--|
| 35. | Biofilament derived | Dr.Subham | AMTZ | 10 Lakh | 2022-23 | |
| | 3D Printed | Banerjee | Vizag | | | |
| | Antimicrobial | | | | | |
| | Wound Dressing for | | | | | |
| | Advanced Wound | | | | | |
| | Care. | | | | | |
| | | | | | | |
| | Based on the AMT7 call for proposal mandate under the areas of innovation viz | | | | | |

Based on the AMTZ call for proposal mandate under the areas of innovation viz. 3D Bioprinting in Advanced Wound Care, we hypothesized that biofilament derived 3D printing could possibly revolutionise patient care by allowing custom-manufacture of devices for individual patients and it is the exploration of this concept, applied specifically to wound dressings, that is the focus of this work. A potential biofilament will be feeded into the FDM mediated 3D printer to fabricate advanced wound dressings against virtual CAD templates of a target wound. Then, further the antimicrobial efficacy of the proposed advanced wound dressings needs to be assessed using an *in-vitro* assay.

PUBLICATIONS (RESEARCH/ REVIEW):

Pharmaceutics

- 1. Pawde, Datta Maroti, Syed Nazrin Ruhina Rahman, Srikanth Ponneganti, Abhinab Goswami, Roshan Murlidhar Borkar, and TamilvananShunmugaperumal. "Analytical Quality-by-Design-Based Systematic Optimization of RP-HPLC Method Conditions to Analyze Simultaneously Chloroquine Phosphate and Flavopiridol in Stress-Induced Combined Drug Solution and Pharmaceutical Emulsions." *Journal of Chromatographic Science* (2022).
- 2. Rahman, Syed Nazrin Ruhina, Abhinab Goswami, AmoolyaSree, Aishwarya Jala, Roshan M. Borkar, and TamilvananShunmugaperumal. "Dual Delivery of Cyclosporin A and Etodolac Using Polymeric Nanocapsules in a Rabbit Eye Model: Ocular Biodistribution and Pharmacokinetic Study." *Journal of Ocular Pharmacology and Therapeutics* 38, no. 10 **(2022)**: 734-744.
- 3. Sekharan, Thenrajan Raja, ShunmugaperumalTamilvanan, ShenbhagakuttiChandrabose Rajesh, and Joslin Jenishiya. "Synergistic Effect of Diclofenac Sodium and Sulfamethoxazole in Pure form, Microparticle Formulation and in Carbopol Incorporated Gel Containing Microparticle Formulation." (2022).
- 4. Agrawal, Mukta, Madhulika Pradhan, Gautam Singhvi, Ravish Patel, and Amit Alexander. "Thermoresponsive in situ gel of curcumin loaded solid lipid nanoparticle: Design, optimization and in vitro characterization." *Journal of Drug Delivery Science and Technology* 71 (2022): 103376.

- Verma, V. S., H. R. Badwaik, Y. Vaishnav, and A. Alex. "Synthesis, Characterization, Molecular Modelling and Biological Evaluation of Substituted Benzo (h) Chromene-3-Carboxylate Derivatives as a Potential Agent for the Treatment of Hyperlipidemia." *Indian Journal of Pharmaceutical Sciences* 84, no. 2 (2022): 453-464.
- 6. Malaiya, Akanksha, ManshaSinghai, Manisha Singh, Shiv Kumar Prajapati, Hira Choudhury, Mahak Fatima, Amit Alexander, Sunil Kumar Dubey, Khaled Greish, and Prashant Kesharwani. "Recent Update on the Alzheimer's Disease Progression, Diagnosis and Treatment Approaches." *Current drug targets* 23 (2022): 978-1001
- 7. Waghule, Tejashree, Ranendra Narayan Saha, Amit Alexander, and Gautam Singhvi. "Tailoring the multi-functional properties of phospholipids for simple to complex self-assemblies." *Journal of Controlled Release* 349 **(2022)**: 460-474.
- 8. Khichariya, Ajita, Gunjan Jeswani, Rajesh Choudhary, Amit Alexander, Kartik T. Nakhate, and Hemant Ramchandra Badwaik. "Formulation of plumbagin-loaded microemulsion: Evaluation of anti-rheumatoid efficacy in Wistar rat model." *Journal of Molecular Liquids* 363 **(2022)**: 119851.
- 9. Prathyusha, Eluri, A. Prabakaran, Hafiz Ahmed, Mithun Rajendra Dethe, Mukta Agrawal, Vijayakumar Gangipangi, S. Sudhagar et al. "Investigation of ROS generating capacity of curcumin-loaded liposomes and its in vitro cytotoxicity on MCF-7 cell lines using photodynamic therapy." *Photodiagnosis and Photodynamic Therapy* 40 (2022): 103091.
- 10. AjitaKhichariya, Amit Alexander, Gunjan Jeswani, Vinay Sagar Verma, Subhash Sahu, Shahbaz Rathor, Kartik T Nakhate, Hemant Ramchandra Badwaik. Estimation of Diclofenac diethylamine and Plumbagin in a drug delivery system by simultaneous equation method. NeuroQuantology. **2022**; 20(8): 5013-5022.
- 11. Ahmed, Hafiz, Shyam Sudhakar Gomte, A. Prabakaran, Mukta Agrawal, and Amit Alexander. "Biomedical applications of mesoporous silica nanoparticles as a drug delivery carrier." *Journal of Drug Delivery Science and Technology* **(2022)**: 103729.
- 12. Phatale, Vivek, Klaudi K. Vaiphei, Shikha Jha, Dnyaneshwar Patil, Mukta Agrawal, and Amit Alexander. "Overcoming skin barriers through advanced transdermal drug delivery approaches." *Journal of Controlled Release* 351 **(2022)**: 361-380.
- 13. Agrawal, Mukta, Upal Roy, and Amit Alexander. "Liposome: A potential drug delivery vector to treat dementia." In *Nanomedicine-Based Approaches for the Treatment of Dementia*, pp. 149-168. Academic Press, 2023.
- 14. Pariskar, Amit, Peeyush Kumar Sharma, Upadhyayula Suryanarayana Murty, and Subham Banerjee. "Effect of Tartrazine as Photoabsorber for Improved Printing Resolution of 3D Printed "Ghost Tablets": Non-Erodible Inert Matrices." *Journal of Pharmaceutical Sciences* (2022).
- 15. Bugga, Paramesha, Md Jahangir Alam, Roshan Kumar, Subhashis Pal, NaibedyaChattopadyay, and Sanjay Kumar Banerjee. "Sirt3 ameliorates mitochondrial dysfunction and oxidative stress through regulating mitochondrial biogenesis and dynamics in cardiomyoblast." *Cellular Signalling* 94 **(2022)**: 110309.
- 16. Syed, Abu Mohammad, Vishal Sharad Chaudhari, Upadhyayula Suryanarayana Murty, Bidya Dhar Sahu, and Subham Banerjee. "Nootkatone Essential Oil-Encapsulated Lipid Nanoparticles Interaction with Rat Cardiomyoblast (H9c2) Cells." *Applied In Vitro Toxicology* 8, no. 1 **(2022)**: 14-23.

- 17. Choudhury, Dinesh, Aishwarya Jala, Upadhyayula Suryanarayana Murty, Roshan M. Borkar, and Subham Banerjee. "In Vitro and In Vivo Evaluations of Berberine-Loaded Microparticles Filled In-House 3D Printed Hollow Capsular Device for Improved Oral Bioavailability." *AAPS PharmSciTech* 23, no. 4 **(2022)**: 1-16.
- 18. Lekurwale, Srushti, Tukaram Karanwad, and Subham Banerjee. "Selective laser sintering (SLS) of 3D printlets using a 3D printer comprised of IR/red-diode laser." *Annals of 3D Printed Medicine* 6 (2022): 100054.
- 19. Chaudhari, Vishal Sharad, Aishwarya Jala, Upadhyayula Suryanarayana Murty, Roshan M. Borkar, and Subham Banerjee. "A sensitive UPLC/ESI/MS/MS method for concomitant quantification of active plant constituent combinations in rat plasma after single oral administration." *Analytical Methods* 14, no. 8 **(2022)**: 834-842.
- 20. Sharma, Peeyush Kumar, Dinesh Choudhury, Vivek Yadav, U. S. N. Murty, and Subham Banerjee. "3D printing of nanocomposite pills through desktop vat photopolymerization (stereolithography) for drug delivery reasons." *3D Printing in Medicine* 8, no. 1 (2022): 1-10.
- 21. Suryavanshi, Purushottam, and Subham Banerjee. "Exploration of theoretical and practical evaluation on Kollidon® SR matrix mediated amorphous filament extrusion of norfloxacin by melt extrusion." *Journal of Drug Delivery Science and Technology* 67 (2022): 102894.
- 22. Bhatt, Ukti, Peeyush Kumar Sharma, Upadhyayula Suryanarayana Murty, and Subham Banerjee. "Systematic evaluations of melt-extruded filament for fused deposition modeling-mediated 3D printing." *Journal of 3D printing in medicine* 6, no. 2 (2022): 77-94.
- 23. Nizami, Hina L., Parmeshwar B. Katare, Pankaj Prabhakar, Ramu Adela, Soumalya Sarkar, Sudheer Arava, Praloy Chakraborty, Subir K. Maulik, and Sanjay K. Banerjee. "Paricalcitol Attenuates Metabolic Syndrome-Associated Heart Failure through Enhanced Mitochondrial Fusion." *Oxidative Medicine and Cellular Longevity* 2022 (2022).
- 24. Thalla, Maharshi, Gangipangi Vijayakumar, SudhagarSelvaraju, and Subham Banerjee. "Pharmacoengineered Lipid Core-Shell Nanoarchitectonics to Influence Human Alveolar Macrophages Uptake for Drug Targeting Against Tuberculosis." *Journal of Inorganic* Organometallic and Polymers and *Materials* (2022): 1-16.
- 25. Suryavanshi, Purushottam, Vishal Sharad Chaudhari, and Subham Banerjee. "Customized 3D-printed hollow capsular device filled with norfloxacin-loaded micropellets for controlled-release delivery." *Drug Delivery and Translational Research* (2022): 1-12.
- 26. Jangid, Ashok Kumar, Raghu Solanki, Sunita Patel, KanakarajuMedicherla, Deep Pooja, and Hitesh Kulhari. "Improving Anticancer Activity of Chrysin using Tumor Microenvironment pH-Responsive and Self-Assembled Nanoparticles." *ACS omega* 7, no. 18 **(2022)**: 15919-15928.
- 27. Jangid, Ashok Kumar, Raghu Solanki, Sunita Patel, Deep Pooja, and Hitesh Kulhari. "Genistein encapsulated inulin-stearic acid bioconjugate nanoparticles: Formulation development, characterization and anticancer activity." *International Journal of Biological Macromolecules* 206 **(2022)**: 213-221.

Pharmacy Practice

- 28. Johny, Ebin, Aishwarya Jala, Bishamber Nath, Md Jahangir Alam, Indra Kuladhipati, Rupam Das, Roshan M. Borkar, and Ramu Adela. "Vitamin D Supplementation Modulates Platelet-Mediated Inflammation in Subjects With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial." *Frontiers in Immunology* 13 (2022).
- 29. Johny, Ebin, Aishwarya Jala, Bishamber Nath, Md Jahangir Alam, Indra Kuladhipati, Rupam Das, Roshan M. Borkar, and Ramu Adela. "Vitamin D Supplementation Modulates Platelet-Mediated Inflammation in Subjects With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial." *Frontiers in Immunology* 13 (2022).
- **30.** Jala, Aishwarya, Bincy Varghese, Gurparmeet Kaur, KarthikrajRajendiran, Ratul Dutta, Ramu Adela, and Roshan M. Borkar. "Implications of endocrine-disrupting chemicals on polycystic ovarian syndrome: A comprehensive review." *Environmental Science and Pollution Research* **(2022)**: 1-30.
- **31.** Nizami, Hina L., Parmeshwar B. Katare, Pankaj Prabhakar, Ramu Adela, Soumalya Sarkar, Sudheer Arava, Praloy Chakraborty, Subir K. Maulik, and Sanjay K. Banerjee. "Paricalcitol Attenuates Metabolic Syndrome-Associated Heart Failure through Enhanced Mitochondrial Fusion." *Oxidative Medicine and Cellular Longevity* 2022 (2022).
- 32. Aishwarya, ThanatharayilSathian, Nadella Mounika, Gayatri Vishwakarma, and Ramu Adela. "Effect of obeticholic acid in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) patients: a systematic review and meta-analysis." *RPS Pharmacy and Pharmacology Reports* 1, no. 1 (2022): rqac001.
- **33.** Jala, Aishwarya, Bincy Varghese, Gurparmeet Kaur, KarthikrajRajendiran, Ratul Dutta, Ramu Adela, and Roshan M. Borkar. "Implications of endocrine-disrupting chemicals on polycystic ovarian syndrome: A comprehensive review." *Environmental Science and Pollution Research* **(2022)**: 1-30.
- 34. George, Rosemol, Christy Thomas, Chippy Anna Joy, Bincy Varghese, Krishna Undela, and Ramu Adela. "Comparative efficacy and safety of oral nifedipine with other antihypertensive medications in the management of hypertensive disorders of pregnancy: a systematic review and meta-analysis of randomized controlled trials." *Journal of Hypertension* 40, no. 10 **(2022)**: 1876-1886.
- 35. Alam, Md Jahangir, Shravan Kumar Uppulapu, Vikas Tiwari, Bincy Varghese, Soheb Anwar Mohammed, Ramu Adela, Sudheer Kumar Arava, and Sanjay K. Banerjee. "Pregestational diabetes alters cardiac structure and function of neonatal rats through developmental plasticity." *Frontiers in Cardiovascular Medicine* (2022).
- 36. Sah, Sujit Kumar, Atiqulla Shariff, Niharika Pathakamuri, Subramanian Ramaswamy, Madhan Ramesh, Krishna Undela, MalavalliSiddalingegowda Srikanth, and Teggina Math Pramod Kumar. "Antifungal therapy in the management of fungal secondary infections in COVID-19 patients: A systematic review and meta-analysis." *Plos one* 17, no. 7 **(2022)**: e0271795.
- **37**. Palapra, Hibathulla, Subeesh K. Viswam, VivekanandanKalaiselvan, and Krishna Undela. "SGLT2 inhibitors associated pancreatitis: signal identification through disproportionality analysis of spontaneous reports and review of case reports." *International Journal of Clinical Pharmacy* **(2022)**: 1-9.

- 38. Konikuzhiyil, MohsinaHyder, VishwanathanBalasubramaniam, Krishna Undela, and SivasankaranPonnusankar. "Prediabetes Education: the Underutilized Tool of Diabetes Prevention among Indian Population." *Indian Journal of Pharmaceutical Education And Research* 56, no. 4 **(2022)**: S613-S619.
- 39. Puvvada RK, Adusumilli P, Maddukuri RK, Samaksha PB, Annam MG, Undela K. "Efficacy and Safety of Hydroxychloroquine in the Treatment of Type-2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials." *Journal of Young Pharmacists*(2022): 14, no. 4: 402-407

Pharmaceutical Analysis

- 40. Rayala, VVS Prasanna Kumari, Kashyap Ajaybhai Trivedi, Suryanarayana Murthy Upadhyayula, SrinivasuGunnam, and Roshan M. Borkar. "A validated chiral chromatographic method for the enantiomeric separation of acalabrutinib." *Chirality* 34, no. 9 (2022): 1247-1256.
- 41. Kumari Rayala, VVS Prasanna, and Jony Susanna Kandula. "Advances and challenges in the pharmacokinetics and bioanalysis of chiral drugs." *Chirality* 34, no. 10 **(2022)**: 1298-1310.
- 42. Chenkual, Laltanpuii, Dimple S. Lalchandani, Sachin Chaturvedi, MahindranMariyappan, and Pawan Porwal. "Development and validation of sensitive high-performance liquid chromatography-photodiode array method for determination of three sulfonated esters and N-methyl-O-phenyldiamine dihydrochloride as potential genotoxic impurities in Amlodipine and Telmisartan fixed-dose combination." *Separation Science Plus* 6 (2023)
- 43. Lalchandani, Dimple S., SreetejaParitala, Pawan Kumar Gupta, and Pawan Kumar Porwal. "Application of Supervised and Unsupervised Learning Approaches for Mapping Storage Conditions of Biopharmaceutical Product—A Case Study of Human Serum Albumin." *Journal of Chromatographic Science* (2022).
- 44. Lalchandani, Dimple S., LaltanpuiiChenkual, MahindranMariappayan, and Pawan K. Porwal. "Significance of stressor media on the stability of statins: a critical assessment." *Chemical Papers* **(2022)**: 1-25.
- 45. Prashanth, Jupally, Sridhar Balasubramanian, VVS Prasanna Kumari Rayala, Pramod Kumar, and P. Radhakrishnanand. "Two stereoisomers of 4-hydroxy prenylamine and its hydrochloride salts." *Journal of Molecular Structure* **(2022)**: 133428.
- 46. Vullendula, Sai Krishna Anand, Athira R. Nair, Dani Lakshman Yarlagadda, KS NavyaSree, Krishnamurthy Bhat, and Swapnil J. Dengale. "Polymeric solid dispersion Vs co-amorphous technology: A critical comparison." *Journal of Drug Delivery Science and Technology* **(2022)**: 103980.
- 47. Uppala, Sravya, Sai Krishna Anand Vullendula, Dani Lakshman Yarlagadda, and Swapnil Jayant Dengale. "Exploring the utility of co-amorphous materials to concurrently improve the solubility and permeability of Fexofenadine." *Journal of Drug Delivery Science and Technology* 72 **(2022)**: 103431.
- 48. KS, NavyaSree, Swapnil J. Dengale, Srinivas Mutalik, and Krishnamurthy Bhat. "Raloxifene HCl-quercetin co-amorphous system: preparation, characterization, and investigation of its behavior in phosphate buffer." *Drug Development and Industrial Pharmacy* 48, no. 6 (2022): 227-238.
- 49. Ponneganti, Srikanth, Upadhyayula Suryanarayana Murty, Chandrakant Bagul, Roshan M. Borkar, and P. Radhakrishnanand. "Phyto-metabolomics of

Phlogacanthusthyrsiformis by using LC-ESI-QTOF-MS/MS and GC/QTOF-MS: Evaluation of antioxidant and enzyme inhibition potential of extracts." *Food Research International* 161 **(2022)**: 111874.

50. PR, Hemanth V., Narasimha M. Beeraka, Pramod Kumar, Hitesh B. Patel, and B. M. Gurupadayya. "UPLC-MS-based Method Development, Validation, and Optimization of Dissolution Using Quality by Design Approach for Low Dose Digoxin: A Novel Strategy." *Current Pharmaceutical Analysis* 18, no. 9 (2022): 841-851.

Pharamcology and Toxicology

- 51. Parthiban, A., R. Sivasankar, BishalRajdev, Radhakrishnan Nandini Asha, Thayalaraj Christopher Jeyakumar, Rajiv Periakaruppan, and V. G. M. Naidu. "Synthesis, in vitro, in silico and DFT studies of indole curcumin derivatives as potential anticancer agents." *Journal of Molecular Structure* 1270 **(2022)**: 133885.
- 52. Puppala, Eswara Rao, Sunepjungla L. Aochenlar, P. A. Shantanu, Sahabuddin Ahmed, Arun Kumar Jannu, Aishwarya Jala, Sai Sudha Yalamarthi, Roshan M. Borkar, Dinesh Mani Tripathi, and V. G. M. Naidu. "Perillyl alcohol attenuates chronic restraint stress aggravated dextran sulfate sodium-induced ulcerative colitis by modulating TLR4/NF-κB and JAK2/STAT3 signaling pathways." *Phytomedicine* 106 **(2022)**: 154415.
- 53. Ghosh, Sitara, Ankana Ghosh, AshithaRajanan, Amal Jyothy Suresh, PratikshaSharadrao Raut, Sourav Kundu, and Bidya Dhar Sahu. "Natural coumarins: Preclinical evidence-based potential candidates to alleviate diabetic nephropathy." *Phytomedicine Plus* **(2022)**: 100379.
- 54. Syed, Abu Mohammad, Sourav Kundu, Chetan Ram, UttamKulhari, Akhilesh Kumar, Madhav NilakanthMugale, Purusottam Mohapatra, Upadhyayula Suryanarayana Murty, and Bidya Dhar Sahu. "Up-regulation of Nrf2/HO-1 and inhibition of TGF-β1/Smad2/3 signaling axis by daphnetin alleviates transverse aortic constriction-induced cardiac remodeling in mice." *Free Radical Biology and Medicine* 186 **(2022)**: 17-30.
- 55. Verma, Monika K., Sanjana Roychowdhury, Bidya Dhar Sahu, Awanish Mishra, and Kalyan K. Sethi. "CRISPR-based point-of-care diagnostics incorporating Cas9, Cas12, and Cas13 enzymes advanced for SARS-CoV-2 detection." *Journal of Biochemical and Molecular Toxicology* 36, no. 8 **(2022)**: e23113.
- 56. Ram, Chetan, ShobhitGairola, Abu Mohammad Syed, UttamKulhari, Sourav Kundu, Madhav NilakanthMugale, Upadhyayula Suryanarayana Murty, and Bidya Dhar Sahu. "Biochanin A alleviates unilateral ureteral obstruction-induced renal interstitial fibrosis and inflammation by inhibiting the TGF-β1/Smad2/3 and NF-kB/NLRP3 signaling axis in mice." *Life Sciences* 298 **(2022)**: 120527.
- 57. Mishra, Awanish, Petro Oliinyk, Roman Lysiuk, LarysaLenchyk, Suraj Singh S. Rathode, HalynaAntonyak, Roman Darmohray et al. "Flavonoids and stilbenoids as a promising arsenal for the management of chronic arsenic toxicity." *Environmental Toxicology and Pharmacology* **(2022)**: 103970.
- 58. Bandopadhyay, Ritam, Suraj Singh S. Rathod, and Awanish Mishra. "Enzyme-Linked Immunosorbent Assay." In *Analysis of Naturally Occurring Food Toxins of Plant Origin*, pp. 215-244. CRC Press.

- 59. Ahmad, Javed, Hassan A. Albarqi, Mohammad Zaki Ahmad, Mohamed AA Orabi, Shadab Md, RitamBandopadhyay, Faraha Ahmed, Mohammad Ahmed Khan, Javed Ahamad, and Awanish Mishra. "Utilization of Nanotechnology to Improve Bone Health in Osteoporosis Exploiting Nigella sativa and Its Active Constituent Thymoquinone." *Bioengineering* 9, no. 11 **(2022)**: 631.
- 60. Lalrengpuii, Judy, Kaisar Raza, Awanish Mishra, and Rahul Shukla. "Retinoid nanoparticulates: approachable gateway for acne treatment." *Health Sciences Review* (2022): 100042.
- 61. Ghosh, Aparajita, Bijoyani Ghosh, Nidhi Parihar, MyrthongIlaweibaphyrnai, Samir R. Panda, Amit Alexander, Naveen Chella, U. S. N. Murty, V. G. M. Naidu, and Deepak B. Pemmaraju. "Nutraceutical prospects of *Houttuynia cordata* against the infectious viruses." *Food Bioscience* 50 (2022): 101977.
- 62. Ghosh, Aparajita, Bijoyani Ghosh, Nidhi Parihar, MyrthongIlaweibaphyrnai, Samir R. Panda, Amit Alexander, Naveen Chella, U. S. N. Murty, V. G. M. Naidu, and Deepak B. Pemmaraju. "Nutraceutical prospects of Houttuynia cordata against the infectious viruses." *Food Bioscience* 50 (2022): 101977.
- 63. Ram, Chetan, ShobhitGairola, Abu Mohammad Syed, Shobhit Verma, Madhav NilakanthMugale, and Bidya Dhar Sahu. "Carvacrol preserves antioxidant status and attenuates kidney fibrosis via modulation of TGF-β1/Smadsignaling and inflammation." *Food & Function* 13, no. 20 **(2022)**: 10587-10600.
- 64. Parthiban, A., R. Sivasankar, BishalRajdev, Radhakrishnan Nandini Asha, Thayalaraj Christopher Jeyakumar, Rajiv Periakaruppan, and V. G. M. Naidu. "Synthesis, in vitro, in silico and DFT studies of indole curcumin derivatives as potential anticancer agents." *Journal of Molecular Structure* 1270 **(2022)**: 133885.
- 65. Yakkala, Prasanna A., Samir R. Panda, Syed Shafi, V. G. M. Naidu, M. Shahar Yar, Philemon N. Ubanako, Samson A. Adeyemi et al. "Synthesis and Cytotoxic Activity of 1, 2, 4-Triazolo-Linked Bis-Indolyl Conjugates as Dual Inhibitors of Tankyrase and PI3K." *Molecules* 27, no. 21 **(2022)**: 7642.
- 66. Gorantla, Srividya, Unnati Batra, R. N. Samshritha, Eswara Rao Puppala, TejashreeWaghule, V. G. M. Naidu, and Gautam Singhvi. "Emerging trends in microneedle-based drug delivery strategies for the treatment of rheumatoid arthritis." *Expert Opinion on Drug Delivery* 19, no. 4 **(2022)**: 395-407.
- 67. Puppala, Eswara Rao, Siddhi Jain, Pritam Saha, Mahesh Rachamalla, N. P. Syamprasad, Sai Sudha Yalamarthi, Md Abubakar et al. "Perillyl alcohol attenuates rheumatoid arthritis via regulating TLR4/NF-κB and Keap1/Nrf2 signaling pathways: A comprehensive study on *in-vitro* and *in-vivo* experimental models." *Phytomedicine* 97 **(2022)**: 153926.
- 68. Ali, Syed Afroz, Samir Ranjan Panda, Mangaldeep Dey, Ashok Kumar Datusalia, V. G. M. Naidu, and Rakesh Kumar Singh. "The Factors Influencing Gut Microbiota in Autoimmune Diseases." In *Role of Microorganisms in Pathogenesis and Management of Autoimmune Diseases*, pp. 69-90. Springer, Singapore, (2022).
- 69. Gorantla, Srividya, Unnati Batra, R. N. Samshritha, Eswara Rao Puppala, TejashreeWaghule, V. G. M. Naidu, and Gautam Singhvi. "Emerging trends in microneedle-based drug delivery strategies for the treatment of rheumatoid arthritis." *Expert Opinion on Drug Delivery* 19, no. 4 **(2022)**: 395-407.
- 70. Thalla, Maharshi, PurushottamSuryavanshi, V. G. M. Naidu, Upadhyayula Suryanarayana Murty, and Subham Banerjee. "Pharmacoengineering: A New Frontier in Cutting-Edge Translational Pharmaceutical Research in

India." *Proceedings of the National Academy of Sciences, India Section B: Biological Sciences* **(2022)**: 1-8.

Biotechnology

- 71. Vijayakumar, Gangipangi, Uppalapati S. Swetha, and SelvarajuSudhagar. "Tamoxifen modulates mitochondrial dynamics through AMPK and MAPK during nutrition deprivation." *Cell Biology International* 46, no. 10 **(2022)**: 1661-1671.
- 72. Sarma, ParthaPratim, NonibalaGurumayum, Suman Kumar Samanta, PuspanjaliKhound, Sima Kumari, Diptimayee Devi, Jayanta Barman, Sanjay Kumar Banerjee, and Rajlakshmi Devi. "Pharmacologically active chemical composite of *Musa balbisiana* ameliorates oxidative stress, mitochondrial cellular respiration, and thereby metabolic dysfunction." *Journal of Food Biochemistry* 46, no. 9 (2022): e14347.
- 73. Bugga, Paramesha, Soheb Anwar Mohammed, Md Jahangir Alam, Parmeshwar Katare, Himanshu Meghwani, Subir Kumar Maulik, Sudheer Arava, and Sanjay Kumar Banerjee. "Empagliflozin prohibits high-fructose diet-induced cardiac dysfunction in rats via attenuation of mitochondria-driven oxidative stress." *Life Sciences* 307 **(2022)**: 120862.
- 74. Sarma, ParthaPratim, NonibalaGurumayum, Suman Kumar Samanta, PuspanjaliKhound, Sima Kumari, Diptimayee Devi, Jayanta Barman, Sanjay Kumar Banerjee, and Rajlakshmi Devi. "Pharmacologically active chemical composite of Musa balbisiana ameliorates oxidative stress, mitochondrial cellular respiration, and thereby metabolic dysfunction." *Journal of Food Biochemistry* 46, no. 9 (2022): e14347.
- 75. Bugga, Paramesha, Soheb Anwar Mohammed, Md Jahangir Alam, Parmeshwar Katare, Himanshu Meghwani, Subir Kumar Maulik, Sudheer Arava, and Sanjay Kumar Banerjee. "Empagliflozin prohibits high-fructose diet-induced cardiac dysfunction in rats via attenuation of mitochondria-driven oxidative stress." *Life Sciences* 307 **(2022)**: 120862.
- 76. Purohit A, Alam MJ, Kandiyal B, Das B, Banerjee SK*. Gut microbiome and nonalcoholic fatty liver disease. Human Microbiome in Health and Disease (Part A); *Progress in Molecular Biology and Translational Science, Elsevier*, (**2022**)
- 77. Alam, Md Jahangir, Vaishnavi Puppala, Shravan K. Uppulapu, Bhabatosh Das, and Sanjay K. Banerjee. "Human microbiome and cardiovascular diseases." *Progress in molecular biology and translational science* 192, no. 1 **(2022)**: 231-279.
- 78. Baygi, SadjadFakouri, Sanjay K. Banerjee, Praloy Chakraborty, Yashwant Kumar, and Dinesh Kumar Barupal. "IDSL. UFA assigns high confidence molecular formula annotations for untargeted LC/HRMS datasets in metabolomics and exposomics." *bioRxiv* (2022).
- 79. Tiwari, Vikas, and Sanjay K. Banerjee. "Therapeutic potential of HDAC inhibitors in the treatment of cardiac diseases: A short review." *Current Drug Targets* (2022).

Medicinal Chemistry

80. Kumar, Gangasani Jagadeesh, Sachin Dattram Pawar, Swati Ramesh Pawar, AbraroddinMumtajoddin Khatib, Anurag Saini, Pintu Das, Kalyan K. Sethi et al. "Process development for the total synthesis of the novel drug metabolite carboxy toremifene as a standard reference material along with characterization and purity assessment for the antidoping quality control purposes." *Drug Testing and Analysis* **(2022)**.

- 81. Sunny, Steeva, Mohit Maingle, and Kapileswar Seth. "Advances in Bifunctional Squaramide-Catalyzed Asymmetric Sulfa-Michael Addition: A Decade Update." *Synlett* (2022).
- 82. Seth, Kapileswar. "Recent Progress in Rare-earth Metal-catalyzedsp 2 and sp 3 C– H Functionalization to Construct C–C and C–heteroelement Bonds." *Organic Chemistry Frontiers* (2022).
- 83. Dixit, Vaibhav A., Upadhyayula Suryanarayana Murty, Priyanka Bajaj, Jochen Blumberger, and Sam P. de Visser. "Mechanisms of Electron Transfer Rate Modulations in Cytochrome P450 BM3." *The Journal of Physical Chemistry B* (2022).
- 84. Dixit, Vaibhav A., and Aniket Kulkarni. "Applications of Bond Energy-Based Thermodynamic Analysis to the Feasibility of Unfunctionalized C– C Cross-Coupling Reactions." *ChemistrySelect* 7, no. 47 **(2022)**: e202203111.
- 85. Radhakrishnanand, P., V. V. S. Rayala, Kashyap Trivedi, Upadhyayula Suryanarayana Murty, and GunnamSrinivasu. "Development of Polar Organic Mode Chromatographic Method by Polysaccharide-Based Immobilized Chiral Selector and Validation for the Determination of the Enantiopurity of Novel Mineralocorticoid Receptor Antagonist Atropisomer–Esaxerenone." *Chromatographia* (2022): 1-10.

Pharmaceutical Technology (Formulations)

86. Ranjan, Om Prakash, Nitesh Kumar, and Vivek Dave. "Cross-linked Alginate Beads of Montelukast Sodium Coated with Eudragit for Chronotherapy: Statistical Optimization, In vitro and In vivo Evaluation." *Current Drug Delivery* **(2022)**.

Medical Devices

- 87. Uppulapu, Shravan Kumar, Md Alam, Santosh Kumar, and Sanjay Kumar Banerjee. "Indazole and its Derivatives in Cardiovascular Diseases: Overview, Current Scenario, and Future Perspectives." *Current Topics in Medicinal Chemistry* (2022)
- 88. Shaw, Priyanka, Naresh Kumar, Maxime Sahun, Evelien Smits, Annemie Bogaerts, and Angela Privat-Maldonado. "Modulating the Antioxidant Response for Better Oxidative Stress-Inducing Therapies: How to Take Advantage of Two Sides of the Same Medal?." *Biomedicines* 10, no. 4 **(2022)**: 823.
- 89. Shaw, Priyanka, Patrick Vanraes, Naresh Kumar, and Annemie Bogaerts. "Possible Synergies of Nanomaterial-Assisted Tissue Regeneration in Plasma Medicine: Mechanisms and Safety Concerns." *Nanomaterials* 12, no. 19 **(2022)**: 3397.

BOOK CHAPTERS:

1. Soma Das, Om Prakash Ranjan, Vanishree Rao, V. Ravichandiran, Nitesh Kumar. Book chapter "Multifunctional liposome-quantum dot hybrid nanocarriers for drug targeting brain tumors". In book Nanocarriers for Drug Targeting to Brain Tumors, Editors: Lalit Kumar, Yashwant Pathak, Elsevier **2022**, Page No: 649-667. (doi.org/10.1016/B978-0-323-90773-6.00020-8)

- 2. Rathode SSS, Mishra PS, Mishra A. **(2022)** Toxicity and biocompatibility perspective of nanomaterials exploited in diagnosis and treatment of infectious diseases, In Jain K, Ahmad J, Eds Nanotheranostics for Treatment and Diagnosis of Infectious Diseases, Academic Press, India, 353-372.
- 3. Gowtham Kenguva, Sunil Kumar Dubey, Smruti Rekha Rout, Mahak Fatima, Amit Alexander, Mohammed A.S. Abourehab, Prashant Kesharwani and Rambabu Dandela. Chapter 3-Solubility enhancement and drug release mechanism of polymeric micelles in Polymeric Micelles for Drug Delivery. Woodhead Publishing Series in Biomaterials by Elsevier. **2022**: 41-44.
- 4. Pramod Kumar, Waibiangki Lyngdoh, Banwari Lal, Amit Alexander. Chapter 16 -Sample preparation techniques for quantitative analysis in brain pharmacokinetics: Application to neurodegenerative diseases, in Nanomedical Drug Delivery for Neurodegenerative Diseases. Academic Press, Elsevier. (**2022**): 261-267.
- 5. Rathod SSS, Kaur G, Sharma N, Khurana N, Mishra A*, **(2022)** Capillary Electrophoresis In Analysis of Naturally Occurring Food Toxins of Plant Origin Eds Nollet LML, Ahmad J, CRC Press, Boca Raton eBook ISBN9781003222194. DOI: 10.1201/9781003222194-16

PATENTS:

- 1. PurushottamSuryavanshi, Subham Banerjee, "*Customized 3D Printed Hollow Capsular Device, Uses and Method of Fabricating Thereof*". Application No. 202211027762. Date of Filing: 13 May, **2022**.
- 2. Deepak PVP, TheranosticNanoformulations and Methods of Preparation Thereof &Quot; Indian Patent Office On 26 July **2022**. Application Number: 202231042832.
- 3. Naveen Chella, Co-Amorphous Niclosamide Compositions and Methods of Preparation Thereof. Application Number: 202231048451, On 25 Aug **2022**.
- 4. Amit Alexander, Sinapic acid based intranasal formulations and methods of preparation thereof. Application Number: 202231043748, On 30 July, **2022**.
- 5. Method for preparation of highly pure curcumin, desmethoxycurcumin and bisdemethoxycurcumin from lakadong turmeric. Dr. Pramod Kumar, Dr. USN Murty, Dr. P. Radhakrishanand, Dr. Kalyan Sethi, Dr. Jyoti Punia, Nomula Mamatha vardhini, Sandeep Jat, Sachin D. Pawar, Anurag Saini, Nayanika Devi, Application No.:202231066460 and filing date: November 18, **2022**.
- 6. Methods for preparation of lutein from marigold flowers, Dr. Kalyan Kumar Sethi, Mr. Mahesh Gopichand Kamble, Ms. KM Abha Mishra, Mr. Hrushikesh Chaudhary, Mr. Ashish Sunil Akkewar, Mr. Sanjay Chaudhary, Mr. Anurag Saini, Ms. Veena KS, Dr. Pramod Kumar, Mr. Sandeep Jatt, Dr.PullapanthulaRadhakrishnanand, Dr.Upadhyayula Suryanarayana Murty, Application No.: 202231062144 and filing date: November 01, **2022**



NIPER, HAJIPUR



Contact Address Export Promotions Industrial Park (EPIP), Industrial Area Hajipur, Dist: Vaishali 844102, Bihar Phone: +91 6224 - 277224 Email: niper.hajipur2007@gmail.com Website: www.niperhajipur.ac.in

From the Director's Desk

NIPER Hajipur is established to meet the country's healthcare needs by providing pharmaceutical education and research. Institute offers MS (Pharm) and Ph.D. programs in six departments: Biotechnology, Pharmacy Practice, Pharmacology and Toxicology, Pharmaceutics, Pharmaceutical Analysis, and Regulatory Toxicology.

The scholars are being trained with strong basics and analytical skills development in the relevant field as per



Prof. V. Ravichandiran

the country's requirement of human resources as an "Atamnirbhar Bharat" The institute is continuously striving hard to enhance the quality of education of existing programmes as per the current requirements of invention and innovation and also to meet the global standards and to attain India's recognition as a "Pharmacy of the World".

The institute has also been recognized in the band of "Band Beginners" under the category "Institute of National Importance & Central Universities/CFTs (Technical)" in ARIIA 2021 by the Ministry of Education, Govt. of India. NIPER Hajipur is among the top 100 colleges of Pharmacy in India, ranking 75th on the NIRF Ranking 2022. The institute has also been recognized as Adverse Drug Reaction Monitoring Center (AMC) under the Pharmacovigilance Programme of India (PvPI) & Medical Device Adverse Event Monitoring Center (MDMC) under the Materiovigilance Programme of India by Indian Pharmacopoeia Commission, Ghaziabad.

NIPER-Hajipur's common research programme mainly focuses on the categories of biological, formulation sciences, and medical devices. In particular, it is developing 'personalized' solutions that utilize basic biology, biotechnology, pharmacology, and micro- and nano-scale technologies to enable a range of therapies for cancer and a particular focus on neurodegenerative disorders and creating a 3-dimensional patient-derived in-vitro model system for drug screening. NIPER Hajipur is working with other NIPERs to evaluate traditional Indian medicine reversing diabetes-induced neuro and nephrotoxicity. Institute has also developed murine cortical 3D cell culture/organoid, and the results have been disseminated in NIPER-PHARMACON 2022.

I am sure that in the coming years, NIPER Hajipur will attain greater heights in the areas of advanced pharmaceutical sciences.

EXTRA-MURAL RESEARCH PROJECTS:

| S. N. | Project Title | Principal Investigators and Centre coordinator's | Funding Agency | Funding Amount | Duration | | |
|----------|---|---|---|---------------------|-------------|--|--|
| 1. | Development of enzyme- mimicking polymeric nanomaterials for biomedical applications | Dr. Abhishek Sahu | DST- SERB | 30 Lakhs | 2 yea rs | | |
| | Enzyme mimicking system that can alleviate oxidative stress has enormous potential as future generation of nanomedicine against many diseases. Nanozyme is an emerging field of research, anticipated to grow exponentially and open up new avenues for various biomedical fields such as biosensing, bioimaging, and theranostic. In this project the objective is to synthesize biocompatible/biodegradable polymer-based nanosystems with enzyme- mimetic activities that can be applied for the treatment of various acute and chronic diseases. The biocompatibility and biodegradability aspect of the proposed polymer-based nanozyme system makes it attractive for clinical development as well as commercialization. | | | | | | |
| 2. | Efficient process development strategies for prevalent "Rare disease" drugs | Murali Kumarasamy Co- PI, Dr.Vipan Parihar (co-PI) | DST Rare Disease Program Grant | 700 Lakhs INR | 5 years | | |
| 3. | Modulation of fluoride-induced histopathological, cognitive- behavioural alteration in adult and developing rodents by naringin | PI: Dr. Nitesh Kumar, PT, NIPER Hajipur Dr. V. Ravichandiran, NIPER Hajipur, Dr. Smitha Shenoy, Department of Pharmacology, KMC,MAHE, Manipal, Dr. Ravindra Shantakumar Swamy, Department of Anatomy, MMMC, MAHE, Manipal | ICMR | 29.92 Lakh | 3 Years | | |
| | Recent literature have some publications indicating chemicals or alkaloids effective in fluorosis. One of the recent publication (Atmaca et al, 2014) have shown biochemical and histological effect of Resveratrol on sodium fluoride 100ppm induced deficits in brain tissue of experimental rat. The present research is much more novel, unique and different in the following ways. The present research emphasizes on the behavioural changes brought about by | | | | | | |

minimum dose of sodium fluoride such as anxiety, depression, attention deficit hyperactivity syndrome and cognition deficits. The present study attempts to evaluate the effect of sodium fluoride on mitochondria and endoplasmic reticulum with the help of Bax/Bcl2 ratio and caspase estimation. The present study attempts to find prenatal and postnatal effect of sodium fluoride on behavioural, Histopathological and biochemical changes and its ameliorative effect by Naringin. Histology of brain tissue includes Golgi stain which quantifies dendritic arborisation, branching point and spine density in hippocampus, prefrontal cortex and locus coeruleus to determine and confirm the behavioural and cognitive changes due to sodium fluoride and its amelioration by Naringin. For the first time locus coeruleus is being investigated for its histological changes such as neurodegeneration and dendritic arborisation induced by sodium fluoride. None of the above have been studied in the Atmaca et al, 2014 or any previous study. Moreover the dose of sodium fluoride used in those studies is 100ppm which is much higher as compared to human exposure. In India 66 million are at risk of fluoride contamination. Excess Fluoride in drinking water results in Dental fluorosis, skeletal fluorosis and Behavioural changes along with learning and memory deficits. Attention deficit hyperactivity disorder, depression, anxiety, decreased learning ability and low IQ has been observed in children due to excess fluoride contamination in drinking water. Dietary supplement with citrus fruits containing Naringin will help avoid and reverse fluorosis induced behavioural changes as a result of its antioxidant, antiinflammatory and neuroprotective effect.

| | minumitetor y unu nour oprotoctive encou | | | | | |
|----|--|------------------------|------|-------|---------|--|
| 4. | Role of sirtuins in | Dr. Smitha Shenoy, | ICMR | 30.13 | 3 Years | |
| | the gender based | HOD, Department of | | Lakh | | |
| | neurodevelopme | Pharmacology, KMC, Ma | | | | |
| | ntal toxicity in | nipal | | | | |
| | fluorosis: a | Dr. Nitesh Kumar, | | | | |
| | preclinical study | PT, NIPER Hajipur (CO- | | | | |
| | | PI), Dr. Sivakumar G | | | | |
| | | Kasturba Medical, | | | | |
| | | College, Manipal, | | | | |
| | | Karnataka, Dr.Somasish | | | | |
| | | Ghosh Dastidar, | | | | |
| | | Kasturba Medical | | | | |
| | | College, Manipal, | | | | |
| | | Karnataka | | | | |

Developing brain is highly vulnerable to environmental toxins. Consumption of beetroot, a rich source of vitamins, minerals and other phytoconstituents has been encouraged as part of nutritional enrichment strategy in fluorosis. Objective of the study is to evaluate the protective effect of betanin on fluoride induced neurotoxicity. The novelty of the study is its focus on a natural product betanin as a preventive intervention against adverse behavioural and neurochemical alterations caused by fluoride in neonates and adult rats. Betanin is present in beetroot which is currently a part of dietary intervention in fluorosis prevalent areas. Docking study: All the phytochemicals will be screened using standard precision and extra precision mode in flexible ligand docking in glide. For each ligand, the docking score and binding energy will be recorded. Molecular dynamic simulation study: Selected modulator will be used for molecular dynamics simulation on selected sirtuin 1. In-vitro study: SHSY5Y cells will be treated with sirtuin 1 modulator + sodium fluoride (NaF) and compared versus untreated control cells and NaF alone treated cells. Wistar rats will be taken for this study. Wistar rats were divided into 7 groups. Group I (Control) will be administered with drinking water. Group II received NaF (10mg/kg). Group III and IV received Betanin (100 and 200mg/kg) respectively. Group V, VI and VII received Betanin (50, 100 and 200mg/kg) along with NaF (10mg/kg). All treatment will be administered orally for 8 weeks both prenatal and postnatal exposure. Novel object recognition test, Open field test and Morris water maze test was performed at 8th and 12th week followed by molecular and biochemical estimations.

PUBLICATIONS (RESEARCH/ REVIEW):

Pharmacy Practice

- 1. Singh, Akanksha, P. Ramalingam, Sameer Dhingra, V. Ravichandiran, and Krishna Murti. "Arsenic: a culpable element and a possible menace for HIV/AIDS patients." *Biological Trace Element Research* 200, no. 12 **(2022)**: 4955-4966.
- 2. Kumar, Arun, Md Samiur Rahman, Mohammad Ali, Pascal Salaun, Arthur Gourain, Suresh Kumar, Ranjit Kumar et al. "Assessment of disease burden in the arsenic exposed population of Chapar village of Samastipur district, Bihar, India, and related mitigation initiative." *Environmental Science and Pollution Research* (2022): 1-17.
- 3. Kumar, V. Udaya, Muhammed Favas Kt, Ayush Sharma, Priya Bisht, Sameer Dhingra, V. Ravichandiran, M. Ramesh, and Krishna Murti. "The Possible Role of Selected Vitamins and Minerals in the Therapeutic Outcomes of Leishmaniasis." *Biological Trace Element Research* (2022): 1-17.
- 4. Karun, Arya, Rimple Jeet Kaur, JaykaranCharan, Krishna Murti, M. Ramesh, V. Ravichandiran, and Sameer Dhingra. "Impact of COVID-19 on Antimicrobial Resistance in Paediatric Population: a Narrative Review." *Current Pharmacology Reports* 8, no. 5 (2022): 365-375.
- 5. Madhu, Maxima, V. Udaya Kumar, Sameer Dhingra, Nitesh Kumar, Sanjiv Singh, V. Ravichandiran, and Krishna Murti. "Nutritional Aspects of People Living with HIV (PLHIV) Amidst COVID-19 Pandemic: an Insight." *Current pharmacology reports* 8, no. 5 (2022): 350-364.
- 6. Sharma, Ayush, Prakash Kumar, Siddhartha Dutta, Rimple Jeet Kaur, JaykaranCharan, Gaurav Chikara, Krishna Murti et al. "Pathophysiological and Genetic Basis of Tenofovir-Induced Acute Renal Dysfunction: Strategies and Recent Developments for Better Clinical Outcomes." *Current Pharmacology Reports* 8, no. 6 (2022): 427-438.
- 7. Lingamaiah, Doddolla, Sunitha NS, Krishna Murti, Sanjiv Singh, V. Ravichandiran, and Sameer Dhingra. "Emicizumab: an FDA-Approved Monoclonal Antibody in the Treatment of Hemophilia A." *Current Pharmacology Reports* 8, no. 2 (2022): 121-129.

- 8. Meenakshi, Sarasa, V. Udaya Kumar, Sameer Dhingra, and Krishna Murti. "Nasal vaccine as a booster shot: a viable solution to restrict pandemic?." *Clinical and Experimental Vaccine Research* 11, no. 2 (2022): 184.
- 9. Meenakshi, Sarasa, V. Udaya Kumar, Reny Sara Raju, Sameer Dhingra, Nitesh Kumar, V. Ravichandiran, and Krishna Murti. "Ayurveda: The Prominence of Herbal Medicine in Containment of COVID-19." *Pharmacognosy Research* 14, no. 3 (2022).
- 10. Devipriya, J. S., Ashok Kumar Gupta, Garapati Pavan, Sameer Dhingra, Krishna Murti, VelayuthamRavichandiran, and Krishna Pandey. "Knowledge, Attitude, and Practices among HIV/Leishmaniasis Co-Infected Patients in Bihar, India." *The American Journal of Tropical Medicine and Hygiene* (2022): tpmd211294-tpmd211294.
- 11. Kumar, Arun, C. Ravi, Sameer Dhingra, Mohammad Ali Krishna Murti, and Ashok Kumar Ghosh. "Arsenic Causing Gallbladder Cancer Disease near the Himalayan bound Rivers in Bihar: A Case study of Gallbladder Cancer." *Journal of Cancer Science and Clinical Therapeutics* 6 (2022): 388-391.
- 12. Dar, Mukhtar Ahmad, Pawan Kumar, Prakash Kumar, Ashish Shrivastava, Muneer Ahmad Dar, Richa Chauhan, Vinita Trivedi et al. "Designing of peptide based multi-epitope vaccine construct against gallbladder cancer using immunoinformatics and computational approaches." *Vaccines* 10, no. 11 (2022): 1850.
- Sartelli, Massimo, Federico Coccolini, Yoram Kluger, ErvisAgastra, Fikri M. Abu-Zidan, Ashraf El Sayed Abbas, Luca Ansaloni et al. "WSES/GAIS/WSIS/SIS-E/AAST global clinical pathways for patients with skin and soft tissue infections." *World journal of emergency surgery* 17, no. 1 (2022): 1-23.
- 14. Dar, Mukhtar Ahmad, Richa Chauhan, Vinita Trivedi, Rishikesh Kumar, and Sameer Dhingra. "Assessing the prevalence of financial toxicity, its predictors and association with health-related quality of life among radiation oncology patients in India: A cross-sectional patient reported outcome study." *International Journal of Radiation Oncology* Biology* Physics* (2022).
- 15. Devipriya, J. S., Ashok Kumar Gupta, Garapati Pavan, Sameer Dhingra, Krishna Murti, VelayuthamRavichandiran, and Krishna Pandey. "Knowledge, Attitude, and Practices among HIV/Leishmaniasis Co-Infected Patients in Bihar, India." *The American Journal of Tropical Medicine and Hygiene* (2022): tpmd211294-tpmd211294.

Pharmaceutical Analysis

- 16. Karthika, Anoop, KowmudiGullapalli, Krishnaveni Nagappan, AnilakumarKandangath Raghavan, and Ramalingam Peraman. "Optimization of ultrasonication-assisted extraction conditions using RSM-I-Optimal experimental design to recover vitamin D2 and K1 from selected green leafy vegetable samples." *Journal of Food Measurement and Characterization* (2022): 1-12.
- 17. Prasad, Surendra Rajit, Prakash Kumar, Saptarshi Mandal, Anu Mohan, Radhika Chaurasia, Ashish Shrivastava, Pallaprolu Nikhil et al. "Mechanistic insight into the role of mevalonate kinase by a natural fatty acid-mediated killing of Leishmania donovani." *Scientific Reports* 12, no. 1 **(2022)**: 16453.

- 18. Thamineni, Rajavardhana, Ramalingam Peraman, Jayakumar Chenniah, GeethavaniMeka, Ashok Kumar Munagala, Vijayakumar Thangavel Mahalingam, and RajanandhMuhasaparur Ganesan. "Level of adherence to anti-tubercular treatment among drug-sensitive tuberculosis patients on a newly introduced daily dose regimen in South India: A cross-sectional study." *Tropical Medicine & International Health* 27, no. 11 **(2022)**: 1013-1023.
- 19. Abdelaziz, MazinAboobaida Abdalla, Vijayan N. AzgerDusthackeer, and Ramalingam Peraman. "Anticancer Activity of Grewia obtusa Fruit on HCT-116, MCF-7, and HeLa Tumour Cells Besides Antitubercular Activity." *Indian Journal of Pharmaceutical Education and Research* 56, no. 3 **(2022)**: 765-771.
- 20. Peraman, Ramalingam, Santhivardhan Chinni, Sathish K. Sure, Vinay Kumar Kutagulla, and MuthukumaranPeraman. "Anti-evolution Drugs: A New Paradigm to Combat Drug Resistance." *Letters in Drug Design & Discovery* 19, no.1 **(2022)**: 2-9.

Pharmaceutics

21. Kumbhar, Smita Tukaram, Ravikant Yashwantrao Patil, Manish Sudesh Bhatia, Prafulla BalkrushnaChoudhari, and Vinod Limbraj Gaikwad. "Synthesis and characterization of chitosan nanoparticles decorated with folate and loaded with dasatinib for targeting folate receptors in cancer cells." *OpenNano* 7 **(2022)**: 100043.

Biotechnology

- 22. Prasad, Surendra Rajit, Prakash Kumar, Saptarshi Mandal, Anu Mohan, Radhika Chaurasia, Ashish Shrivastava, Pallaprolu Nikhil et al. "Mechanistic insight into the role of mevalonate kinase by a natural fatty acid-mediated killing of Leishmania donovani." *Scientific Reports* 12, no. 1 **(2022)**: 16453.
- 23. Kumar, Prakash, Pawan Kumar, Debabrata Mandal, and RavichandiranVelayutham. "The emerging role of Deubiquitinases (DUBs) in parasites: А foresight review." *Frontiers* in Cellular and Infection *Microbiology* (2022): 1403.
- 24. Nayak, Suman, Prakash Kumar, Ravi Shankar, Asish Kumar Mukhopadhyay, Debabrata Mandal, and Prolay Das. "Biomass derived self-assembled DNA-dot hydrogels for enhanced bacterial annihilation." *Nanoscale* 14, no. 43 (2022): 16097-16109.
- Kant, Vishnu, Pawan Kumar, Ravi Ranjan, Prakash Kumar, Debabrata Mandal, and Saravanan Vijayakumar. "In silico screening, molecular dynamic simulations, and in vitro activity of selected natural compounds as an inhibitor of Leishmania donovani 3-mercaptopyruvate sulfurtransferase." *Parasitology Research* 121, no. 7 (2022): 2093-2109.
- 26. Kwon, Kiyoon, Junyoung Jung, Abhishek Sahu, and Giyoong Tae. "Nanoreactor for cascade reaction between SOD and CAT and its tissue regeneration effect." *Journal of Controlled Release* 344 **(2022)**: 160-172.
- 27. Kumarasamy, Murali, Ngoc Tran, Javier Patarroyo, Sushmita Mishra, Marco Monopoli, Emilia Madarasz, and Victor Puntes. "The effects of silver nanoparticle shape on protein adsorption and neural stem cell viability." *ChemistrySelect* 7, no. 39 **(2022)**: e202201917.

28. Sharma, Akshansh, DevanshiShambhwani, Sadanand Pandey, Jay Singh, HauzelLalhlenmawia, Murali Kumarasamy, Sachin Kumar Singh et al. "Advances in Lung Cancer Treatment Using Nanomedicines." *ACS omega* **(2022)**.

Pharmacology and Toxicology

- 29. Nayak, Akshatha G., P. Ashwini Aithal, Nitesh Kumar, Smita Shenoy, and Maya Roche. "Augmented rescue of macroglobulins by supplementation of anti-snake venom with methanolic extract of Andrographis paniculata in Najanaja envenomation." *3 Biotech* 12, no. 11 **(2022)**: 310.
- 30. Madhu, Maxima, V. Udaya Kumar, Sameer Dhingra, Nitesh Kumar, Sanjiv Singh, V. Ravichandiran, and Krishna Murti. "Nutritional Aspects of People Living with HIV (PLHIV) Amidst COVID-19 Pandemic: an Insight." *Current pharmacology reports* 8, no. 5 (2022): 350-364.
- 31. Bisht, Priya, V. Udaya Kumar, Ruchi Pandey, RavichandiranVelayutham, and Nitesh Kumar. "Role of PARP Inhibitors in Glioblastoma and Perceiving Challenges as Well as Strategies for Successful Clinical Development." *Frontiers in Pharmacology* 13 (2022).
- 32. Shenoy, Ganesh, Smita Shenoy, B. Sathish Pai, Nitesh Kumar, Arul Amuthan, Manjunath Shetty, Mohandas Rao, Kanthilatha Pai, and K. Bharath Rao. "A Subchronic 90-day Oral Toxicity Study of SivanarVembuKhuzhiThailam in Rats." *Journal of International Dental and Medical Research* 15, no. 1 (2022): 88-93.
- 33. Nanaware, Harshal R., Sudheer Moorkoth, Nitesh Kumar, Shiny Jasphin, Arya Raveendran, and Bhim Bahadur Chaudhari. "Amino Acids from Urine as Possible Biomarkers for Early Detection of Vancomycin Nephrotoxicity." *Indian Journal of Pharmaceutical Education and Research* 56, no. 3 **(2022)**: 795-803.
- 34. Meenakshi, Sarasa, V. Udaya Kumar, Reny Sara Raju, Sameer Dhingra, Nitesh Kumar, V. Ravichandiran, and Krishna Murti. "Ayurveda: The Prominence of Herbal Medicine in Containment of COVID-19." *Pharmacognosy Research* 14, no. 3 (2022).
- 35. Mahatme, Simran, K. Vaishali, Nitesh Kumar, Vanishree Rao, Rakesh Krishna Kovela, and Mukesh Kumar Sinha. "Impact of high-intensity interval training on cardio-metabolic health outcomes and mitochondrial function in older adults: a review." *Medicine and Pharmacy Reports* 95, no. 2 **(2022)**: 115.
- 36. Bhaskaran, NavyaAjitkumar, Srinivas Reddy Jitta, SriPragnyaCheruku, Nitesh Kumar, and Lalit Kumar. "Orally delivered solid lipid nanoparticles of irinotecan coupled with chitosan surface modification to treat colon cancer: preparation, invitro and in-vivo evaluations." *International Journal of Biological Macromolecules* 211 **(2022)**: 301-315.
- 37. Sodum, Nalini, Vanishree Rao, Sri PragnyaCheruku, Gautam Kumar, RunaliSankhe, Anoop Kishore, Nitesh Kumar, and C. Mallikarjuna Rao. "Amelioration of high-fat diet (HFD)+ CCl4 induced NASH/NAFLD in CF-1 mice by activation of SIRT-1 using cinnamoyl sulfonamide hydroxamate derivatives: insilico molecular modelling and in-vivo prediction." *3 Biotech* 12, no. 7 (2022): 147.
- 38. Rao, Vanishree, Rashmi Bhushan, Priyanka Kumari, Sri PragnyaCheruku, V. Ravichandiran, and Nitesh Kumar. "Chemobrain: A review on mechanistic insight, targets and treatments." *Adv Cancer Res* 155 **(2022)**: 29-76.

- 39. Rai, Amita, Raghavendra Shetty, Harish Prabhu, ArunaTheerthahalli, N. Kumar, N. Krishnadas, and A. H. Khan. "A Very Sensitive Bioanalytical Method for the Estimation of Escitalopram in Rat Plasma Using Liquid Chromatography with Tandem Mass Spectrometry-Application to Animal Pharmacokinetic Study." *Indian Journal of Pharmaceutical Sciences* 84, no. 2 (2022): 380-389.
- 40. Barodia, Kalgi, Sri PragnyaCheruku, Abhinav Kanwal, Aayush Menon, RutuRajeevan, Aniket Rukade, Raghavendra Udaya Kumar Shenoy et al. "Effect of Moringa oleifera leaf extract on exercise and dexamethasone-induced functional impairment in skeletal muscles." *Journal of Ayurveda and Integrative Medicine* 13, no. 1 **(2022)**: 100503.
- 41. Ranjan, Om P., Nitesh Kumar, and Vivek Dave. "Cross-linked Alginate Beads of Montelukast Sodium Coated with Eudragit for Chronotherapy: Statistical Optimization, In vitro and In vivo Evaluation." *Current Drug Delivery* 19, no. 10 **(2022)**: 1047-1060.
- 42. Vaishali, K., Nitesh Kumar, Vanishree Rao, Rakesh K. Kovela, and Mukesh Kumar Sinha. "Exercise and Mitochondrial Function: Importance and Inference-A Mini Review." *Current Molecular Medicine* 22, no. 9 (2022): 755-760.
- 43. Baranwal, Aadrika, Punita Aggarwal, Amita Rai, and Nitesh Kumar. "Pharmacological actions and underlying mechanisms of catechin: A review." *Mini Reviews in Medicinal Chemistry* 22, no. 5 **(2022)**: 821-833.

BOOK CHAPTERS:

- V. Kumar, Maxima Madhu, and Krishna Murti. An overview on leishmaniasis, Book Chapter. Book Name: Viral, parasitic, Bacterial and Fungal Infections, Academic Press, Elsevier Science, **2022**, ISBN: 978-0-323-85730-7. pp – 389-406
- 2. Das S, Ranjan OP, Rao V, Ravichandiran V, Kumar N. Multifunctional liposomequantum dot hybrid nanocarriers for drug targeting to brain tumors. InNanocarriers for Drug-Targeting Brain Tumors **2022** Jan 1 (pp. 649-677). Elsevier.
- 3. Bhushan R, Ravichandiran V, Kumar N. An overview of the anatomy and physiology of the brain.In Nanocarriers for Drug-Targeting Brain Tumors. **2022** Jan 1:3-29.
- 4. Kumar, Lalit, and Yashwant Pathak, eds. *Nanocarriers for Drug-Targeting Brain Tumors*. Elsevier, 2022.

PATENTS:

- 1. Nandanwar Hemraj S.; Jachak Sanjay M.; TambatRushikesh R.; Chandal N.; Mahey N.; kalia R.; IngawaleRajnita R (2020). Use of novel pyrole derivatives as inhibitors of resistance-nodulation cell division (RND) efflux system. Indian Patent 202011054425.
- Bharali, Alakesh; Bhattacharya, Sumanta; Chatterjee, Bramhajit; Das, Sonjit; Kumar, Nitesh; Kumar Mishra, Vikram Viswajit Binod; Mishra, Amrita; Samanta, Amit; Sharma, Satyam. POLYHERBAL FORMULATION FOR IMPROVING FERTILITY.DE 20 2022 102 391 U1 2022.06.15. Applied 3-05-2022, Granted-15-06-2022 (Germany)

UTILITY PATENT APPLICATION:

1. Pranay Wal, V. Ravichandiran, Ankita Wal, Ashwini K. Rai, Krishna murti, Nitesh Kumaer, Sameer Dhingra, Harshit Chaurasia. Title: "A chewing Gum Disolution apparatus for improved drug release study. Indian Patent Number-40222 Application Number 2021110567886 A. Date of Filing: 7/12/2021, Publication Date 17/12/2021



NIPER, HYDERABAD



Contact Address

Balanagar, Hyderabad - 500 037, Telangana, India. Phone: +91 40 23073741 / 40; +91 40 23074750 (Extn No: 2001 to 2044) Email: info.niperhyd@gov.in Website: www.niperhyd.ac.in

From the Director's Desk

NIPER Hyderabad started its journey in 2007. The institute has a total of eleven academics departments [M.S. (Pharm.) (Medicinal Chemistry, Pharmaceutical Analysis, Pharmacology and Toxicology, Pharmaceutics, Regulatory Toxicology, Natural Products. Pharmacoinformatics. Regulatory Affairs & MTech (Process Chemistry & Medical Devices) and MBA (Pharm.)], which hosts more than 363 students pursuing post-graduate studies. About 138 PhD Students are pursuing their research for doctoral degree programmes.

The continuous efforts made in the last few years by NIPER Hyderabad have resulted in the 2nd rank (Score: 79.46) in the 'Pharmacy' category in the National Institutional Ranking Framework (NIRF) ranking during the year 2021-22.



Dr Shashi Bala Singh

The Institute faculty is active in a broad spectrum of research in cancer, inflammation, arthritis, diabetes, neurodegenerative and infectious diseases, and anti-microbials, starting from Drug Discovery to Formulation Development and Preclinical studies. Some of the key research areas of NIPER, Hyderabad is:

- Synthesis of New Chemical Entities (NCEs) for Anti-Cancer, Anti-inflammatory etc.
- Innovative strategies for the synthesis of natural/unnatural or key intermediates/ building blocks
- Combinatorial chemistry and Computer Aided Drug Design (CADD)
- Green chemistry protocols for pharmaceutical importance and to preserve nature.
- Biocatalysis and Biotransformation, which include a biocatalytic route to synthesise APIs
- Diabetes and diabetic neuropathy research
- Peptidomimetics as therapeutic agents and Drug Delivery Systems
- Impurity Profiling and Analytical Method Development
- Standardization of Herbal drugs
- Stability Improvement Methods
- In vitro and In vivo Screening of New Chemical Entities (NCEs) for various activities
- Drug Metabolism and Pharmacokinetic studies (DMPK)
- Novel Drug Delivery Systems and Nanomedicine
- Improvement in Bioavailability
- Application of QBD in Formulation Design and Processing
- Bioavailability improvement using nanotechnology, lipid-based systems and crystal engineering techniques.
- Co-crystal, polymorphism and amorphism study and characterisation
- Thermal characterisation of drugs and small molecules

- Affordable Medical and PoC Devices such as Paper-based Microfluidic Devices (PBMD), Lateral Flow Immunoassay (LFIA), Polymer Microfluidic devices and their application in clinical diagnosis.
- Portable/handheld electronic devices, Dual chamber injectors (Epi-injections) and Dual chamber pediatric dosing system
- Organoids and Organ-on-a-chip, as platform technology as an alternative to animal testing for high throughput drug screening and as Disease models
- 3D bioprinting and microfabrication

EXTRA-MURAL RESEARCH PROJECTS

| S.N. | Title of the | PI and Co PI | Name of | Sanctioned | Duration | | |
|------|---|---|---|---|--|--|--|
| | Project | | Funding | Amount | of the | | |
| | | | Agency | | project | | |
| 1. | Lateral Flow | Dr. Vivek | Department | 110 Lakh | 5 years | | |
| | Immunoassay | Borse | of Science | | | | |
| | based Point-of- | | and | | | | |
| | Care Oral Cancer | | Technology, | | | | |
| | Diagnostic kit | | Govt. of India | | | | |
| | (OCDk) | | | | | | |
| | The proof of concept | | - | | | | |
| | of oral cancer bioma | | | - | | | |
| | flow detection systy such is IL6 and IL8 e | | | i using oral ca | licer markers | | |
| 2. | Comprehensive | Dr. Rajesh | DST-SERB- | 27.30 Lakh | 2 years | | |
| 4. | three-dimensional | Sonti | SRG | 27.50 Lakii | 2 years | | |
| | structural analysis | bonti | bitte | | | | |
| | of macrocyclic | | | | | | |
| | peptide disulfides | | | | | | |
| | by biophysical | | | | | | |
| | methods | | | | | | |
| | The project deals w | ith the determi | nation of 3D sol | ution structure | e of this first- | | |
| | | | | | | | |
| | in-class peptide drug using NMR Studies. The study incorporates aromatic, D- amino acids and prolines at strategic positions to generate different | | | | | | |
| | amino acids and | prolines at s | trategic positio | ons to genera | ate different | | |
| | macrocyclic rings by | y using syntheti | ic peptides. Base | ed on above da | ta structures | | |
| | macrocyclic rings by will be calculated a | y using syntheti | ic peptides. Base | ed on above da | ita structures | | |
| | macrocyclic rings by will be calculated a using NMR | y using syntheti and the role of | ic peptides. Base disulfide confo | ed on above da rmations will | ta structures be evaluated | | |
| 3. | macrocyclic rings by will be calculated a using NMR Structure | y using syntheti and the role of Dr. Rajesh | ic peptides. Base disulfide confo Granules | ed on above da | ta structures | | |
| 3. | macrocyclic rings by will be calculated a using NMR Structure elucidation of | y using syntheti and the role of | ic peptides. Base disulfide confo | ed on above da rmations will | ta structures be evaluated | | |
| 3. | macrocyclic rings by will be calculated a using NMR Structure elucidation of Ibuprofen related | y using syntheti and the role of Dr. Rajesh | ic peptides. Base disulfide confo Granules | ed on above da rmations will | ta structures be evaluated | | |
| 3. | macrocyclic rings by will be calculated a using NMR Structure elucidation of Ibuprofen related 2 unknown | y using syntheti and the role of Dr. Rajesh | ic peptides. Base disulfide confo Granules | ed on above da rmations will | ta structures be evaluated | | |
| 3. | macrocyclic rings by will be calculated a using NMR Structure elucidation of Ibuprofen related 2 unknown impurities | y using syntheti and the role of Dr. Rajesh Sonti | ic peptides. Base disulfide confo Granules India Ltd | ed on above da rmations will 3.87Lakh | ta structures be evaluated 0.16 Years | | |
| 3. | macrocyclic rings by will be calculated a using NMR Structure elucidation of Ibuprofen related 2 unknown impurities The project deals | y using syntheti and the role of Dr. Rajesh Sonti with the struct | ic peptides. Base disulfide confo Granules India Ltd ture elucidatior | ed on above da rmations will 3.87Lakh of Ibuprofen | 0.16 Years | | |
| 3. | macrocyclic rings by will be calculated a using NMR Structure elucidation of Ibuprofen related 2 unknown impurities The project deals unknown impurities | y using syntheti and the role of Dr. Rajesh Sonti with the struct s, which funding | ic peptides. Base disulfide confo Granules India Ltd ture elucidatior g company Gran | ed on above da rmations will 3.87Lakh of Ibuprofen ules India Ltd | 0.16 Years | | |
| 3. | macrocyclic rings by will be calculated a using NMR Structure elucidation of Ibuprofen related 2 unknown impurities The project deals unknown impurities do. The structure elucidation of structure elucidation of 100 mm mounities | y using syntheti and the role of Dr. Rajesh Sonti with the struct s, which funding | ic peptides. Base disulfide confo Granules India Ltd ture elucidatior g company Gran | ed on above da rmations will 3.87Lakh of Ibuprofen ules India Ltd | 0.16 Years | | |
| | macrocyclic rings by will be calculated a using NMR Structure elucidation of Ibuprofen related 2 unknown impurities The project deals unknown impurities do. The structure el Mass. | y using syntheti and the role of Dr. Rajesh Sonti with the struct s, which funding ucidation of the | ic peptides. Base disulfide confo Granules India Ltd ture elucidatior g company Gran | ed on above da rmations will 3.87Lakh a of Ibuprofen ules India Ltd rill be done usi | ta structures be evaluated 0.16 Years -related two would like to ng NMR and | | |
| 3. | macrocyclic rings by will be calculated a using NMR Structure elucidation of Ibuprofen related 2 unknown impurities The project deals unknown impurities do. The structure el Mass. Determination of | y using syntheti and the role of Dr. Rajesh Sonti with the struct s, which funding ucidation of the Dr. Rajesh | ic peptides. Base disulfide confo Granules India Ltd ture elucidatior g company Gran | ed on above da rmations will 3.87Lakh of Ibuprofen ules India Ltd | 0.16 Years | | |
| | macrocyclic rings by will be calculated a using NMR Structure elucidation of Ibuprofen related 2 unknown impurities The project deals unknown impurities do. The structure el Mass. | y using syntheti and the role of Dr. Rajesh Sonti with the struct s, which funding ucidation of the | ic peptides. Base disulfide confo Granules India Ltd ture elucidation g company Gran ese impurities w Orbicular | ed on above da rmations will 3.87Lakh a of Ibuprofen ules India Ltd rill be done usi | ta structures be evaluated 0.16 Years -related two would like to ng NMR and | | |
| | macrocyclic rings by will be calculated a using NMR Structure elucidation of Ibuprofen related 2 unknown impurities The project deals unknown impurities do. The structure el Mass. Determination of PDMS in the | y using syntheti and the role of Dr. Rajesh Sonti with the struct s, which funding ucidation of the Dr. Rajesh | ic peptides. Base disulfide confo Granules India Ltd ture elucidation g company Gran ese impurities w Orbicular Pharmaceuti cal | ed on above da rmations will 3.87Lakh a of Ibuprofen ules India Ltd rill be done usi | ta structures be evaluated 0.16 Years -related two would like to ng NMR and | | |
| | macrocyclic rings by will be calculated a using NMR Structure elucidation of Ibuprofen related 2 unknown impurities The project deals unknown impurities do. The structure el Mass. Determination of PDMS in the octreotide | y using syntheti and the role of Dr. Rajesh Sonti with the struct s, which funding ucidation of the Dr. Rajesh | ic peptides. Base disulfide confo Granules India Ltd ture elucidation g company Gran ese impurities w Orbicular Pharmaceuti | ed on above da rmations will 3.87Lakh a of Ibuprofen ules India Ltd rill be done usi | ta structures be evaluated 0.16 Years -related two would like to ng NMR and | | |
| | macrocyclic rings by will be calculated a using NMR Structure elucidation of Ibuprofen related 2 unknown impurities The project deals unknown impurities do. The structure el Mass. Determination of PDMS in the octreotide formulation | y using syntheti and the role of Dr. Rajesh Sonti with the struct s, which funding ucidation of the Dr. Rajesh Sonti | ic peptides. Base disulfide confo Granules India Ltd ture elucidation g company Gran ese impurities w Orbicular Pharmaceuti cal Technologies Pvt. Ltd. | ed on above da rmations will 3.87Lakh a of Ibuprofen ules India Ltd rill be done usi 0.45 Lakh | ta structures be evaluated 0.16 Years -related two would like to ng NMR and 0.08 Years | | |
| | macrocyclic rings by will be calculated a using NMR Structure elucidation of Ibuprofen related 2 unknown impurities The project deals unknown impurities do. The structure el Mass. Determination of PDMS in the octreotide formulation using qNMR | y using syntheti and the role of Dr. Rajesh Sonti with the struct s, which funding ucidation of the Dr. Rajesh Sonti | ic peptides. Base disulfide confo Granules India Ltd ture elucidation g company Gran ese impurities w Orbicular Pharmaceuti cal Technologies Pvt. Ltd. chnologies Pvt | ed on above da rmations will 3.87Lakh a of Ibuprofen ules India Ltd rill be done usi 0.45 Lakh provides the | ta structures be evaluated 0.16 Years -related two would like to ng NMR and 0.08 Years project. Ltd, | | |
| | macrocyclic rings by will be calculated a using NMR Structure elucidation of Ibuprofen related 2 unknown impurities The project deals unknown impurities do. The structure el Mass. Determination of PDMS in the octreotide formulation using qNMR M/s Orbicular Pha | y using syntheti and the role of Dr. Rajesh Sonti with the struct s, which funding ucidation of the Dr. Rajesh Sonti rmaceutical Te d like to deter | ic peptides. Base disulfide confo Granules India Ltd ture elucidation g company Gran ese impurities w Orbicular Pharmaceuti cal Technologies Pvt. Ltd. chnologies Pvt rmine and quar | ed on above da rmations will 3.87Lakh a of Ibuprofen ules India Ltd rill be done usi 0.45 Lakh provides the | ta structures be evaluated 0.16 Years -related two would like to ng NMR and 0.08 Years project. Ltd, | | |
| | macrocyclic rings by will be calculated a using NMR Structure elucidation of Ibuprofen related 2 unknown impurities The project deals unknown impurities do. The structure el Mass. Determination of PDMS in the octreotide formulation using qNMR M/s Orbicular Pha wherein they would | y using syntheti and the role of Dr. Rajesh Sonti with the struct s, which funding ucidation of the Dr. Rajesh Sonti rmaceutical Te d like to deter | ic peptides. Base disulfide confo Granules India Ltd ture elucidation g company Gran ese impurities w Orbicular Pharmaceuti cal Technologies Pvt. Ltd. chnologies Pvt rmine and quar | ed on above da rmations will 3.87Lakh a of Ibuprofen ules India Ltd rill be done usi 0.45 Lakh provides the | ta structures be evaluated 0.16 Years -related two would like to ng NMR and 0.08 Years project. Ltd, | | |
| 4. | macrocyclic rings by will be calculated a using NMR Structure elucidation of Ibuprofen related 2 unknown impurities The project deals unknown impurities do. The structure el Mass. Determination of PDMS in the octreotide formulation using qNMR M/s Orbicular Pha wherein they woul octreotide formulation | y using syntheti and the role of Dr. Rajesh Sonti with the struct s, which funding ucidation of the Dr. Rajesh Sonti rmaceutical Te d like to deter | ic peptides. Base disulfide confo Granules India Ltd ture elucidation g company Gran ese impurities w Orbicular Pharmaceuti cal Technologies Pvt. Ltd. chnologies Pvt rmine and quat | ed on above da rmations will 3.87Lakh a of Ibuprofen ules India Ltd rill be done usi 0.45 Lakh provides the ntify PDMS co | ta structures be evaluated 0.16 Years -related two would like to ng NMR and 0.08 Years project. Ltd, ontent in the | | |

| | between their drug product and | | Technologies Pvt. Ltd. | | |
|----|---|--|---|--|---|
| | innovator product | | I VEI LECA | | |
| | Orbicular Pharmace establish NMR-base and innovator produ | d studies comp | | | |
| 6. | To study the efficacy of therapeutic plant molecule in animal models to treat Chronic Obstructive Pulmonary Disease (COPD) by the lung regeneration/repa ir process | Dr. Dharmendra Kumar Khatri | NBI Bioascience PVT LTD. Gurgaon | 24.27 Lakh | 1 year |
| | To study the efficac Chronic Obstructi regeneration/repair using smoking of 5 of Saw dust)/day for formulation for 60 recovery. The project deals w models to treat Chr lung regeneration/ developed using th (Burning smoke of were treated with t showed significant r | ve Pulmonan process. The cigarettes/grou a period of 30 days provided with the efficacy conic Obstructiv (repair proces e smoking of so Saw dust)/per he formulation | Ty Disease COPD model w p per day and p days. The anim by the sponsor of therapeutic re Pulmonary D s. The COPD 5 cigarettes/gro day for a perio | (COPD) by vas successfull collution (Burn nals were trea red and showe plant molecul visease (COPD) model was cup per day a cod of 30 days. | the lung y developed ing smoke of ted with the ed significant es in animal through the successfully nd pollution The animals |
| 7. | To perform the stereotaxic surgery using rotenone to create mice model of Parkinson's Disease | Dharmendra Kumar Khatri | Sai Life Sciences, Hyderabad | 1.77 Lakh | 0.2 Years |
| | The main objective model of Parkinson' employed in the p duration of reach bil very complex as it r animals living after p | s disease using present project lateral surgery equires expert | a stereataxic in is the chroni is 40-50 minute to perform this | strument. The c surgical pro s. The surgical | methodology ocedure. The procedure is |
| 8. | Development of Parkinson's model in mice utilizing stereotaxic | Dharmendra Kumar Khatri | Sai Life Sciences, Hyderabad | 3.70 Lakh | 0.3 Years |

| | equipment via ICV | | | | | | | |
|-----|--|--------------------------|-----------------|-----------------|---------------|--|--|--|
| | injection | | | | | | | |
| | The present proposition mouse model which | is very well es | tablished and p | racticed both | national and | | | |
| | globally for pre-clinical drug discovery. This chemical-induced PD model is | | | | | | | |
| | used extensively to | 0 | | 0 | | | | |
| | The animal model performed with ICV injection using the stereotaxic instrument and was done successfully | | | | | | | |
| | The present proposal involves the ICV injection of chemical to induce PD | | | | | | | |
| | mouse model which | is very well es | tablished and p | racticed both | national and | | | |
| | globally for pre-clin | | | | | | | |
| | used extensively to | | | | | | | |
| | The animal model | • | | ion using the | e stereotaxic | | | |
| | instrument and was | | 0 | 1 | | | | |
| 9. | Evaluation of | Dharmendra | Sai Life | 0.84 Lakh | 0.3 Years | | | |
| | Efficacy of Test | Kumar | Sciences, | | | | | |
| | compound in U87- | Khatri | Hyderabad | | | | | |
| | MG (Human | | | | | | | |
| | glioblastoma) | | | | | | | |
| | orthotopic mouse model | | | | | | | |
| | The present propos | sal involves th | - ICV injection | of chemical t | o induce PD | | | |
| | mouse model which | | | | | | | |
| | globally for pre-clin | • | • | | | | | |
| | used extensively to | - | | | | | | |
| | The animal model | - | | - | - | | | |
| | instrument and was | • | | 0 | | | | |
| | The present propos | sal involves the | e ICV injection | of chemical t | o induce PD | | | |
| | mouse model which | | - | | | | | |
| | globally for pre-clin | - | | | | | | |
| | used extensively to | 0 | | 0 | | | | |
| | The animal model | • | , | ion using the | e stereotaxic | | | |
| 10 | instrument and was | | | 22 (0 L al-h | 2 | | | |
| 10. | Role of age- and sex-specific gut | Dr. Manoj P. Dandekar | DST-SERB | 32.69 Lakh | 2 years | | | |
| | microbiota in | Danuekai | | | | | | |
| | brain injury for | | | | | | | |
| | microbiome-based | | | | | | | |
| | therapeutics | | | | | | | |
| | Assessment of int | estinal microl | bial communiti | ies in the r | egulation of | | | |
| | neurological and ne | | | | - | | | |
| | manner | after | bra | ain | injury? | | | |
| | Investigation of | changes i | n gut-microł | piome brain | signaling | | | |
| | Brains and blood | - | - | | - | | | |
| | neuronal cell dea | | | | | | | |
| | We have been anal | | | | | | | |
| | potent bacteriother | | · · · | • • | | | | |
| | microbiome-based t | | | er-specific neu | rological and | | | |
| | neuropsychiatric be | naviors occurs | JUST- I BI. | | | | | |

| | The project Investig and blood samples v death and prolifer Hyderabad analyses bacteriotherapy. Thi therapy for address | vill be processe ation marker the specific gu s project's resu ing the gender | d for the neuro and CRF expr at microbial cor alts may help de | inflammatory, ession. In pro mmunities to d erive the micro | neuronal cell oject NIPER, esign potent biome-based |
|-----|---|---|--|--|--|
| | behaviours that occu | ır post-TBI. | | | |
| 11. | To examine the therapeutic potential of pan- bacteria + glutamine in the management of obsessive- compulsive disorders (OCD) in Wistar rats. 2. To assess the safety of 2 probiotics (<i>Streptococcus</i> <i>salivarius</i> and <i>Bacillus subtilis</i>) products in | Dr. Manoj P. Dandekar | Unique Biotech | 7.5 Lakh | 10 months |
| | Sprague-Dawley | | | | |
| | rats. | | | | |
| | To examine the ther the management of To assess the safet Bacillus subtilis WE found promisi salivarius UBSS-01 a In this project, the th in managing obsess investigated. This w salivarius UBSS-01 a rats. It was found Streptococcus saliva the rat study. | obsessive-com y of 2 probioti UBBS-14) ng effects of nd Bacillus sub herapeutic pote sive-compulsive vill help assess and Bacillus sub that promising urius UBSS-01 a | pulsive disorde cs (Streptococc products in probiotic in (tilis UBBS-14 fo ntial of Cognisol disorders (OC the safety of 2 tilis UBBS-14) p effects of pro and Bacillus sub | ers (OCD) in V cus salivarius V Sprague-Da OCD model. S und safe in rat (pan-bacteria D) in Wistar 1 2 probiotics (S products in Spr biotics in the ptilis UBBS-14 | Vistar. rats. JBSS-01 and wley rats. treptococcus study. + glutamine) rats is being treptococcus ague-Dawley OCD model. were safe in |
| 12. | To examine the therapeutic potential of multi- strain probiotic + glutamine and Bacillus coagulans Unique IS-2 in vascular dementia model of rats | Dr. Manoj P. Dandekar | Unique Biotech | 5.0 Lakh | 10 months |
| | To examine the ther Bacillus coagulans | | | | |

| | We are testing the e | ficacy of this pr | obiotic in rat m | odel of vascula | r domontia |
|-----|--|---|---|---|---------------------------------------|
| | In this project, the t | | | | |
| | and Bacillus coagula | | | | |
| | | | | | |
| | from therapeutic pe | otential, the en | ficacy of this p | | lat model of |
| 4.0 | vascular dementia. | | DOM | 400 (1 1 1 | - |
| 13. | NHC catalyzed | Vinaykumar | DST | 128.6 Lakh | 5 years |
| | asymmetric | Kanchupalli | | | |
| | synthetic | | | | |
| | transformations | | | | |
| | with allene | | | | |
| | compounds | | | | |
| | Synthesis and chara | cterization of va | arious derivative | es of allene com | pounds |
| | Synthesis and char | acterization of | various imine co | ompounds | |
| | Optimization with | different Chiral | NHC catalysts | | |
| | Generality and sub | strate scope of | methodology | | |
| | Mechanistic studie | s for the import | ant reaction | | |
| | The project deals | - | | vsed asymmet | ric syntheti |
| | transformations wi | | | | |
| | Synthesis and chara | | | | |
| | Optimization with d | | - | | F |
| 14. | Development, | Dr. Saurabh | DRDO, | 9.9 Lakh | 1 year |
| | evaluation and | Srivastava | TEZPUR | | |
| | characterization of | and | | | |
| | hydrophobic | Dr.Neelesh | | | |
| | nanoparticles | Kumar | | | |
| | impregnated | Mehra | | | |
| | fabrics to be | Mema | | | |
| | assessed as dress | | | | |
| | materials for | | | | |
| | defence | | | | |
| | | | | | |
| | | a au acachiller a | مسمو المعمد المسمو | | d analyzation |
| | The project has been | | | | nd evaluation |
| | The project has been of Fabric with Impre | gnated hydrop | hobic Nanoparti | cles. | |
| | The project has been of Fabric with Impre The project is relate | gnated hydropl d to developed | hobic Nanoparti and evaluation | cles. of Fabric with | |
| 15 | The project has been of Fabric with Impre The project is relate hydrophobic Nanopa | gnated hydropl d to developed articles for defe | hobic Nanoparti and evaluation nce applications | cles. of Fabric with s. | Impregnated |
| 15. | The project has been of Fabric with Impre The project is relate hydrophobic Nanopa Development and | egnated hydropl d to developed articles for defe Dr. Saurabh | hobic Nanoparti and evaluation nce applications NBI | cles. of Fabric with | |
| 15. | The project has been of Fabric with Impre The project is relate hydrophobic Nanopa Development and evaluation of oral | gnated hydropl d to developed articles for defe Dr. Saurabh Srivastava | hobic Nanoparti and evaluation nce applications NBI Elements | cles. of Fabric with s. | Impregnated |
| 15. | The project has been of Fabric with Impre The project is relate hydrophobic Nanopa Development and evaluation of oral drug delivery | gnated hydropl d to developed articles for defe Dr. Saurabh Srivastava and | hobic Nanoparti and evaluation nce applications NBI | cles. of Fabric with s. | Impregnated |
| 15. | The project has been of Fabric with Impre The project is relate hydrophobic Nanopa Development and evaluation of oral drug delivery systems for colon | gnated hydropl d to developed articles for defe Dr. Saurabh Srivastava and Dr. | hobic Nanoparti and evaluation nce applications NBI Elements | cles. of Fabric with s. | Impregnated |
| 15. | The project has been of Fabric with Impre The project is relate hydrophobic Nanopa Development and evaluation of oral drug delivery systems for colon targeting of drugs | gnated hydropl d to developed articles for defe Dr. Saurabh Srivastava and Dr. Dharmendra | hobic Nanoparti and evaluation nce applications NBI Elements | cles. of Fabric with s. | Impregnated |
| 15. | The project has been of Fabric with Impre The project is relate hydrophobic Nanopa Development and evaluation of oral drug delivery systems for colon targeting of drugs for the local & | egnated hydropl d to developed articles for defe Dr. Saurabh Srivastava and Dr. Dharmendra Kumar | hobic Nanoparti and evaluation nce applications NBI Elements | cles. of Fabric with s. | Impregnated |
| 15. | The project has been of Fabric with Impre The project is relate hydrophobic Nanopa Development and evaluation of oral drug delivery systems for colon targeting of drugs for the local & systemic actions | egnated hydropl d to developed articles for defe Dr. Saurabh Srivastava and Dr. Dharmendra Kumar Khatri | hobic Nanoparti and evaluation nce applications NBI Elements Gurugram | cles. of Fabric with s. 8. 26 Lakh | Impregnated |
| 15. | The project has been of Fabric with Impre The project is relate hydrophobic Nanopa Development and evaluation of oral drug delivery systems for colon targeting of drugs for the local & | egnated hydropl d to developed articles for defe Dr. Saurabh Srivastava and Dr. Dharmendra Kumar Khatri | hobic Nanoparti and evaluation nce applications NBI Elements Gurugram | cles. of Fabric with s. 8. 26 Lakh | Impregnated |
| 15. | The project has been of Fabric with Impre The project is relate hydrophobic Nanopa Development and evaluation of oral drug delivery systems for colon targeting of drugs for the local & systemic actions | egnated hydropl d to developed articles for defe Dr. Saurabh Srivastava and Dr. Dharmendra Kumar Khatri evaluation of o | hobic Nanoparti and evaluation nce applications NBI Elements Gurugram ral drug delive | cles. of Fabric with s. 8. 26 Lakh ry formulation | Impregnated |
| 15. | The project has been of Fabric with Impre The project is relate hydrophobic Nanopa Development and evaluation of oral drug delivery systems for colon targeting of drugs for the local & systemic actions Development and e | egnated hydropl d to developed articles for defe Dr. Saurabh Srivastava and Dr. Dharmendra Kumar Khatri evaluation of o g of drugs for th | hobic Nanoparti and evaluation nce applications NBI Elements Gurugram ral drug delive ne local & system | cles. of Fabric with s. 8. 26 Lakh 8. 26 Lakh ry formulation nic actions | Impregnated 1 year , which wil |
| 15. | The project has been of Fabric with Impre The project is relate hydrophobic Nanopa Development and evaluation of oral drug delivery systems for colon targeting of drugs for the local & systemic actions Development and e target colon targeting | egnated hydropl d to developed articles for defe Dr. Saurabh Srivastava and Dr. Dharmendra Kumar Khatri evaluation of o g of drugs for the clements Gurugs | hobic Nanoparti and evaluation nce applications NBI Elements Gurugram ral drug delive ne local & system ram funded for | cles. of Fabric with s. 8. 26 Lakh ry formulation nic actions the developme | Impregnated 1 year a, which wil |
| 15. | The project has been of Fabric with Impre The project is relate hydrophobic Nanopa Development and evaluation of oral drug delivery systems for colon targeting of drugs for the local & systemic actions Development and e target colon targeting The project is NBI E | gnated hydroph d to developed articles for defe Dr. Saurabh Srivastava and Dr. Dharmendra Kumar Khatri evaluation of o g of drugs for th clements Gurug rug delivery for | hobic Nanoparti and evaluation nce applications NBI Elements Gurugram ral drug delive ne local & syster ram funded for mulation, whicl | cles. of Fabric with s. 8. 26 Lakh ry formulation nic actions the developme | Impregnated 1 year a, which wil |
| 15. | The project has been of Fabric with Impre The project is relate hydrophobic Nanopa Development and evaluation of oral drug delivery systems for colon targeting of drugs for the local & systemic actions Development and e target colon targetin The project is NBI E evaluation of oral dr | gnated hydroph d to developed articles for defe Dr. Saurabh Srivastava and Dr. Dharmendra Kumar Khatri evaluation of o g of drugs for th clements Gurug rug delivery for | hobic Nanoparti and evaluation nce applications NBI Elements Gurugram ral drug delive ne local & syster ram funded for mulation, whicl | cles. of Fabric with s. 8. 26 Lakh ry formulation nic actions the developme | Impregnated 1 year a, which wil |

| | Program | | | | | | | |
|-----|--|---|--------------------------|------------------|---------------|--|--|--|
| | TSCOST | | | | | | | |
| | To train 10 partic Conduct | the | program | as | defined | | | |
| | Outcomes: Successf Sciences Sector Skill | | | | tion by Life | | | |
| | The project deals v | | | in entrepreneu | urship in Six | | | |
| | months duration in | the Life Science | s Sector. | | | | | |
| 17. | Developing the novel P450 | Dr. Priyanka Bajaj | DST | 112.4 Lakh | 5 years | | | |
| | enzymes for | | | | | | | |
| | aromatic | | | | | | | |
| | nitrations | | | | | | | |
| | Developing novel ni | 0. | • | | | | | |
| | In this DST-funded | | | is developing | novel P450 | | | |
| | enzymes for aromat | | | | - | | | |
| 18. | Development of | Dr. Priyanka | DBT-BIRAC | 50 Lakh | 2 years | | | |
| | biocatalytic | Bajaj and | | | | | | |
| | cyclopropanation | Dr. Vikas | | | | | | |
| | process for the | Tyagu, TIET, | | | | | | |
| | synthesis of | Patiala | | | | | | |
| | pharmaceuticals | | | | | | | |
| | precursors at gram | | | | | | | |
| | scale. | hin for ADI armt | haaia | | | | | |
| | Engineering Myoglo This DBT-BIRAC-fur | | | ocatalytic cycle | nronanation | | | |
| | process for synthe | · · | • | | • • | | | |
| | synthesis at the grar | 0 1 | feedeleans preed | ingere ingegre | | | | |
| 19. | Biocatalytic | Dr. Priyanka | Amilife | 42 Lakh | 0.5years | | | |
| | synthesis of | Bajaj and | Sciences | - | | | | |
| | Eslicarbazapine | Dr. Vinay | | | | | | |
| | 1 | Kumar, | | | | | | |
| | | NIPER, HYD | | | | | | |
| | Biocatalytic synthes | is of Eslicarbaza | ipine | | | | | |
| | In this project team of NIPER, Hyderabad was involved in developing a | | | | | | | |
| | In this project tea | m of NIPER, H | lyderabad was | involved in o | developing a | | | |
| | In this project tea biocatalytic route to | | | | | | | |
| 20. | | | | | | | | |
| 20. | biocatalytic route to | synthesise Esli | carbazepine for | Amilife Science | es | | | |
| 20. | biocatalytic route to Exploiting the | synthesise Esli Dr. Vaibhav | carbazepine for IISC, | Amilife Science | es | | | |
| 20. | biocatalytic route to Exploiting the electron transfer | synthesise Esli Dr. Vaibhav Dixit and | carbazepine for IISC, | Amilife Science | es | | | |
| 20. | biocatalytic route to Exploiting the electron transfer (ET) parameters for the prediction of | synthesise Esli Dr. Vaibhav Dixit and Dr. Priyanka | carbazepine for IISC, | Amilife Science | es | | | |
| 20. | biocatalytic route to Exploiting the electron transfer (ET) parameters for the prediction of selectivities in | synthesise Esli Dr. Vaibhav Dixit and Dr. Priyanka | carbazepine for IISC, | Amilife Science | es | | | |
| 20. | biocatalytic route to Exploiting the electron transfer (ET) parameters for the prediction of selectivities in Cytochrome P450 (CYP450) | synthesise Esli Dr. Vaibhav Dixit and Dr. Priyanka | carbazepine for IISC, | Amilife Science | es | | | |
| 20. | biocatalytic route to Exploiting the electron transfer (ET) parameters for the prediction of selectivities in Cytochrome P450 (CYP450) catalyzedbiotransf | synthesise Esli Dr. Vaibhav Dixit and Dr. Priyanka | carbazepine for IISC, | Amilife Science | es | | | |
| 20. | biocatalytic route to Exploiting the electron transfer (ET) parameters for the prediction of selectivities in Cytochrome P450 (CYP450) catalyzedbiotransf ormations of | synthesise Esli Dr. Vaibhav Dixit and Dr. Priyanka | carbazepine for IISC, | Amilife Science | es | | | |
| 20. | biocatalytic route to Exploiting the electron transfer (ET) parameters for the prediction of selectivities in Cytochrome P450 (CYP450) catalyzedbiotransf | synthesise Esli Dr. Vaibhav Dixit and Dr. Priyanka | carbazepine for IISC, | Amilife Science | es | | | |

| | Elucidation of mecha | ansim of Floctro | n Transfor in D | 450BMF3 | | | | |
|-----|--|------------------------------|-----------------|----------------|---------------|--|--|--|
| | The project deals wi | | | | eters for the | | | |
| | prediction of sel | | | | | | | |
| | biotransformations | | • | • | j catalyseu | | | |
| 21. | Building | Dr. B. | Indian | 118.2Lakh | 2 yrs | | | |
| 21. | Innovative | Lakshmi | Council of | 110.2.10.11 | 2 y 13 | | | |
| | Ecosystems: | Laksiiiii | Social | | | | | |
| | Lesson from a | | Science | | | | | |
| | Comparative Study | | Research | | | | | |
| | on Pharmaceutical | | (ICSSR), | | | | | |
| | and Medical | | Ministry of | | | | | |
| | Devices Industries | | Education | | | | | |
| | of India and | | Luucation | | | | | |
| | Taiwan | | | | | | | |
| | Collaboration with I | nstitute of Man [,] | gement of Tech | nology Nation | al Vang Ming | | | |
| | Chiao | Tung | Univers | | Taiwan | | | |
| | Objectives: Compa | 0 | | | | | | |
| | | co-system | in Indi | | Taiwan | | | |
| | Deliverables: Develo | • | | | | | | |
| | Taiwan Pharmaceu | • | | | | | | |
| | research organizati | | | | | | | |
| | conclusions and sug | | | e the tata and | u report the | | | |
| | The project deals with | 0 | | Pharmacoutical | and Medical | | | |
| | Devices innovation | - | | | | | | |
| | reports. To suggest 1 | | | - | the uata and | | | |
| 22. | Targeting the | Nitin Pal | Department | 113.6 Lakh | 5 years | | | |
| 22. | cytochrome bd | Kalia | of | | byears | | | |
| | oxidase for the | | Biotechnolog | | | | | |
| | development of | | y, New Delhi, | | | | | |
| | rational drug | | Govt of India | | | | | |
| | combination for | | | | | | | |
| | tuberculosis | | | | | | | |
| | Indentification and | | ion cvt-bd in | hibitors Effec | t of cvt-bd | | | |
| | | | • | | | | | |
| | inhibitors on potency of Q203. Combination of cyt-bd inhibitors with other anti-tuberculosis drugs targeting oxidative phosphorylation. Target validation | | | | | | | |
| | and characterization | | | | | | | |
| | on animal model of t | | | | | | | |
| | In this project, NI | | d targets the | cvtochrome bo | d oxidase to | | | |
| | develop a rational d | | | | | | | |
| | the identification and | 0 | | · · · | | | | |
| | effect of cyt-bd inhi | | - | | - | | | |
| | with the combination | | | | | | | |
| | targeting oxidative | - | | | - | | | |
| | validation and char | | - | - | - | | | |
| | study of combination | | - | | , an enteacy | | | |
| 23. | Identification of | Nitin Pal | SERB-DST, | 31.66 Lakh | 2 years | | | |
| | Novel | Kalia | New Delhi, | | _ , cur 5 | | | |
| | Topoisomerase | | Govt of India | | | | | |
| | Inhibitors | | | | | | | |
| L | Innonors | 1 | I | 1 | I | | | |

| | targeting Pseudomonas | | | | |
|-----|---|--|--|--|----------------------------|
| | aeruginosa | | | | |
| | Identification of nov | el scaffolds targ | geting Type II Ba | acterial Topois | omerase in I |
| | aeruginosa. Target v | validation, char | acterization, an | d in vitro safe | ety of Type l |
| | topoisomerase inhib | itors. Effect of ' | Type II topoisor | nerase inhibito | ors on biofilr |
| | formation in P. aeru | | | | |
| | inhibitors of <i>P. aerug</i> | - | 5 | 51 | 1 |
| | The project deals | • | ation of Novel | Topoisomera | se Inhibitor |
| | targeting Pseudomo | | | - | |
| | identified type II top | - | | | - |
| 24. | Generation and | Amol G. | Bristol Myers | | 1 year |
| | Structural | Dikundwar | Squibb | | 1 your |
| | Characterization of | Diffundituri | Company, | | |
| | Modified Solid- | | USA | | |
| | state Forms of | | 034 | | |
| | APIs (Grant for | | | | |
| | | | | | |
| | PhD Fellowship) Generation and Stru | , atural Charact | arization of Ma | dified Colid at | Lata Farma a |
| | various APIs | ictural charact | enzation of MC | amed Sona-si | ate romis c |
| | | according of | d atmustured a | | of modifie |
| | This deals with the | - | ia structural ci | laracterisation | of modifie |
| 25 | solid-state various A | | NT 1 1 | 10111 | |
| 25. | Tracing a Root | S. | Nakoda | 1.8 Lakh | 0.5 years |
| | | | C1 | | |
| | Cause for the | Gananadham | Chemicals | | |
| | Formation of N- | u and | Limited, | | |
| | Formation of N- methyl Impurity in | u and Amol G. | | | |
| | Formation of N- methyl Impurity in Norfloxacin | u and Amol G. Dikundwar | Limited, Hyderabad | | |
| | Formation of N- methyl Impurity in Norfloxacin To identify the Ro | u and Amol G. Dikundwar | Limited, Hyderabad | of N-methyl | Impurity i |
| | Formation of N- methyl Impurity in Norfloxacin To identify the Ro Norfloxacin | u and Amol G. Dikundwar oot Cause for | Limited, Hyderabad the Formation | - | |
| | Formation of N- methyl Impurity in Norfloxacin To identify the Ro Norfloxacin in this project niper, | u and Amol G. Dikundwar oot Cause for team is trying | Limited, Hyderabad the Formation to identify the ca | - | |
| | Formation of N- methyl Impurity in Norfloxacin To identify the Ro Norfloxacin in this project niper, formation of n-meth | u and Amol G. Dikundwar oot Cause for team is trying yl impurity in n | Limited, Hyderabad the Formation to identify the ca orfloxacin | ause and mech | anism for th |
| 26. | Formation of N- methyl Impurity in Norfloxacin To identify the Ro Norfloxacin in this project niper, formation of n-meth Quantification of | u and Amol G. Dikundwar oot Cause for team is trying yl impurity in n Amol G. | Limited, Hyderabad the Formation to identify the ca orfloxacin Nakoda | - | |
| 26. | Formation of N- methyl Impurity in Norfloxacin To identify the Ro Norfloxacin in this project niper, formation of n-meth | u and Amol G. Dikundwar oot Cause for team is trying yl impurity in n | Limited, Hyderabad the Formation to identify the ca orfloxacin | ause and mech | anism for th |
| 26. | Formation of N- methyl Impurity in Norfloxacin To identify the Ro Norfloxacin in this project niper, formation of n-meth Quantification of Polymorphic Impurity in | u and Amol G. Dikundwar oot Cause for team is trying yl impurity in n Amol G. | Limited, Hyderabad the Formation to identify the ca orfloxacin Nakoda Chemicals Limited, | ause and mech | anism for th |
| 26. | Formation of N- methyl Impurity in Norfloxacin To identify the Ro Norfloxacin in this project niper, formation of n-meth Quantification of Polymorphic | u and Amol G. Dikundwar oot Cause for team is trying yl impurity in n Amol G. | Limited, Hyderabad the Formation to identify the ca orfloxacin Nakoda Chemicals | ause and mech | anism for th |
| 26. | Formation of N- methyl Impurity in Norfloxacin To identify the Ro Norfloxacin in this project niper, formation of n-meth Quantification of Polymorphic Impurity in | u and Amol G. Dikundwar oot Cause for team is trying yl impurity in n Amol G. | Limited, Hyderabad the Formation to identify the ca orfloxacin Nakoda Chemicals Limited, | ause and mech | anism for th |
| 26. | Formation of N- methyl Impurity in Norfloxacin To identify the Ro Norfloxacin in this project niper, formation of n-meth Quantification of Polymorphic Impurity in Famotidine API | u and Amol G. Dikundwar oot Cause for team is trying yl impurity in n Amol G. Dikundwar | Limited, Hyderabad the Formation to identify the ca orfloxacin Nakoda Chemicals Limited, Hyderabad | ause and mech | anism for th |
| 26. | Formation of N- methyl Impurity in Norfloxacin To identify the Ro Norfloxacin in this project niper, formation of n-meth Quantification of Polymorphic Impurity in Famotidine API (advisory project) | u and Amol G. <u>Dikundwar</u> oot Cause for team is trying yl impurity in n Amol G. Dikundwar | Limited, Hyderabad the Formation to identify the ca orfloxacin Nakoda Chemicals Limited, Hyderabad | ause and mech 0.70 Lakh | anism for th |
| 26. | Formation of N- methyl Impurity in Norfloxacin To identify the Ro Norfloxacin in this project niper, formation of n-meth Quantification of Polymorphic Impurity in Famotidine API (advisory project) Quantification of pol | u and Amol G. <u>Dikundwar</u> oot Cause for team is trying t yl impurity in n Amol G. Dikundwar ymorphic impu | Limited, Hyderabad the Formation to identify the ca orfloxacin Nakoda Chemicals Limited, Hyderabad arity in an API o help Nakoda C | ause and mech 0.70 Lakh hemicals Limit | anism for th |
| 26. | Formation of N- methyl Impurity in Norfloxacin To identify the Ro Norfloxacin in this project niper, formation of n-meth Quantification of Polymorphic Impurity in Famotidine API (advisory project) Quantification of pol The project is an adv | u and Amol G. <u>Dikundwar</u> oot Cause for team is trying t yl impurity in n Amol G. Dikundwar ymorphic impu | Limited, Hyderabad the Formation to identify the ca orfloxacin Nakoda Chemicals Limited, Hyderabad arity in an API o help Nakoda C | ause and mech 0.70 Lakh hemicals Limit | anism for th |
| | Formation of N- methyl Impurity in Norfloxacin To identify the Ro Norfloxacin in this project niper, formation of n-meth Quantification of Polymorphic Impurity in Famotidine API (advisory project) Quantification of pol The project is an adv Hyderabad, quantify To explore the | u and Amol G. Dikundwar oot Cause for team is trying f yl impurity in n Amol G. Dikundwar ymorphic impu visory project to Polymorphic In | Limited, Hyderabad the Formation to identify the ca orfloxacin Nakoda Chemicals Limited, Hyderabad rity in an API help Nakoda C mpurity in Famo | ause and mech 0.70 Lakh hemicals Limit ptidine API. | anism for th 0.5 years ed, |
| | Formation of N- methyl Impurity in Norfloxacin To identify the Ro Norfloxacin in this project niper, formation of n-meth Quantification of Polymorphic Impurity in Famotidine API (advisory project) Quantification of pol The project is an adv Hyderabad, quantify | u and Amol G. Dikundwar oot Cause for team is trying f yl impurity in n Amol G. Dikundwar ymorphic impur visory project to Polymorphic In Nitin Pal | Limited, Hyderabad the Formation to identify the ca orfloxacin Nakoda Chemicals Limited, Hyderabad rity in an API help Nakoda C mpurity in Famo | ause and mech 0.70 Lakh hemicals Limit ptidine API. | anism for th 0.5 years ed, |
| | Formation of N- methyl Impurity in Norfloxacin To identify the Ro Norfloxacin in this project niper, formation of n-meth Quantification of Polymorphic Impurity in Famotidine API (advisory project) Quantification of pol The project is an adv Hyderabad, quantify To explore the Mycobacterium tuberculosis | u and Amol G. Dikundwar oot Cause for team is trying f yl impurity in n Amol G. Dikundwar ymorphic impur visory project to Polymorphic In Nitin Pal | Limited, Hyderabad the Formation to identify the ca orfloxacin Nakoda Chemicals Limited, Hyderabad rity in an API help Nakoda C mpurity in Famo | ause and mech 0.70 Lakh hemicals Limit ptidine API. | anism for th 0.5 years ed, |
| | Formation of N- methyl Impurity in Norfloxacin To identify the Ro Norfloxacin in this project niper, formation of n-meth Quantification of Polymorphic Impurity in Famotidine API (advisory project) Quantification of pol The project is an adv Hyderabad, quantify To explore the Mycobacterium tuberculosis transcription | u and Amol G. Dikundwar oot Cause for team is trying f yl impurity in n Amol G. Dikundwar ymorphic impur visory project to Polymorphic In Nitin Pal | Limited, Hyderabad the Formation to identify the ca orfloxacin Nakoda Chemicals Limited, Hyderabad rity in an API help Nakoda C mpurity in Famo | ause and mech 0.70 Lakh hemicals Limit ptidine API. | anism for th 0.5 years ed, |
| | Formation of N- methyl Impurity in Norfloxacin To identify the Ro Norfloxacin in this project niper, formation of n-meth Quantification of Polymorphic Impurity in Famotidine API (advisory project) Quantification of pol The project is an adv Hyderabad, quantify To explore the Mycobacterium tuberculosis transcription terminator factor | u and Amol G. Dikundwar oot Cause for team is trying f yl impurity in n Amol G. Dikundwar ymorphic impur visory project to Polymorphic In Nitin Pal | Limited, Hyderabad the Formation to identify the ca orfloxacin Nakoda Chemicals Limited, Hyderabad rity in an API help Nakoda C mpurity in Famo | ause and mech 0.70 Lakh hemicals Limit ptidine API. | anism for th 0.5 years ed, |
| | Formation of N- methyl Impurity in Norfloxacin To identify the Ro Norfloxacin in this project niper, formation of n-meth Quantification of Polymorphic Impurity in Famotidine API (advisory project) Quantification of pol The project is an adv Hyderabad, quantify To explore the Mycobacterium tuberculosis transcription terminator factor Rho mediated | u and Amol G. Dikundwar oot Cause for team is trying f yl impurity in n Amol G. Dikundwar ymorphic impur visory project to Polymorphic In Nitin Pal | Limited, Hyderabad the Formation to identify the ca orfloxacin Nakoda Chemicals Limited, Hyderabad rity in an API help Nakoda C mpurity in Famo | ause and mech 0.70 Lakh hemicals Limit ptidine API. | anism for th 0.5 years ed, |
| | Formation of N- methyl Impurity in Norfloxacin To identify the Ro Norfloxacin in this project niper, formation of n-meth Quantification of Polymorphic Impurity in Famotidine API (advisory project) Quantification of pol The project is an adv Hyderabad, quantify To explore the Mycobacterium tuberculosis transcription terminator factor | u and Amol G. Dikundwar oot Cause for team is trying f yl impurity in n Amol G. Dikundwar ymorphic impur visory project to Polymorphic In Nitin Pal | Limited, Hyderabad the Formation to identify the ca orfloxacin Nakoda Chemicals Limited, Hyderabad rity in an API help Nakoda C mpurity in Famo | ause and mech 0.70 Lakh hemicals Limit ptidine API. | anism for th 0.5 years ed, |

| | mediated lethality fo | or drug discover | ٠v | | | | | |
|------|---|-------------------|--------------------|------------------|---------------|--|--|--|
| | In this project, PI is | | | tuberculosis | transcription | | | |
| | terminator factor Rh | | | | | | | |
| 28. | Biocatalytic | Dr. Priyanka | AmilifeScienc | 30.33 Lakh | 0.5 years | | | |
| _0. | Process | Bajaj | es | 00002000 | | | | |
| | optimization for | | | | | | | |
| | synthesis of | | | | | | | |
| | Sitagliptin | | | | | | | |
| | Process optimization | n for synthesis o | f Sitaglintin | | | | | |
| | In this project, NIF | | | eveloped and | optimised a | | | |
| | biocatalytic Process | | | | | | | |
| 29. | A Workshop on | Dr. Manoj | SERB | 4.00Lakh | 3 months | | | |
| - ,. | Preclinical and | Dandekar | 0 LILE | no o Lann | | | | |
| | Molecular | Dunuenur | | | | | | |
| | Neuropharmacolo | | | | | | | |
| | gy Training | | | | | | | |
| | Preclinical and M | olecular Neur | opharmacology | Training" so | cheduled on | | | |
| | September 12-19, 20 | | op | | | | | |
| | We provided training to 21 students participated from all over the India. | | | | | | | |
| | The project was to conduct a workshop on preclinical and molecular | | | | | | | |
| | neuropharmacology | | • | • | | | | |
| 30. | To Examine the | Dr. Manoj | IBRO | 5.18 Lakh | 1 year | | | |
| | Role of Gut | Dandekar | | | 5 | | | |
| | Microbiome in the | | | | | | | |
| | Manifestation and | | | | | | | |
| | Treatment of | | | | | | | |
| | Depression Using | | | | | | | |
| | Preclinical and | | | | | | | |
| | Clinical Studies | | | | | | | |
| | To Examine the Role | e of Gut Microbi | ome in the Man | ifestation and ' | Treatment of | | | |
| | Depression Us | ing Precli | inical and | Clinical | Studies | | | |
| | This is a collaborativ | e research grar | nt to visit the Un | iversity of Corl | ĸ, Ireland. | | | |
| | This is collaborative | research with | the University | of Cork, Ireland | d to Examine | | | |
| | the Role of Gut Micr | obiome in the I | Manifestation ar | nd Treatment o | of Depression | | | |
| | Using Preclinical and | d Clinical Studie | | | | | | |
| 31. | Decoding the | Dr. Priyanka | DST-SERB- | 29.89 Lakh | 2 years | | | |
| | catalytic | Bajaj | SRG | | | | | |
| | mechanism and | | | | | | | |
| | active site of very | | | | | | | |
| | unique and novel | | | | | | | |
| | Nitrating P450 | | | | | | | |
| | with the aim of | | | | | | | |
| | developing an | | | | | | | |
| | efficient artificial | | | | | | | |
| | metalloenzyme for | | | | | | | |
| | regio- and | | | | | | | |
| | chemospecific | | | | | | | |
| | aromatic | | | | | | | |

| | nitrations | | | | | | | |
|-----|--|-------------------|-------------------|------------------|--------------|--|--|--|
| | Elucidation of the m | echanism of Nit | rating P450 | | | | | |
| | In this project, PI is decoding the catalytic mechanism and active site of uniqu | | | | | | | |
| | and novel Nitrating P450 to develop an efficient artificial metalloenzyme fo | | | | | | | |
| | regio- and them spe | | - | | - | | | |
| | | | iti ations and er | | | | | |
| 22 | of Nitrating P450 | DeAuelC | | 20 421 -11 | 2 | | | |
| 32. | Co-amorphous | Dr. Amol G. | DST-SERB- | 30.42Lakh | 2 years | | | |
| | forms for | Dikundwar | SRG | | | | | |
| | Bioavailability | | | | | | | |
| | Enhancement of | | | | | | | |
| | poorly soluble | | | | | | | |
| | drugs: Design, | | | | | | | |
| | synthesis, | | | | | | | |
| | characterization | | | | | | | |
| | and in vivo studies | | | | | | | |
| | Devemopment of co- | -amorphous for | ms of poorly wa | ter soluble dru | ıgs | | | |
| | The project PI would | d like to design, | synthesis, char | acterisation an | d perform i | | | |
| | vivo studies for the | | | | | | | |
| | Enhance the bioavai | lability | _ | | | | | |
| 33. | Development of | Dr Neelesh | DST- | 29.20Lakh | 3 Years | | | |
| | Novel Eye Drops of | Kumar | Nanomission | | | | | |
| | fixed dose | Mehra and | | | | | | |
| | combination for | Dr | | | | | | |
| | Effective Ocular | Dharmendra | | | | | | |
| | Delivery | Khatri & Dr | | | | | | |
| | Denvery | Vivek Singh | | | | | | |
| | Main aim in the pre | | on, to design, d | evelonment ar | d evaluatio | | | |
| | of novel nanoformu | | | | | | | |
| | disease (glaucoma) | | 0 | | | | | |
| | | levelopment | | - | - | | | |
| | physicochemical tec | | | | | | | |
| | clinical testing | iniques tonow | | ina in vivo sta | ules for pre | | | |
| | Main aim in the pre | sent investigati | on to design d | evelonment ar | nd evaluatio | | | |
| | of novel nanoformu | | - | - | | | | |
| | disease (glaucoma) | | 0 | • | | | | |
| | | | with extensive | - | - | | | |
| | physicochemical tec | • | | | | | | |
| | clinical testing | iniques tonow | | inu ni vivo stu | ules for pre | | | |
| | chinear testing | | | | | | | |
| | | | | | | | | |
| 34. | Process | Dr. Y. V. | Nakoda | 1.80Lakh | 1 year | | | |
| 51. | improvement for | Madhavi | Chemicals | TIOULANII | I ycar | | | |
| | the stage-II of | | Pvt. Ltd | | | | | |
| | Acetazolomide | | 1 VI. LIU | | | | | |
| | | uor the origin - | process | | | | | |
| | Cost improvement o | 0 | A | II of A astanala | midauraadh | | | |
| | The project aim is to | | | | | | | |
| | Nakoda Chemicals | rvt. Ltd, to ma | ike the process | more afforda | die than th | | | |
| | existing process | | | | | | | |

| 25 | T | D - N l l | | 26 421 -11 | 2 1/2 |
|-----|------------------------|------------------|-------------------|------------------|----------------|
| 35. | Therapeutic | Dr Neelesh | DST-SERB- | 26.43Lakh | 2 Years |
| | Potential of the | Kumar | SRG | | |
| | Nanoformulations | Mehra | | | |
| | for Wound Healing | | | | |
| | Activity in Diabetic | | | | |
| | Foot Ulcer | | | | |
| | Development of the | - | | | |
| | In this project, PI is | | pical Nanoformu | ulations for Wo | ound Healing |
| | Activity in Diabetic I | | [| Γ | Γ |
| 36. | Development and | Dr Neelesh | DST inspire | 24.62 Lakh | 5 Years |
| | Evaluation of | Kumar | Department | | |
| | Functional | Mehra | of Science | | |
| | Nanoformulations | | and | | |
| | for Effective | | Technology, | | |
| | Management of | | Govt. of India | | |
| | Colorectal Cancer | | | | |
| | Development of nov | el formulation f | or colorectal ca | ncer | • |
| | The project is to de | evelop and eval | luation of funct | ional nanoforr | nulations for |
| | effective manageme | nt of colorectal | cancer | | |
| 37. | Novel synthetic | Dr. Y.V. | DST | 45 Lakh | 3 years |
| | process and | Madhavi and | | | |
| | formulation | Dr. K. Vinay | | | |
| | development of | Kumar, Dr. | | | |
| | ELIGLŪSTAT | Pankaj | | | |
| | tartrate | Kumar | | | |
| | | Singh, Dr. | | | |
| | | Nitin Pal | | | |
| | | Kalia | | | |
| | To develop a cost ef | | for the API. Elig | lustat which is | used for the |
| | treatment of Gauche | | | | |
| | The project deals wi | | | rocess for the A | PI. Eliglustat |
| | which is used for the | | - | | |
| 38. | Pharmacological | Dr Neelesh | CCRUM New | 24.53Lakh | 3 years |
| | activities and pre- | Kumar | Delhi | | |
| | clinical screening | Mehra | | | |
| | of the promising | | | | |
| | unani medicines | | | | |
| | against hepatic | | | | |
| | disease | | | | |
| | uisease | | | | |
| | Development of new | formulation fo | r NASH | | |
| | Project involves ph | | | re-clinical scre | ening of the |
| | promising unani me | - | - | | |
| 39. | Determination of | Dr. Sandeep | Hikal | 4.36Lakh | 6 months |
| 57. | residual catalase | Kumar | 1111111 | noolaini | |
| | and monoamine | | | | |
| | oxidase enzyme in | | | | |
| | - | | | | |
| | drug sample by | | | | |

| | sodium dodecyl sulfate polyacrylamide gel electrophoresis | | | | |
|-----|---|--|--|---|---|
| | To carryout the prot Hikal Pharmaceutics residual catalase and dodecyl sulfate-poly | al gave this pro d monoamine o acrylamide gel | oject to develop xidase enzymes electrophoresis | a method for in drug sampl | determining es by sodium |
| 40. | Synthesis of Empagliflozin Intermediate (advisory) | Dr. Srinivas Nanduri | Nakoda Chemicals Pvt. Ltd | 0.70 Lakh | 6 months |
| 41. | Repurposing Oxiconazole:Alone and in combination with PUFA's as a broad spectrum antibacterial | Dr. Siddharth Chopra and Dr. Srinivas Nanduri | DBT | 39.41 Lakh | 3 Years |
| | To evluate the anti-to drug and study its sy Gentamycin, Amikac In this project, the Oxiconazole, a repur with other FDA-app leading to combinati | ynergistsic activ cin & Daptomyc NIPER team is posed anti-fung roved drugs su | vity with other F in leading to cor s evaluating the gal drug and stu | FDA approved on bination drug anti-bacterial dying its syner | drugs such as s potential of gistic activity |
| 42. | Design, synthesis and biological evaluation of new GSK3β inhibitors as promising therapeutic agents for treating Traumatic brain injury and consequent neuronal degenerative diseases | Dr. Srinivas Nanduri and Dr. Y. V. Madhavi, Dr. D. K. Khatri, Dr. Kailash Manda, | ICMR | 49.90Lakh | 3 Years |
| | To synthesize vario treatment of Trauma AD and PD The project involves 3B enzyme for the neurological disease | atic brain injury synthesise of v treatment of | y and consequer arious new cher Traumatic bra | nt neurological mical entities ta | diseases like argeting GSK- |
| 43. | Development of scalable, safe and | Dr. Y. V. Madhavi and | National Research and | 10 Lakh | 1 year |

| | | | | I | 1 | | | | | | |
|-----|---|--|-------------------------------------|--------------------------------------|--|--|--|--|--|--|--|
| | cost effective | Dr. Srinivas | Development | | | | | | | | |
| | process for the API | Nanduri | Corporation | | | | | | | | |
| | of | | | | | | | | | | |
| | Umifenovir(Arbido | | | | | | | | | | |
| | l) a promising | | | | | | | | | | |
| | repurposed drug | | | | | | | | | | |
| | for COVID19 in | | | | | | | | | | |
| | India | | | | | | | | | | |
| | To develop a cost eff | ective and safe | process for Arbi | idol(IImifenovi | r) | | | | | | |
| | Project involved the | | | | | | | | | | |
| | for the API of Umife | _ | | | - | | | | | | |
| | 19. | | j, a promising r | epui poseu uru | | | | | | | |
| 44. | Advances in the | Dr Venkata | DST-SERB | 1.50Lakh | 3 Months | | | | | | |
| 44. | | | | 1.50Lakii | 5 MOIIUIS | | | | | | |
| | Natural Products | Rao | Symposia/Se | | | | | | | | |
| | Research for the | | minar | | | | | | | | |
| | Treatment of | | | | | | | | | | |
| | Infectious Diseases | | | | | | | | | | |
| | and Metabolic | | | | | | | | | | |
| | Disorders | | | | | | | | | | |
| | Objective was to bring recent advancement in use of natural product for | | | | | | | | | | |
| | various treatment | | | | | | | | | | |
| | The project was to organise a seminar on Advances in Natural Products | | | | | | | | | | |
| | Research for the Tre | atment of Infec | tious Diseases a | nd Metabolic D | isorders. | | | | | | |
| 45. | Design and | Dr. Pankaj K. | EpigeneresP | 5.54 Lakh | 0.33 Year | | | | | | |
| | development of | Singh and | vt. Ltd. | | | | | | | | |
| | herbal formulation | Dr. Saurabh | V di El cui | | | | | | | | |
| | to improve flow | Srivastava | | | | | | | | | |
| | properties | 511045tava | | | | | | | | | |
| | To improve flow | w properties | of powder | formulation | containing | | | | | | |
| | phytopharmaceutica | . . | 1 | IOI IIIulatioii | containing | | | | | | |
| 46. | Troubleshooting of | Dr. Pankaj K. | EpigeneresP | 2.59Lakh | 0.25 Year | | | | | | |
| | powder | Singh | vt. Ltd. | | | | | | | | |
| | formulation issues | 0 | | | | | | | | | |
| 47. | Analysis the role of | Dr. Santosh | DST-SERB | 2.60 Lakh+ | 2+1year | | | | | | |
| | extracellular | Kumar Guru | | 4. 0 Lakh | (Extended) | | | | | | |
| | vesicles | Rumar Guru | | 1. O Luiti | (Extended) | | | | | | |
| | (Exosomes) in | | | | | | | | | | |
| | drug tolerant | | | | | | | | | | |
| | persister cells and | | | | | | | | | | |
| | | | | | | | | | | | |
| | its contribution to | | | | | | | | | | |
| | | | | | | | | | | | |
| | cancer-initiation | | C 1 | | Use of Exosome in Diagnostic marker for breast cancer. | | | | | | |
| | Use of Exosome in D | - | | | | | | | | | |
| | Use of Exosome in D In this project, PI i | s involved in a | analysing the ro | ole of extracel | | | | | | | |
| | Use of Exosome in D In this project, PI i (Exosomes) in drug | s involved in a g-tolerant pers | analysing the ro ister cells and | ole of extracell its contribution | on to cancer | | | | | | |
| | Use of Exosome in D In this project, PI i (Exosomes) in drug initiation. The exoso | s involved in a g-tolerant pers ome discovered | analysing the ro ister cells and | ole of extracell its contribution | on to cancer | | | | | | |
| | Use of Exosome in D In this project, PI i (Exosomes) in drug | s involved in a g-tolerant pers ome discovered | analysing the ro ister cells and | ole of extracell its contribution | on to cancer | | | | | | |
| 48. | Use of Exosome in D In this project, PI i (Exosomes) in drug initiation. The exoso | s involved in a g-tolerant pers ome discovered | analysing the ro ister cells and | ole of extracell its contribution | on to cancer | | | | | | |

| | in Breast Cancer | | | | | | | |
|-----|--|------------------|-----------------------------|------------------|---------------|--|--|--|
| | To overcome chemo | resistance in h | reast cancer | | | | | |
| | Cancer is a major public health burden in both developed and developing | | | | | | | |
| | countries. The one of the main causes of the failure of cancer treatment a increase of mortality rate during cancer is due to development of dr | | | | | | | |
| | | | | | | | | |
| | resistance in cance | | | - | - | | | |
| | important mechanis | 0 | | | | | | |
| | | | | | | | | |
| | more emphasise (Ringborg and Platz 1996; Szakács et al. 2006; Sui et al. 2013). The crosstalk between these two mechanisms may be cause of development of drug resistance against conventional anticancer drugs. Autophagy is a controlled, conserved physiological process of eukaryotes, which regulate cellular homeostasis via degradation of cellular components with the help of | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | autophagy-related g | | | | | | | |
| | in the earliest stage | | | | | | | |
| | breast tumours. On | - | - | | | | | |
| | (Flynn and Schiema | | | | | | | |
| | et al. 2013). Accordi | | - | | | | | |
| | not occur due to | - | | | | | | |
| | sprouting of new b | • | | | | | | |
| | oxygen and nutrien | | | | | | | |
| | 1971). However, in | | | - | | | | |
| | HIF-1 α (Mazure and | | | | | | | |
| | induce neovascular | | | | | | | |
| | genes (Ramakrishna | - | | | | | | |
| | but the mechanism | | | - | - | | | |
| | angiogenesis are not | | | | | | | |
| | cells (CSCs) via indu | | | | | | | |
| | Therefore, in this pr | | | | | | | |
| | the processes angio | genesis and aut | ophagy and the | catalytic activ | ity of HIF-1α | | | |
| | if silenced, then what | it happen in hyp | oxia process. | | | | | |
| 49. | Identification of | Dr. Santosh | ICMR | 53.0 Lakh | 3 Years | | | |
| | molecular | Kumar Guru | | | | | | |
| | reprogramming | | | | | | | |
| | landscape of pre | | | | | | | |
| | and post- | | | | | | | |
| | neoadjuvant | | | | | | | |
| | chemotherapy in | | | | | | | |
| | Gastric Cancer and | | | | | | | |
| | its therapeutic | | | | | | | |
| | implications | | | | | | | |
| | Identification of m | nolecular repro | ogrammin <mark>g lan</mark> | dscape of pre | e and post- | | | |
| | neoadjuvant chemot | therapy in Gastr | ric Cancer and it | s therapeutic ir | nplications | | | |
| | Cancer drugs typica | lly produce sho | rt-lived clinical | remissions due | e to acquired | | | |
| | drug resistance, whi | | | | | | | |
| | high doses of anticat | | | | | | | |
| | weakly proliferative | | | | | | | |
| | markers associated | | | | | | | |
| | rates were highest i | | | | - | | | |
| | 2016, the leading ty | pes of cancer ir | n India those res | sponsible for m | ore than 5% | | | |

| | of the total cancer among both sexes combined, were gastric cancer (14%). As per recent report, Stomach and Esophageal cancer is the 4th and 6th most common cancer-related deaths in south and northeast states. Also, the regional variation exists in the rates of gastric cancer in India. Novelty and Innovation: After neoadjuvant chemotherapy the drug-tolerant cell population emerged, are highly expressed undruggable transcription factors, epigenetically silenced genes, de-novo mutations, epithelial mesenchymal transformation/autophagy. Cyclin-dependent kinase 9 (CDK9) promotes transcriptional elongation through RNAPII pause release and essential for maintaining gene silencing at heterochromatic loci. We hypothesize that targeting CDK9, reactivates epigenetically silenced genes, hypersensitize to chromatin-modifying agents within the drug-tolerant sub-population and therapeutic intervention of undruggable transcription factors in cancer by in-vitro, in-vivo model and 3D organoid model from gastric patients from Indian Population. | | | | | |
|-----|---|--|--|--|--|--|
| 50. | Noscapine and its Derivatives for the treatment of drug- tolerant persister cell in Breast cancer | Dr. Santosh Kumar Guru | ICMR | 57.0 Lakh | 3years | |
| | Treatment of drug- and its Derivatives Despite a favorable experience recurren Recurrence largely a remain after treatmon relapses can arise of transiently drug-too reversible, non-muta shifts and stem hypothesized to und throughput method currently possible to factors. To address to study the mechanistor regain proliferative The main aim of this helps tumor aggress induce the emergen tolerant cells/persistor initiating cells (Can target these cancer development of chemotherapeutic a benefit of cancer drug state referred to as the development of studying the mechan effective Noscapine | initial response arises as a resul ent. Recently it lue to the pres lerant cells th ational mechanic cell-like popul erlie persister p s to concurrent to distinguish to this need, we we mus underlying capacity under is project is how siveness. Exposi- nce of a subpop ster cells, which cer stem cells) r-initiating cells drug resistant gents remains ug therapy. In the the drug-tolera tumor cells re- unisms that under the underlying | e, triple negative within months it of the growth was shown that ence of persiste at are able to isms. Tumor dou ilations are a phenotype. How otly track cell s the relative cor ill be generating the ability of a r constant trea w drug tolerant sure to high dos pulation of wea h display marke b. The main obj s by Noscapine ce during tre a critical prob his project we w ant persister state esistance to a w | e breast cancer s or years after of residual can t in multiple ca er cells, a subp survive ther rmancy, stocha mongst the rever, given the state and linea atribution of e g the Watermel small population the watermel small population the watermel small population the the the set of anticance kly proliferative ers associated fective of this and its derive eatment of co lem that limits will discover a re te, that appear variety of cance | patients will er diagnosis. cer cells that ncer types of oopulation of apy through stic cell state mechanisms lack of high- ige, it is not ach of these lon library to on of cells to memotherapy. survive and er drugs can ve and drug- with cancer- project is to vatives. The cancer with s the clinical novel cellular s to promote er drugs. By o develop an | |

| | drug tolerance, thereby improving the efficacy of cancer drugs. | | | | | | |
|-----|---|-----------------|-------------------|---------------------------------------|----------------|--|--|
| 51. | Product validation, | Dr. Jitender | ICMR | 57.0 Lakh | 3years | | |
| | preclinical testing | Madan and | | | - | | |
| | and safety | Dr Pankaj | | | | | |
| | evaluation of a | Kumar Singh | | | | | |
| | smart film forming | _ | | | | | |
| | topical dermal gel | | | | | | |
| | in the management | | | | | | |
| | of chemotherapy- | | | | | | |
| | induced peripheral | | | | | | |
| | neuropathy | | | | | | |
| | Formulation and dev | velopment of sn | hart film forming | g topical derma | al gel against | | |
| | peripheral neuropat | - | | | 0 0 | | |
| | In this project, the te | am of investiga | tors have devel | oped and form | ulated a | | |
| | smart film forming t | 0 | | • | | | |
| 52. | Development of a | Dr. Santosh | ICMR | 48.0 Lakh | 3Years | | |
| | novel mercury | Kumar Guru | | | | | |
| | based organo- | | | | | | |
| | metallic complex | | | | | | |
| | for acute leukemia | | | | | | |
| | treatment | | | | | | |
| | A novel mercury-bas | sed organo-met | allic complex for | r acute leukemi | ia treatment | | |
| | Metals are essentia | l cellular comp | onents selected | d by nature to | o function in | | |
| | several indispensab | le biochemical | processes for li | ving organism | s. Metals are | | |
| | endowed with unio | que characteris | tics that inclue | de redox activ | vity, variable | | |
| | coordination modes, and reactivity towards organic substrates. Due to their | | | | | | |
| | reactivity, metals are tightly regulated under normal conditions and aberrant | | | | | | |
| | metal ion concentrations are associated with various pathological disorders, including cancer. For these reasons, coordination complexes, either as drugs or prodrugs, become very attractive probes as potential anticancer agents. The use of metals and their salts for medicinal purposes, from iatrochemistry to modern day, has been present throughout human history. The discovery of cisplatin, cis-[Pt(II) (NH(3))(2)Cl(2)], was a defining moment which triggered | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | the interest in platin | | | | - | | |
| | novel anticancer drugs. selected metals that have gained considerable interest | | | | | | |
| | in both the develop | | | | | | |
| | metals as probes to | - | | | - | | |
| | emphasized. Finally | | | | | | |
| | bioinorganic chemi | | | | | | |
| | treatment is designe | | | | | | |
| 53. | Exploration of the | Dr. Santosh | DST-SERB | 22.36 Lakh | 2Years | | |
| | crosstalk between | Kumar Guru | | | | | |
| | RNA methylation | | | | | | |
| | and YAP/ TAZ | | | | | | |
| | pathway in drug | | | | | | |
| | tolerant breast | | | | | | |
| | | | 1 | i i i i i i i i i i i i i i i i i i i | | | |
| | cancer persistent cells | | | | | | |

To understand signaling pathway between RNA methylation and YAP/ TAZ pathway in drug-tolerant breast cancer persistent cells Breast cancer (BC) is a common cause of death among the Indian women (1). Despite significant progress and achievements in the management of this disease, a significant proportion of patients continue to experience recurrence, even after adjuvant therapy. Evaluation of the drug tolerant persistent cells (DTC) have revealed the molecular profiles and imparted a better treatment regime, but still better understanding of these DTC is needed to improve therapeutic process. One of the burning illustrations of this cancer persistence was reported to be intra-tumoral heterogeneity, which may arise due to nongenetic reprograms associated with ribosome dependent RNA methylation (2). The persistent cancer cells undergo many epigenetic or transcriptional reprogramming, which drives them to attain a slow proliferative stage and hence, evade the effect of anticancer treatment (2). This slow proliferation rate is recently found to be associated with dampened protein synthesis process, and hence, ribosome dependent translation efficiency (3). One probable cause of this reduced translation efficiency was found to be epigenetic modifications (methylation) of adenosines of mRNA (4). This mRNA methylation process is mainly orchestrated by a complex of methyltransferase, primarily METTL3 (5). Consequently, the target mRNA with m6A has a higher capability of translating itself to its protein (6). This reversible and dynamic mechanism has been found to be involved in stem cell maintenance as well (6), whereby MYC, BCL2, PTEN etc target genes were methylated by elevated levels of METTL3 and promotes pluripotency among the cancer cells. YAP and TAZ oncoproteins are well known transcription factors, which on phosphorylation gets sequestered in the cytoplasm and undergo proteasomal degradation (7). Recent reports have demonstrated their role in generations of chemo tolerance in several cancers, including breast cancer (8), since these proteins are involved in stem cell maintenance as well. On the other hand, analysis of TCGA datasets unveiled frequent amplification with overexpression of both YAP and TAZ proteins in BC samples (cbioportal.org). However, details of treatment procedure in those patients were not available. Till date, several studies have been carried out to target YAP and TAZ for therapeutic interventions (3, 8), but still the mystery has been unsolved. Recently, a group has indicated the probable crosstalk between these two pathways that is YAP/TAZ and RNA methylation in chemo tolerant lung cancer cells (9), where METLL3 was found to increase the m6A level of YAP and increased its translation turnover. However, this is the only study, evaluating the probable link between these two axes, which needs to be validated independently. Further, chemotherapeutically treated primary tumors have not been analyzed, till now. Again, the effect of RNA methylation circuit on TAZ protein is still unexplored.

| 54. | Evaluation of Anti- | Dr | Aurigene | 17.17Lakh | 6 Months |
|-----|---------------------|-------------|--------------|-----------|----------|
| | fibrotic effects of | ChandraiahG | Discovery | | |
| | AUR101 and | odugu | Technologies | | |
| | AUR103 Calcium | | Ltd. | | |
| | in Bleomycin | | | | |
| | Induced | | | | |
| | Pulmonary | | | | |
| | Fibrosis model | | | | |

| | To evaluate the An Bleomycin Induced H Aurigene Discovery group has evaluation Bleomycin Induced H | Pulmonary Fibr Technologies 1 of Anti-fibroti | osis model Ltd funded the c effects of AUR | e project., whe | rein the PIs | |
|-----|---|---|--|-----------------|--------------|--|
| 55. | Preclinical evaluation of UNIM-401 and UNIM-403 against experimentally induced psoriasis and UNIM-004 and UNIM-005 for their efficacy against experimentally induced vitiligo in mice | Dr ChandraiahG odugu | AYUSH | 58.13Lakh | 3 Years | |
| | Preclinical evaluation of Unani formulations UNIM-401 and UNIM-403 against experimentally induced psoriasis and UNIM-004 and UNIM-005 formulatiomns against experimentally induced vitiligo in mice In this project first PIs team has experimentally induced vitiligo in mice. Later this mice model were used in the preclinical evaluation of Unani formulations UNIM-401 and UNIM-403 against experimentally induced psoriasis and UNIM- 004 and UNIM-005 formulations. | | | | | |
| 56. | Evaluation of Anti- fibrotic effects of ODM-203 alone and combination of ODM-203 with Prednisolone in Bleomycin Induced Pulmonary Fibrosis model | Dr ChandraiahG odugu | Aurigene Discovery Technologies Ltd. | 17.70Lakh | 6 Months | |
| | To evaluate the Anti-fibrotic effects of ODM-203 alone and combination of ODM-203 with Prednisolone in Bleomycin Induced Pulmonary Fibrosis model The project involves the development of a Bleomycin-Induced Pulmonary Fibrosis model and its use in evaluating the Anti-fibrotic effects of ODM-203 alone and the combination of ODM-203 with Prednisolone. | | | | | |
| 57. | An Instrument- free microfluidic system for extraction of nucleic acid based on biochemically functionalized paper platform | Dr. Amit Asthana and SowjanyaGol i | ICMR | 16.60 Lakh | 3 years | |
| | To fabricate microflu | | | | | |

| molecule kinase inhibitors as novel antimicrobial and antibiofilm agents against Klebsiella | Vasundhra Bhandari | | | | | |
|---|---|--|---|--|--|--|
| pneumonia | | | | | | |
| Ser/Thr kinases | | | | | | |
| КрпК | | | | | | |
| Structure-based in s screening against kp antimicrobials In vitro testing of dis | onK (Serine/thr against scovered kinase | eonine-protein <i>K. pn</i> o inhibitors again | kinase) to find eumoniae nst sensitive an | l prospective infections. d multidrug- | | |
| | resistant <i>K. pneumoniae</i> strains. | | | | | |
| - | Decipher the function of kinase inhibition in controlling essential processes in bacteria, such as antibiotic resistance, pathogenicity, biofilm formation, or cell division. | | | | | |
| Project involved Str inhibitors library scr find prospective ant vitro testing of disc | Project involved Structure-based in silico analysis and small molecule kinase inhibitors library screening against kpnK (Serine/threonine-protein kinase) to find prospective antimicrobials against K. pneumoniae infections. Later the In vitro testing of discovered kinase inhibitors against sensitive and multidrug- resistant K. pneumoniae strains. | | | | | |

PUBLICATIONS (RESEARCH/ REVIEW):

Pharmaceutics

- 1. Shah, Saurabh, Paras Famta, DeepkumarBagasariya, KondasinghCharankumar, Anupama Sikder, Rama Kashikar, Arun K. Kotha et al. "Tuning Mesoporous Silica Nanoparticles in Novel Avenues of Cancer Therapy." Molecular Pharmaceutics 19, no. 12 **(2022)**: 4428-4452.
- 2. Bhosale, Vaishnavi A., Vaibhavi Srivastava, Bhavana Valamla, Rati Yadav, Shashi Bala Singh, and Neelesh Kumar Mehra. "Preparation and Evaluation of Modified Chitosan Nanoparticles Using Anionic Sodium Alginate Polymer for Treatment of Ocular Disease." Pharmaceutics 14, no. 12 **(2022)**: 2802.
- 3. Kharat, Pratik, Padakanti Sandeep Chary, Valamla Bhavana, Naveen Rajana, Geetanjali Devabattula, ChandraiahGodugu, Shashi Bala Singh, and Neelesh Kumar Mehra. "Thymoquinone-Loaded Essential Oil–Based Emulgel as an Armament for Anti-psoriatic Activity." AAPS PharmSciTech 24, no. 1 (2022): 26.
- 4. Rajana, Naveen, Aare Mounika, Padakanti Sandeep Chary, Valamla Bhavana, Anuradha Urati, Dharmendra Khatri, Shashi Bala Singh, and Neelesh Kumar Mehra. "Multifunctional hybrid nanoparticles in diagnosis and therapy of breast cancer." Journal of Controlled Release 352 **(2022)**: 1024-1047.
- 5. Chary, Padakanti Sandeep, Naveen Rajana, Geetanjali Devabattula, Valamla Bhavana, Hoshiyar Singh, ChandraiahGodugu, Santosh Kumar Guru, Shashi Bala Singh, and Neelesh Kumar Mehra. "Design, Fabrication and Evaluation of Stabilized Polymeric mixed micelles for Effective Management in Cancer Therapy." Pharmaceutical Research 39, no. 11 **(2022)**: 2761-2780.

- 6. Nakmode, Deepa, Valamla Bhavana, Pradip Thakor, Jitender Madan, Pankaj Kumar Singh, Shashi Bala Singh, Jessica M. Rosenholm, Kuldeep K. Bansal, and Neelesh Kumar Mehra. "Fundamental aspects of lipid-based excipients in lipid-based product development." Pharmaceutics 14, no. 4 **(2022)**: 831.
- 7. Kumar, Ankaj, Bhavana Valamla, Pradeep Thakor, Padakanti Sandeep Chary, Naveen Rajana, and Neelesh Kumar Mehra. "Development and evaluation of nanocrystals loaded hydrogel for topical application." Journal of Drug Delivery Science and Technology 74 **(2022)**: 103503.
- 8. Valamla, Bhavana, Pradip Thakor, Rashmi Phuse, Mayuri Dalvi, Pratik Kharat, Ankaj Kumar, Dilip Panwar, Shashi Bala Singh, PastorinGiorgia, and Neelesh Kumar Mehra. "Engineering drug delivery systems to overcome the vaginal mucosal barrier: Current understanding and research agenda of mucoadhesive formulations of vaginal delivery." Journal of Drug Delivery Science and Technology **(2022)**: 103162.
- 9. Sharma, Reena, Kaushik Kuche, Pradip Thakor, Valamla Bhavana, Saurabh Srivastava, Neelesh Kumar Mehra, and Sanyog Jain. "Chondroitin Sulfate: Emerging biomaterial for biopharmaceutical purpose and tissue engineering." Carbohydrate Polymers **(2022)**: 119305.
- 10. Jyothi, Vaskuri GS Sainaga, Jyoti Pawar, Valencia Fernandes, Rahul Kumar, Chandni Singh, Shashi Bala Singh, Jitender Madan, and Dharmendra Kumar Khatri. "Film forming topical dermal spray of meloxicam attenuated pain and inflammation in carrageenan-induced paw oedema in Sprague Dawley rats." Journal of Drug Delivery Science and Technology 70 **(2022)**: 103195.
- 11. Chandrama Singh, Shashi, Muskan Choudhary, Atul Mourya, Dharmendra Kumar Khatri, Pankaj Kumar Singh, Jitender Madan, and Harshpal Singh. "Acute and Subacute Toxicity Assessment of Andrographolide-2-hydroxypropyl-βcyclodextrin Complex via Oral and Inhalation Route of Administration in Sprague-Dawley Rats." The Scientific World Journal 2022 **(2022)**.
- 12. Shah, Saurabh, Paras Famta, Vinod Tiwari, Arun K. Kotha, Rama Kashikar, Mahavir BhupalChougule, Young Hun Chung et al. "Instigation of the epoch of nanovaccines in cancer immunotherapy." Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology **(2022)**: e1870.
- 13. Shah, Saurabh, Paras Famta, DeepkumarBagasariya, KondasinghCharankumar, EtikalaAmulya, Dharmendra Kumar Khatri, Rajeev Singh Raghuvanshi, Shashi Bala Singh, and Saurabh Srivastava. "Nanotechnology based drug delivery systems: Does shape really matter?." International Journal of Pharmaceutics **(2022)**: 122101.
- 14. Kashikar, Rama, Arun K. Kotha, Saurabh Shah, Paras Famta, Shashi Bala Singh, Saurabh Srivastava, and Mahavir BhupalChougule. "Advances in nanoparticle mediated targeting of RNA binding protein for cancer." Advanced Drug Delivery Reviews **(2022)**: 114257.
- 15. Famta, Paras, Saurah Shah, Naitik Jain, Syed Shahrukh, Shashi Bala Singh, and Saurabh Srivastava. "Strategic combinatorial delivery of tranilast and paclitaxel using differently functionalized PLGA nanoparticles for enhanced penetration and accumulation in Breast tumor." *Medical Hypotheses* 169 **(2022)**: 110981.
- 16. Jain, Naitik, Syed Shahrukh, Paras Famta, Saurabh Shah, Ganesh Vambhurkar, Dharmendra Kumar Khatri, Shashi Bala Singh, and Saurabh Srivastava. "Immune Cell–Camouflaged Surface-Engineered Nanotherapeutics for Cancer Management." *Acta Biomaterialia* (2022).

- 17. Famta, Paras, Saurabh Shah, Naitik Jain, KondasinghCharan Kumar, DeepkumarBagasariya, Dharmendra Kumar Khatri, Rajeev Singh Raghuvanshi, Shashi Bala Singh, and Saurabh Srivastava. "Tumor-promoting aftermath post-chemotherapy: A focus on breast cancer." *Life Sciences* (2022): 121125.
- 18. Sikder, Anupama, Ganesh Vambhurkar, EtikalaAmulya, DeepkumarBagasariya, Paras Famta, Saurabh Shah, Dharmendra Kumar Khatri, Shashi Bala Singh, V. R. Sinha, and Saurabh Srivastava. "Advancements in redox-sensitive micelles as nanotheranostics: A new horizon in cancer management." *Journal of Controlled Release* 349 **(2022)**: 1009-1030.
- 19. Bagasariya, Deepkumar, KondasinghCharankumar, Saurabh Shah, Paras Famta, Dharmendra Khatri, Rajeev Singh Raghuvanshi, Shashi Bala Singh, and Saurabh Srivastava. "Biomimetic nanotherapeutics: Employing nanoghosts to fight melanoma." *European Journal of Pharmaceutics and Biopharmaceutics* (2022).
- 20. Famta, Paras, Saurabh Shah, Dharmendra Kumar Khatri, Santosh Kumar Guru, Shashi Bala Singh, and Saurabh Srivastava. "Enigmatic role of exosomes in breast cancer progression and therapy." *Life Sciences* 289 **(2022)**: 120210.
- 21. Prasannanjaneyulu, Velpula, Shweta Nene, Harsha Jain, RimshaNooreen, Shivam Otavi, Palak Chitlangya, and Saurabh Srivastava. "Old drugs, new tricks: Emerging role of drug repurposing in the management of atopic dermatitis." *Cytokine & growth factor reviews* (2022).
- 22. Shah, Saurabh, Paras Famta, Rajeev Singh Raghuvanshi, Shashi Bala Singh, and Saurabh Srivastava. "Lipid polymer hybrid nanocarriers: Insights into synthesis aspects, characterization, release mechanisms, surface functionalization and potential implications." *Colloid and Interface Science Communications* 46 **(2022)**: 100570.
- 23. Jain, Harsha, Geetanjali Devabattula, Aditi Bhat, Harshita Dalvi, NagarjunRangaraj, ChandraiahGodugu, and Saurabh Srivastava. "Topical delivery of Bruton's tyrosine kinase inhibitor and curcumin-loaded nanostructured lipid carrier gel: Repurposing strategy for the psoriasis management." *Pharmaceutical Development and Technology* 27, no. 9 (2022): 975-988.
- 24. Famta, Paras, Saurabh Shah, Valencia Fernandes, KondasinghCharan Kumar, DeepkumarBagasariya, Khan SabiyaSamim, Dharmendra Kumar Khatri, Shashi Bala Singh, and Saurabh Srivastava. "Quality by design (QbD) assisted Fabrication & evaluation of Simvastatin loaded Nano-Enabled thermogel for melanoma therapy." *International Journal of Pharmaceutics* 628 **(2022)**: 122270.
- 25. Shah, Saurabh, Paras Famta, Valencia Fernandes, DeepkumarBagasariya, KondasinghCharankumar, Dharmendra Kumar Khatri, Shashi Bala Singh, and Saurabh Srivastava. "Quality by design steered development of Niclosamide loaded liposomal thermogel for Melanoma: In vitro and Ex vivo evaluation." *European Journal of Pharmaceutics and Biopharmaceutics* 180 **(2022)**: 119-136.
- 26. Nooreen, Rimsha, Shweta Nene, Harsha Jain, VelpulaPrasannanjaneyulu, Palak Chitlangya, Shivam Otavi, Dharmendra Kumar Khatri, Rajeev Singh Raghuvanshi, Shashi Bala Singh, and Saurabh Srivastava. "Polymer nanotherapeutics: A versatile platform for effective rheumatoid arthritis therapy." *Journal of Controlled Release* 348 **(2022)**: 397-419.
- 27. Vambhurkar, Ganesh, EtikalaAmulya, Anupama Sikder, Saurabh Shah, Paras Famta, Dharmendra Kumar Khatri, Shashi Bala Singh, and Saurabh Srivastava.

"Nanomedicine based potentially transformative strategies for colon targeting of peptides: State-of-the-art." *Colloids and Surfaces B: Biointerfaces* (2022): 112816.

- 28. Pathade, Vrushali, Shweta Nene, Shreya Ratnam, Dharmendra Kumar Khatri, Rajeev Singh Raghuvanshi, Shashi Bala Singh, and Saurabh Srivastava. "Emerging insights of peptide-based nanotherapeutics for effective management of rheumatoid arthritis." *Life Sciences* (2022): 121257.
- 29. Chellappan, Dinesh Kumar, Keshav Raj Paudel, Nian Wan Tan, Ka Seng Cheong, Samantha Sert Qi Khoo, Su Min Seow, JestinChellian et al. "Targeting the mitochondria in chronic respiratory diseases." *Mitochondrion* **(2022)**.
- 30. Jyothi, Vaskuri GS Sainaga, Chanti Babu Katta, Siva Singothu, Kumari Preeti, Vasundhra Bhandari, Shashi Bala Singh, and Jitender Madan. "Analysis of the therapeutic efficacy of meloxicam-loaded solid lipid nanoparticles topical gel in Wistar rats knee osteoarthritis." Journal of Drug Delivery Science and Technology 77 **(2022)**: 103914.
- 31. Harsiddharay, RavalKavit, Anand Gupta, Pankaj Kumar Singh, Suruchi Rai, Yuvraj Singh, Mani Sharma, Vivek Pawar, Ashwini S. Kedar, Jiaur Rahman Gayen, and Manish K. Chourasia. "Poly-L-lysine Coated Oral Nanoemulsion for Combined Delivery of Insulin and C-Peptide." Journal of Pharmaceutical Sciences 111, no. 12 (2022): 3352-3361.
- 32. Vishnumurthy, Rajendra Herur, M. Gnana Ruba Priya, Pankaj Kumar Singh, and Prashant Tiwari. "Microencapsulation of celecoxib using various methods and polymers." Journal of Health Sciences 6, no. S6: 6647-6662.
- 33. Patil, Rashmi Madhukar, Pratik Pramod Deshpande, Mayur Aalhate, SamanthulaGananadhamu, and Pankaj Kumar Singh. "An Update on Sophisticated and Advanced Analytical Tools for Surface Characterization of Nanoparticles." Surfaces and Interfaces **(2022)**: 102165.
- 34. Gupta, Ujala, Brojendra Nath Saren, KedarKhaparkhuntikar, Jitender Madan, and Pankaj Kumar Singh. "Applications of lipid-engineered nanoplatforms in the delivery of various cancer therapeutics to surmount breast cancer." Journal of Controlled Release 348 **(2022)**: 1089-1115.
- 35. Mahajan, Srushti, Mayur Aalhate, Santosh Kumar Guru, and Pankaj Kumar Singh. "Nanomedicine as a magic bullet for combating lymphoma." Journal of Controlled Release 347 **(2022)**: 211-236.
- 36. Das, Uddipta, Pankaj Wadhwa, Pankaj Kumar Singh, Dheeraj Varma Kalidindi, and Kalpana Nagpal. "The Role of Polymers and Excipients for Better Gastric Retention of Captopril." Critical Reviews[™] in Therapeutic Drug Carrier Systems 39, no. 6 **(2022)**.
- 37. Prajapati, Balram, Indrani Maji, Rahul Kumar, DevendrasinghTomar, Dharmendra Kumar Khatri, Jitender Madan, and Pankaj Kumar Singh. "Strategy to counteract the pyrazinamide induced hepatotoxicity by developing naringin based Coamorphous system with supplementary benefits." Journal of Drug Delivery Science and Technology 69 **(2022)**: 103181.

Medical Devices

38. Shiju, Thomas Michael, Chaturvedula Tripura, Pritam Saha, ArushiMansingh, VenkatapathiChalla, Ira Bhatnagar, Narayana Nagesh, and Amit Asthana. "Ready-to-use vertical flow paper device for instrument-free room temperature reverse transcription." New Biotechnology 68 **(2022)**: 77-86.

- 39. Walia, Sunil, Amit Asthana, Juewen Liu, and Sushanta Mitra. "A Low-Cost Cellulose-Based POC Device for Detection of COVID-19." In Electrochemical Society Meeting Abstracts 241, no. 53, pp. 2176-2176. The Electrochemical Society, Inc., (**2022**).
- 40. Preethi, Mosam, Lavanika Roy, Sukanya Lahkar, and Vivek Borse. "Outlook of various diagnostics and nanodiagnostic techniques for COVID-19." Biosensors and Bioelectronics: X 12 **(2022)**: 100276.
- 41. Kaur, Jasmeen, Mosam Preethi, Rohit Srivastava, and Vivek Borse. "Role of IL-6 and IL-8 biomarkers for optical and electrochemical based point-of-care detection of oral cancer." Biosensors and Bioelectronics: X **(2022)**: 100212.
- 42. Roy, Lavanika, PronamikaBuragohain, and Vivek Borse. "Strategies for sensitivity enhancement of point-of-care devices." Biosensors and Bioelectronics: X 10 (2022): 100098.

Chemical Sciences

- 43. Kumar, Sanjeev, SaiprasadNunewar, and VinaykumarKanchupalli. "Rh (III)-Catalyzed Cross-Coupling/Annulation of Two Carbene Precursors: Construction of Dihydrobenzo [c] chromen-6-one Scaffolds and Application in the Total Synthesis of Cannabinol." Asian Journal of Organic Chemistry 11, no. 1 **(2022)**: e202100689.
- 44. Kumar, Sanjeev, SaiprasadNunewar, Tharun Kumar Sabbi, and VinaykumarKanchupalli. "Synthesis of Indenone Derivatives by Rh (III)-Catalyzed C–H Functionalization of Sulfoxonium Ylides with 1, 3-Diynes." Organic Letters 24, no. 18 **(2022)**: 3395-3400.
- 45. Nunewar, Saiprasad, Sanjeev Kumar, Pendam Priyanka, Pradeep Girase, and VinaykumarKanchupalli. "The solvent-controlled Rh (iii)-catalyzed switchable [4+ 2] annulation of 2-arylIndoles with iodonium ylides." Chemical Communications 58, no. 41 **(2022)**: 6140-6143.
- 46. Nunewar, Saiprasad, Sanjeev Kumar, Akhilesh Waman Meshram, and VinaykumarKanchupalli. "Ru (II)-Catalyzed C-H Functionalization of 2-Arylbenzimidazoles with Iodonium Ylides: A Straightforward Access to Bridgehead Polycyclic N-Heterocycles." The Journal of Organic Chemistry 87, no. 21 (2022): 13757-13762.
- 47. Kanchupalli, Vinaykumar, Laxman AnandraoThorbole, Jagadeesh Kalepu, Desna Joseph, Mohammad Arshad, and Sreenivas Katukojvala. "Rhodium-CatalyzedEnal Transfer with N-Methoxypyridazinium Salts." Organic Letters 24, no. 21 **(2022)**: 3850-3854.
- 48. Kumar, Sanjeev, Tharun Kumar Sabbi, Rasika Pingale, Pradeep Girase, and VinaykumarKanchupalli. "1, 3-Diynes: A Versatile Precursor in Transition-Metal Catalyzed (Mediated) C– H Functionalizations." The Chemical Record **(2022)**: e202200228.
- 49. Engle, Kritika, and Gautam Kumar. "Cancer multidrug-resistance reversal by ABCB1 inhibition: A recent update." European Journal of Medicinal Chemistry **(2022)**: 114542.
- 50. Makhal, Priyanka N., Srinivas Reddy Dannarm, ArbazSujat Shaikh, Rajesh Sonti, and Venkata Rao Kaki. "TBHP-Mediated Selenocyclization of N-Allylbenzamides/Benzthioamides via In-Situ Generation of "PhSeOH" Species." ChemistrySelect 7, no. 14 **(2022)**: e202200933.

- 51. Kumar Sahoo, Santosh, Mohammad Naiyaz Ahmad, Grace Kaul, Srinivas Nanduri, Arunava Dasgupta, Sidharth Chopra, and Venkata Madhavi Yaddanapudi. "Exploration of Isoxazole-Carboxylic Acid Methyl Ester Based 2-Substituted Quinoline Derivatives as Promising Antitubercular Agents." Chemistry & Biodiversity 19, no. 7 **(2022)**: e202200324.
- 52. Bora, Darshana, Anamika Sharma, StephyElza John, and NagulaShankaraiah. "Development of hydrazide hydrazone-tethered combretastatin-oxindole derivatives as antimitotic agents." *Journal of Molecular Structure* 1275 **(2023)**: 134675.
- 53. Bora, Darshana, StephyElza John, Mary SravaniGalla, Manda Sathish, and NagulaShankaraiah. "Rh (III)-catalysed site-selective alkylation of β-carbolines/isoquinolines and tandem CH/CN functionalization to construct indolizine-indole frameworks." *Molecular Catalysis* 533 (2022): 112783.
- 54. John, StephyElza, Darshana Bora, Sowmya Dastari, Durgesh GurukkalaValapil, and NagulaShankaraiah. "Synthesis of alpha-pyrones and chromen-2-ones by transition-metal catalyzed annulations of sulfoxonium and iodonium ylides with cis-stilbene acids." *New Journal of Chemistry* 46, no. 41 **(2022)**: 19722-19730.
- 55. Laxmikeshav, Kritika, Pooja Sharma, Manisurya Palepu, Pravesh Sharma, Ashutosh Mahale, Joel George, Regur Phanindranath et al. "Benzimidazole based bis-carboxamide derivatives as promising cytotoxic agents: Design, synthesis, in silico and tubulin polymerization inhibition." *Journal of Molecular Structure* 1271 **(2023):** 134078.
- 56. Soni, Jay Prakash, AkshayKumawat, Manda Sathish, Sachin Yadav, Nayan Arvind Jadhav, and NagulaShankaraiah. "Catalyst-Free Site-Selective Diverse Functionalization of Inherent C–H Bonds in 1-Aryl-β-carbolines, Norharmane and Harmine." *ChemistrySelect* 7, no. 29 **(2022)**: e202202299.
- 57. Patra, Sandip, Priyanka MAKHAL, Shubham Jaryal, M. O. R. E. Nilesh, and Venkata Rao Kaki. "Anthocyanins: Plant-based flavonoid pigments with diverse biological activities." *International Journal of Plant Based Pharmaceuticals* 2, no. 1 (2022): 118-127.
- 58. John, StephyElza, Darshana Bora, and NagulaShankaraiah. "Ru (ii)-Catalyzed regioselective carbene insertion into β-carbolines and isoquinolines." *Organic & Biomolecular Chemistry* 20, no. 29 **(2022)**: 5852-5860.
- 59. Kadagathur, Manasa, Sandip Patra, Geetanjali Devabattula, Joel George, Regur Phanindranath, ArbazSujat Shaikh, Dilep Kumar Sigalapalli et al. "Design, synthesis of DNA-interactive 4-thiazolidinone-based indolo-/pyrroloazepinone conjugates as potential cytotoxic and topoisomerase I inhibitors." *European Journal of Medicinal Chemistry* 238 **(2022)**: 114465.
- 60. Prakash Soni, Jay, Manda Sathish, Fabiane M. Nachtigall, Leonardo S. Santos, and NagulaShankaraiah. "Brown Seaweed-Derived Alginic Acid: An Efficient and Reusable Catalyst for Pictet-Spengler Reaction to Access Tetrahydro-β-Carboline and Tetrahydroisoquinoline Frameworks." *Asian Journal of Organic Chemistry* 11, no. 5 (2022): e202200129.
- 61. Soni, Jay P., Nayan Arvind Jadhav, and NagulaShankaraiah. "The Expedition of Azido-reductive Cyclization Approaches Towards Various Heterocycles." *Current Organic Chemistry* 26, no. 4 (2022): 382-398.
- 62. Jhingran, Sarthak, Kritika Laxmikeshav, SayaliMone, Venkata K Rao, and NagulaShankaraiah. "The Syntheses and Medicinal Attributes of Phenanthrenes

as Anticancer Agents: A Quinquennial Update." *Current Medicinal Chemistry* 29, no. 20 **(2022)**: 3530-3556.

- 63. Tokala, Ramya, Darshana Bora, and NagulaShankaraiah. "Contribution of Knoevenagel Condensation Products toward the Development of Anticancer Agents: An Updated Review." *ChemMedChem* 17, no. 8 **(2022)**: e202100736.
- 64. Shaikh, ArbazSujat, GaddamKiranmai, G. Parimala Devi, Priyanka N. Makhal, Dilep Kumar Sigalapalli, Ramya Tokala, Venkata Rao Kaki et al. "Exploration of mercaptoacetamide-linked pyrimidine-1, 3, 4-oxadiazole derivatives as DNA intercalative topo II inhibitors: Cytotoxicity and apoptosis induction." *Bioorganic & Medicinal Chemistry Letters* 65 **(2022)**: 128697.
- 65. Kadagathur, Manasa, ArbazSujat Shaikh, Biswajit Panda, Joel George, Regur Phanindranath, Dilep Kumar Sigalapalli, Nagesh A. Bhale et al. "Synthesis of indolo/pyrroloazepinone-oxindoles as potential cytotoxic, DNA-intercalating and Topo I inhibitors." *Bioorganic Chemistry* 122 **(2022)**: 105706.
- 66. Laxmikeshav, Kritika, Akash P. Sakla, StephyElza John, and NagulaShankaraiah. "One-pot, microwave-assisted copper (i)-catalysed dithiocarbamation: facile introduction of dithiocarbamate on imidazopyridines." *Green Chemistry* 24, no. 3 (2022): 1259-1269.
- 67. Mandumpala, Janice Jacson, Stephin Baby, Antriya Annie Tom, ChandraiahGodugu, and NagulaShankaraiah. "Role of histone demethylases and histone methyltransferases in triple-negative breast cancer: Epigenetic mnemonics." *Life Sciences* (2022): 120321.
- 68. Laxmikeshav, Kritika, Pooja Kumari, and NagulaShankaraiah. "Expedition of sulfur-containing heterocyclic derivatives as cytotoxic agents in medicinal chemistry: a decade update." *Medicinal Research Reviews* 42, no. 1 (2022): 513-575.
- 69. Parupalli, Ramulu, Ravikumar Akunuri, Grace Kaul, Abdul Akhir, Deepanshi Saxena, Shaik Mahammad Ghouse, Venkata Madhavi Yaddanapudi, Sidharth Chopra, and Srinivas Nanduri. "Serendipitous identification of phenylhydrazine derivatives as potent inhibitors of carbapenem-resistant Acinetobacter baumannii." *Future Medicinal Chemistry* 14, no. 22 (2022): 1621-1634.
- 70. Akunuri, Ravikumar, Tanveer Unnissa, ManasaVadakattu, SushmithaBujji, Shaik Mahammad Ghouse, Venkata Madhavi Yaddanapudi, Sidharth Chopra, and Srinivas Nanduri. "Bacterial Pyruvate Kinase: A New Potential Target to Combat Drug-Resistant Staphylococcus aureus Infections." *ChemistrySelect* 7, no. 29 (2022): e202201403.
- 71. Imran, Mohmmad, Mohammad Naiyaz Ahmad, Arunava Dasgupta, Preeti Rana, Nanduri Srinivas, and Sidharth Chopra. "Novel approaches for the treatment of infections due to multidrug-resistant bacterial pathogens." *Future Medicinal Chemistry* 14, no. 15 **(2022)**: 1133-1148.
- 72. Akunuri, Ravikumar, Tanveer Unnissa, Grace Kaul, Abdul Akhir, Deepanshi Saxena, MohmaddWajidali, Vaishnavi Veerareddy, Venkata Madhavi Yaddanapudi, Sidharth Chopra, and Srinivas Nanduri. "Synthesis and antibacterial evaluation of rhodanine and its related heterocyclic compounds against S. aureus and A. baumannii." *Chemistry & Biodiversity* 19, no. 7 **(2022)**: e202200213.
- 73. Srikanth, Danaboina, Swanand Vinayak Joshi, Mahammad Ghouse Shaik, Gaurav Pawar, SushmithaBujji, VinaykumarKanchupalli, Sidharth Chopra, and Srinivas Nanduri. "A comprehensive review on potential therapeutic inhibitors of

nosocomial Acinetobacter baumannii superbugs." *Bioorganic Chemistry* (2022): 105849.

- 74. Chinchilli, Krishna K., Venkata N. Royyala, Pavitra S. Thacker, Andrea Angeli, Srikanth Danaboina, Priti Singh, Srinivas Nanduri, Claudiu T. Supuran, and Mohammed Arifuddin. "Design, synthesis, SAR, and biological evaluation of saccharin-based hybrids as carbonic anhydrase inhibitors." *Archiv der Pharmazie* 355, no. 8 (2022): 2200019.
- 75. Tamang, Nitesh, Christopher Andrews, Sai Kiran Mavileti, Srinivas Nanduri, Nageswara Rao Golakoti, and Balasubramanyam Karanam. "Anti-cancer activity of heteroaromatic acetals of andrographolide and its isomers." *New Journal of Chemistry* 46, no. 20 **(2022)**: 9745-9754.
- 76. Pawar, Gaurav, Shaik Mahammad Ghouse, Swayamsiddha Kar, Sai Manohar Chelli, Srinivas Reddy Dannarm, Jitendra Gour, Rajesh Sonti, and Srinivas Nanduri. "SmI2-mediated C-alkylation of Ketones with Alcohols under Microwave Conditions: A Novel Route to Alkylated Ketones." *Chemistry–An Asian Journal* 17, no. 8 (2022): e202200041.
- 77. Pawar, Gaurav, Shaikh Mohammad Ghouse, Swanand Vinayak Joshi, Preeti Rana, Swayamsiddha Kar, P. Mahesh Sarma, Srinivas Reddy Dannarm, Rajesh Sonti, and Srinivas Nanduri. "Cu (I)-Catalyzed Microwave-Assisted Multicomponent Reaction Towards Synthesis of Diverse Fluorescent Quinazolino [4, 3-b] quinazolin-8-ones and Their Photophysical Study." *ChemistrySelect* 7, no. 14 (2022): e202200500.
- 78. Akunuri, Ravikumar, ManasaVadakattu, Grace Kaul, Abdul Akhir, Deepanshi Saxena, Mohammad Naiyaz Ahmad, SushmithaBujji et al. "Synthesis and Antibacterial Evaluation of 3, 4-Dihydro-1H-benzo [b] azepine-2, 5-dione Derivatives." *ChemistrySelect* 7, no. 7 **(2022)**: e202104478.
- 79. Rajakumara, Eerappa, Suman Abhishek, Kulhar Nitin, Dubey Saniya, Priyanka Bajaj, Ulrich Schwaneberg, and Mehdi D. Davari. "Structure and Cooperativity in Substrate–Enzyme Interactions: Perspectives on Enzyme Engineering and Inhibitor Design." *ACS Chemical Biology* 17, no. 2 **(2022)**: 266-280.
- 80. Dixit, Vaibhav A., Upadhyayula Suryanarayana Murty, Priyanka Bajaj, Jochen Blumberger, and Sam P. de Visser. "Mechanisms of Electron Transfer Rate Modulations in Cytochrome P450 BM3." *The Journal of Physical Chemistry B* 126, no. 47 **(2022)**: 9737-9747.
- 81. Singh, Priti, Santosh Kumar Sahoo, Nerella Sridhar Goud, Baijayantimala Swain, Venkata Madhavi Yaddanapudi, and Mohammed Arifuddin. "Microwave-Assisted Copper-Catalyzed One-Pot Synthesis of 2-Aryl/Heteroaryl-4-Quinolones via Sequential Intramolecular Aza-Michael Addition and Oxidation." *Asian Journal of Organic Chemistry* 11, no. 7 **(2022)**: e202200181.
- 82. Singh, Priti, Nerella Sridhar Goud, Baijayantimala Swain, Santosh Kumar Sahoo, Abhishek Choli, Andrea Angeli, Bhoopendra Singh Kushwah, Venkata Madhavi Yaddanapudi, Claudiu T. Supuran, and Mohammed Arifuddin. "Synthesis of a new series of quinoline/pyridine indole-3-sulfonamide hybrids as selective carbonic anhydrase IX inhibitors." *Bioorganic & Medicinal Chemistry Letters* 70 **(2022)**: 128809.
- 83. Baliram Gaikwad, Nikhil, Santosh Kumar Sahoo, OjaswithaOmmi, Mohammad Naiyaz Ahmad, Afroz Pathan, Grace Kaul, Srinivas Nanduri, Arunava Dasgupta, Sidharth Chopra, and Venkata Madhavi Yaddanapudi. "Identification of 1, 3-

Substituted Pyrazole-Based Carboxamide Derivatives as Potent Antitubercular Agents." ChemistrySelect 7, no. 40 **(2022)**: e202203333.

- 84. Sahoo, Santosh Kumar, SarvanMaddipatla, Siva Nageswara Rao Gajula, Mohammad Naiyaz Ahmad, Grace Kaul, Srinivas Nanduri, Rajesh Sonti, Arunava Dasgupta, Sidharth Chopra, and Venkata Madhavi Yaddanapudi. "Identification of nitrofuranylchalcone tethered benzoxazole-2-amines as potent inhibitors of drug resistant Mycobacterium tuberculosis demonstrating bactericidal efficacy." Bioorganic & Medicinal Chemistry 64 **(2022)**: 116777.
- 85. Sahoo, Santosh K., Siva NR Gajula, Mohammad N. Ahmad, Grace Kaul, Srinivas Nanduri, Rajesh Sonti, Arunava Dasgupta, Sidharth Chopra, and Venkata M. Yaddanapudi. "Bioevaluation of quinoline-4-carbonyl derivatives of piperazinyl-benzothiazinones as promising antimycobacterial agents." Archiv der Pharmazie 355, no. 11 **(2022)**: 2200168.
- 86. Sahoo, Santosh Kumar, Mohammad Naiyaz Ahmad, Grace Kaul, Srinivas Nanduri, Arunava Dasgupta, Sidharth Chopra, and Venkata Madhavi Yaddanapudi. "Synthesis and evaluation of triazole congeners of nitro-benzothiazinones potentially active against drug resistant Mycobacterium tuberculosis demonstrating bactericidal efficacy." RSC Medicinal Chemistry 13, no. 5 **(2022)**: 585-593.
- 87. Sahoo, Santosh Kumar, OjaswithaOmmi, SarvanMaddipatla, Priti Singh, Mohammad Naiyaz Ahmad, Grace Kaul, Srinivas Nanduri, Arunava Dasgupta, Sidharth Chopra, and Venkata Madhavi Yaddanapudi. "Isoxazole carboxylic acid methyl ester-based urea and thiourea derivatives as promising antitubercular agents." Molecular Diversity **(2022)**: 1-16.
- 88. Singh, Priti, Nerella Sridhar Goud, Baijayantimala Swain, Santosh Kumar Sahoo, Abhishek Choli, Andrea Angeli, Bhoopendra Singh Kushwah, Venkata Madhavi Yaddanapudi, Claudiu T. Supuran, and Mohammed Arifuddin. "Synthesis of a new series of quinoline/pyridine indole-3-sulfonamide hybrids as selective carbonic anhydrase IX inhibitors." Bioorganic & Medicinal Chemistry Letters 70 **(2022)**: 128809.
- 89. Swain, Baijayantimala, Santosh Kumar Sahoo, Priti Singh, Andrea Angeli, Venkata Madhavi Yaddanapudi, Claudiu T. Supuran, and Mohammed Arifuddin. "Exploration of 2-phenylquinoline-4-carboxamide linked benzene sulfonamide derivatives as isoform selective inhibitors of transmembrane human carbonic anhydrases." European Journal of Medicinal Chemistry 234 **(2022)**: 114247.
- 90. Swain, Baijayantimala, Abrar Khan, Priti Singh, Vaibhav S. Marde, Andrea Angeli, Krishna Kartheek Chinchilli, Venkata Madhavi Yaddanapudi, Simone Carradori, Claudiu T. Supuran, and Mohammed Arifuddin. "Design, Synthesis and Biological Assessment of Rhodanine-Linked Benzenesulfonamide Derivatives as Selective and Potent Human Carbonic Anhydrase Inhibitors." Molecules 27, no. 22 **(2022)**: 8028.
- 91. Swain, Baijayantimala, Abrar Khan, Priti Singh, Vaibhav S. Marde, Andrea Angeli, Krishna Kartheek Chinchilli, Venkata Madhavi Yaddanapudi, Simone Carradori, Claudiu T. Supuran, and Mohammed Arifuddin. "Design, Synthesis and Biological Assessment of Rhodanine-Linked Benzenesulfonamide Derivatives as Selective and Potent Human Carbonic Anhydrase Inhibitors." Molecules 27, no. 22 **(2022)**: 8028.

Biological Sciences

- 92. Sood, Anika, Valencia Fernandes, Kumari Preeti, Mayuri Khot, Dharmendra Kumar Khatri, and Shashi Bala Singh. "Fingolimod Alleviates Cognitive Deficit in Type 2 Diabetes by Promoting Microglial M2 Polarization via the pSTAT3-jmjd3 Axis." Molecular Neurobiology **(2022)**: 1-22.
- 93. Fernandes, Valencia, Anika Sood, Kumari Preeti, Dharmendra Kumar Khatri, and Shashi Bala Singh. "Neuroepigenetic alterations in the prefrontal cortex of type 2 diabetic mice through DNA hypermethylation." Molecular Biology Reports (2022): 1-12.
- 94. Khan, Islauddin, Kumari Preeti, Valencia Fernandes, Dharmendra Kumar Khatri, and Shashi Bala Singh. "Role of MicroRNAs, aptamers in neuroinflammation and neurodegenerative disorders." Cellular and Molecular Neurobiology 42, no. 7 (2022): 2075-2095.
- 95. Khot, Mayuri, Anika Sood, Kamatham Pushpa Tryphena, Sabiya Khan, Saurabh Srivastava, Shashi Bala Singh, and Dharmendra Kumar Khatri. "NLRP3 inflammasomes: A potential target to improve mitochondrial biogenesis in Parkinson's disease." European Journal of Pharmacology **(2022)**: 175300.
- 96. Fernandes, Valencia, Kumari Preeti, Anika Sood, Kala P. Nair, Sabiya Khan, BS Shankaranarayana Rao, Dharmendra Kumar Khatri, and Shashi Bala Singh. "Neuroepigenetic Changes in DNA Methylation Affecting Diabetes-Induced Cognitive Impairment." Cellular and Molecular Neurobiology **(2022)**: 1-16.
- 97. Naren, Padmashri, Anjali Cholkar, SuchitaKamble, Khan SabiyaSamim, Saurabh Srivastava, Jitender Madan, Neelesh Mehra, Vinod Tiwari, Shashi Bala Singh, and Dharmendra Kumar Khatri. "Pathological and Therapeutic Advances in Parkinson's Disease: Mitochondria in the Interplay." Journal of Alzheimer's Disease Preprint **(2022)**: 1-30.
- 98. Rathour, Deepak, Shruti Shah, Sabiya Khan, Pankaj Kumar Singh, Saurabh Srivastava, Shashi Bala Singh, and Dharmendra Kumar Khatri. "Role of gut microbiota in depression: Understanding molecular pathways, recent research, and future direction." Behavioural Brain Research (2022): 114081.
- 99. Khan, Islauddin, Kumari Preeti, Rahul Kumar, Dharmendra Kumar Khatri, and Shashi Bala Singh. "Activation of SIRT1 by silibinin improved mitochondrial health and alleviated the oxidative damage in experimental diabetic neuropathy and high glucose-mediated neurotoxicity." Archives of Physiology and Biochemistry (2022): 1-17.
- 100. Arruri, Vijay Kumar, Chayanika Gundu, Anil Kumar Kalvala, Bhoomika Sherkhane, Dharmendra Kumar Khatri, and Shashi Bala Singh. "Carvacrol abates NLRP3 inflammasome activation by augmenting Keap1/Nrf-2/p62 directed autophagy and mitochondrial quality control in neuropathic pain." Nutritional neuroscience 25, no. 8 **(2022)**: 1731-1746.
- 101. Tryphena, Kamatham Pushpa, Urati Anuradha, Rohith Kumar, Shruti Rajan, Saurabh Srivastava, Shashi Bala Singh, and Dharmendra Kumar Khatri. "Understanding the Involvement of microRNAs in Mitochondrial Dysfunction and Their Role as Potential Biomarkers and Therapeutic Targets in Parkinson's Disease." Journal of Alzheimer's Disease Preprint: 1-16.
- 102. Khatri, Dharmendra Kumar, Kumari Preeti, ShivrajTonape, Sheoshree Bhattacharjee, Monica Patel, Saurabh Shah, Pankaj Kumar Singh et al.

"Nanotechnological Advances for Nose to Brain Delivery of Therapeutics to Improve the Parkinson Therapy." Current Neuropharmacology **(2022)**.

- 103. Gundu, Chayanika, Vijay Kumar Arruri, Bhoomika Sherkhane, Dharmendra Kumar Khatri, and Shashi Bala Singh. "Indole-3-propionic acid attenuates high glucose induced ER stress response and augments mitochondrial function by modulating PERK-IRE1-ATF4-CHOP signalling in experimental diabetic neuropathy." Archives of Physiology and Biochemistry **(2022)**: 1-14.
- 104. Nellaiappan, Karthika, Kumari Preeti, Dharmendra K. Khatri, and Shashi Bala Singh. "Diabetic complications: an update on pathobiology and therapeutic strategies." Current diabetes reviews 18, no. 1 **(2022)**: 31-44.
- 105. Gundu, Chayanika, Vijay Kumar Arruri, Bhoomika Sherkhane, Dharmendra Kumar Khatri, and Shashi Bala Singh. "GSK2606414 attenuates PERK/p-eIF2 α /ATF4/CHOP axis and augments mitochondrial function to mitigate high glucose induced neurotoxicity in N2A cells." Current Research in Pharmacology and Drug Discovery 3 **(2022)**: 100087.
- 106. Begum, Nusrat, Aniket Mandhare, Kamatham Pushpa Tryphena, Saurabh Srivastava, Mohd Farooq Shaikh, Shashi Bala Singh, and Dharmendra Kumar Khatri. "Epigenetics in depression and gut-brain axis: A molecular crosstalk." Frontiers in Aging Neuroscience 14 **(2022)**.
- 107. Kharwar, Akash, Mohd Rabi Bazaz, and Manoj P. Dandekar. "Quantitative and qualitative characterization of commercially available oral suspension of probiotic products containing Bacillus Clausii spores." *BMC microbiology* 22, no. 1 (2022): 1-11.
- 108. Singh, Aditya A., Akash Kharwar, and Manoj P. Dandekar. "A Review on Preclinical Models of Ischemic Stroke: Insights Into the Pathomechanisms and New Treatment Strategies." *Current Neuropharmacology* 20, no. 9 (2022): 1667-1686.
- **109**. Palepu, Mani Surya Kumar, and Manoj P. Dandekar. "Remodeling of microbiota gut-brain axis using psychobiotics in depression." *European Journal of Pharmacology* **(2022)**: 175171.
- 110. Rahman, Ziaur, and Manoj P. Dandekar. "Implication of Paraprobiotics in Age-Associated Gut Dysbiosis and Neurodegenerative Diseases." *NeuroMolecular Medicine* (2022): 1-13.
- **111.** Rahman, Zara, TulasiPasam, Rishab, and Manoj P. Dandekar. "Binary classification model of machine learning detected altered gut integrity in controlled-cortical impact model of traumatic brain injury." *International Journal of Neuroscience* **(2022)**: 1-12.
- 112. Dandekar, Manoj P., Mani Surya Kumar Palepu, SrilakshmiSatti, Yash Jaiswal, Aditya A. Singh, Surya Prakash Dash, Siva Nageswara Rao Gajula, and Rajesh Sonti. "Multi-strain probiotic formulation reverses maternal separation and chronic unpredictable mild stress-generated anxiety-and depression-like phenotypes by modulating gut microbiome-brain activity in rats." *ACS Chemical Neuroscience* 13, no. 13 **(2022)**: 1948-1965.
- 113. Dandekar, Manoj P., Xing Yin, Tao Peng, Sridevi Devaraj, Rodrigo Morales, David D. McPherson, and Shao-Ling Huang. "Repetitive xenon treatment improves poststroke sensorimotor and neuropsychiatric dysfunction." *Journal of Affective Disorders* 301 (2022): 315-330.
- 114. Dandekar, Manoj P., Xing Yin, Tao Peng, Sridevi Devaraj, Rodrigo Morales, David D. McPherson, and Shao-Ling Huang. "Repetitive xenon treatment improves post-

stroke sensorimotor and neuropsychiatric dysfunction." *Journal of Affective Disorders* 301 **(2022)**: 315-330.

- 115. Balasubramanian, Ramya, Mohd Rabi Bazaz, TulasiPasam, NaserunnisaSharief, LaximanVelip, GananadhamuSamanthula, and Manoj P. Dandekar. "Involvement of Microbiome Gut–Brain Axis in Neuroprotective Effect of Quercetin in Mouse Model of Repeated Mild Traumatic Brain Injury." NeuroMolecular Medicine (2022): 1-13.
- 116. Devsani, Namrata, Divya Vemula, and Vasundhra Bhandari. "The glycoprotein gp63–a potential pan drug target for developing new antileishmanial agents." Biochimie**(2022)**.
- 117. Vemula, Divya, Perka Jayasurya, VarthiyaSushmitha, Yethirajula Naveen Kumar, and Vasundhra Bhandari. "CADD, AI and ML in Drug Discovery: A Comprehensive Review." European Journal of Pharmaceutical Sciences **(2022)**: 106324.
- 118. Kandpal, Meenakshi, Omkar Indari, BudhadevBaral, Shweta Jakhmola, Deeksha Tiwari, Vasundhra Bhandari, Rajan Kumar Pandey, Kiran Bala, AvinashSonawane, and Hem Chandra Jha. "Dysbiosis of Gut Microbiota from the Perspective of the Gut–Brain Axis: Role in the Provocation of Neurological Disorders." Metabolites 12, no. 11 **(2022)**: 1064.
- 119. Kashyap, Dharmendra, Mrutyunjaya Panda, BudhadevBaral, Nidhi Varshney, Vasundhra Bhandari, Hamendra Singh Parmar, Amit Prasad, and Hem Chandra Jha. "Outer Membrane Vesicles: An Emerging Vaccine Platform." Vaccines 10, no. 10 **(2022)**: 1578.
- 120. Brahma, Umarani, Akash Suresh, Shweta Murthy, Vasundhra Bhandari, and Paresh Sharma. "Antibiotic Resistance and Molecular Profiling of the Clinical Isolates of Staphylococcus aureus Causing Bovine Mastitis from India." Microorganisms 10, no. 4 **(2022)**: 833.
- 121. Kumar, Rahul, T. Amruthanjali, Siva Singothu, Shashi Bala Singh, and Vasundhra Bhandari. "Uncoupling proteins as a therapeutic target for the development of new era drugs against neurodegenerative disorder." Biomedicine & Pharmacotherapy 147 **(2022)**: 112656.
- 122. Bhandari, Vasundhra, and Akash Suresh. "Next-Generation Approaches Needed to Tackle Antimicrobial Resistance for the Development of Novel Therapies Against the Deadly Pathogens." Frontiers in Pharmacology 13 **(2022)**.
- 123. Gurram, Sowmyasree, Pratibha Anchi, Biswajit Panda, Sayali Santosh Tekalkar, Ravindra Bapu Mahajan, and ChandraiahGodugu. "Amelioration of experimentally induced inflammatory arthritis by intra-articular injection of visnagin." Current Research in Pharmacology and Drug Discovery 3 **(2022)**: 100114.
- 124. Allawadhi, Prince, Amit Khurana, Nilofer Sayed, ChandraiahGodugu, and DivyaVohora. "Ameliorative effect of cerium oxide nanoparticles against Freund's complete adjuvant-induced arthritis." Nanomedicine 17, no. 6 **(2022)**: 383-404.
- 125. Saifi, Mohd Aslam, ArbazSujat Shaikh, Venkata Rao Kaki, and ChandraiahGodugu. "Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes." Journal of Cellular Physiology 237, no. 5 (2022): 2516-2527.
- 126. Saifi, Mohd Aslam, and ChandraiahGodugu. "Copper chelation therapy inhibits renal fibrosis by modulating copper transport proteins." BioFactors 48, no. 4 (2022): 934-945.

- 127. Anchi, Pratibha, Biswajit Panda, Ravindra Bapu Mahajan, and ChandraiahGodugu. "Co-treatment of Nimbolide augmented the anti-arthritic effects of methotrexate while protecting against organ toxicities." Life Sciences 295 **(2022)**: 120372.
- 128. Aslam Saifi, Mohd, Rishabh Hirawat, and ChandraiahGodugu. "Lactoferrin-Decorated Cerium Oxide Nanoparticles Prevent Renal Injury and Fibrosis." Biological Trace Element Research **(2022)**: 1-9.
- 129. Anchi, Pratibha, ShrilekhaChilvery, SayaliTekalkar, Siva Nageswara Rao Gajula, Rajesh Sonti, and ChandraiahGodugu. "Nimbolide loaded sustained release microparticles as single-dose formulations for effective management of arthritis." Journal of Drug Delivery Science and Technology 75 **(2022)**: 103638.
- 130. Saifi, Mohd Aslam, SapanaBansod, and ChandraiahGodugu. "COVID-19 and fibrosis: mechanisms, clinical relevance, and future perspectives." Drug Discovery Today **(2022)**: 103345.
- 131. Chilvery, Shrilekha, Amit Yelne, Amit Khurana, Mohd Aslam Saifi, SapanaBansod, Pratibha Anchi, and ChandraiahGodugu. "Acetaminophen induced hepatotoxicity: An overview of the promising protective effects of natural products and herbal formulations." Phytomedicine **(2022)**: 154510.
- 132. Khurana, Amit, Mohd Aslam Saifi, and ChandraiahGodugu. "Yttrium Oxide Nanoparticles Attenuate L-Arginine Induced Chronic Pancreatitis." Biological Trace Element Research **(2022)**: 1-14.
- 133. Hirawat, Rishabh, Namrata Jain, Mohd Aslam Saifi, Mahesh Rachamalla, and ChandraiahGodugu. "Lung Fibrosis: Post-COVID-19 Complications and Evidences." International Immunopharmacology **(2022)**: 109418.
- 134. Balasubramanian, Ramya, Mohd Rabi Bazaz, TulasiPasam, NaserunnisaSharief, LaximanVelip, GananadhamuSamanthula, and Manoj P. Dandekar. "Involvement of Microbiome Gut–Brain Axis in Neuroprotective Effect of Quercetin in Mouse Model of Repeated Mild Traumatic Brain Injury." NeuroMolecular Medicine (2022): 1-13.

Regulatory Affairs

- 135. Sabanis, Chetan D., Bharathi R Kannan, Ramesh Joga, Simran, Sandeep Kumar, and Neeraj Kumar. "Potential of novel self-assembled functionalized carbon nanotubes for selective tumor targeting." Pharmaceutical Patent Analyst 11, no. 3 (2022): 111-117.
- 136. Grover, Parul, Lovekesh Mehta, Tanveer Naved, Sandeep Kumar, and Gorav Monga. "Identification and characterization of in vitro metabolites of belinostat by rat liver microsomes using ultra performance liquid chromatography coupled with tandem mass spectrometry." Indian J. Pharm. Educ. Res. 56 (2022): S58-S60.
- Goyal, Pankaj, Vartika Mishra, Isha Dhamija, Neeraj Kumar, and Sandeep Kumar.
 "Immobilization of catalase on functionalized magnetic nanoparticles: a statistical approach." 3 Biotech 12, no. 5 (2022): 108.
- 138. Grover, Parul, Monika Bhardwaj, L. Mehta, T. Naved, and S. Kumar. "Identification and Characterization of In Vitro Metabolites of Ibrutinib by Rat Liver Microsomes Using Ultra-Performance Liquid Chromatography Coupled with Tandem Mass Spectrometry." Indian Journal of Pharmaceutical Sciences 84, no. 3 **(2022)**: 762-771.

- 139. Tijani, Akeemat O., Jivesh Garg, Dorcas Frempong, Gabrielle Verana, Jagroop Kaur, Ramesh Joga, Chetan D. Sabanis, Sandeep Kumar, Neeraj Kumar, and Ashana Puri. "Sustained drug delivery strategies for treatment of common substance use disorders: Promises and challenges." Journal of Controlled Release 348 (2022): 970-1003.
- 140. Singh, Jatinder, Isha Dhamija, HarmanpreetMeehenian, Neeraj Kumar, Simran Simran, MuskanMuskan, Madan L. Verma, and Sandeep Kumar. "Chronicle updates in cyclodextrin-based carriers for drug delivery." Bulletin of the National Research Centre 46, no. 1 (2022): 202.
- 141. Monga G, Koppula S, Simran, Devi K, S S, S K. Exploring Efficacy of Bauhinia Variegata as Medicinal Herb in Combating Different Clinical Conditions: A Systematic Review. Bioequivalence & Bioavailability International Journal 2022;10.23880/beba-16000175.
- 142. Joga, Ramesh, Christy J. Pulini-Kunnel, Chetan D. Sabanis, Simran, Sandeep Kumar, and Neeraj Kumar. "Highly stable, non-toxic and functionalized nanoemulsion for the early diagnosis and amelioration of cancer." Pharmaceutical Patent Analyst 11, no. 5 (2022): 155-162.

Pharmaceutical Analysis

- 143. Gajula, Siva Nageswara Rao, TanaazNavinNathani, Rashmi Madhukar Patil, Sasikala Talari, and Rajesh Sonti. "Aldehyde oxidase mediated drug metabolism: an underpredicted obstacle in drug discovery and development." Drug Metabolism Reviews 54, no. 4 **(2022)**: 427-448.
- 144. Purushotham, Manasa, Bishwajit Paul, Siva Nageswara Rao Gajula, Biswajit Sahariah, and Rajesh Sonti. "Deciphering C–H… O/X weak hydrogen bonding and halogen bonding interactions in aromatic peptoids." New Journal of Chemistry 46, no. 41 **(2022)**: 19648-19657.
- 145. Moi, Smriti, ShamasoddinShekh, K. Kasi Amarnath Reddy, Pooja Dhurjad, Rajesh Sonti, and KonkalluHanumaeGowd. "Peptide Cysteine Thiols Act as Photostabilizer of Avobenzone through Stabilizing the Transition State of Keto-Enol Tautomerization." Photochemistry and Photobiology **(2022)**.
- 146. Rao Gajula, Siva Nageswara, NathaniTanaazNavin, Sasikala Talari, Chinmayee Shende, and Rajesh Sonti. "Green bioanalysis: an innovative and eco-friendly approach for analyzing drugs in biological matrices." Bioanalysis 14, no. 12 (2022): 881-909.
- 147. Dhurjad, Pooja, Choudhary SampatDhalaram, Nazish Ali, Nikita Kumari, and Rajesh Sonti. "Metal–organic frameworks in chiral separation of pharmaceuticals." Chirality 34, no. 11 **(2022)**: 1419-1436.
- 148. Grzesiek, Stephan, Johannes Paladini, Judith Habazettl, and Rajesh Sonti. "Imatinib disassembles the regulatory core of Abelson kinase by binding to its ATP site and not by binding to its myristoyl pocket." Magnetic Resonance 3, no. 1 (2022): 91-99.
- 149. Dhurjad, Pooja, ChinmayiDhavaliker, Kajal Gupta, and Rajesh Sonti. "Exploring drug metabolism by the gut microbiota: modes of metabolism and experimental approaches." Drug Metabolism and Disposition 50, no. 3 **(2022)**: 224-234.
- 150. Dhiman, Vivek, Saranjit Singh, Ankit Balhara, Bhoopendra Singh Kushwah, LaximanVelip, Vijaya MadhyanapuGolla, and GananadhamuSamanthula. "Stress degradation study on entrectinib and characterization of its degradation

products using HRMS and NMR." Journal of Pharmaceutical and Biomedical Analysis 208 **(2022)**: 114459.

- 151. Velip, Laximan, Vivek Dhiman, Bhoopendra Singh Kushwah, Vijaya MadhyanapuGolla, and S. Gananadhamu. "Identification and characterization of urapidil stress degradation products by LC-Q-TOF-MS and NMR: Toxicity prediction of degradation products." Journal of Pharmaceutical and Biomedical Analysis 211 **(2022)**: 114612.
- 152. Kushwah, Bhoopendra Singh, Vijaya MadhyanapuGolla, Vivek Dhiman, and GananadhamuSamanthula. "Forced degradation studies on axitinib and characterization of its degradation products by liquid chromatography-high resolution mass spectrometry and nuclear magnetic resonance spectroscopy along with its in silico toxicity assessment." Separation Science Plus 5, no. 8 (2022): 431-441.
- 153. Kushwah, B. S., S. Singh, M. M. Thummar, A. Balhara, and G. Samanthula. "Characterization of potential degradation products of brexpiprazole by LC-MS/TOF and NMR, and prediction of their physicochemical properties by ADMET Predictor TM." Rapid Communications in Mass Spectrometry: RCM (2022): e9415-e9415.
- 154. Kushwah, Bhoopendra Singh, Hara Prasad Padhy, Rahul Khemchandani, Vijaya MadhyanapuGolla, Vinay Kumar Kanchupalli, Rajesh Sonti, and GananadhamuSamanthula. "Structural characterization of novel hydrolytic and oxidative degradation products of acalabrutinib by LC-Q-TOF-MS, H/D exchange and NMR." Journal of Pharmaceutical and Biomedical Analysis 221 (2022): 115077.
- 155. Kushwah, Bhoopendra Singh, Laximan Ganesh Velip, Kala Kumar Bharani, Prasad V. Surya, Suprita Sinha, Amit Khurana, Yogeshwar Kankarne, Anil Kumar Banothu, and SamanthulaGananadhamu. "A sensitive method for determination of nimesulide and its hydroxy metabolite in milk using validated UPLC-MS method." Talanta Open 6 **(2022)**: 100160.
- 156. Patil, Smita S., Samina K. Tadavi, Amol Dikundwar, and Ratnamala S. Bendre. "The transition metal complexes of Fe (II), Ni (II) and Cu (II) derived from phthalazine based ligands: Synthesis, crystal structures and biological activities." Journal of Molecular Structure 1247 **(2022)**: 131293.
- 157. Ramachandran, Ravikumar, Mallikarjun Narayanam, Robert Wethman, Karthik Jayaraman, Amol Dikundwar, and Hemant Bhutani. "Applications of Raman Spectroscopy in Solvent Distillation and Exchange During Early-Phase Chemical Synthesis." Spectroscopy 37, no. 5 (2022): 28-39.
- 158. Thomas, Sajesh P., Amol G. Dikundwar, Sounak Sarkar, Mysore S. Pavan, Rumpa Pal, Venkatesha R. Hathwar, and Tayur N. Guru Row. "The relevance of experimental charge density analysis in unravelling noncovalent interactions in molecular crystals." Molecules 27, no. 12 **(2022)**: 3690.

BOOK CHAPTERS:

- Gajula, Siva Nageswara Rao, Sakina Asgar Vora, Amol G. Dikundwar, and Rajesh Sonti. "*In Vitro* Drug Metabolism Studies Using Human Liver Microsomes." (2022).
- 2. Dhiman, Vivek, Kanchan Patil, LaximanVelip, MVN Kumar Talluri, and SamanthulaGananadhamu. "Comprehensive degradation profiling and influence of different oxidizing reagents on tinoridine hydrochloride: Structural characterization of its degradation products using HPLC and HRMS." *Rapid Communications in Mass Spectrometry* 36, no. 1 (2022): e9210.
- 3. Khatri, Dharmendra Kumar, Jitender Madan, Kiran Jyoti, and Shashi Bala Singh. "Decoding the signaling cascaded in immunotherapy of cancer: role played by nanoimmunoadjuvants." In *Multifunctional Nanocarriers*, pp. 347-377. Elsevier, **2022**.
- 4. Gugulothu, Dalapathi, and Dharmendra Kumar Khatri. "Emerging applications of bionanomaterials in medicine and drug delivery." *Bionanotechnology: Emerging Applications of Bionanomaterials* (2022): 129-185.
- 5. Singh, Pankaj Kumar, Dharmendra Kumar Khatri, Shashi Bala Singh, and Anitha Sriram, eds. *An Update on SARS-CoV-2: Damage-response Framework, Potential Therapeutic Avenues and the Impact of Nanotechnology on COVID-19 Therapy.* Bentham Science Publishers, **2022**.
- 6. Mounica, Padala Krishna, Geetanjali Devabattula, and ChandraiahGodugu. "Role of Indian Ginseng Withaferin A in ROS-Induced Cancer Chemoprevention and Cancer Therapy." In *Handbook of Oxidative Stress in Cancer: Therapeutic Aspects*, pp. 327-349. Singapore: Springer Nature Singapore, 2022.
- 7. BhavnanaValamla, Pradip Thakor, Arvind Gulbake, Satish Shilpi and Neelesh Kumar Mehra. Micro- and Nanotechnologies Approaches: Concepts and Application. In. Micro and Nanotechnologies Based Product Development. CRC Press, UK. 2022. ISBN 9780367488451 p.p. 03-14
- 8. Bhavana, Valamla, Padakanti Sandeep Chary, Naveen Rajana, and Neelesh Kumar Mehra. "Nanomedicine for targeting breast cancer stem cells." In *Targeted Nanomedicine for Breast Cancer Therapy*, pp. 281-301. Academic Press, 2022.
- 9. Chary, Padakanti Sandeep, Naveen Rajana, Valamla Bhavana, Pankaj Kumar Singh, Saurabh Srivastava, Jitender Madan, Shashi Bala Singh, and Neelesh Kumar Mehra. "Nanotechnology: advanced drug-targeting concepts, fundamentals, and strategies." In *Multifunctional Nanocarriers*, pp. 1-24. Elsevier, 2022.
- 10. Jain, Harsha, Harshita Dalvi, Aditi Bhat, Aashruti Agrawal, Jitender Madan, Pankaj Kumar Singh, Neelesh Kumar Mehra, Shashi Bala Singh, and Saurabh Srivastava. "Nanomaterials in nose-to-brain delivery: a synergistic breakthrough in meeting the unmet." In *Multifunctional Nanocarriers*, pp. 379-400. Elsevier, 2022.
- 11. Shah, Saurabh, NagarjunRangaraj, Punna Rao Ravi, Rajeev Singh Raghuvanshi, Shashi Bala Singh, and Saurabh Srivastava. "COVID-19 outbreak: comprehensive update on epidemiology, transmission, and treatment opportunities." In *Coronavirus Drug Discovery*, pp. 17-36. Elsevier, 2022.
- 12. Dalvi, Harshita, Aditi Bhat, Harsha Jain, Shashi Bala Singh, and Saurabh Srivastava. "Roles of online social media platforms and artificial intelligence in diffusing the impact of COVID-19 as scientists find a cure." In *Coronavirus Drug Discovery*, pp. 349-362. Elsevier, 2022.

- 13. Kotha, Arun K., Rama Kashikar, Paras Famta, Saurabh Shah, Saurabh Srivastava, and Mahavir BhupalChougule. "Nanomaterials Mediated Diagnosis of Lung Cancer." In *Nanomaterials for Cancer Detection Using Imaging Techniques and Their Clinical Applications*, pp. 225-259. Cham: Springer International Publishing, 2022.
- 14. Shah, Saurabh, Vivek Ranjan Sinha, Shashi Bala Singh, and Saurabh Srivastava. "Roles of nanoparticles in drug discovery and delivery." In *Applications of Nanotechnology in Drug Discovery and Delivery*, pp. 3-26. Elsevier, 2022.
- 15. Micro- and Nano-technologies: Concept, advancement and applications. Publisher: CRC Press, UK. Editor(s) Dr.Neelesh Kumar Mehra &Dr. Arvind Gulbake. First Edition. 2022.ISBN 9780367488451
- 16. Multifunctional Nanocarriers". Editer(s). Dr.Neelesh Kumar Mehra, Dr, Jitender Madan, Dr Saurabh Srivastava, Dr Pankaj Kumar Singh. Publisher: Elsevier Pvt. Ltd. First Edition. 2022. ISBN 9780323852944
- Vivek Borse, Pranjal Chandra, and Rohit Srivastava (Eds.) "BioSensing, Theranostics, and Medical Devices: From Laboratory to Point-of-Care Testing", Springer Nature, Singapore, 2022 (Book – ISBN - 978-981-16-2781-1) https://doi.org/10.1007/978-981-16-2782-8

PATENTS:

- 1. Valamla B.; Panwar P.; Kumar A.; Thakor.; Singh SB.; Mehra NK.; (2020). Stable Pharmaceutical Composition of Ferulic Acid and Essential Oil Particulate Emulsified Systems and Method thereof. Indian Patent 202041049335
- 2. Pratik K Kharat.; Dalvi M.; Valamla B.; Thakor P.; Geetanjali.; Godugu C.; Singh SB.; Mehra NK.; (2020). Pharmaceutical Composition of Thymoquinone and Essential Oil Particulate Emulsified Systems and Method Thereof. Indian Patent: IN202041054610.
- 3. Vaskuri G.S Sainaga Jyothi, HarithasreeVeerabomma, Dr. Jitender Madan, Dr. Shashi Bala Singh, Dr. Rahul Kumar, Dr. Dharmendra Kumar Khatri **(2022)**. Anti-Inflammatory Composition And Method of Preparation Thereof. Indian Patent IN 202241050316.
- 4. Harsha Jain; Dr. Saurabh Srivastava; Dr. Shashi Bala Singh: Topical Pharmaceutical composition for treatment of psoriasis; Patent application number: IN 202041046470
- 5. Dr. Shashi Bala Singh; Dr. Saurabh Srivastava; Atmakuri Srividya; Shweta Nene: Pharmaceutical composition of tofacitinib for the management of atopic dermatitis; Patent application number: 202141019173 A
- 6. NagulaShankaraiah, Kishna Ram Senwar, Pankaj Sharma, VGM Naidu, Dinesh Thummuri; Benzylideneindolinones Useful as Anticancer Agents and Process of Preparing the Same; year **2022**, Application No 7129/CHE/2015, granted No 408084



NIPER, KOLKATA



Contact Address Chunilal Bhawan (Adjacent to BCPL), 168, Maniktala Main Road P.O. Bengal Chemicals, P.S. Phoolbagan Kolkata – 700054 [West Bengal] Phone: +91(033)-23200086 Email: info.office@niperkolkata.edu.in Website: www.niperkolkata.edu.in

From the Director's Desk

National Institute of Pharmaceutical Education & Research (NIPER), Kolkata was established in 2007 as an autonomous body under the aegis of Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers, Government of India

The Institute endeavors to provide high quality education in the areas of Pharmaceutical Sciences and to promote innovative and applied research through academic and research activities amongst the young generation, by way of introducing various courses in PG and Ph.D. level.



Prof V Ravichandiran

Initially, the Institute has operated under mentorship of premier Institute of the Council of Scientific & Industrial Research, India i.e., Indian Institute of Chemical Biology (CSIR-IICB), Kolkata. Later, in 2018 the Institute started functioning Individually at a leased campus of M/s. Bengal Chemicals and Pharmaceuticals, Kolkata situated at Chunilal Bhawan, 168, Maniktala Main Road, Kolkata – 700 054.

The Institute has started M.S. (Pharm) with three departments viz., Medicinal Chemistry, Natural Products, Pharmacoinformatics in 2007. At present, the institute has M.S (Pharm) and PhD in seven departments namely, Medicinal Chemistry, Natural Products, Pharmacoinformatics, Pharmacology & Toxicology, Pharmaceutics, Medical Devices and Pharmaceutical Analysis.

The Institute is focusing on multi-disciplinary research to bring out viable process technology/products, to identify lead molecules and to improve the efficacy and safety of pharmaceutical agents by utilizing established instrumentation facility like NMR, LC-MS, Animal Imaging, confocal microscopy, flow reactor, ultracentrifuge, Spray dryer, Real time PCR, DSC, SEM, TGA, Zetasizer, Rheometer etc. along with animal house and cell culture facilities.

Our faculty members of various departments are working in newer areas of pharmaceutical sciences to contribute towards the institute research objectives.

The Department of Medicinal Chemistry is involved in the development of Nucleic acidbased therapeutics based on promising technologies such as RNA interference technology (RNAi), antisense technology (ASO), SMaRT technology and CRISPR-Cas technology for treating Rare Diseases including various disorders. They also involved in development of process technology for the synthesis of API/KSM using green chemistry and flow chemistry and using utilizing atmospheric nitrogen for synthesis of nitrogen containing organic compounds as potential therapeutic agents. Development of static in-equilibrium peptide assembly especially peptide hydrogels for different applications like catalysis, sensing, storage and controlled release of biomolecules and therapeutics. They are also involved in the development of antibody-recruiting molecules against bacteria and cancer and development of cell penetrating fluorescent probes as diagnostic tools. **The Department of Natural Products** is involved in identification and evaluation of novel secondary metabolites from natural products and studying drug herb interactions using LC-MS and CRISPR-cas mediated targeted genome editing in the context of inflammatory disorders. While **Department of Pharmacology and Toxicology** is involved in identifying therapeutic targets against diabetes associated CNS complication and non-alcoholic steatohepatitis (NASH). It is also involved in exosome mediated siRNA delivery against heart disease, IBD and screening of natural and synthetic compounds for anti-dengue activity. **Department of Pharmacologies** is involved in computational study of non-covalent interactions and analyze its effect with electron-donating and withdrawing groups. It is also involved in molecular modelling and cheminformatics study to identify novel molecules against bacterial and viral targets.

Department of Pharmaceutics is involved in developing various lipid-based formulations like lipidic micelles, nanostructured lipid carrier, solid lipid nanoparticles for enhancement of oral & ocular bioavailability. It is involved in formulation development of novel topical and controlled release formulations, solid dispersions for improving the bioavailability of drugs, development of hydrogels in wound healing and haemostatic dressing applications. **Department of Medical Devices** is currently exploring 3D bioprinting option for organ-on-chip and disease-on-dish models and piezoelectric membranes as sensors. It is also involved in fabrication of scaffolds for tissue engineering using electrospinning, CNC machining, lyophilisation and are developing bioinspired hydrogels for accelerated wound healing.

The Institute has established *Centre for Marine Therapeutics* along with seven research institutes viz., NIPER Guwahati, IISER Kolkata, NIO Goa, CDRI Lucknow, JNCASR Bangalore and IIIM Jammu which is funded by DoP and DST, New Delhi.

The Institute has established "*Centre for Nucleic acid therapeutics*" along with NIPER Guwahati, Hajipur and CSIR-IACS at NIPER Kolkata to synthesis ASOs for treating rare disease and to train the students and faculty in the proposed area which is funded by Department of Pharmaceuticals and DST, New Delhi

EXTRA-MURAL RESEARCH PROJECTS

| S.N. | Project Title | Principal Investigators and Centre coordinator's | Fundin g Agency | Funding Amount | Duration | |
|------|--|---|-----------------------|-------------------|-----------|--|
| 1. | Introduction of Crispr CAS System in Lysmaniaparasite : Functional assay of Miltefosine transporter | Dr.Dipanjan Ghosh | WBDBT | 37.95 Lakh | 5 years | |
| | | | | | | |
| 2. | of gene function aff Development of an efficient foodgrade genome engineering platform for Lactic Acid Bacteria using CRISPR-Cas9 of Lactobacillus fermentum M1 | Prof. Swadesh Ranjann Biswas; Co PI- Dr.Dipanjan Ghosh, Dr V. Ravichandiran | DBT | 65Lakh | 3 years | |
| | Recently, there has | a (LAB) received attent been a surge in the in as in biomedicine and l | terest in m | odulating the g | genome of | |

| | food quality and control intractable diseases: intestinal infections, obesity, hypertension, colon cancer, etc. One of the key factors to explore LAB beyond the scope of traditional genetic engineering is intricately linked to the development of food-grade CRISPR-Cas9 genome engineering tool. Commercial CRISPR-Cas9 is not food-grade; hence it is unsuitable for human application. | | | | | | | | |
|----|---|--|--|---|---|---|--|--|--|
| | | 0 | | • | • | | | | |
| | | develop a food-grade | | | - | | | | |
| | | entum M1, promoters, | | | | | | | |
| | | ll from food-grade LAI | | • | | U 1 | | | |
| | knock-in and knockout in vivo in Lactococcus and Lactobacillus. Products of | | | | | | | | |
| | | is technology will have | | | | | | | |
| 3. | Dinitrogen | Dr. Murali Mohan | SERB | 24.86Lakh | 2 | Year | | | |
| | Fixation by | Guru, | | | S | | | | |
| | Heterobimetallic | | | | | | | | |
| | Complexes under | | | | | | | | |
| | Visible Light for | | | | | | | | |
| | the Access of | | | | | | | | |
| | Organonitrogen | | | | | | | | |
| | Compounds as | | | | | | | | |
| | Potential | | | | | | | | |
| | Biological | | | | | | | | |
| | Targets | | | | | | | | |
| | Dinitrogen cleavage and functionalization is a long-standing challenge for synthesis of nitrogen containing organic compounds. The conversion of dinitrogen and hydrogen to ammonia by the Haber-Bosch synthesis uses 2% of the world's energy consumption, but without this process, half of the current word population could not be fed. Therefore, more efficient ways to convert | | | | | | | | |
| | U U | - | nitrogen to ammonia is still a quest of utmost importance. Equally attractive, | | | | | | |
| | but equally or even more challenging is the direct conversion of dinitrogen to | | | | | | | | |
| | | | | | | n to | | | |
| | organonitrogen con | mpounds, thus elimina | ting the ne | ed to use of am | monia | n to as an | | | |
| | organonitrogen con intermediate. The c | mpounds, thus elimina current research proje | ting the ne ct is focuse | ed to use of am d on fixation of | imonia f atmos | n to as an | | | |
| | organonitrogen con intermediate. The o N2 gas into small o | mpounds, thus elimina current research proje rganic molecules to sy | ting the ne ct is focuse nthesize ar | ed to use of am d on fixation of nalogous nitrog | imonia f atmos gen | n to as an | | | |
| | organonitrogen con intermediate. The o N2 gas into small o containing drug co | mpounds, thus elimina current research proje | ting the ne ct is focuse nthesize ar | ed to use of am d on fixation of nalogous nitrog | imonia f atmos gen | n to as an | | | |
| 4. | organonitrogen con intermediate. The o N2 gas into small o | mpounds, thus elimina current research proje rganic molecules to sy | ting the ne ct is focuse nthesize ar | ed to use of am d on fixation of nalogous nitrog | imonia f atmos gen | n to as an | | | |
| 4. | organonitrogen con intermediate. The o N2 gas into small o containing drug con science. | mpounds, thus elimina current research proje rganic molecules to sy mpounds for the poter | ting the ne ct is focuse nthesize ar ntial applica | ed to use of am d on fixation of nalogous nitrog ations in therap | nmonia f atmos gen Deutic | n to as an pheric | | | |
| 4. | organonitrogen con intermediate. The o N2 gas into small o containing drug con science. Type 2 Diabetes associated | mpounds, thus elimina current research proje rganic molecules to sy mpounds for the poter Dr. V | ting the ne ct is focuse nthesize ar ntial applica | ed to use of am d on fixation of nalogous nitrog ations in therap | amonia f atmos gen Deutic 3 | n to as an pheric | | | |
| 4. | organonitrogen con intermediate. The o N2 gas into small o containing drug con science. Type 2 Diabetes | mpounds, thus elimina current research proje rganic molecules to sy mpounds for the poter Dr. V Ravichandiran, | ting the ne ct is focuse nthesize ar ntial applica | ed to use of am d on fixation of nalogous nitrog ations in therap | amonia f atmos gen Deutic 3 | n to as an pheric | | | |
| 4. | organonitrogen con intermediate. The o N2 gas into small o containing drug con science. Type 2 Diabetes associated cognitive decline: | mpounds, thus elimina current research proje rganic molecules to sy mpounds for the poter Dr. V Ravichandiran, Dr. Sugato | ting the ne ct is focuse nthesize ar ntial applica | ed to use of am d on fixation of nalogous nitrog ations in therap | amonia f atmos gen Deutic 3 | n to as an pheric | | | |
| 4. | organonitrogen con intermediate. The of N2 gas into small of containing drug con science. Type 2 Diabetes associated cognitive decline: Molecular | mpounds, thus elimina current research proje rganic molecules to sy mpounds for the poter Dr. V Ravichandiran, Dr. Sugato Banerjee, | ting the ne ct is focuse nthesize ar ntial applica | ed to use of am d on fixation of nalogous nitrog ations in therap | amonia f atmos gen Deutic 3 | n to as an pheric | | | |
| 4. | organonitrogen con intermediate. The of N2 gas into small of containing drug con science. Type 2 Diabetes associated cognitive decline: Molecular pathways and | mpounds, thus elimina current research proje rganic molecules to sy mpounds for the poter Dr. V Ravichandiran, Dr. Sugato Banerjee, Dr. Somasundaram | ting the ne ct is focuse nthesize ar ntial applica | ed to use of am d on fixation of nalogous nitrog ations in therap | amonia f atmos gen Deutic 3 | n to as an pheric | | | |
| 4. | organonitrogen con intermediate. The of N2 gas into small of containing drug con science. Type 2 Diabetes associated cognitive decline: Molecular pathways and intervention strategies | mpounds, thus elimina current research proje rganic molecules to sy mpounds for the poter Dr. V Ravichandiran, Dr. Sugato Banerjee, Dr. Somasundaram | ting the ne ct is focuse nthesize ar ntial applica ICMR | ed to use of am d on fixation of nalogous nitrog ations in therap 55.71Lakh | amonia f atmos gen peutic 3 s | n to as an pheric Year | | | |
| 4. | organonitrogen con intermediate. The of N2 gas into small o containing drug con science. Type 2 Diabetes associated cognitive decline: Molecular pathways and intervention strategies Role of NMDA med | mpounds, thus elimina current research proje rganic molecules to sy mpounds for the poter Dr. V Ravichandiran, Dr. Sugato Banerjee, Dr. Somasundaram Arumugam | ting the ne ct is focuse nthesize ar ntial applica ICMR | ed to use of am d on fixation of nalogous nitrog ations in therap 55.71Lakh n and its effect | amonia f atmos gen beutic 3 s on dia | n to as an pheric Year betes | | | |
| 4. | organonitrogen con intermediate. The of N2 gas into small of containing drug con science. Type 2 Diabetes associated cognitive decline: Molecular pathways and intervention strategies Role of NMDA med associated neurode | mpounds, thus elimina current research proje rganic molecules to sy mpounds for the poter Dr. V Ravichandiran, Dr. Sugato Banerjee, Dr. Somasundaram Arumugam | ting the ne ct is focuse nthesize ar ntial applica ICMR ICMR | ed to use of am d on fixation of nalogous nitrog ations in therap 55.71Lakh 55.71Lakh n and its effect ed. The project | amonia f atmos gen peutic 3 s on dia focuse | n to as an pheric Year betes s on | | | |
| 4. | organonitrogen con intermediate. The of N2 gas into small of containing drug con science. Type 2 Diabetes associated cognitive decline: Molecular pathways and intervention strategies Role of NMDA med associated neurode understanding the | mpounds, thus elimina current research proje rganic molecules to sy mpounds for the poter Dr. V Ravichandiran, Dr. Sugato Banerjee, Dr. Somasundaram Arumugam | ting the ne ct is focuse nthesize ar ntial applica ICMR ICMR onal calcium e determine r in diabete | ed to use of am d on fixation of alogous nitrog ations in therap 55.71Lakh n and its effect ed. The project | amonia f atmos gen beutic 3 s on dia focuse ognitive | n to as an pheric Year betes s on | | | |
| 4. | organonitrogen con intermediate. The of N2 gas into small of containing drug con science. Type 2 Diabetes associated cognitive decline: Molecular pathways and intervention strategies Role of NMDA med associated neurode understanding the | mpounds, thus elimina current research proje rganic molecules to sy mpounds for the poter Dr. V Ravichandiran, Dr. Sugato Banerjee, Dr. Somasundaram Arumugam iated increase in neuro egeneration is yet to be role of NMDA receptor us design future thera | ting the ne ct is focuse nthesize ar ntial applica ICMR ICMR onal calcium e determine r in diabete | ed to use of am d on fixation of alogous nitrog ations in therap 55.71Lakh n and its effect ed. The project | amonia f atmos gen beutic 3 s on dia focuse ognitive | n to as an pheric Year betes s on | | | |
| 4. | organonitrogen con intermediate. The of N2 gas into small o containing drug con science. Type 2 Diabetes associated cognitive decline: Molecular pathways and intervention strategies Role of NMDA med associated neurode understanding the decline. It will help | mpounds, thus elimina current research proje rganic molecules to sy mpounds for the poter Dr. V Ravichandiran, Dr. Sugato Banerjee, Dr. Somasundaram Arumugam iated increase in neuro egeneration is yet to be role of NMDA receptor us design future thera | ting the ne ct is focuse nthesize ar ntial applica ICMR ICMR onal calcium e determine r in diabete | ed to use of am d on fixation of alogous nitrog ations in therap 55.71Lakh n and its effect ed. The project | amonia f atmos gen beutic 3 s on dia focuse ognitive | n to as an pheric Year betes s on | | | |
| | organonitrogen con intermediate. The of N2 gas into small of containing drug con science. Type 2 Diabetes associated cognitive decline: Molecular pathways and intervention strategies Role of NMDA med associated neurode understanding the decline. It will help associated neurode | mpounds, thus elimina current research proje rganic molecules to sy mpounds for the poter Dr. V Ravichandiran, Dr. Sugato Banerjee, Dr. Somasundaram Arumugam iated increase in neuro egeneration is yet to be role of NMDA receptor us design future thera | ting the ne ct is focuse nthesize an itial applica ICMR ICMR onal calcium e determine c in diabete speutic stra | ed to use of am d on fixation of alogous nitrog ations in therap 55.71Lakh m and its effect ed. The project is associated co tegies against | amonia f atmos gen beutic 3 s on dia focuse bgnitive diabete | n to as an pheric Year Vear betes s on e es | | | |
| | organonitrogen con intermediate. The of N2 gas into small of containing drug con science. Type 2 Diabetes associated cognitive decline: Molecular pathways and intervention strategies Role of NMDA med associated neurode understanding the decline. It will help associated neurode Elucidating Role | mpounds, thus elimina current research proje rganic molecules to sy mpounds for the poter Dr. V Ravichandiran, Dr. Sugato Banerjee, Dr. Somasundaram Arumugam iated increase in neuro egeneration is yet to be role of NMDA receptor us design future thera egeneration. Dr. Ashutosh | ting the ne ct is focuse nthesize ar ntial applica ICMR ICMR onal calcium e determine c in diabete apeutic stra | ed to use of am d on fixation of alogous nitrog ations in therap 55.71Lakh m and its effect ed. The project is associated co tegies against | amonia f atmos gen beutic 3 s on dia focuse ognitive diabete | n to as an pheric Year Vear betes s on e es | | | |

| | | I | 1 | | 1 | | |
|----|---|--|--|---|---|--|--|
| | (MAMs) and ER | | | | | | |
| | Stress Associated | | | | | | |
| | Neuroinflammati | | | | | | |
| | on in | | | | | | |
| | Experimental | | | | | | |
| | Diabetic | | | | | | |
| | Neuropathy | | | | | | |
| | In this research pro | oject we are evaluating | g the role of | f mitochondria | l associated | | |
| | membranes and El | R stress in the pathoph | ysiology of | neuropathic p | ain. Diabetes | | |
| | is a major challenge that will be faced by the whole world and condition for India is very gloomy as it will turn out to be Diabetic capital of World in the | | | | | | |
| | | | | | | | |
| | coming decades. Diabetes induced complications make the life of diabetic | | | | | | |
| | - | enge. Neuropathy and | | | | | |
| | | ith diabetes. We have l | - | - | | | |
| | - | e serious limitations lil | | - | | | |
| | | orming potential. So, th | | | | | |
| | | fying novel mechanism | | | - | | |
| | | elopment. We will eval | | 0 | 0 | | |
| | - | es and study the role o | | | | | |
| | | hing the role of mitoch | | | | | |
| | | physiology of neuropa | | | | | |
| | | hibitors to target thes | - | | - | | |
| | | ictional and sensorimo | | | - | | |
| | neuropathy. | | tor deficits | seen ni ulabet | .ic | | |
| 6. | Development of | Dr. Sharada | DST- | 18.30 Lakh | 3 Years | | |
| 0. | novel membrane | Prasanna Swain | SERB | 10.30 Lakii | 5 Tears | | |
| | stabilizing | and Dr.Sidhartha | JERD | | | | |
| | antimicrobial | Sankar Kar | | | | | |
| | | Salikal Kal | | | | | |
| | peptidomimetics | | | | | | |
| | targeting | | | | | | |
| | carbapenem- | | | | | | |
| | resistant strains | | | | | | |
| | | | | | | | |
| | of Acinetobacter | | | | | | |
| | of Acinetobacter baumannii in | | | | | | |
| 1 | of Acinetobacter baumannii in ventilator- | | | | | | |
| | of Acinetobacter baumannii in ventilator- associated | | | | | | |
| | of Acinetobacter baumannii in ventilator- associated pneumonia | | | | | | |
| | of Acinetobacter baumannii in ventilator- associated pneumonia The WHO has repo | rted emergence of Acia | | | | | |
| | of Acinetobacter baumannii in ventilator- associated pneumonia The WHO has repo associated pneumo | onia in COVID-19 patie | nt. The obje | ectives are (i) t | o design and | | |
| | of Acinetobacter baumannii in ventilator- associated pneumonia The WHO has repo associated pneumo synthesize novel m | onia in COVID-19 patie embrane stabilizing a | nt. The obje ntimicrobia | ectives are (i) t al peptidomime | o design and etics in | | |
| | of Acinetobacter baumannii in ventilator- associated pneumonia The WHO has repo associated pneumo synthesize novel m quantitative, physi | onia in COVID-19 patie embrane stabilizing an cochemical terms, (ii) | nt. The obje ntimicrobia to study me | ectives are (i) t al peptidomime embrane disruj | o design and etics in ption activity | | |
| | of Acinetobacter baumannii in ventilator- associated pneumonia The WHO has repo associated pneumo synthesize novel m quantitative, physi of synthesized com | onia in COVID-19 patie lembrane stabilizing an cochemical terms, (ii) lpounds using bacteria | nt. The obje ntimicrobia to study me I membran | ectives are (i) t al peptidomime embrane disruj ae mimicking m | o design and etics in ption activity odel, (iii) | | |
| | of Acinetobacter baumannii in ventilator- associated pneumonia The WHO has repo associated pneumo synthesize novel m quantitative, physi of synthesized com molecular dynamic | onia in COVID-19 patie tembrane stabilizing an cochemical terms, (ii) tpounds using bacteria cs simulation of compo | nt. The objent ntimicrobia to study me l membran ounds to un | ectives are (i) t al peptidomime embrane disruj le mimicking m derstand intera | o design and etics in ption activity nodel, (iii) action with | | |
| | of Acinetobacter baumannii in ventilator- associated pneumonia The WHO has repo associated pneumo synthesize novel m quantitative, physi of synthesized com molecular dynamic bacterial cell mem | onia in COVID-19 patie tembrane stabilizing an cochemical terms, (ii) pounds using bacteria cs simulation of compo brane. The outcome of | nt. The objentimicrobia to study me Il membran ounds to un the project | ectives are (i) t al peptidomime embrane disruj le mimicking m derstand intera may open nev | o design and etics in ption activity odel, (iii) action with v avenue for | | |
| | of Acinetobacter baumannii in ventilator- associated pneumonia The WHO has repo associated pneumo synthesize novel m quantitative, physi of synthesized com molecular dynamic bacterial cell mem development of po | onia in COVID-19 patie tembrane stabilizing an cochemical terms, (ii) pounds using bacteria cs simulation of compo brane. The outcome of tent biocompatible pe | nt. The object ntimicrobia to study me al membran ounds to un the project ptidomime | ectives are (i) t al peptidomime embrane disrug le mimicking m derstand intera may open nev tics for treatme | o design and etics in ption activity odel, (iii) action with v avenue for | | |
| | of Acinetobacter baumannii in ventilator- associated pneumonia The WHO has repo associated pneumo synthesize novel m quantitative, physi of synthesized com molecular dynamic bacterial cell mem development of po infections caused b | onia in COVID-19 patie nembrane stabilizing an cochemical terms, (ii) pounds using bacteria cs simulation of compo prane. The outcome of tent biocompatible per py resistant Acinetobac | nt. The objent ntimicrobia to study me il membran unds to un the project ptidomime ter bauma | ectives are (i) t al peptidomime embrane disrup le mimicking m derstand intera may open nev tics for treatme nnii. | o design and etics in ption activity nodel, (iii) action with v avenue for ent of | | |
| 7. | of Acinetobacter baumannii in ventilator- associated pneumonia The WHO has repo associated pneumo synthesize novel m quantitative, physi of synthesized com molecular dynamic bacterial cell mem development of po infections caused b | onia in COVID-19 patie tembrane stabilizing an cochemical terms, (ii) pounds using bacteria cs simulation of compo brane. The outcome of tent biocompatible per by resistant Acinetobac Dr.Pallab Datta, | nt. The object ntimicrobia to study me al membran ounds to un- the project ptidomime ter bauman DST- | ectives are (i) t al peptidomime embrane disrug le mimicking m derstand intera may open nev tics for treatme | o design and etics in ption activity odel, (iii) action with v avenue for | | |
| 7. | of Acinetobacter baumannii in ventilator- associated pneumonia The WHO has repo associated pneumo synthesize novel m quantitative, physi of synthesized com molecular dynamic bacterial cell mem development of po infections caused b | onia in COVID-19 patie nembrane stabilizing an cochemical terms, (ii) pounds using bacteria cs simulation of compo prane. The outcome of tent biocompatible per py resistant Acinetobac | nt. The objent ntimicrobia to study me il membran unds to un the project ptidomime ter bauma | ectives are (i) t al peptidomime embrane disrup le mimicking m derstand intera may open nev tics for treatme nnii. | o design and etics in ption activity nodel, (iii) action with v avenue for ent of | | |

| t | tanium implants | | | | |
|---|---|-------------|-------------|-------------------|------------|
| I | ncrease in human life expecta | ncy, rising | obesity am | ongst the popu | lation and |
| a | doption of sedentary lifestyle | has increa | sed the ris | k factor for dise | eases like |
| | steoarthritis of load-bearing l | | | | |
| | uccessful clinical intervention | | | - | - |
| | nd improved quality of life for | 0 | | . | |
| | and, a large number of arthro | | - | | |
| | ome reports show only aroun | | | | |
| | xtend beyond patient lifespar | | | | |
| | ecoming the primary reason | | | | |
| | iomaterial-associated infection | | | - | |
| | taphylococcus aureus, Staphyl | - | | - | |
| | scherichia coli, or Pseudomon | - | | - | - |
| | ne implant substrates as mult | | | | |
| - | olysaccharide. of the implant | | | | |
| | xtracellular layer prevents an | | | | |
| | urfaces with antibiofilm pepti | | | | |
| - | otency and specificity, and ca onventional antimicrobials, a | | | - | |
| | esistance. The aim of this proj | | • | 00 | |
| | orous titanium implants for in | • | - | | |
| | sseointegration properties. T | | | | |
| | esign of porous femoral stem | | | | |
| | natching the bone condition o | | | | |
| | nost suitable for grafting on sa | | | | |
| | s well as coating stability. The | | | | |
| | arried out followed by the bio | | | | |
| | tandards. A mechanistic unde | - | | - | - |
| | nermodynamics between bac | - | | | |
| | lso be studied. | 1 | | | |
| | | | | | |

PUBLICATIONS (RESEARCH/ REVIEW):

Pharmaceutics

- 1. Paul, Brahamacharry, Raghuvir H. Gaonkar, Debasmita Dutta, Rajesh Dasi, Biswajit Mukherjee, Shantanu Ganguly, and Sujoy K. Das. "Inhibitory potential of iRGD peptide-conjugated garcinol-loaded biodegradable nanoparticles in rat colorectal carcinoma." *Materials Science and Engineering: C* (2022): 112714.
- 2. Chinnaiyan, Santhosh Kumar, Rajesh Pandiyan, Subramanian Natesan, Srikanth Chindam, Ajay Kumar Gouti, and AbimanyuSugumaran. "Fabrication of basil oil Nanoemulsion loaded gellan gum hydrogel—evaluation of its antibacterial and anti-biofilm potential." *Journal of Drug Delivery Science and Technology* 68 (2022): 103129.
- 3. Preethi, Selvamuthu, Arunachalam Arulraj, Ramalinga Viswanathan Mangalaraja, Velayutham Ravichandran, and Natesan Subramanian. "Biomass-derived Carbonbased Materials for Microbicidal Applications." Biomass-Derived Carbon Materials: Production and Applications **(2022)**: 63-92. (Book Chapter)

Pharmacology and Toxicology

- 4. Tangelloju, Ajay, Rudra Chakravarti, Rajveer Singh, Bireswar Bhattacharya, Arijit Ghosh, Sujit K. Bhutia, VelayuthamRavichandiran, and Dipanjan Ghosh. "A Review on the Current Status of Homeopathy in the Clinical Management of Cancer." *Current Drug Targets* 23, no. 13 **(2022)**: 1252-1260.
- 5. Verma, Smita, Rajesh Kumar Patidar, Ratnesh Tiwari, RavichandiranVelayutham, and Nihar Ranjan. "Fragment-Based Design of Small Molecules to Study DNA Minor Groove Recognition." *The Journal of Physical Chemistry B* 126, no. 38 (2022): 7310-7320.
- 6. Siddhi, Jain, Bhoomika Sherkhane, Anil Kumar Kalavala, Vijay Arruri, RavichandiranVelayutham, and Ashutosh Kumar. "Melatonin prevents diabetesinduced nephropathy by modulating the AMPK/SIRT1 axis: Focus on autophagy and mitochondrial dysfunction." *Cell Biology International* **(2022)**.
- 7. Khodve, Gopal Bhagwan, and Sugato Banerjee. "Artificial Intelligence in Efficient Diabetes Care." *Current Diabetes Reviews* (2022).
- 8. MohanaSundaram, ArunSundar, ShanmugarajanThukaniSathanantham, and RavichandiranVelayutham. "Taking cognizance of the risks associated with COVID-19, vaccine, and treatment in liver transplant recipients–A commentary on "The urgency of the Covid-19 vaccine in liver transplantation patients: What, how, and when?" (Int J Surg 2022; 100 (Suppl): 106492)." *International Journal of Surgery (London, England)* (2022).
- 9. Singh, Rajveer, Shivani Chandel, Arijit Ghosh, Tushar Matta, Anupam Gautam, Arka Bhattacharya, SrivalliputturuSarath Babu et al. "Glucogallin Attenuates the LPS-Induced Signaling in Macrophages and Protects Mice against Sepsis." *International Journal of Molecular Sciences* 23, no. 19 **(2022)**: 11254.
- 10. Madhu, Maxima, V. Udaya Kumar, Sameer Dhingra, Nitesh Kumar, Sanjiv Singh, V. Ravichandiran, and Krishna Murti. "Nutritional Aspects of People Living with HIV (PLHIV) Amidst COVID-19 Pandemic: an Insight." *Current pharmacology reports* (2022): 1-15.

- 11. Khan, Anam Najib, Rajveer Singh, Arka Bhattacharya, Sonu Kumar, Arijit Ghosh, Debasish Nag, VelayuthamRavichandiran, and Dipanjan Ghosh. "Glucogallin Attenuates RAW 264.7 Cells from Arsenic Trioxide Induced Toxicity via the NFκB/NLRP3 Pathway." *Molecules* 27, no. 16 (2022): 5263.
- 12. Gundu, Chayanika, Vijay Kumar Arruri, Poonam Yadav, UmashankerNavik, Ashutosh Kumar, Veda Sudhir Amalkar, Ajit Vikram, and Ravinder Reddy Gaddam. "Dynamin-Independent Mechanisms of Endocytosis and Receptor Trafficking." *Cells* 11, no. 16 **(2022)**: 2557.
- 13. Mallick, Keya, and Sugato Banerjee. Antidepresants: Potential Therapeutics against Leishmeniasis. *International Journal of Pharmacy and Pharmaceutical Sciences* 14(3) **(2022)**: 1-7.
- 14. Watanabe, Kenichi, Masao Hirayama, Somasundaram Arumugam, Masayoshi Sugawara, Hisanori Kato, Sumiko Nakamura, Ken'ichiOhtsubo et al. "Effect of heat-moisture treated brown rice crackers on postprandial flow-mediated dilation in adults with mild endothelial dysfunction." *Heliyon* 8, no. 8 **(2022)**: e10284.
- 15. Basu, Amitava, Sugato Banerjee, AmalenduSamanta, Rakhi Chowdhury, and Subhamay Panda. "Holistic strategies to mitigate the economic, societal, and health burden of the Coronavirus disease-2019 pandemic." In *Computational Approaches for Novel Therapeutic and Diagnostic Designing to Mitigate SARS-CoV2 Infection*, pp. 97-114. Academic Press, 2022.
- 16. Sukla, Soumi, Himadri Nath, Mohd Kamran, Sarfaraz Ahmad Ejazi, Nahid Ali, Pradeep Das, V. Ravichandiran, Syamal Roy, and Subhajit Biswas. "Detection of Leptomonasseymourinarna-like virus in serum samples of visceral leishmaniasis patients and its possible role in disease pathogenesis." *Scientific Reports* 12, no. 1 (2022): 1-10.
- 17. Kumar, Sonu, Debrupa Dutta, VelayuthamRavichandiran, and SoumiSukla. "Monoclonal antibodies: a remedial approach to prevent SARS-CoV-2 infection." *3 Biotech* 12, no. 9 **(2022)**: 1-16.
- 18. Karun, Arya, Rimple Jeet Kaur, JaykaranCharan, Krishna Murti, M. Ramesh, V. Ravichandiran, and Sameer Dhingra. "Impact of COVID-19 on Antimicrobial Resistance in Paediatric Population: a Narrative Review." *Current Pharmacology Reports* (2022): 1-11.
- 19. Sekowski, Szymon, EwaOlchowik-Grabarek, Alina T. Dubis, Lokesh Sharan, Ashutosh Kumar, NodiraAbdulladjanova, Paula Markiewicz, and Maria Zamaraeva. "Inhibition of AGEs formation, antioxidative, and cytoprotective activity of Sumac (Rhus typhina L.) tannin under hyperglycemia: molecular and cellular study." *Molecular and Cellular Biochemistry* **(2022)**: 1-15.
- 20. Nath, Himadri, Abinash Mallick, Subrata Roy, Tathagata Kayal, Sumit Ranjan, Susanta Sengupta, SoumiSukla, and Subhajit Biswas. "COVID-19 serum can be cross-reactive and neutralizing against the dengue virus, as observed by the dengue virus neutralization test." *International Journal of Infectious Diseases* 122 (2022): 576-584.
- 21. Kumar, V.U., Muhammed Favas KT, Ayush Sharma, Priya Bisht, Sameer Dhingra, V. Ravichandiran, M. Ramesh, and Krishna Murti. "The Possible Role of Selected Vitamins and Minerals in the Therapeutic Outcomes of Leishmaniasis." Biological Trace Element Research **(2022)**: 1-17.

- 22. Arumugam, Somasundaram, WawaimuliArozal, and Koji Ikeda. "Anti-Inflammatory Agents in the Context of Age-Related Cardiometabolic Disease: Ethnopharmacological Perspectives." *Frontiers in Pharmacology* 13 **(2022)**.
- Das, Pamelika, Pappula Mounika, Manoj LimbrajYellurkar, Vani Sai Prasanna, Sulogna Sarkar, RavichandiranVelayutham, and Somasundaram Arumugam. "Keratinocytes: An Enigmatic Factor in Atopic Dermatitis." *Cells* 11, no. 10 (2022): 1683.
- 24. Jugait, Simrandeep, Aparna Areti, KarthikaNellaiappan, Priyanka Narwani, Priya Saha, RavichandiranVelayutham, and Ashutosh Kumar. "Neuroprotective Effect of Baicalein Against Oxaliplatin-Induced Peripheral Neuropathy: Impact on Oxidative Stress, Neuro-inflammation and WNT/β-Catenin Signaling." *Molecular Neurobiology* 59, no. 7 (2022): 4334-4350.
- 25. Kumar, Kankanala Naveen, Malladi Mounika Reddy, Hirave Panchami, RavichandiranVelayutham, Devendra Kumar Dhaked, and Sharada Prasanna Swain. "Thiourea as oxyanion stabilizer for Iridium catalyzed, base free green synthesis of amines: Synthesis of cardiovascular drug ticlopidine." *Molecular Catalysis* 524 **(2022)**: 112324.
- 26. Gupta, Rahul, Arijit Ghosh, Rudra Chakravarti, Rajveer Singh, VelayuthamRavichandiran, SnehasiktaSwarnakar, and Dipanjan Ghosh. "Cas13d: a new molecular scissor for transcriptome engineering." *Frontiers in Cell and Developmental Biology* 10 **(2022)**.
- 27. Ghosh, Anisa, SoumiSukla, Himadri Nath, Rajdeep Saha, Abhishek De, and Subhajit Biswas. "Non-structural protein 1 (NS1) variants from dengue virus clinical samples revealed mutations that influence NS1 production and secretion." *European Journal of Clinical Microbiology & Infectious Diseases* 41, no. 5 (2022): 803-814.
- 28. Suzuki, Hiroshi, Kenichi Watanabe, Somasundaram Arumugam, Manoj LimbrajYellurkar, Remya Sreedhar, Rejina Afrin, and Hirohito Sone. "Meal Ingestion of Ceraceomycestessulatus Strain BDM-X (Agaricomycetes) Protects against Nonalcoholic Steatohepatitis in Mice." *International Journal of Medicinal Mushrooms* 24, no. 1 (2022).
- 29. Chakravarti, Rudra, Swadhin Kumar Lenka, Anupam Gautam, Rajveer Singh, VelayuthamRavichandiran, Syamal Roy, and Dipanjan Ghosh. "A Review on CRISPR-Mediated Epigenome Editing: A Future Directive for Therapeutic Management of Cancer." *Current Drug Targets* (2022).
- 30. Sarkar, Suparna Roy, Papiya Mitra Mazumder, and Sugato Banerjee. "Oligosaccharide and Flavanoid Mediated Prebiotic Interventions to Treat Gut Dysbiosis Associated Cognitive Decline." *Journal of Neuroimmune Pharmacology* (2022): 1-17.
- 31. Ghosh, Arijit, Anupam Gautam, Rahul Gupta, Rajveer Singh, RavichandiranVelayutham, Dipanjan Ghosh, and Syamal Roy. "An insight into SARS-CoV2 structure, Pathogenesis, target hunting for drug development and vaccine initiatives." *RSC Medicinal Chemistry* (2022).
- 32. Roy, Subrata, SoumiSukla, Abhishek De, and Subhajit Biswas. "Non-cytopathic herpes simplex virus type-1 isolated from acyclovir-treated patients with recurrent infections." *Scientific reports* 12, no. 1 **(2022)**: 1-15.
- Yadav, Poonam, Chandan Chauhan, Sanjiv Singh, Sugato Banerjee, and Krishna Murti. "β-sitosterol in Various Pathological Conditions: An Update." Current Bioactive Compounds 18, no. 6 (2022): 19-27.

- 34. MohanaSundaram, ArunSundar, ShanmugarajanThukaniSathanantham, Lukas Sveikata, Rakesh Shyam Lalla, Renata Sveikatienė, Ajeet Kaushik, and RavichandiranVelayutham. "Aducanumab and adenoviral COVID-19 vaccines: increased cerebral hemorrhage risk?." Expert Review of Neurotherapeutics 22, no. 4 **(2022)**: 283-286.
- 35. Choudhary, Preety, Tapasi Roy, Abhishek Chatterjee, Vineet Kumar Mishra, Suyash Pant, and SnehasiktaSwarnakar. "Melatonin rescues swim stress induced gastric ulceration by inhibiting matrix metalloproteinase-3 via down-regulation of inflammatory signaling cascade." Life Sciences 297 **(2022)**: 120426.
- 36. Nath, Shalini, Chhabinath Mandal, Uttara Chatterjee, and Chitra Mandal. "Correction: Association of cytosolic sialidase Neu2 with plasma membrane enhances Fas-mediated apoptosis by impairing PI3K-Akt/mTOR-mediated pathway in pancreatic cancer cells." Cell Death & Disease 13, no. 3 **(2022)**.
- 37. Dutta, Naibedya, Deepak Bharadwaj Pemmaraju, Suvranil Ghosh, Asif Ali, Ayan Mondal, Chirantan Majumder, Vinod K. Nelson et al. "Alkaloid-rich fraction of Ervatamia coronaria sensitizes colorectal cancer through modulating AMPK and mTOR signalling pathways." Journal of Ethnopharmacology 283 **(2022)**: 114666.
- 38. Sharma, Ayush, Akanksha Singh, Mukhtar Ahmad Dar, Rimple Jeet Kaur, JaykaranCharan, Katia Iskandar, Mainul Haque, Krishna Murti, V. Ravichandiran, and Sameer Dhingra. "Menace of antimicrobial resistance in LMICs: Current surveillance practices and control measures to tackle hostility." Journal of Infection and Public Health 15, no. 2 **(2022)**: 172-181.
- 39. Singh, Akanksha, P. Ramalingam, Sameer Dhingra, V. Ravichandiran, and Krishna Murti. "Arsenic: a culpable element and a possible menace for HIV/AIDS patients." Biological Trace Element Research 200, no. 12 **(2022)**: 4955-4966.
- 40. Balasubramaniam, Boopathi, ThondimuthuVinitha, SolaiMeenal, LappasiMohanramVenkataKrishna, VelayuthamRavichandiran, and Krishnaswamy Balamurugan. "p38-MAPK recruits the proteolytic pathways in Caenorhabditis elegans during bacterial infection." International Journal of Biological Macromolecules 204 **(2022)**: 116-135.
- 41. Basu, Amitava, Sugato Banerjee, AmalenduSamanta, Rakhi Chowdhury, and Subhamay Panda. "Holistic strategies to mitigate the economic, societal, and health burden of the Coronavirus disease-2019 pandemic." In Computational Approaches for Novel Therapeutic and Diagnostic Designing to Mitigate SARS-CoV2 Infection, pp. 97-114. Academic Press, 2022.

Medical Devices

- 42. Banerjee, Dishary, Yogendra Pratap Singh, Pallab Datta, VeliOzbolat, Aaron O'Donnell, Miji Yeo, and Ibrahim T. Ozbolat. "Strategies for 3D bioprinting of spheroids: A comprehensive review." *Biomaterials* (2022): 121881.
- 43. McLaughlin, Caroline, Pallab Datta, Yogendra P. Singh, Alexis Lo, Summer Horchler, Irina A. Elcheva, Ibrahim T. Ozbolat, Dino J. Ravnic, and Srinivas V. Koduru. "Mesenchymal Stem Cell-Derived Extracellular Vesicles for Therapeutic Use and in Bioengineering Applications." *Cells* 21 **(2022)**: 3366.
- 44. Barua, Ranjit, Surajit Das, Amit RoyChowdhury, and Pallab Datta. "Simulation and experimental investigation of the surgical needle deflection model during the rotational and steady insertion process." *The International Journal of Artificial Organs* (2022): 03913988221136154.

- 45. MohanaSundaram A, Shanmugarajan TS, Velayutham R. Strides Toward a Better Understanding of the "Current Efforts and Challenges Facing Responses to Monkeypox in United Kingdom". *Biomedical Journal*. 2022 Oct 10: S2319-4170(22)00140-8.
- 46. Barua, Ranjit, Sudipto Datta, Amit RoyChowdhury, and Pallab Datta. "Study of the surgical needle and biological soft tissue interaction phenomenon during insertion process for medical application: A Survey." *Proceedings of the Institution of Mechanical Engineers, Part H: Journal of Engineering in Medicine* 236, no. 10 (2022): 1465-1477.
- 47. Datta, Pallab, Laura Y. Cabrera, and Ibrahim T. Ozbolat. "Ethical challenges with 3D bioprinted tissues and organs." *Trends in Biotechnology* **(2022)**.
- 48. Chakraborty, Arindam, Kalash Darshan Sahare, Pallab Datta, Santanu Majumder, Amit Roychowdhury, and BikramjitBasu. "Probing the Influence of Hybrid Thread Design on Biomechanical Response of Dental Implants: Finite Element Study and Experimental Validation." *Journal of Biomechanical Engineering* 145, no. 1 (2022): 011011.
- 49. Chakraborty, Arindam, Pallab Datta, Cheruvu Siva Kumar, Santanu Majumder, and Amit Roychowdhury. "Probing combinational influence of design variables on bone biomechanical response around dental implant-supported fixed prosthesis." *Journal of Biomedical Materials Research Part B: Applied Biomaterials* (2022).
- 50. Das, Samir, Amit Roy Chowdhury, and Pallab Datta. "Modelling cell deformations in bioprinting process using a multicompartment-smooth particle hydrodynamics approach." Proceedings of the Institution of Mechanical Engineers, Part H: Journal of Engineering in Medicine 236, no. 6 **(2022)**: 867-881.
- 51. Mohan, TarunShyam, Pallab Datta, SepehrNesaei, VeliOzbolat, and Ibrahim T. Ozbolat. "3D coaxial bioprinting: Process mechanisms, bioinks and applications." *Progress in Biomedical Engineering* **(2022)**.
- 52. Banerjee, Abhinaba, Sudipto Datta, Ankita Das, Amit Roy Chowdhury, and Pallab Datta. "A Micro-Scale Non-Linear Finite Element Model to Optimize the Mechanical Behavior of Bioprinted Constructs." 3D Printing and Additive Manufacturing 9, no. 6 **(2022)**: 490-502.

Pharmacoinformatics

- 53. Dar, Mukhtar Ahmad, Pawan Kumar, Prakash Kumar, Ashish Shrivastava, Muneer Ahmad Dar, Richa Chauhan, Vinita Trivedi et al. "Designing of peptide based multi-epitope vaccine construct against gallbladder cancer using immunoinformatics and computational approaches." *Vaccines* 10, no. 11 **(2022)**: 1850.
- 54. Pant, Suyash, and Nihar R. Jena. "C-Terminal Extended Hexapeptides as Potent Inhibitors of the NS2B-NS3 Protease of the ZIKA Virus." *Frontiers in Medicine* 9 (2022).
- 55. Ghosh, Arijit, Anupam Gautam, Rahul Gupta, Rajveer Singh, RavichandiranVelayutham, Dipanjan Ghosh, and Syamal Roy. "An insight into SARS-CoV2 structure, Pathogenesis, target hunting for drug development and vaccine initiatives." *RSC Medicinal Chemistry* (2022).
- 56. Reetu, Reetu, Aakriti Garg, Kuldeep K. Roy, Anupam Roy, Sreya Gupta, and Chandi C. Malakar. "In-silico studies for targeting PPARγ for the Type II Diabetes Mellitus." *Materials Today: Proceedings* 57 **(2022)**: 44-48.

- 57. Pant, S., G. Bhattacharya, and N. R. Jena. "Structures and dynamics of peptide and peptidomimetic inhibitors bound to the NS2B-NS3 protease of the ZIKA virus." *Journal of Biomolecular Structure and Dynamics* **(2022)**: 1-13.
- 58. Garg, Aakriti, Kamal Kant, Kuldeep K. Roy, Abhishek Sahoo, Chandi C. Malakar, and Sreya Gupta. "Docking-based evaluation against Human Tankyrase-1 and Tankyrase-2 enzyme." Materials Today: Proceedings 57 **(2022)**: 300-306.
- 59. Khan, Pathan Mohsin, and Kunal Roy. "Chemometric modelling of heat release capacity, total heat release and char formation of polymers to assess their flammability characteristics." Molecular Informatics 41, no. 1 **(2022)**: 2000030.

Medicinal Chemistry and Pharmaceutical Analysis

- 60. Kar, Sidhartha Sankar, Nrusingha Prasad Nanda, V. Ravichandiran, and Sharada Prasanna Swain. "Silane promoted glycosylation and its applications for synthesis of sugar compounds and active pharmaceutical ingredients (APIs)." *New Journal of Chemistry* 46, no. 45 **(2022)**: 21519-21535.
- 61. Kommineni, Nagavendra, David Paul, Raju Saka, Wahid Khan, and SatheeshkumarNanjappan. "Stealth Liposomal Chemotherapeutic Agent for Triple Negative Breast Cancer with Improved Pharmacokinetics." *Nanotheranostics* 6, no. 4 **(2022)**: 424-435.
- 62. Verma, Smita, Rajesh K. Patidar, Khushboo Tiwari, Ratnesh Tiwari, Jaya Baranwal, RavichandiranVelayutham, and Nihar Ranjan. "Preferential Recognition of Human Telomeric G-Quadruplex DNA by a Red-Emissive Molecular Rotor." *The Journal of Physical Chemistry B* 126, no. 38 **(2022)**: 7298-7309.
- 63. Verma, Smita, Rajesh Kumar Patidar, Ratnesh Tiwari, RavichandiranVelayutham, and Nihar Ranjan. "Fragment-Based Design of Small Molecules to Study DNA Minor Groove Recognition." *The Journal of Physical Chemistry B* 126, no. 38 (2022): 7310-7320.
- 64. Pramanik, Bapan, and Sahnawaz Ahmed. "Peptide-based low molecular weight photosensitive supramolecular gelators." *Gels* 8, no. 9 **(2022)**: 533.
- 65. Kommineni, Nagavendra, David Paul, Raju Saka, Wahid Khan, and SatheeshkumarNanjappan. "Stealth Liposomal Chemotherapeutic Agent for Triple Negative Breast Cancer with Improved Pharmacokinetics." *Nanotheranostics* 6, no. 4 **(2022)**: 424-435.
- 66. Sharma, Yogesh Brijwashi, Suyash Pant, Devendra Kumar Dhaked, and Murali Mohan Guru. "Borane-catalyzed dehydrogenative C–C bond formation of indoles with N-tosylhydrazones: an experimental and computational study." *Organic Chemistry Frontiers* (2022).
- 67. Sharma, Yogesh Brijwashi, Rajveer Singh, Chetan Paul Singh, Yogesh P. Bharitkar, and Abhijit Hazra. "Design, Synthesis and Cytotoxicity Evaluation of Tetrahydro β-Carboline-Attached Spiroindolones/Spiroacenapthylene by Using Lemon Juice as a Green Biocatalyst System." *ChemistrySelect* 7, no. 14 (2022): e202200707.
- 68. Prasanth, Thumpati, Gargi Chakraborti, Tirtha Mandal, VelayuthamRavichandiran, and Jyotirmayee Dash. "Cycloaddition of N-sulfonyl and N-sulfamoylazides with alkynes in aqueous media for the selective synthesis of 1, 2, 3-triazoles." *Green Chemistry* 24, no. 2 **(2022)**: 911-915.
- 69. Garg, Aakriti, Narender Goel, Nipun Abhinav, Tanmay Varma, AnushreeAchari,

Pinaki Bhattacharjee, Izaz Monir Kamal et al. "Virtual screening of natural products inspired in-house library to discover potential lead molecules against the SARS-CoV-2 main protease." *Journal of Biomolecular Structure and Dynamics* **(2022)**: 1-13.

- 70. Swain, Sharada Prasanna, K. Naveen Kumar, MouzmaMhate, Hirave Panchami, and V. Ravichandiran. "Copper (II) bromide catalysed one pot bromination and amination for the green, cost-effective synthesis of clopidogrel." Molecular Catalysis 522 (2022): 112210.
- 71. Susanna, K. Jony, Rahul Gajbhiye, Bhaskar Sarmah, SachinDattram Pawar, Pakhuri Mehta, Upadhyayula Suryanarayana Murty, V. Ravichandiran, Amit Alexander, and Pramod Kumar. "Simultaneous Method Development and Validation of Anastrozole Along with Piperine: Degradation Studies and Degradants Characterization Using LC-QTOF-ESI-MS Along with In-silico ADMET Predictions." Current Drug Metabolism 23, no. 2 **(2022)**: 113-130.

Natural Products

- 72. MohanaSundaram, ArunSundar, ShanmugarajanThukaniSathanantham, and RavichandiranVelayutham. "Long COVID-19 and used cooking oil consumption in India: The potential for concurrent and cascading scourges– Correspondence." *International Journal of Surgery (London, England)* 107 **(2022)**: 106972.
- 73. Kumar, Sonu, Rajveer Singh, Debrupa Dutta, Shivani Chandel, Arka Bhattacharya, VelayuthamRavichandiran, and SoumiSukla. "In Vitro Anticancer Activity of Methanolic Extract of Justicia adhatoda Leaves with Special Emphasis on Human Breast Cancer Cell Line." *Molecules* 27, no. 23 **(2022)**: 8222.
- 74. Prasad, Surendra Rajit, Prakash Kumar, Saptarshi Mandal, Anu Mohan, Radhika Chaurasia, Ashish Shrivastava, Pallaprolu Nikhil et al. "Mechanistic insight into the role of mevalonate kinase by a natural fatty acid-mediated killing of Leishmania donovani." *Scientific Reports* 12, no. 1 **(2022)**: 1-19.
- 75. Mallesh, Rathnam, Juhee Khan, Krishnangsu Pradhan, Rajsekhar Roy, Nihar Ranjan Jana, Parasuraman Jaisankar, and Surajit Ghosh. "Design and Development of Benzothiazole-Based Fluorescent Probes for Selective Detection of Aβ Aggregates in Alzheimer's Disease." ACS Chemical Neuroscience 13, no. 16 (2022): 2503-2516.
- 76. Tangelloju, Ajay, Rudra Chakravarti, Rajveer Singh, Bireswar Bhattacharya, Arijit Ghosh, Sujit K. Bhutia, VelayuthamRavichandiran, and Dipanjan Ghosh. "A Review on the Current Status of Homeopathy in the Clinical Management of Cancer." *Current Drug Targets* 23, no. 13 **(2022)**: 1252-1260.
- 77. Yatham, Priyanka, Devendra Shukla, Amit K. Srivastava, V. S. Pragadheesh, and Deepak Kumar. "Purification and identification of anticancer organosulfidesfromFerulaassa-foetida gum: integrative analysis employing GC/GC-MS/RP-HPLC/NMR." **(2022)**.
- 78. Nanjappan, Satheesh Kumar, Ravi AdinarayanSomabattini, and VelayuthamRavichandiran. "Investigation of the effect of Acai berry on the pharmacokinetics of Atorvastatin, Alogliptin and Empagliflozin: a herb-drug interaction study." *Journal of Pharmacy and Pharmacology* (2022).
- 79. Khan, Anam Najib, Rajveer Singh, Arka Bhattacharya, Rudra Chakravarti, Syamal Roy, VelayuthamRavichandiran, and Dipanjan Ghosh. "A Short Review on

Glucogallin and its Pharmacological Activities." *Mini Reviews in Medicinal Chemistry* **(2022)**.

- 80. Bolla, Lavanya, Pratima Srivastava, VelayuthamRavichandiran, and Satheesh Kumar Nanjappan. "Cytochrome P450 and P-gp Mediated Herb-Drug Interactions and Molecular Docking Studies of Garcinol." *Membranes* 11, no. 12 (2021): 992.
- 81. Singh, Meenakshi, Bhakti Umesh Hirlekar, Shagufta Mondal, Suyash Pant, Devendra K. Dhaked, V. Ravichandiran, Abhijit Hazra, and Yogesh P. Bharitkar. "Isolation of phytochemicals from Dolichandrone atrovirens followed by semisynthetic modification of ixoside via azomethine ylide cycloaddition; computational approach towards chemo-selection." Natural Product Research (2022): 1-10.

BOOK CHAPTERS:


- 1. Satheesh Kumar Nanjappan and Shruti Surendran and David Paul. Pharmacokinetics and pharmacodynamics of peptidomimetics. Peptide andPeptidomimeticTherapeutics. AcademicPress. **2022**. ISBN: 978-0-12-820141-1.
- 2. Nanjappan, S.K., Paul, D., Ramani, R., Arumugam, S.,Chellappan, D.K. **(2022)**. Profiling of Trace Elements and Regulatory Landscape of Dietary Herbal Supplements. In: Aftab, T. (eds) Environmental Challenges and Medicinal Plants. Environmental Challenges and Solutions. Springer, Cham, **2022**, ISBN978-3-030-92049-4, pp 303-317
- 3. Basu A, **Banerjee S**, Samanta A, Chowdhury R, Panda S. Holistic strategies to mitigate the economic, societal, and health burden of theCoronavirus disease-2019 pandemic. Computational Approaches for Novel Therapeutic and Diagnostic Designing to Mitigate SARS-CoV-2Infection.Springer, Chapter 6, **2022**. 97–114.
- 4. Preethi Selvamuthu, Arulraj Arunachalam, Mangalaraja V Ramalinga, Ravichandran Velayutham, Subramanian Natesan; Biomass-DerivedCarbon-Based Materials for Microbicidal Applications. In: Biomass-Derived Carbon Materials: Production and Applications; Wiley-VCHGmbH,USA; ISBN: 978-3-527-34926-5. PP-63-92
- 5. Gupta, S.Overview on Biological Activities of Thiazole Derivatives. Publishing group: Spinger Nature. ISBN:978-981-16-8398-5DOI:10.1007/978-981-16-8399-2.
- 6. Gupta, S. Overview on Biological Activities of Imidazole Derivatives. Publishing group: Spinger Nature. ISBN:978-981-16-8398-5DOI:10.1007/978-981-16-8399-2.
- 7. Gupta, S. Overview on Biological Activities of Pyrazole Derivatives. Publishing group: Spinger Nature. ISBN:978-981-16-8398-5DOI:10.1007/978-981-16-8399-2.
- 8. Gupta, S. An Overview on Biological Evaluation of Tetrazole Derivatives. Publishing group: Spinger Nature. ISBN:978-981-16-8398-5DOI:10.1007/978-981-16-8399-2.
- 9. Gupta, S. An Overview on Biological Activity of Benzimidazole Derivatives. Publishing group: Spinger Nature. ISBN:978-981-16-8398-5DOI: 10.1007/978-981-16-8399-2.
- 10. Gupta, S. An overview on Biological Activities of Oxazole, Isoxazoles and 1,2,4-

oxadiazoles Derivatives. Publishing group: Spinger Nature. ISBN:978-981-16-8398-5 DOI: 10.1007/978-981-16-8399-2.

11. Gupta, S. An Overview on Biological Activities of 1,2,3-Triazole Derivatives. Publishing group: Spinger Nature. ISBN:978-981-16-8398-5DOI:10.1007/978-981-16-8399-2.

PATENTS:

 Swain, S.P., Ravichandiran, V., Jana, A. Novel synthesis of 2-Cyano-4' methylbophenyl for the preparation of sartans. (2022). ApplicationNo.202231022417. Dateof application15.04.2022. Docket No. 11044



NIPER, RAEBARELI



Contact Address Bijnor-Sisendi Road, Sarojini Nagar, Near CRPF Base Camp, Lucknow (UP)- 226002 Phone : +91 522 - 2497903 Fax: +91 522 - 2497905 Email: director@niperraebareli.edu.in Website: https://niperraebareli.edu.in

121

From the Director's Desk

The National Institute of Pharmaceutical Education and Research (NIPER), Raebareli was established in 2008. It offers doctoral and master's programs in Medicinal Chemistry, Pharmaceutics, Pharmacology & Toxicology, Regulatory Toxicology, and Biotechnology with 265 currently enrolled students. We are currently operating from our transit campus in with world-class Lucknow а Central Instrumentation facility within the premises and an animal house to perform pre-clinical studies.

NIPER-Raebareli has emerged as an Institution of significance both in academics and research particularly in Central India with modern laboratories, and highly sophisticated



instruments. We have achieved several milestones and Pharma industries have shown interest in collaborating with us besides training our students on a short-term and long-term basis.

NIPER-R is actively involved in the following Research Areas:

- Neurodegenerative diseases
- ➢ Tuberculosis
- > Development and evaluation of drugs using Nano formulations.
- > Development of green and eco-friendly synthetic methods
- > Heavy Metal Toxicity
- Japanese Encephalitis

The Institute initiated collaborative projects/ work with national and international academic and research institutes in areas of immediate importance such as *Japanese Encephalitis*, Tuberculosis, and Neurodegenerative diseases. An online portal has been created to facilitate seamless sample analysis for drug discovery.We are also providing highly skilled human resources for Indian pharmaceutical industries such as Intas, Curadev, APCER Life Science, Almelo, Piramal Jubilant Chemsys, Lupin, Patanjali, Medivisual, Novo Nordisk, etc.

- $_{\odot}$ $\,$ The Institute has filed 23 patents and one copyright till 2023.
- The Institute received nearly 1.76 Cr. Rupees as an extramural research grant for research in the thematic areas of the Institute.
- Around **393** publications (Research/review articles, books and/or book chapters) have been published since 2011; out of which **276** publications are from the work of the last 3 years in journals of international repute.
- The Division of Pharmaceutics at NIPER-Raebareli developed new technologies for nano-based drug-delivery systems for better delivery of anti-psychotic and anti-tubercular drugs.
- NIPER- Raebareli has various centralized state of art facilities like a Cell Culture Facility, Central Animal Facility, Imaging facility (FT-IR spectrometer, Cary Eclipse, 12-Cell Cary 100 UV and Multi-Mode Plate Reader), and Central Instrumentation Facility.

- Central Instrumentation Facility has been created housing sophisticated instruments such as Nuclear Magnetic Resonance (NMR), Zetasizer, HPLC, Bioanalyzer, DSC, DSC for molecules, LC-MS (QTOF-HRMS), Hot Stage Microscope, Flow-cytometry, Animal imaging system, Lyophilizer, Calorimeter, CD Spectrometer, Digital Polarimeter, Probe Sonicator, Confocal system, etc.
- Dr. Ashok K. Datusalia was awarded membership of the International Society for Neurochemistry (ISN)-School Initiative. Dr.Sapana Kushwaha became Associate Topic Editor for Frontiers in Toxicology "Rising Stars" in Developmental and Reproductive Toxicology. Dr.Sapana Kushwaha was also awarded the International Union of Toxicology (IUTOX) Travel Award, 2022 by the IUTOX Education Committee, USA. Dr.Keerti Jain was enlisted among World's Top 2% Scientists, consecutively for the years 2020 and 2021 in the field of Pharmacology & Pharmacy, a list created by Stanford University, USA.
- **Dr. Ravinder K. Kaundal**published his research article entitled "*Large-Scale multiplexed mosaic CRISPR Perturbation in the whole organism*" in Cell Journal (**Impact factor = 66.85**). This is the highest impact factor paper in the history of all NIPERs.
- **Dr Nihar Ranjan** published his research paper in the Journal of American Chemical Society **(Impact Factor 16.3)** which is a prestigious journal of Chemistry.
- The institute also inducted faculty through the **"Ramalingaswami Re-entry Fellowship**" DBT, Ministry of Science and Technology, Government of India.

EXTRA-MURAL RESEARCH PROJECTS

| S.N. | Title of the Project | PI | Name of Funding | Sanctioned Amount | Duration of the |
|------|--|--|---|---|---|
| | | | Agency | (₹) | project |
| 1. | Aminoglycoside (Tobramycin) Based Hybrid Small Molecules Targeting Bacterial Rnra A-site for Developing New Anti-Tuberculosis Agent | Dr Nihar Ranjan | DST SERB | 41.44 Lakh | 3 years |
| | The main objective aminoglycoside mimics The deliverables inclu- the nucleic acids and showed that some of t better inhibition of bac antibiotics (Tobamyci development of antibio | s in order to o ded synthesis l testing ant the developed cterial strains n, isoniazid) | levelop new potent s of new molecules imicrobial activitie l molecules equal a belonging to the E | t anti tuberculo , its binding st es. The result and in certain SKAPE class, tl | osis agents. tudies with s obtained cases even nan control |
| 2. | Comprehensive Biological Evaluation Of Different Drug Loaded Surface Engineered Dendrimer Conjugates For Treatment Of Cancer | Dr Keerti Jain | ICMR | 17.40 Lakh | 3 years |
| | The aim of the project drug-loaded Poly(ami molecular weight, siz conjugates on the drug targeted delivery of bi comprehensive exan characterization, biolo platform, developmen and development of dendrimers. | doamine) (Pa te and archi g delivery an oactives. The nination of ogical interac t and charact | AMAM) dendriment tecture of surface d investigation of deliverables of th dendrimers-bas tions, cytotoxicity terization of ligano | r, to study th e engineered developed con e project will ed formulati , and safety a l conjugated o | e effect of dendrimer jugates for range from on, their at a single lendrimers |
| 3. | Exploring the immunomodulatory activities of novel Toll-like receptor- signaling inhibitors in peripheral blood mononuclear cells from lupus patients: A study to identify TLRs as drug targets | Dr Sandeep Chaudhary | DST SERB | 68.01 Lakh | 3 years |

| | for lupus | | | | |
|----|---------------------------|------------------|---------------------|----------------|--------------|
| | Identify whether MPP | 0 | - | | |
| | IL1R and IL-18R-depen | ndent proinfla | ammatory cytokine | expression in | peripheral |
| | blood mononuclear o | cells (PBMCs |) of normal indiv | viduals, Syste | mic Lupus |
| | Erythematosus (SLE) | and Lupus | nephritis patients | and further | to Identify |
| | whether Myd88 in | | | | |
| | Erythematosus (SLE) | | | | |
| | | | | | |
| | analogues.Through our | - | | - | |
| | of the biology of TLR | S IN PBMC OF | r nealtny donors, s | SLE and Lupu | s nephritis |
| | patients. | | · | | |
| 4. | Novel Synthesis of | Dr Abha | UPCST | 9.30 Lakh | 2 years |
| | flavonoid- | Sharma | | | |
| | hydroxypyridinone | | | | |
| | hybrids as potential | | | | |
| | anti- Alzheimer | | | | |
| | agents | | | | |
| | The objective of this | project is to | aunthogizo and a | haractorized | , corios of |
| | | | | | |
| | flavonoid-hydroxypyri | | | 0 0 | 0 |
| | targets of Alzheimer | | - | | |
| | compounds that could | | 0 | • | |
| | plan of study. The or | | - | - | esign new |
| | molecules or modify th | e lead identif | ied from this proje | ct | |
| 5. | Regulation of Stress | Dr Ashok | International | 3.35 Lakh | 1 year |
| | Response and | Datusalia | Society For | | - |
| | Neuroinflammatory | | Neurochemistry | | |
| | Markers in Diet- | | (ISN) | | |
| | induced obesity and | | | | |
| | Aging | | | | |
| | 0 0 | rill aturdur tha | modulation by di | tinduced ehe | aiter of the |
| | The present project w | - | - | | - |
| | stress response in ageo | | | | |
| | changes measured at s | | | | |
| | its kind, which will into | | | | |
| | stress-induced region | | | | |
| | fundamental issues v | vhich will be | e investigated in | these studies | , including |
| | glutamate release dyn | amics and he | ow diet-induced o | besity aggrava | ted neuro- |
| | inflammation affect ne | uronal brain a | aging. | | |
| 6. | Dual nanoengineered | Dr Rahul | DST SIRE | 11.88 Lakh | 1year |
| | BBB-penetrating | Shukla | | | |
| | lipid nanoparticles | biruidu | | | |
| | | | | | |
| | for targeting cerebral | | | | |
| | carcinoma | | | 1. 1 | |
| | Vincristine nanocrysta | | | | |
| | targeting to brain. It w | - | | | |
| | another advantage wit | h sphingolipi | ds about its abunda | ance presence | in CNS and |
| | its myelination proc | | | | |
| | approachable way fo | | | | |
| | development of platfe | | | | |
| | approaches for indus | - | | | |
| | approaches for mous | anai applica | | in toxicity p | otential to |

| | peripheral organs. BB | B permeabilit | ty of developed for | rmulations car | h be tested | | | |
|----|---|---------------|----------------------|-----------------|-------------|--|--|--|
| | using the in vitro model. This is an excellent screening tool before proceeding | | | | | | | |
| | for in vivo experiments | 5. | | | | | | |
| 7. | Toxicity Screening of | Dr Ashok | AAL Biosciences | 3.50 Lakh | 1 year | | | |
| | Agrochemical | К. | | | | | | |
| | NanoBioDAP | Datusalia | | | | | | |
| | NanoBioDAP is a bio | | | | - | | | |
| | Phosphorous macronutrients to crop. The product has the nutrients present in | | | | | | | |
| | stable nanocrystal forms, which leads to their higher use efficiency as well as | | | | | | | |
| | longer availability to crop due to their slow release. The guidelines for | | | | | | | |
| | evaluation of Nano-based Agri-input and Food products in India and The | | | | | | | |
| | Fertilizer control order | | - | | | | | |
| | their safety on human | | | | | | | |
| | using in vitro and in v absolutely safe when t | | | | | | | |
| | by using animal system | | | | | | | |
| | and irritation test is fu | | 6 | | | | | |
| | inputs. | | a to certify the sur | | manougri | | | |
| 8. | Evaluation of the | Dr | DST SERB | 40.40 Lakh | 3 years | | | |
| _ | neuroprotective | Ravinder K | | | - 9 | | | |
| | potential of SERCA | Kaundal | | | | | | |
| | activators in | | | | | | | |
| | experimental models | | | | | | | |
| | of cerebral ischemia. | | | | | | | |
| | The Objectives of the | | | | | | | |
| | activators in in- vitro | | | | | | | |
| | neuroprotective poten | | | | | | | |
| | ischemia., to study the | | | | | | | |
| | the molecular mechan activators in <i>in-vitro</i> a | | | | | | | |
| | also answer if SERCA a | | | | | | | |
| | the treatment of cereb | | | | | | | |
| | pathological events inv | | | - | | | | |
| | also open new therape | | | | | | | |
| | Training of manpower | | | | | | | |
| | Development of a facili | | | ctive potential | of | | | |
| | pharmacological interv | | | | | | | |
| | models of ischemic neu | ironal injury | | | | | | |
| 9. | Discovering the anti- | Dr | ICMR | 10.81 Lakh | 3 years | | | |
| | inflammatory effects | Sandeep | | | | | | |
| | of novel Toll-like | Chaudhary | | | | | | |
| | receptor signaling | | | | | | | |
| | inhibitors on | | | | | | | |
| | rheumatoid arthritis | | | | | | | |
| | mononuclear cells | | | | | | | |
| | and synovial | | | | | | | |
| | fibroblasts: An in | | | | | | | |
| | vitro study to identify | | | | | | | |
| | TLR signal | | | | | | | |

| | To investigate the effective of the effe | LRs; spontan tory cytokin onses; NF-kB mplex induc l synovial fibr apeutics for H of the Toll-lil Moreover, dr We have ide TLRs using a unction of synovial fibr analogues ca cells and syno | eous and MyD88- e production; TL and MAPK pathwa ced by IL-1R in roblasts. There is a Rheumatoid arthrit ke receptors (TLRs ugs that block TLH ntified methylpipe an entirely novel of MPP analogues is roblasts is not been n inhibit TLR/IL-1 ovial fibroblasts. Re | dependent TL R3 and IL-1 ays induced by n rheumatoic an urgent nee- tis (RA). Recer s) play importa R signaling par ridino-pyrazol drug screening in rheumatoic n investigated R biology in r sults from this | R signaling R induced IL-1R and d arthritis d for more at evidence ant roles in thways are e (MPP) as g platform. d arthritis so far. We heumatoid study may | | |
|-----|--|---|--|--|---|--|--|
| 10. | Designing of senolytic agents for the treatment of Alzheimer's disease | Dr Gopal Lal Khatik | DST SERB | 394.37 Lakh | 3 years | | |
| | Objectives of the current research project included design, synthesis and evaluation of senolytic agents for management of Alzheimer's disease. Utilizing in-silico and wet lab experiment this research project aimed to identify the lead lead molecule to be helpful in the possible treatment or management of Alzheimer's disease. The deliverables could be training in the synthetic and medicinal chemistry which able to generate the data for potential agents. The outcomes of the project will be patents and publications along with skilled manpower. Further the lead molecule will be optimized with good efficacy. Further these outcomes can be explored to prepare the suitable formulation to administer in animal initially and later human being. | | | | | | |
| 11. | Development of modified kynurenic acid-based scaffolds for treatment of post- traumatic stress disorder | Dr Áshok K. Datusalia | UPCST | 6 Lakh | 3 years | | |
| | disorderThe objectives of current research project are to synthesize kynurenic acid (KYNA)-based scaffolds and evaluate them on stress-induced neurobehavioral and functional changes in stress. The proposed research work will lead to generate novel KYNA scaffolds with potential neuroprotective activity. The research project outcomes will be patentable as kynurenic acid analogues/scaffolds as neuroprotective agents which can be beneficial in the cure and mitigation of PTSD. | | | | | | |
| 12. | Neurobehavioral and molecular neuroplasticity differences in stress response circuitry for resilience and | Dr Ashok K. Datusalia | SERB-DST | 29.94 Lakh | 2 years | | |

| vulnerability for post-traumatic stress disorder | | | | |
|--|--|--|---|--|
| In this proposed work, footshock-stress induc with vulnerable and re- and expression of their response circuits. Fina pharmacological agen differences in PTSD r understanding about ir resilient. The long-tern from stress vulnerable | ed differentia silient behavi target genes lly, rescue ex its to valida resilient and ndividual diffe n goal of PI re | al changes in stres or. We will use qPO at short- and long- periments in-vivo ate the neurobel vulnerable rats. The erences in stress re evolves around the | s response cir CR assessment term after stre will be carried havioral and This will esta sponse as vulr | cuit linked of miRNAs ss in stress d out using molecular blish early herable and |

PUBLICATIONS (RESEARCH/ REVIEW):

Medicinal Chemistry

- 1. Ng, Jerome PL, Mohit K. Tiwari, Ali Adnan Nasim, Rui Long Zhang, Yuanqing Qu, Richa Sharma, Betty Yuen Kwan Law et al. "Biological evaluation in resistant cancer cells and study of mechanism of action of Arylvinyl-1, 2, 4-Trioxanes." *Pharmaceuticals* 15, no. 3 **(2022)**: 360.
- 2. Khatik, Gopal L. "Catalyst-free, One-pot Synthesis of 2-Aryl Benzimidazoles from Orthophenylenediamine and Aryl Aldehyde in Acetonitrile." *Letters in Organic Chemistry* 19, no. 12 **(2022)**: 1070-1076.
- 3. Thakur, Ashima, Muskan Gori, and Abha Sharma. "Synthetic fluorescent organic molecule for the detection of diethylcyanophosphonate via ON-OFF sensing mechanism: paper strips system for real-time application." *International Journal of Environmental Analytical Chemistry* (2022): 1-14.
- 4. Prasanna, Chandu Anantha Lakshmi, and Abha Sharma. "Pharmacological exploration of triazole based therapeutics for Alzheimer disease: An overview." *Current Drug Targets* (2022).
- Kaur, Jaskiran, Monica Gulati, Paras Famta, Leander Corrie, Ankit Awasthi, Sumant Saini, Gopal L. Khatik et al. "Polymeric micelles loaded with glyburide and vanillic acid: I. Formulation development, in-vitro characterization and bioavailability studies." *International Journal of Pharmaceutics* 624 (2022): 121987.
- 6. Verma, Smita, Rajesh Kumar Patidar, Ratnesh Tiwari, RavichandiranVelayutham, and Nihar Ranjan. "Fragment-Based Design of Small Molecules to Study DNA Minor Groove Recognition." *The Journal of Physical Chemistry B* 126, no. 38 (2022): 7310-7320.
- Yadav, L., Shyamlal, B. R. K., Tiwari, M. K., A, A. R. T., Sen, J., & Chaudhary, S. TMEDA-Catalyzed Regioselective Decarboalkoxy C–N Bond Formation: A Unified Direct Access to Indolo[2,1-a]isoquinoline and Dibenzopyrrocoline Alkaloids. *Chemistry An Asian Journal*. 2022. 17(16): e202200398.
- 8. Thakur, Ashima, and Abha Sharma. "Imidazo [1, 2-a] pyridine based small organic fluorescent molecules for selective detection of nerve agents simulants." *Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy* 282 **(2022)**: 121633.

- Venugopala, Katharigatta N., PottathilShinu, Christophe Tratrat, Pran Kishore Deb, Raquel M. Gleiser, Sandeep Chandrashekharappa, Deepak Chopra et al. "1, 2, 3-Triazolyl-tetrahydropyrimidine Conjugates as Potential Sterol Carrier Protein-2 Inhibitors: Larvicidal Activity against the Malaria Vector Anopheles arabiensis and In Silico Molecular Docking Study." *Molecules* 27, no. 9 (2022): 2676.
- Venugopala, Katharigatta N., Nizar A. Al-Shar'i, Lina A. Dahabiyeh, Wafa Hourani, Pran Kishore Deb, Melendhran Pillay, Bashaer Abu-Irmaileh et al. "Antitubercular, cytotoxicity, and computational target validation of dihydroquinazolinone derivatives." *Antibiotics* 11, no. 7 (2022): 831.
- 11. Nair, Vipin A., Aiyagala MM Mallikarjunaswamy, Gopal L. Khatik, Prashanth Vishwa, and Sakthivel Kandaiah. "A convenient synthesis of 3-arylideneindolin-2-ones and evaluation of their photoelectrochemical properties." *Organic Communications* 15, no. 3 (2022).
- 12. Ombase, Pankaj, Rajesh Kumar Patidar, Lachhman Singh, Jaya Baranwal, Nidhi Srivastava, and Nihar Ranjan. "Human telomeric G-quadruplex DNA enabled preferential recognition of copper (II) and Iron (III) ions sensed by a red emissive probe." *Tetrahedron Letters* 111 **(2022)**: 154181.
- 13. Verma, Smita, Rajesh K. Patidar, Khushboo Tiwari, Ratnesh Tiwari, Jaya Baranwal, RavichandiranVelayutham, and Nihar Ranjan. "Preferential Recognition of Human Telomeric G-Quadruplex DNA by a Red-Emissive Molecular Rotor." *The Journal of Physical Chemistry B* 126, no. 38 **(2022)**: 7298-7309.
- 14. Sharma, Richa, and Sandeep Chaudhary. "Regiodivergent Cu-Promoted, AcOH-Switchable Distal Versus Proximal Direct Cyanation of 1-Aryl-1 H-indazoles and 2-Aryl-2 H-indazoles via Aerobic Oxidative C–H Bond Activation." *The Journal of Organic Chemistry* (2022).
- 15. Chandran, R., Abha Sharma, and Keshri Nath Tiwari. "Molecular Rearrangement of 2-Substituted Indazolones: Unorthodox Access to 2-Carboxylate-2, 3-dihydroquinazolin-4-(1H)-one Scaffold." *Asian Journal of Organic Chemistry* (2022).
- 16. Pawar, Rajashree, PreetiChaudhran, Dheeraj Pandey, and Abha Sharma. "Chemical Modifications of Pyridoxine for Biological Applications: An Overview." *Current topics in medicinal chemistry*.
- 17. Thakur, Ashima, Jayant Patwa, Suyash Pant, Swaran Jeet Singh Flora, and Abha Sharma. "Synthesis and evaluation of small organic molecule as reactivator of organophosphorus inhibited acetylcholinesterase." *Drug and Chemical Toxicology* (2022): 1-16.
- Sharma, Richa, Ravi Kant Yadav, Mukesh Jain, Jyoti Joshi, and Sandeep Chaudhary. "Oxidant-Switched Palladium-Catalyzed Regioselective Mono-versus Bis-ortho-Aroylation of 1-Aryl-1 H-indazoles with Aldehydes via C–H Bond Activation." The Journal of Organic Chemistry 87, no. 5 (2022): 2668-2685.

Pharmacology and Toxicology/Regulatory Toxicology

19. Dhiman, Ashish, Mayank Handa, MunindraRuwali, Dhirendra Pratap Singh, Prashant Kesharwani, and Rahul Shukla. "Recent trends of natural based therapeutics for mitochondria targeting in Alzheimer's disease." *Mitochondrion* (2022).

- 20. Dey, Mangaldeep, and Rakesh Kumar Singh. "Chronic oral exposure of aluminum chloride in rat modulates molecular and functional neurotoxic markers relevant to Alzheimer's disease." *Toxicology Mechanisms and Methods* **(2022)**: 1-12.
- 21. Gaun, Sachin, Syed Afroz Ali, Pooja Singh, Jayant Patwa, Swaran Jeet Singh Flora, and Ashok Kumar Datusalia. "Melatonin ameliorates chronic copper-induced lung injury." *Environmental Science and Pollution Research* **(2022)**: 1-14.
- 22. Urati, Anuradha, Mangaldeep Dey, Avtar Singh Gautam, and Rakesh Kumar Singh. "Iron-induced cellular in vitro neurotoxic responses in rat C6 cell line." *Environmental Toxicology* **(2022)**.
- 23. Khan, SabiyaSamim, Ankita Sharma, and Swaran JS Flora. "Phytochemicals in the Management of Arsenic Toxicity." *Chemical Research in Toxicology* (2022).
- 24. Liu, Bo, Zhengyu Jing, Xiaoming Zhang, Yuxin Chen, Shaoshuai Mao, Ravinder Kaundal, Yan Zou et al. "Large-scale multiplexed mosaic CRISPR perturbation in the whole organism." *Cell* 185, no. 16 **(2022)**: 3008-3024.
- 25. Samim, Khan Sabiya, Gopal L. Khatik, and Ashok K. Datusalia. "Strategies for treatment of disease-associated dementia beyond Alzheimer disease: An update." *Current Neuropharmacology* (2022).
- 26. Naqvi, Saba, Vitaly A. Khanadeev, Boris N. Khlebtsov, Nikolai G. Khlebtsov, Monika S. Deore, and Gopinath Packirisamy. "Albumin-Based Nanocarriers for the Simultaneous Delivery of Antioxidant Gene and Phytochemical to Combat Oxidative Stress." *Frontiers in Cell and Developmental Biology* 10 **(2022)**.
- 27. Dey, Mangaldeep, and Rakesh Kumar Singh. "Exposure of aluminium to C6 glioma cells modulates molecular and functional neurotoxic markers." *Journal of Biochemical and Molecular Toxicology* (2022): e23210.
- 28. Flora, Swaran JS, Keerti Jain, ArchnaPanghal, and Jayant Patwa. "Chemistry, Pharmacology, and Toxicology of MonoisoamylDimercaptosuccinic Acid: A Chelating Agent for Chronic Metal Poisoning." *Chemical research in toxicology* 35, no. 10 **(2022)**: 1701-1719.
- 29. Dwivedi, Mitesh, Sanjay Tiwari, E. Helen Kemp, and Rasheedunnisa Begum. "Implications of regulatory T cells in anti-cancer immunity: from pathogenesis to therapeutics." *Heliyon* (2022): e10450.
- 30. Dubey, Itishree, Sabbir Khan, and Sapana Kushwaha. "Developmental and reproductive toxic effects of exposure to microplastics: A review of associated signaling pathways." *Frontiers in Toxicology* 4 **(2022)**.
- 31. Sahu, Rohan Chand, Teeja Suthar, Anchal Pathak, and Keerti Jain. "Interventions for the Prevention and Treatment of Japanese Encephalitis." *Current Infectious Disease Reports* (2022): 1-16.
- 32. Sathua, Kshirod Bihari, and Rakesh Kumar Singh. "Mitochondrial biogenesis alteration in arsenic-induced carcinogenesis and its therapeutic interventions." *Toxin Reviews* (2022): 1-13.
- 33. Rachamalla, Mahesh, Joshi Chinthada, Sapana Kushwaha, Sravan Kumar Putnala, ChittaranjanSahu, Gopabandhu Jena, and Som Niyogi. "Contemporary Comprehensive Review on Arsenic-Induced Male Reproductive Toxicity and Mechanisms of Phytonutrient Intervention." *Toxics* 10, no. 12 **(2022)**: 744.
- 34. Sun, Yiwen, Wenyanag Lin, Ravinder Kaundal, and Tian Chi. "iMAPping the Perturb-Atlas." *Life Medicine* **(2022)**.
- 35. Seth, Mahesh Kumar, Rakesh Kumar Singh, M. Ejaz Hussain, Santosh Pasha, and Mohammad Fahim. "Toxicity Study of 3-Thienylalanine-Ornithine-Proline (TOP)

Using as Novel ACE Inhibitor." *International Journal of Peptide Research and Therapeutics* 28, no. 5 (2022): 1-11.

- 36. Pandey, Shivam Kumar, and Rakesh Kumar Singh. "Recent developments in nucleic acid-based therapies for Parkinson's disease: Current status, clinical potential, and future strategies." *Frontiers in Pharmacology* 13 **(2022)**.
- 37. Goswami, D., Urati, A., Angati, A., Kumari, N., & Singh, R. K. Pharmacological and pathological relevance of S100 proteins in neurological disorders. *CNS & Neurological Disorders Drug Targets.* **(2022)**.
- 38. Garg, A., Kaity, S., Thakur, M., Datusalia, A. K., & Kumar, A. Future Prospective and Challenging. In Current Molecular Pharmacology. 2022. (Accepted)
- 39. Gautam, Avtar Singh, Chinna babu Pulivarthi, and Rakesh Kumar Singh. "Proinflammatory IL-17 levels in serum/cerebrospinal fluid of patients with neurodegenerative diseases: a meta-analysis study." Naunyn-Schmiedeberg's Archives of Pharmacology **(2022)**: 1-12.
- 40. Sala, Nathalie, Caterina Paoli, TizianaBonifacino, Jessica Mingardi, Emanuele Schiavon, Luca La Via, Marco Milanese et al. "Acute ketamine facilitates fear memory extinction in a rat model of PTSD along with restoring glutamatergic alterations and dendritic atrophy in the prefrontal cortex." Frontiers in Pharmacology 13 **(2022)**: 353.
- 41. Kaundal, Ravinder K., Ashok Kumar Datusalia, and Shyam S. Sharma. "Posttranscriptional regulation of Nrf2 through miRNAs and their role in Alzheimer's disease." Pharmacological Research 175 **(2022)**: 106018.
- 42. Dey, Mangaldeep, and Rakesh Kumar Singh. "Neurotoxic effects of aluminium exposure as a potential risk factor for Alzheimer's disease." Pharmacological Reports 74, no. 3 (2022): 439-450.

Pharmaceutics

- 43. Singh, Ajit, Rewati Raman Ujjwal, Ashish Kumar, Rahul K. Verma, and Rahul Shukla. "Formulation and optimization of silymarin-encapsulated binary micelles for enhanced amyloid disaggregation activity." *Drug Development and Industrial Pharmacy* **(2022)**: 1-11.
- 44. Singh, Ajit, Rewati R. Ujjwal, Saba Naqvi, Rahul K. Verma, Sanjay Tiwari, Prashant Kesharwani, and Rahul Shukla. "Formulation development of tocopherol polyethylene glycol nanoengineered polyamidoamine dendrimer for neuroprotection and treatment of Alzheimer disease." *Journal of Drug Targeting* (2022): 1-15.
- 45. Handa, Mayank, Sandeep Kr Maharana, Kamlesh Pal, and Rahul Shukla. "Biocompatible Nanomaterials for Burns." *Current Pharmaceutical Biotechnology* (2022).
- 46. Juneja, Mehak, Teeja Suthar, Vishwas P. Pardhi, Javed Ahmad, and Keerti Jain. "Emerging trends and promises of nanoemulsions in therapeutics of infectious diseases." *Nanomedicine* 0 **(2022)**.
- 47. Ahmad, Javed, Md Rizwanullah, Teeja Suthar, Hassan A. Albarqi, Mohammad Zaki Ahmad, Parameswara Rao Vuddanda, Mohammad Ahmed Khan, and Keerti Jain. "Receptor-targeted surface-engineered nanomaterials for breast cancer imaging and theranostic applications." *Critical Reviews™ in Therapeutic Drug Carrier Systems* 39, no. 6 **(2022)**.

- 48. Mazahir, F., & Yadav, A. K. Recent Trends in Nano-Particulate Carriers for the Diagnosis and Treatment of Alzheimer's Disease. Begell House, *CNS & Neurological Disorders Drug Targets.* **(2022)**.
- 49. Saini, Vanshul, Ajit Singh, Rahul Shukla, Keerti Jain, and A. K. Yadav. "Silymarin-Encapsulated Xanthan Gum–Stabilized Selenium Nanocarriers for Enhanced Activity Against Amyloid Fibril Cytotoxicity." *AAPS PharmSciTech* 23, no. 5 (2022): 1-14.
- 50. Sarolia, Jayant, Deepak Kumar, Shailesh A. Shah, Pratap Bahadur, and Sanjay Tiwari. "Thermodynamics of pluronic 103 micellization in mannitol solution: Analyses based on isothermal titration calorimetry." *Colloids and Surfaces A: Physicochemical and Engineering Aspects* **(2022)**: 129240.
- 51. Kansara, V., Tiwari, S., & Patel, M. Graphene quantum dots: A review on the effect of synthesis parameters and theranostic applications. Elsevier, *Colloids and Surfaces B: Biointerfaces*. **(2022)**. *217*: 112605.
- 52. Bhogale, Deepali, Farhan Mazahir, and Awesh K. Yadav. "Recent Synergy of Nanodiamonds: Role in Brain-Targeted Drug Delivery for the Management of Neurological Disorders." *Molecular Neurobiology* (2022): 1-19.
- 53. Vasdev, Nupur, Mayank Handa, Prashant Kesharwani, and Rahul Shukla. "Rosemary oil low energy nanoemulsion: Optimization, μrheology, in silico, in vitro and Ex vivo characterization." *Journal of Biomaterials Science, Polymer Edition*(2022): 1-20.
- 54. Handa, Mayank, Waleed H. Almalki, Rahul Shukla, Obaid Afzal, Abdul Malik Saleh AlfawazAltamimi, Sarwar Beg, and Mahfoozur Rahman. "Active pharmaceutical ingredients (APIs) in ionic liquids: an effective approach for API physiochemical parameter optimization." *Drug Discovery Today* (2022).
- 55. Khairnar, Pooja, Mayank Handa, and Rahul Shukla. "Nanocrystals: an approachable delivery system for anticancer therapeutics." *Current Drug Metabolism* 23, no. 8 **(2022)**: 603-615.
- 56. Singh, Nidhi, Mayank Handa, Vanshikha Singh, Prashant Kesharwani, and Rahul Shukla. "Lymphatic targeting for therapeutic application using nanoparticulate systems." *Journal of Drug Targeting* **(2022)**: 1-17.
- 57. Mule, Shubham, Pooja Khairnar, and Rahul Shukla. "Recent advances in nanocrystals heralding greater potential in brain delivery." *Particle & Particle Systems Characterization* 39, no. 9 **(2022)**: 2200087.
- 58. Handa, Mayank, Ajit Singh, Dheeraj Bisht, Prashant Kesharwani, and Rahul Shukla. "Potential of particle size less than 15 nm via olfactory region for direct brain delivery via Intranasal route." *Health Sciences Review* **(2022)**: 100038.
- 59. Beg, Sarwar, Mayank Handa, Rahul Shukla, Mahfoozur Rahman, Waleed H. Almalki, Obaid Afzal, and Abdulmalik Saleh AlfawazAltamimi. "Wearable smart devices in cancer diagnosis and remote clinical trial monitoring: Transforming the healthcare applications." *Drug Discovery Today* (2022).
- 60. Kesharwani, Prashant, Rahul Chadar, Rahul Shukla, Gaurav K. Jain, Geeta Aggarwal, Mohammed AS Abourehab, and Amirhossein Sahebkar. "Recent advances in multifunctional dendrimer-based nanoprobes for breast cancer theranostics." *Journal of Biomaterials Science, Polymer Edition* 33, no. 18 **(2022)**: 2433-2471.
- 61. Lalrengpuii, Judy, Kaisar Raza, Awanish Mishra, and Rahul Shukla. "Retinoid nanoparticulates: approachable gateway for acne treatment." *Health Sciences Review* (2022): 100042.

- 62. Rathod, Sachin, Shristi Arya, ShirishaKanike, Shailesh A. Shah, Pratap Bahadur, and Sanjay Tiwari. "Advances on nanoformulation approaches for delivering plant-derived antioxidants: A case of quercetin." *International Journal of Pharmaceutics* (2022): 122093.
- 63. Singh, Ajit, AkshadaMhaske, and Rahul Shukla. "Fabrication of TPGS-Grafted Polyamidoamine Dendrimer for Enhanced Piperine Brain Delivery and Pharmacokinetics." *AAPS PharmSciTech* 23, no. 7 **(2022)**: 1-14.
- 64. Mhaske, Akshada, Sanjiv Singh, Mohammed AS Abourehab, Akhilesh Kumar, Prashant Kesharwani, and Rahul Shukla. "Recent pharmaceutical engineered trends as theranostics for Japanese Encephalitis." *Process Biochemistry* **(2022)**.
- 65. Patel, Parth, Mayank Handa, Keerti Jain, and Rahul Shukla. "Recent pharmaceutical engineered approaches as prophylaxis and management of frostbite." *Journal of Drug Delivery Science and Technology* **(2022)**: 103838.
- 66. Soni, Mukesh, Mayank Handa, Kamalinder K. Singh, and Rahul Shukla. "Recent nanoengineered diagnostic and therapeutic advancements in management of Sepsis." *Journal of Controlled Release* 352 **(2022)**: 931-945.
- 67. Pardhi, Vishwas P., Teeja Suthar, Ankita Sharma, and Keerti Jain. "Bedaquiline fumarate microemulsion: formulation optimization, rheological characterization and in vitro studies." *Nanomedicine* 0 (2022).
- 68. Rahman, Mahfoozur, Joina Gunjan Singh, Obaid Afzal, Abdulmalik Saleh AlfawazAltamimi, Majed Alrobaian, Jamshed Haneef, Md Abul Barkat et al. "Preparation, Characterization, and Evaluation of Curcumin–Graphene Oxide Complex-Loaded Liposomes against Staphylococcus aureus in Topical Disease." *ACS Omega* (2022).
- 69. Singh, Ajit, Ajay Vaish, and Rahul Shukla. "Box-Behnken design optimized silibinin loaded glycerylmonooleatenanoliquid crystal for brain targeting." Chemistry and Physics of Lipids 244 **(2022)**: 105193.
- 70. Patel, P., Kumar, K., Jain, V. K., Popli, H., Yadav, A. K., & amp; Jain, K. Nanotheranostic for Diagnosis and Treatment of Breast Cancer. Bentham Science, Current Pharmaceutical Design. 2022. (In-Press)
- 71. Khairnar, Pooja, Mukesh Soni, Mayank Handa, Yassine Riadi, Prashant Kesharwani, and Rahul Shukla. "Recent highlights on Omicron as a new SARS-COVID-19 variant: evolution, genetic mutation, and future perspectives." Journal of Drug Targeting 30, no. 6 **(2022)**: 603-613.
- 72. Kumari, Shweta, Prabhat Kumar Choudhary, Rahul Shukla, Amirhossein Sahebkar, and Prashant Kesharwani. "Recent advances in nanotechnology-based combination drug therapy for skin cancer." Journal of Biomaterials Science, Polymer Edition 33, no. 11 **(2022)**: 1435-1468.
- 73. Ekal, Neha S., Rahul Patil, Nihar Ranjan, Pratap Bahadur, and Sanjay Tiwari. "Oxidation state of graphene oxide nanosheets drives their interaction with proteins: A case of bovine serum albumin." Colloids and Surfaces B: Biointerfaces 212 **(2022)**: 112367.
- 74. Gade, Anushree, Ankita Sharma, Nidhi Srivastava, and S. J. S. Flora. "Surface plasmon resonance: A promising approach for label-free early cancer diagnosis." ClinicaChimica Acta **(2022)**.
- 75. Gowda, BH Jaswanth, Mohammed Gulzar Ahmed, Amirhossein Sahebkar, Yassine Riadi, Rahul Shukla, and Prashant Kesharwani. "Stimuli-responsive microneedles as a transdermal drug delivery system: a demand-supply strategy." Biomacromolecules 23, no. 4 **(2022)**: 1519-1544.

- 76. Jain, K., & amp; Zhong, J. Theranostic applications of nanomaterials. Bentham Science, Current Pharmaceutical Design, 2022. 28(2); pp. 77.
- 77. Kansara, Vrushti, Rahul Shukla, Swaran Jeet Singh Flora, Pratap Bahadur, and Sanjay Tiwari. "Graphene quantum dots: Synthesis, optical properties and navigational applications against cancer." Materials Today Communications (2022): 103359.
- 78. Arya, Shristi, Rajesh Patidar, Debes Ray, Vinod K. Aswal, Nihar Ranjan, Pratap Bahadur, and Sanjay Tiwari. "Structural transitions in TPGS micelles induced by trehalose as a model cryoprotectant." Colloids and Surfaces A: Physicochemical and Engineering Aspects 642 **(2022)**: 128714.

Biotechnology

- 79. Mathur, Pooja Goswami Jyoti, and Nidhi Srivastava. "Silica nanoparticles as novel sustainable approach for plant growth and crop protection." *Heliyon* **(2022)**: e09908.
- 80. Pinapati, Kishore Kumar, Reetika Tandon, Pratima Tripathi, and Nidhi Srivastava. "Recent advances to overcome the burden of Japanese encephalitis: A zoonotic infection with problematic early detection." *Reviews in Medical Virology* **(2022)**: e2383.
- 81. Goswami, Pooja, Mamta Sharma, Nidhi Srivastava, and Jyoti Mathur. "Assessment of the fungicidal efficacy of biogenic SiO2 NPs in Eruca sativa against fusarium wilt." *Journal of Natural Pesticide Research* 2 **(2022)**: 100011.

BOOK CHAPTERS:

- 1. Yadav, R. K., Deshmukh, V. V., Boralkar, T. M., Jain, M., & Chaudhary, S. **(2022)**. Cheaper Transition –Metals Based Nanocatalyzed Organic Transformations and Synthesis of Bioactive Heterocycles: Strategic Approaches and Sustainable Applications. In K. L. Ameta& R. Kant (Eds.), *Nanocatalysis-Synthesis of Bioactive Heterocycles* (1st ed.). CRC Press, Boca Raton. ISBN: 978-100-31-4148-8.
- 2. Soni, M., Handa, M., & Shukla, R. **(2022)**. Nano Drug Delivery Approaches for Lymphatic Filariasis Therapeutics. In *Nanotechnology for Infectious Diseases*, Springer, Singapore. ISBN: 978-981-16-9190-4. Pp. 263-279.
- 3. Khairnar, P. S., Singh, A., & Shukla, R. **(2022)**. Futuristic Potential of Nanoantibiotics Against Multidrug Resistant Tuberculosis. In *Nanotechnology for Infectious Diseases*, Springer, Singapore. 978-981-16-9190-4. pp. 387-417.
- 4. Handa, M., Khairnar, P., Kesharwani, P., Shukla, R. **(2022)**. Nanotechnologymediated combinational drug delivery approach for cancer therapy, Academic Press, Cambridge. ISBN: 978-0-323-85873-1. pp 297-330.
- 5. Patel, P., & Jain, K. **(2022)**. Concept of Quantum Dots as Nano Drug Delivery System. In Sushil Kashaw, Samaresh Sau, and Arun Iyer (Eds.) *Progress and Prospect of Nanocarriers: Design, Concept and Recent Advances*, Academic Press, Cambridge. ISBN: 978-012-81-9979-4.
- 6. Jain, K., & Ahmad, J. (Eds.). **(2022)**. *Nanotheranostics for Treatment and Diagnosis of Infectious Diseases* (1st Ed.). Academic Press, Cambridge. ISBN: 978-032-39-1201-3.
- 7. Paul, G., Gupta, U., Shah, H., Mazahir, F., & Yadav, A. K. **(2022)**. Inorganic and Metal-Based Nanoparticles. **(Accepted)**

- 8. Kumar, J., Verma, S., Mazahir, F., & Yadav, A. K. **(2022)**. Regulatory Issues of Synbiotics in Cancer. In *Synbiotics for Management of Cancer*. Springer-Nature, Singapore. ISBN: 978-981-19-7549-3.
- 9. Srivastava, V., Handa, M., & Shukla, R. **(2022)**. 3D Nanoprinting in the Biomedical Industries. In Ajit Behera, Tuan Anh Nguyen, Ram K Gupta (Eds.), *Smart 3D Nanoprinting:Fundamentals, Materials, and Applications,* CRC Press. Boca Ratan. ISBN:978-100-31-8940-4. pp. 16.
- 10. Goyal, D., Dey, M., & Singh, R. K. **(2022)**. The Link Between Gut Microbiota and Autoimmune Diseases. In The Role of Microbes in Autoimmune Diseases. (Accepted)
- 11. Mazahir, F., Birajdar, S., Bhogale, D., Bhosale, A., & Yadav, A. K. **(2022)**. 3D Nanoprinting in the Biomedical/Health Care Application. In A. Behera, T. A. Nguyen, & R. K. Gupta (Eds.), Smart 3D Nanoprinting: Fundamentals, Materials, and Applications, Routledge, London. ISBN 978-103-20-3861-2. pp. 14.
- 12. Kumari, N., Abbas, M. S., Amin, F., Yadav, S. K., Naqvi, S., & Raza, S. S. **(2022)**. Role of MicroRNAs in Stroke Pathology and Recovery. In S. S. Raza (Ed.), Regenerative Therapies in Ischemic Stroke Recovery, Springer Singapore. ISBN: 978-981-16-8562-0. pp. 221–238.
- 13. Verma, V., Rao, L., Joshi, S., Choudhary, M., & Srivastava, N. **(2022)**. Value-added product development from food scraps. In HrudayanathThatoi, Sonali Mohapatra and Swagat Kumar Das(Eds.) *Innovations in Fermentation and Phytopharmaceutical Technologies*, (1st Edi., Ch. 19,) Academic Press, Cambridge. ISBN: 978-012-82-1877-8. pp. 417-435.
- Ali, S. A., Panda, S. R., Dey, M., Datusalia, A. K., Naidu, V. G. M., & Singh, R. K. (2022). The Factors Influencing Gut Microbiota in Autoimmune Diseases. Role of Microorganisms in Pathogenesis and Management of Autoimmune Diseases. Volume I: Liver, Skin, Thyroid, Rheumatic & Myopathic Diseases. Springer, Singapore. ISBN: 978-981-19-1946-6. pp- 69-90.
- 15. Tripathi, P. **(2022)**. Immunosuppression in patients with Diabetes mellitus. In Rajeev Tyagi, Prakriti Sharma, and Praveen Sharma, *Immunosupression and Immunomodulation*, IntechOpen Publisher, London. ISBN:978-1-83768-072-6. pp. 1-22.
- 16. Gupta, U., Suryawanshi, A., Mazahir, F., & Yadav, A. K. **(2022)**. Use of Nano formulation in the treatment of Neurogenerative Disorders. *Selective Treatment Strategies for Neurodegenerative Disorders Using Nanomedicine*. (Accepted)
- 17. Verma, S., Gaikwad, M., Paul, G., & Yadav, A. K. **(2022)**. Overview of Blood Brain Barrier (BBB) Transport Mechanism. In *Selective Treatment Strategies for Neurodegenerative Disorders*. https://easychair.org/account/signin_timeout? l=GswrXmTrS3Tove6Omd2Bw6 (Accepted)
- 18. Khatik, G. L., Srivastava, A., &Divita, K. M. (2022.). Five-membered ring fused pyrimidine-based derivatives and their biological properties. In Raj Kumar, *Fused Pyrimidine-Based Drug Discovery*. Academic Press, Cambridge. ISBN: 978-012-82-4531-6.
- Mahajan, A. T., Khatik, G. L., & Chaudhary, S. (2022). Antibiofilm properties of biosurfactants: A tool against the food pathogens. In Dr.Inamuddin, Charles Adetunji (Eds.) Applications of Next Generation Biosurfactants in the Food Sector (1st Ed., Ch. 5) Elsevier, Academic Press, Cambridge. ISBN: 978-012-82-4283-4.

- 20. Singhal, G., & Srivastava, N. **(2022)**. A Practical Handbook of Life Sciences (1st.). Cambridge Scholars Publishing, Cambridge. ISBN: 978-152-75-8869-1.
- Rao, G., Rao, A., Nandeshwarappa, B. P., Ningegowda, R., Mudnakudu-Nagaraju, K. K., &Chandrashekharapp, S. (2022). Fabrication of disposable sensor strips for point-of-care testing of environmental pollutants. In J. G. Manjunatha& C. M. Hussain (Eds.), *Carbon Nanomaterials-Based Sensors: Emerging Research Trends in Devices and Applications,* Academic Press, Cambridge. ISBN: 978-032-39-1174-0. pp. 77–94.
- 22. Tripathi, P., & Srivastava, S. P. **(2022)**. Non-coding RNAs in Health and Diseases. In G. Sethi, M. Garg, & A. K. Pandey (Eds.), *Transcription and Translation in Health and Disease*, Academic Press, Cambridge. ISBN: 978-032-39-9521-4.
- 23. Atpadkar, P. P., Gopavaram, S., & Chaudhary, S. **(2022)**. Natural–Product– Inspired Bioactive Alkaloids agglomerated with Potential Antioxidant Activity: Recent Advancements on Structure-Activity Relationship studies and Future Perspectives. In *Vitamins and Hormones*. (In Press)
- 24. Sonam, S., Patel, P., Pandey, D., Sharma, A., & Jain, K. (2023). Quantum Dots: Functionalization and Theranostic Applications. In *Multifunctional And Targeted Theranostic Nanomedicines - Formulation, Design, And Applications*. (Accepted)
- 25. Pullivarthi, C., Choubey, S. S., Pandey, S. K., Gautam, A. S., & Singh, R. K. **(2022)**. Receptor Tyrosine Kinases (RTKS): From Biology to Pathophysiology. In *Receptor Tyrosine Kinases in Neurodegenerative and Psychiatric Disorders*. (Accepted)

PATENTS:

- 1. Dr. A. K. Yadav; Dr. S. K. Mishra; R. Jain **(2022)** Hyaluronic Acid Anchored DnaNanoclews For Targeted Delivery Of 5-Florouracil And Method Thereof. Indian Patent 202211010250.
- 2. Dr.Keerti Jain; Parth R. Patel; Teeja Suthar; Ashima Thakur; Dr.Abha Sharma **(2022)** Novel Dendrimer Conjugates For Targeted Delivery Of Drug(S) To Treat Life-Threatening Diseases. Indian Patent 202211039492.
- 3. Dr. Sandeep Chandrashekharappa; Ms. Surbhi **(2022)** Method For Synthesis Of Chrysin; Tectochrysin; And Their Derivatives Thereof For Use In Pharmaceutical Applications. Indian Patent 202211047585.
- Dr. Gopal Lal Khatik; Dr. Ashok Kumar Datusalia; Ramesh Ambtwar; Swati Verma (2022) Method for chemical synthesis of kynurenic acid; ethyl ester and amide derivatives thereof. Indian Patent 202211065540.

NIPER, S.A.S. NAGAR



Contact Address

Sector 67, S.A.S. Nagar (Mohali)-160062, Punjab Phone:+91 172-2214682; +91 172-2214683; +91 172-2292000 Website: https://niper.gov.in

From the Director's Desk

National Institute of Pharmaceutical Education and Research, SAS Nagar (Mohali), is working in the areas of pharmaceutical research focused at (i) new molecular entities and (ii) enhancing affordability of medicines, with the aim of enhancing drug security within the country. Drug discovery requires multi-level strategies. At NIPER SAS Nagar, we adopt an iterativeapproach which begins with preliminary identification of targets using AI/ML, computational biology and *in silico* drug design methodologies.These are validated on the bench using tools of modern biology.Generation of ligands for these targets involves synthetic routes



Prof. Dulal Panda

via chemical means or using natural products scaffolds. The Institute is working on evidence-based research in traditional medicines and phytopharmaceuticals for life style diseases including diabesity (association of obesity with diabetes).Macromolecular ligands like proteins and peptides are created using tools of recombinant DNA technology and evaluated *in vitro* using cell culture models and *in vivo* animal models. The combination of chemical and biological space to streamline drug discovery, design, development and optimization, by facilitating hit identification, hit-to-lead selection, and ADMET (absorption, distribution, metabolism, excretion, and toxicity) optimization, is well explored at the Institute. The success of this approach is seen in validation of several targets for drug repurposing, matching with our goal of making drugs affordable.

An important national priority isdiscovery of new molecules for neglected diseases affecting India. The Institute is working on identification of new druggable targets in tuberculosis (also multi-drug resistant TB, MDR), malaria, leishmaniasis (kala azar), nosocomial infections, viral infections and Antimicrobial Resistance (AMR). The diseases of high burden like neurodegenerative diseases, stroke, diabetes and its complications, cancer, etc. are being studied intensively for development of new drug molecules (chemical and biological) as well as repurposing of existing drugs.Animal models are available for these diseases. The toxicity of developed molecules is investigated in the GLP-compliant National Toxicology Centre. This facility is also used extensively by the industry.With the growing impetus on biopharmaceuticals, Institute has developed strong expertise in this area. Work is undertaken using peptides, proteins including nanobodiesand nucleic acids as well as development of stabilized protein formulations.Some of these nucleic acids are being developed as biosensors. We hope to replace antibodies in diagnostic kits, which will increase their shelf life and reduce the cost.

Computational and high throughput pharmaceutics to design chemistry-based interventions for improving biopharmaceutical profile, DMPK studies, safety pharmacology, pre-formulation profiling, scale up of NCEs, pre-clinical efficacy studies using conventional or 'enabling' animal formulations, are also in place. Development of novel drug delivery routes (nanoformulations, liposomes, etc.) as well as increasing the solubility of existing drugs are two areas where the Institute has achieved significant success and also the maximum industry participation. The molecules of Productivity Linked Incentive Scheme of Bulk drugs are explored for the research and technology

development at NIPER SAS Nagar. We perform pilot studies for APIs and dosage form and prepare 'Technical Data Package" for technology transfer to industry partner for drug development. We have not only been successful in scaling up of processes but have also been able to help the local industries by simplifying synthetic routes of their products, adopting greener and sustainable processes, thereby reducing the cost of the process. Several of the technologies developed by us in-house have been transferred to the industry and commercialized, for example: compositions and methods for trapping and inactivating pathogenic microbes and spermatozoa Phexxi (by EvoFem Inc.) and quick disintegrating taste masked composition Zinc Sulphate Tablets (by IDPL). Further, some of our technologies have been licensed out to the companies, viz. a novel one-step process for preparation of nanocrystalline solid dispersions (NanoCrySP technology) and Pharmaceutical Compositions for Enhancing Anticancer Efficacy of Tamoxifen. We also have a strong portfolio of technologieswhich are ready for licensing out to pharmaceutical companies. We hope that with the participation and cooperation of the domestic pharmaceutical industry, we can work towards reducing the import burden of the country in the area of APIs and KSMs significantly.

The Institute is actively working with different tertiary care hospitals in the city and interacting with patients under clinical care. We also focus on pharmacovigilance, and HEOR (health economics and outcomes research) studies. As can be seen, NIPER SAS Nagar is undertaking research activities in India-specific and global trending areas of pharmaceutical research to ensure seamless integration of various functions to achieve translational goals. The Institute works on domain-relevant challenges and has the intellectual and infrastructure capability to address these.

EXTRA-MURAL RESEARCH PROJECTS

| S. N. | Title of the Project | PI | Name of Funding Agency | Sanctione d Amount (₹) | Duration of the project |
|-------|---|---|---|--|---|
| 1. | Biophysical and biochemical characterization of non-human insertion in <i>Leishmania</i> - specific aminoacyl- tRNA synthetase: Possible drug target against visceral leishmaniasis' | Dr Rajat Banerjee (Calcutta University), Dr Sushma Singh (NIPER, SAS Nagar), Dr Chiranjib Pal, WBSU Kolkata | ICMR | 39.67 Lakhs | 03 years |
| | Leishmania donovar azar), one of the six Organization, accour an annual incidence confirmed cases occu synthetases are kno across organisms, sc agents based on the pathogens and huma that one of the aaRS insertion which is insertion could be Biophysical, Molecul vivo we will explo- survivability. | major parasitic d nts for an estimat e of about 2 mil ur in India, Nepal, own as potential ientists have beer structural different ans. Recently seque s, arginyl-tRNA sy completely abse developed as potential lar Biology, cell b | iseases recog ied 10-15 mill lion new cas Bangladesh at drug targets able to gener nces in the ca enced Leishm ynthetase, cor nt in human tential drug to piology techni | nized by the lion cases we es. Of these and Sudan. Am s. Despite the rate effective talytic clefts of nania species ntains 100-re . We propose carget. Using ques both in | World Health orldwide with , 90% of the ninoacyl-tRNA eir similarity anti-infective of aaRSs from also revealed sidue specific sed that this Biochemical, witro and in |
| 2. | Development of Novel Bispecific Nano-Antibody for Clinical Use | Prof. Abhay H. Pande and Prof. G. B. Jena | DST-SERB | 53.72 lakh | 3 yrs |
| | Chronic inflammator more than half of all IL-23 play are key di IL-23 with their rec antibodies (DAbs) ha monoclonal antibod pro-inflammatory dr single domain antib IL23) simultaneously | l death in the wor rivers of inflamm eptors inhibit inf as emerged as a p ies (MAbs). Since rivers of inflamm ody that neutrali | rld today. Incr ation. Blockin lammatory sig ootential alter e, both TNF-α ation, so we a ze both of cy | eased levels g interaction gnaling pathy native to the and IL-23 a re developin tokines (TNF | of TNF-α and of TNF-α and ways. Domain conventional are important g a bispecific 2-α as well as |
| 3. | Development of a generic method for aptamer-based | Prof. Ipsita Roy | ICMR | 33 lakh + Manpower | Three years |

| | data ati an af | | | | | |
|----|--|--------------------|----------------|----------------|----------------|--|
| | detection of | | | | | |
| | protein oligomers | ular mimic of colu | hla aligamana | | | |
| | Synthesis of a molect | | 0 | | the eligenment | |
| | Selection of high af | nnity aptamers v | vnich bind sp | becifically to | the oligomer | |
| | mimic | 1 . 1 / 1 | | C | 1 1 1 | |
| | Development of 'sar | idwich detection | tool for oligo | omers formed | a by different | |
| | proteins | | 0000 | | | |
| 4. | Reprofiling of | Prof. Ipsita Roy | SERB | 42 lakh | Three years | |
| | molecules for | | | | | |
| | inhibition of | | | | | |
| | aggregation of α - | | | | | |
| | synuclein in vitro | | | | | |
| | and in cell model of | | | | | |
| | Parkinson's | | | | | |
| | disease | | | | | |
| | Effect of selected app | | | - | | |
| | Effect of selected app | | on aggregatio | n of α-synucl | ein in yeast | |
| | and mammalian cells | | _ | | | |
| | Effect of selected | | | | | |
| | aggregation of α -syn | | | | | |
| 5. | Design of a | Prof. Ipsita Roy | DBT | 158 lakh | Three years | |
| | switchable system | | | | | |
| | for controlled | | | | | |
| | activation of the | | | | | |
| | proteostasis | | | | | |
| | network | | | | | |
| | To express and purif | - | - | | | |
| | To select specific apt | - | | - | | |
| | To characterize the | | een Hsf1 and | N-terminal | Hsp90 in the | |
| | presence of selected | - | C | | с | |
| | To design 'intramer | and antidote se | quences for e | expression of | f aptamers in | |
| | cells | c (| | | . 11 | |
| | To design a system | | | | - | |
| | expressing mutant | | | gated polygi | utamine tract | |
| (| and its effect on aggr | | | 101.11 | 2 V | |
| 6. | Scaffold hopping of | Prof. S.K. | CSIR, GoI | 12 Lakh | 3 Year | |
| | natural alkaloids | Guchhait | | | | |
| | and analog-focused | | | | | |
| | strategic synthesis: | | | | | |
| | Discovery of | | | | | |
| | target-specific | | | | | |
| | antiproliferative | | | | | |
| | agents | | | | | |
| | Anticancer drug dis | | | | | |
| | considered in this p | | | - | | |
| | which are important | t biological proce | ss for evoluti | on. The analo | ogs of several | |
| | which are important biological process for evolution. The analogs of several such natural products are designed. Natural products Rutecarpine, | | | | | |
| | | _ | ned. Natura | - | - | |

| | potential. The strate "C=O") switched ar modified derivatives molecules. The en- established to prepa will be done. | nalogs of these n s to generate new vironment-friendl | natural produ 7, patentable y organic c | acts and the and potentia hemistry ap | ir molecular- lly anticancer proaches are | | |
|----|---|---|--|---|---|--|--|
| 7. | Multifunctional ylides yielding novel masked synthons in construction of privileged heterocyclic scaffolds: A rational integration with target-based anticancer drug discovery | Prof. Sankar K Guchhait | SERB-DST, GoI | 41.40 Lakh | 3 Year | | |
| | The structures of marketed drugs and clinical trial agents mostly contain nitrogen heterocyclic molecular skeletons. Exploring new synthetic strategy for preparation of bioactive nitrogen heterocycles is always important. In this project, "ylide yielding masked synthon" as a new synthetic organic chemistry tool towards construction of pharmaceutically-privileged diverse heterocyclic skeletons has been considered. Previously unknown chemical reactivity feature of designed suitably-tethered various multifunctional ylides in reaction with electrophilic nucleophilic bifunctional substrates have been discovered and are being investigated. This will be rationally integrated with the natural products/drugs/bioactive agents-inspired anticancer drug | | | | | | |
| 8. | discovery research. Computational Approaches for Pharmacovigilance : An Integrated and Semantically- Enriched Frameworks Lab development and new Anti-diabetic drugs ADR Signal Detection using FAERS tool | Dr Dipika Bansal | Indian Council of Medical Research (ICMR) | 38.23 Lakh | 36 Months | | |
| | Preclinical and clinic majority of serious a developed vigilance which represent som diabetes drugs, the causal relationship b data mining lab w generation programs | dverse drug react programme will d ne of a drug's unkn "Signals" of ADR etween an advers vill facilitate add | tions (ADRs), etect rare and nown safety riss will report e event and a litionally to | but not all of l unexpected isks. For rece information drug. The est conduct the | them. A well- serious ADRs, ntly approved on a possible ablishment of pilot signal | | |

| | Pharmacovigilance r | programme of Indi | a (PvPI). | | | | | |
|-----|---|---|--|---|---|--|--|--|
| 9. | In silico, | Prof. Prabha | ICMR | 33.98 | 3 years | | | |
| | Biochemical and | Garg and | | Lakh | b yourb | | | |
| | Structural | DrChaaya | | Luiti | | | | |
| | Characterization of | Iyengar Raje | | | | | | |
| | the Mycobacterium | iyengai Naje | | | | | | |
| | | | | | | | | |
| | tuberculosis (M.tb) | | | | | | | |
| | elongation factors | | | | | | | |
| | (EF-Tu, EF-Ts and | | | | | | | |
| | EF-G) | | | | | | | |
| | Mtb elongation- Tu, Ts and G factors are promising drug targets, however | | | | | | | |
| | structure of these p | proteins in Mtb is | s not resolve | d. Hence ide | ntifying their | | | |
| | protein structure wi | ill provide a mech | anism for the | e design of in | hibitors. This | | | |
| | study will analyse th | he following aspe | cts of these e | longation fac | tors i.e. (i) in | | | |
| | silico analysis and co | | | | | | | |
| | Mtb proteins (iii) att | _ | | | | | | |
| | inhibitors to target p | _ | - | | 0 | | | |
| 10. | Early detection of | Prof. Prabha | SERB | 19.20 | 2 years | | | |
| | colorectal cancer | Garg | NPDF | Lakh | | | | |
| | using deep | durb | | | | | | |
| | learning and gene | | | | | | | |
| | expression studies | | | | | | | |
| | _ | | | | | | | |
| | to identify target | | | | | | | |
| | genes for drug | | | | | | | |
| | repurposing | | | | | | | |
| | | 1 | | · 1 | 1 1 | | | |
| | The project has three | | - | - | - | | | |
| | The project has three model for the early | diagnosis of colo | prectal cancer | . Second to i | dentify nove | | | |
| | The project has three model for the early genes that might reg | diagnosis of colo gulate (up/ down) | orectal cancer in colorectal | : Second to i cancer and c | dentify nove an be used as | | | |
| | The project has thre model for the early genes that might reg potential targets us | diagnosis of colo gulate (up/ down) ing NGS and mic | prectal cancer in colorectal roarray gene | : Second to i cancer and c expression o | dentify nove an be used as lata. Third to | | | |
| | The project has three model for the early genes that might reg potential targets us identify potential dr | diagnosis of colo gulate (up/ down) ing NGS and mic rug candidates (d | orectal cancer in colorectal roarray gene rug-repurposi | : Second to i cancer and c expression c ing) based or | dentify nove an be used as lata. Third to the selected | | | |
| | The project has thre model for the early genes that might reg potential targets us identify potential dr overexpressing gen | diagnosis of colo gulate (up/ down) ing NGS and mic rug candidates (d | orectal cancer in colorectal roarray gene rug-repurposi | : Second to i cancer and c expression c ing) based or | dentify novel an be used as lata. Third to n the selected | | | |
| | The project has three model for the early genes that might reg potential targets us identify potential dr | diagnosis of colo gulate (up/ down) ing NGS and mic rug candidates (d | orectal cancer in colorectal roarray gene rug-repurposi | : Second to i cancer and c expression c ing) based or project yet t | dentify novel an be used as lata. Third to n the selected | | | |
| 11. | The project has thre model for the early genes that might reg potential targets us identify potential dr overexpressing gen | diagnosis of colo gulate (up/ down) ing NGS and mic rug candidates (d | orectal cancer in colorectal roarray gene rug-repurposi | : Second to i cancer and c expression c ing) based or | dentify nove an be used as lata. Third to the selected | | | |
| 11. | The project has thre model for the early genes that might reg potential targets us identify potential dr overexpressing gen receiving funds. | diagnosis of colo gulate (up/ down) ing NGS and mic rug candidates (di es and their pro | orectal cancer in colorectal roarray gene rug-repurposi oteins. The p | : Second to i cancer and c expression c ing) based or project yet t | dentify novel an be used as lata. Third to n the selected to start after | | | |
| 11. | The project has three model for the early genes that might reg potential targets us identify potential dr overexpressing gen receiving funds. Development of | diagnosis of colo gulate (up/ down) ing NGS and mic rug candidates (di es and their pro Prof. Sanjay | orectal cancer in colorectal roarray gene rug-repurposi oteins. The p | 25.51 Second to it cancer and concer and concer and concerning the second concerning of the second concerning | dentify novel an be used as lata. Third to n the selected to start after | | | |
| 11. | The project has three model for the early genes that might reg potential targets us identify potential dr overexpressing gen receiving funds. Development of scientific | diagnosis of colo gulate (up/ down) ing NGS and mic rug candidates (di es and their pro Prof. Sanjay | orectal cancer in colorectal roarray gene rug-repurposi oteins. The p | 25.51 Second to it cancer and concer and concer and concerning the second concerning of the second concerning | dentify nove an be used as lata. Third to n the selected to start after | | | |
| 11. | The project has three model for the early genes that might reg potential targets us identify potential dr overexpressing gen receiving funds. Development of scientific monograph amd | diagnosis of colo gulate (up/ down) ing NGS and mic rug candidates (di es and their pro Prof. Sanjay | orectal cancer in colorectal roarray gene rug-repurposi oteins. The p | 25.51 Second to it cancer and concer and concer and concerning the second concerning of the second concerning | dentify nove an be used as lata. Third to n the selected to start after | | | |
| 11. | The project has three model for the early genes that might reg potential targets us identify potential dr overexpressing gen receiving funds. Development of scientific monograph amd quality standards for selected Indian | diagnosis of colo gulate (up/ down) ing NGS and mic rug candidates (di es and their pro Prof. Sanjay | orectal cancer in colorectal roarray gene rug-repurposi oteins. The p | 25.51 Second to it cancer and concer and concer and concerning the second concerning of the second concerning | dentify nove an be used as lata. Third to n the selected to start after | | | |
| 11. | The project has three model for the early genes that might reg potential targets us identify potential dr overexpressing gen receiving funds. Development of scientific monograph amd quality standards for selected Indian medicinal plants | diagnosis of colo gulate (up/ down) ing NGS and mic rug candidates (di es and their pro Prof. Sanjay Jachak | orectal cancer in colorectal roarray gene rug-repurposi oteins. The p NMPB | 25.51 25.51 25.51 25.4 25.51 | dentify novel an be used as lata. Third to n the selected to start after 3 years | | | |
| 11. | The project has three model for the early genes that might reg potential targets us identify potential dr overexpressing gen receiving funds. Development of scientific monograph amd quality standards for selected Indian medicinal plants Document published a | diagnosis of colo gulate (up/ down) ing NGS and mic rug candidates (di es and their pro Prof. Sanjay Jachak | orectal cancer in colorectal roarray gene rug-repurposi oteins. The p NMPB | 25.51 Lakh | dentify novel an be used as lata. Third to the selected o start after 3 years | | | |
| 11. | The project has three model for the early genes that might reg potential targets us identify potential dr overexpressing gen receiving funds. Development of scientific monograph amd quality standards for selected Indian medicinal plants Document published a medicinal plants will | diagnosis of colo gulate (up/ down) ing NGS and mic- rug candidates (di es and their pro Prof. Sanjay Jachak | orectal cancer in colorectal roarray gene rug-repurposi oteins. The p NMPB | Second to it cancer and cancer | dentify novel an be used as lata. Third to the selected o start after 3 years ure on selected , common and | | | |
| 11. | The project has three model for the early genes that might reg potential targets us identify potential dr overexpressing gen receiving funds. Development of scientific monograph amd quality standards for selected Indian medicinal plants Document published a medicinal plants will local names of conse | diagnosis of colo gulate (up/ down) ing NGS and mic rug candidates (di es and their pro Prof. Sanjay Jachak and unpublished litt be documented wi rved medicinal pla | orectal cancer in colorectal roarray gene rug-repurposi oteins. The p NMPB NMPB erature: The av nich includes s ints, their loca | Second to it cancer and cancer | dentify novel an be used as lata. Third to the selected o start after 3 years ure on selected c, common and tion, identified | | | |
| 11. | The project has three model for the early genes that might reg potential targets us identify potential dr overexpressing gen receiving funds. Development of scientific monograph amd quality standards for selected Indian medicinal plants Document published a medicinal plants will local names of conse medicinal value or us | diagnosis of colo gulate (up/ down) ing NGS and mic rug candidates (di es and their pro Prof. Sanjay Jachak and unpublished lite be documented wh rved medicinal pla ses of each medici | orectal cancer in colorectal roarray gene rug-repurposi oteins. The p NMPB NMPB erature: The av nich includes s ints, their loca nal plant genu | Second to it cancer and cancer | dentify novel an be used as lata. Third to the selected o start after 3 years ure on selected c, common and tion, identified otographs and | | | |
| 11. | The project has three model for the early genes that might reg potential targets us identify potential dr overexpressing gen receiving funds. Development of scientific monograph amd quality standards for selected Indian medicinal plants Document published a medicinal plants will local names of conse medicinal value or us general morphological | diagnosis of colo gulate (up/ down) ing NGS and mic rug candidates (di es and their pro Prof. Sanjay Jachak and unpublished lite be documented wi rved medicinal pla ses of each medici l description of each | orectal cancer in colorectal roarray gene rug-repurposi oteins. The p NMPB NMPB erature: The av nich includes s ints, their loca nal plant genu genus/species | Second to it cancer and cancer | dentify nove an be used as lata. Third to the selected o start after 3 years ure on selected c, common and tion, identified otographs and | | | |
| 11. | The project has three model for the early genes that might reg potential targets us identify potential dr overexpressing gen receiving funds. Development of scientific monograph amd quality standards for selected Indian medicinal plants Document published a medicinal plants will local names of conse medicinal value or us general morphological specific plant part used | diagnosis of colo gulate (up/ down) ing NGS and mic- rug candidates (di es and their pro- Prof. Sanjay Jachak and unpublished lite be documented wh rved medicinal pla ses of each medici description of each d for extraction of p | orectal cancer in colorectal roarray gene rug-repurposi oteins. The p NMPB NMPB erature: The av nich includes s ants, their loca nal plant genu genus/species hytochemicals | Second to it cancer and cancer | dentify nove an be used as lata. Third to the selected o start after 3 years ure on selected , common and tion, identified otographs and al constituents | | | |
| 11. | The project has three model for the early genes that might reg potential targets us identify potential dr overexpressing gen receiving funds. Development of scientific monograph amd quality standards for selected Indian medicinal plants Document published a medicinal plants will local names of conse medicinal value or us general morphological | diagnosis of colo gulate (up/ down) ing NGS and mic- rug candidates (di- es and their pro- Prof. Sanjay Jachak and unpublished lite be documented wh rved medicinal plat ses of each medici description of each d for extraction of p on medicinal plant | orectal cancer in colorectal roarray gene rug-repurposi oteins. The p NMPB NMPB erature: The av nich includes s ints, their loca nal plant genu genus/species hytochemicals s characterizat | Second to it cancer and cancer | dentify novel an be used as lata. Third to a the selected o start after 3 years ure on selected otographs and al constituents uses: The data | | | |
| 11. | The project has three model for the early genes that might reg potential targets us identify potential dr overexpressing gen receiving funds. Development of scientific monograph amd quality standards for selected Indian medicinal plants Document published a medicinal plants will local names of conse medicinal value or us general morphological specific plant part used Develop monographs | diagnosis of colo gulate (up/ down) ing NGS and mic rug candidates (di es and their pro- Prof. Sanjay Jachak Ind unpublished lite be documented wh rved medicinal plat ses of each medici description of each d for extraction of p on medicinal plant morphological, and | erature: The avnich includes since and plant genus hytochemicals and communication a | 25.51 Lakh | dentify novel an be used as lata. Third to a the selected o start after 3 years ure on selected c, common and tion, identified otographs and al constituents uses: The data nation, will be | | | |
| 11. | The project has three model for the early genes that might reg potential targets us identify potential dr overexpressing gen receiving funds. Development of scientific monograph amd quality standards for selected Indian medicinal plants Document published a medicinal plants will local names of conse medicinal value or us general morphological specific plant part used Develop monographs collected, after broad | diagnosis of colo gulate (up/ down) ing NGS and mic rug candidates (di es and their pro- Prof. Sanjay Jachak I description of each d for extraction of p on medicinal plant morphological, and of a monograph for | orectal cancer in colorectal roarray gene rug-repurposi oteins. The p NMPB erature: The av nich includes s ints, their loca nal plant genu genus/species hytochemicals s characterizat atomical and c | Second to it cancer and cancer | dentify novel an be used as lata. Third to a the selected o start after 3 years are on selected ton, identified otographs and al constituents uses: The data nation, will be | | | |
| 11. | The project has three model for the early genes that might reg potential targets us identify potential dr overexpressing gen receiving funds. Development of scientific monograph amd quality standards for selected Indian medicinal plants Document published a medicinal plants will local names of conse medicinal value or us general morphological specific plant part used Develop monographs collected, after broad compiled in the form | diagnosis of colo gulate (up/ down) ing NGS and mic rug candidates (di es and their pro- Prof. Sanjay Jachak I description of each d for extraction of p on medicinal plant morphological, and of a monograph for | orectal cancer in colorectal roarray gene rug-repurposi oteins. The p NMPB erature: The av nich includes s ints, their loca nal plant genu genus/species hytochemicals s characterizat atomical and c | Second to it cancer and cancer | dentify nove an be used as lata. Third to the selected o start after 3 years are on selected toon, identified otographs and al constituents uses: The data nation, will be | | | |

| | from Azines and their application in | Bharatam | | plus consumabl | |
|-----|--|---|--|--|---|
| | Organometallic Catalysis | | | es and contingen cies | |
| 13. | Pincer complexes car metal interacting with four nitrogen atoms, transition metals form catalysis. In this proje These newly generate organic molecules, for | three nitrogen ato of which three ca ing pincer complex ct, we propose the ed catalysts will be | ms. 1,1-diamir n easily coor es. These comp generate them e used to gene | noazines are co dinate with P olex can show using cost effe | ompounds with d/Fe or other organometallic ective methods. |
| | Structural and Biochemical Characterization of Glyceraldehyde-3- phosphate dehydrogenase (GAPDH) A.baumannii and design of inhibitors. STRY SPONSORED PR disclosed as per the C | Dr.Chaaya Iyengar And Prof TP Singh, AIIMS New Delhi, Dr. Manoj Raje (IMTECH) | ICMR Istry sponsore | | 4 years |
| 15. | Particle Size analysis of Clotrimazole and Naproxen in respective dosage forms using Hot stage microscopy | Prof. Arvind K. Bansal | Olive Healthcare | 1.18 Lakh | 1 month |
| 16. | Advice on re- development of a corticosteroid | Prof. Arvind K. Bansal | Nordic Group B.V. | 75 Euro/ Hour | 1 year |
| 17. | Expert Advice on Oral Solid Dosage Forms | Prof. Arvind K. Bansal | Oncogen Pharma (Malaysia) Sdn. Bhd | 30,000/- and 55000/- per hour | 1 year |
| 18. | Advice on Pharmaceutial Development of Parenteral Product | Prof. Arvind K. Bansal | Nordic Group B.V. | 16.31 lakh | 1 year |
| 19. | Advice on Formualtion related issues | Prof. Arvind K. Bansal | Zoetis Pharmaceu tical Research | 14000/- per hour | 1 year |

| | | | Pvt Ltd | | |
|-----|--|---------------------------|---|--|--------|
| 20. | Expert opinion in patent related issue | Prof. Arvind K. Bansal | Rajeshwari & Associates | 25000/- per hour | 1 year |
| 21. | Expert Advice on Oral Solid Dosage Forms | Prof. Arvind K. Bansal | Novugen Oncology Sdn. Bhd | 30,000/- and 55000/- per hour | 1 year |
| 22. | Characterization and Comparative evaluation of Solid state properties for Reference and Test Product | Prof. Arvind K. Bansal | Gulbrands en Technologi es | 2.54 lakh | 1 year |
| 23. | Identification, isolation and particle size analysis of APIs in respective dosage forms using HSM | Prof. Arvind K. Bansal | Pharmania gaREsearc h Centre SDN BHD | 2.06 lakh | 1 year |
| 24. | Particle size analysis of API in Reference and Test Formualtion using Hot stage microscopy | Prof. Arvind K. Bansal | Emcure Pharmaceu ticals Ltd | 1.42 lakh | 1 year |
| 25. | Identification, isolation and particle size analysis of APi in Reference and Test samples using Hot stage microscopy | Prof. Arvind K. Bansal | Bilss GVS Pharma Ltd(R&D Centre) | 1.42 lakh | 1 year |
| 26. | Identification, isolation and particle size analysis of Brivaracetam in Briviact Tablets using Hot stage microscopy | Prof. Arvind K. Bansal | Zenvision Pharma LLP | 0.70 lakh | 1 year |
| 27. | Particle size analysis of API in Formulation using Hot stage miscoscopy | Prof. Arvind K. Bansal | Barooque Pharmaceu ticals Pvt Ltd | 0.65 lakh | 1 year |
| 28. | Identification, isolation and | Prof. Arvind K. Bansal | Jubilant Generics | 1.30 lakh | 1 year |

| | particle size | | Ltd (R&D) | | |
|-----|---|---------------------------|---|-----------|--------|
| | analysis of Azilsartan in Formulations using Hot Stage Microscopy | | | | |
| 29. | Identification, isolation and particle size analysis of API in Samples using Hot Stage Microscopy | Prof. Arvind K. Bansal | Arzneimitt el-Alfa Private limited | 1.95 lakh | 1 year |
| 30. | Particle Size analysis of Fidaxomicin in Tablets using Hot stage microscopy | Prof. Arvind K. Bansal | Torrent Pharmaceu ticals Ltd | 1.30 lah | 1 year |
| 31. | Particle Size analysis of Bilastine in Dosage form using Hot stage microscopy | Prof. Arvind K. Bansal | Torrent Pharmaceu ticals Ltd | 1.30 lakh | 1 year |
| 32. | Particle size analysis of API in Suppository Samples using Hot stage Microscopy | Prof. Arvind K. Bansal | Slayback Pharma India LLP | 3.25 lakh | 1 year |
| 33. | Particle Size analysis of API in Formulations using Hot stage microscopy | Prof. Arvind K. Bansal | Natco Pharma Limited | 1.41 lakh | 1 year |
| 34. | Reverse Engineering of API in Referene and test samples using Hot stage microscopy | Prof. Arvind K. Bansal | Apothecon Pharmaceu ticals Pvt Ltd | 1.30 lakh | 1 year |
| 35. | IdentifIcation, isolation and particle size analysis of Rivaroxaban in RLD sample using Hot stage microscopy | Prof. Arvind K. Bansal | Titan Labotarori es Pvt Ltd (R&D) | 0.7a lakh | 1 year |
| 36. | Particle size analysis of API in | Prof. Arvind K. Bansal | Glenmark Pharmaceu | 2.60 lakh | 1 year |

| | Formulations using HSM | | ticals Ltd | | |
|-----|--|---------------------------|--|-----------|--------|
| 37. | Evaluation of Solid state of Indomethacin in Reference Product and Test Product Suppository Samples | Prof. Arvind K. Bansal | Slayback Pharma India LLP | 3.90 lakh | 1 year |
| 38. | Particle Size analysis of API in Formulation sample | Prof. Arvind K. Bansal | DifGen Pharmaceu ticals Pvt. Ltd | 0.71 lakh | 1 year |
| 39. | IdentifIcation, isolation and Particle size analysis of Ibrutinib in Imbruvica Tablets using Hot stage microscopy | Prof. Arvind K. Bansal | Sakar Healthcare ltd | 0.65 lakh | 1 year |
| 40. | Particle size analysis of Progesterone in Tablets using Hot Stage Microscopy | Prof. Arvind K. Bansal | Glenmark Pharmaceu ticals Ltd | 3.90 lakh | 1 year |
| 41. | Particle size analysis of API in Temazepam capsules using Hot Stage Microscopy | Prof. Arvind K. Bansal | JAMP India Pharmaceu ticals Pvt Ltd | 0.71 lakh | 1 year |
| 42. | Comparative evaluation of samples using PXRD | Prof. Arvind K. Bansal | Novick Bioscience s Pvt Ltd | 0.34 lakh | 1 year |
| 43. | Particle Size analysis of Clotrimazole and Naproxen in respective dosage forms using Hot stage microscopy | Prof. Arvind K. Bansal | Olive Healthcare | 1.18 lakh | 1 year |
| 44. | Identification, isolation and particle size analysis of Ambrisentan, Edoxaban and | Prof. Arvind K. Bansal | PHARMAC TİVE İLAÇ SAN.VE TİC.A.Ş. | 2.66 lakh | 1 year |

| | Obeticholic acid in respective dosage forms using Hot stage microscopy | | | | |
|-----|--|---------------------------|---|-----------|----------|
| 45. | Identification, isolation and particle size analysis of Nitrofurantoin in Samples using Hot Stage Microscopy | Prof. Arvind K. Bansal | Arzneimitt el-Alfa Private limited | 1.95 lakh | 1 year |
| 46. | Surface Area analysis of samples using BET method | Prof. Arvind K. Bansal | Sanofi- Synthelabo (india) Pvt Ltd | 2.36 lakh | 1 year |
| 47. | Surface Area analysis of samples using BET method | Prof. Arvind K. Bansal | Sanofi- Synthelabo (india) Pvt Ltd | 0.20 lakh | 1 year |
| 48. | Quantification of clavulanic acid production | Prof Ipsita Roy | KinvanPvt. Ltd. | 4.00 lakh | 0.5 year |

PUBLICATIONS (RESEARCH/ REVIEW):

Biotechnology

- 1. Kumari A, Prassanawar, SS, Panda D. β-III Tubulin Levels Determine the Neurotoxicity Induced by Colchicine-Site Binding Agent Indibulin, ACS Chem Neurosci, **(2022)**, doi: 10.1021/acschemneuro.2c00324
- Lin H-YJ, Battaje RR, Tan J, Doddareddy M, Dhaked HPS, Srivastava S, Hawkins BA, Al-Shdifat LMH, Hibbs DE, Panda D, Groundwater PW, Discovery of 2',6-Bis(4hydroxybenzyl)-2-acetylcyclohexanone, a Novel FtsZ Inhibitor, Molecules, 27(20) (2022): 6993. 10.3390/molecules27206993
- 3. Dhameliya TM, Tiwari R, Patel KI, Vagolu SK, Panda D, Sriram D, Chakraborti AK, Bacterial FtsZ inhibition by benzo[d]imidazole-2-carboxamide derivative with anti-TB activity, Future medicinal chemistry, 141(19) **(2022)**: 1361-1373. 10.4155/fmc-2022-0120
- 4. Pushpakaran A, Battaje RR, Panda D, Vitamin K3 inhibits FtsZ assembly, disrupts the Z-ring in Streptococcus pneumoniae and displays anti-pneumococcal activity, Biochemical Journal, 479 (14) **(2022)**:1543-1558. 10.1042/BCJ20220077
- 5. Venkatramani A, Mukherjee S, Kumari A, Panda D, Shikonin impedes phase separation and aggregation of tau and protects SH-SY5Y cells from the toxic effects of tau oligomers, International Journal of Biological Macromolecules,. 204**(2022)**: 19-33. 10.1016/j.ijbiomac.2022.01.172
- 6. Kirar, Seema, YeddulaNikhileshwar Reddy, Uttam Chand Banerjee, and JayeetaBhaumik. "Development of Meso-Substituted Heterocyclic BODIPY-Based Polymeric Nanoparticles for Pathogen Inhibition using Photodynamic Therapy." *ChemPhotoChem* (2022): e202200172.
- 7. Nankar, Sunil A., Sakeel Ahmed, Shyam S. Sharma, and Abhay H. Pande. "Apolipoprotein-mimetic Peptides: Current and Future Prospectives." *Current Protein and Peptide Science* 23, no. 11 (2022): 757-772.
- 8. Ghosh, Srijit, MohdRihan, Sakeel Ahmed, Abhay H. Pande, and Shyam Sunder Sharma. "Immunomodulatory potential of apolipoproteins and their mimetic peptides in asthma: Current perspective." *Respiratory Medicine* **(2022)**: 107007.
- 9. Dhameliya, Tejas M., Rishu Tiwari, Kshitij I. Patel, Siva Krishna Vagolu, Dulal Panda, Dharmarajan Sriram, and Asit K. Chakraborti. "Bacterial FtsZ inhibition by benzo [d] imidazole-2-carboxamide derivative with anti-TB activity." *Future Medicinal Chemistry* 14, no. 19 **(2022)**: 1361-1373.
- 10. Anakha, J., Priyanka S. Kawathe, Sayantap Datta, Snehal Sainath Jawalekar, Uttam Chand Banerjee, and Abhay H. Pande. "Human arginase 1, a Jack of all trades?." *3 Biotech* 12, no. 10 **(2022)**: 1-9.
- 11. Singh, Kuljit, Ratnika Sethi, Eshita Das, and Ipsita Roy. "The role of the glycerol transporter channel Fps1p in cellular proteostasis during enhanced proteotoxic stress." *Applied Microbiology and Biotechnology* 106, no. 18 **(2022)**: 6169-6180.
- Pallapati, Anusha Rani, Shivcharan Prasad, and Ipsita Roy. "Glycerol 3-phosphate dehydrogenase regulates heat shock response in Saccharomyces cerevisiae." *Biochimica et Biophysica Acta (BBA)-Molecular Cell Research* 1869, no. 5 (2022): 119238.
- 13. Venkatramani, Anuradha, Sandipan Mukherjee, Anuradha Kumari, and Dulal Panda. "Shikonin impedes phase separation and aggregation of tau and protects

SH-SY5Y cells from the toxic effects of tau oligomers." *International Journal of Biological Macromolecules* 204 **(2022)**: 19-33.

- 14. Nankar, Sunil A., Priyanka S. Kawathe, and Abhay H. Pande. "HDL, ApoA-I and ApoE-Mimetic Peptides: Potential Broad Spectrum Agent for Clinical Use?." *International Journal of Peptide Research and Therapeutics* 28, no. 2 (2022): 1-11.
- 15. Shah, Archana P., Neha Hura, Neerupudi Kishore Babu, Nibedita Roy, Vajja Krishna Rao, Anindita Paul, Pradyot Kumar Roy, Sushma Singh, and Sankar K. Guchhait. "A Core-Linker-Polyamine (CLP) Strategy Enables Rapid Discovery of Antileishmanial Aminoalkylquinolinecarboxamides That Target Oxidative Stress Mechanism." *ChemMedChem* 17, no. 16 **(2022)**: e202200109.
- 16. Paul, Anindita, and Sushma Singh. "Visceral leishmaniasis in the COVID-19 pandemic era." *Transactions of The Royal Society of Tropical Medicine and Hygiene* **(2022)**.

Pharmacology and Toxicology

- 17. Sheth, Vaibhav G., Nisha Sharma, ShaheenWasil Kabeer, and Kulbhushan Tikoo. "Lactobacillus rhamnosus supplementation ameliorates high fat diet-induced epigenetic alterations and prevents its intergenerational inheritance." *Life Sciences* 311 **(2022)**: 121151.
- 18. Kaur, Jaspreet, Ankush Sheoran, Vinod Kumar, Kulbhushan Tikoo, Bhupender Singh, Anupama Kaushik, and Sonal Singhal. "Development of perceptive multianalyte sensing platform based on fluorescent CdS QDs for selective and sensitive assay of virulent contaminants in aqueous medium." *Journal of Environmental Chemical Engineering* 10, no. 6 **(2022)**: 108562.
- 19. Tesfaye, Solomon, KaleabAsres, Sebastian Guenther, and Prati Pal Singh. "Antimalarial effect of a combination of risedronate and azithromycin against Plasmodium yoeliinigeriensis infection in Swiss mice." *Parasitology International* 91 **(2022)**: 102655.
- Singh, Sneha, Paramdeep Kaur, Diksha Aggarwal, Vinod Kumar, Kulbhushan Tikoo, Sandeep Bansal, and Sonal Singhal. "Polyaniline enwrapped CoFe2O4/g-CN ternary nanocomposite for adsorption driven photocatalytic degradation of explicitly diverse organic pollutants." *Journal of Alloys and Compounds* 923 (2022): 166255.
- 21. Tyagi, Richa, Bhupesh Vaidya, and Shyam Sunder Sharma. "Crosstalk between neurological, cardiovascular, and lifestyle disorders: insulin and lipoproteins in the lead role." *Pharmacological Reports* **(2022)**: 1-28.
- Sharma, Komal, Shams Aaghaz, Indresh K. Maurya, Shivaprakash M. Rudramurthy, Shreya Singh, Vinod Kumar, Kulbhushan Tikoo, and Rahul Jain. "Antifungal evaluation and mechanistic investigations of membrane active short synthetic peptides-based amphiphiles." *Bioorganic Chemistry* 127 (2022): 106002.
- 23. Vaidya, Bhupesh, Ipsita Roy, and Shyam Sunder Sharma. "Neuroprotective Potential of HC070, a Potent TRPC5 Channel Inhibitor in Parkinson' s Disease Models: A Behavioral and Mechanistic Study." *ACS Chemical Neuroscience* 13, no. 18 **(2022)**: 2728-2742.
- 24. Garg, Twinkle, Jaspreet Kaur, Paramdeep Kaur, Vinod Kumar, Kulbhushan Tikoo, Anupama Kaushik, and Sonal Singhal. "An innovative Z-scheme

g-C3N4/ZnO/NiFe2O4 heterostructure for the concomitant photocatalytic removal and real-time monitoring of noxious fluoroquinolones." *Chemical Engineering Journal* 443 **(2022)**: 136441.

- 25. Sardoiwala, Mohammed Nadim, Soni Jignesh Mohanbhai, Avinash Chandra Kushwaha, Atul Dev, Liku Biswal, Shyam Sunder Sharma, Subhasree Roy Choudhury, and SurajitKarmakar. "Melatonin mediated inhibition of EZH2-NOS2 crosstalk attenuates inflammatory bowel disease in preclinical in vitro and in vivo models." *Life Sciences* (2022): 120655.
- 26. Ahmed, Sakeel, Abhay H. Pande, and Shyam Sunder Sharma. "Therapeutic potential of ApoE-mimetic peptides in CNS disorders: Current perspective." *Experimental Neurology* (2022): 114051.
- Thapak, Pavan, Mahendra Bishnoi, and Shyam Sunder Sharma. "Tranilast, a Transient Receptor Potential Vanilloid 2 Channel (TRPV2) Inhibitor Attenuates Amyloid β-Induced Cognitive Impairment: Possible Mechanisms." *NeuroMolecular Medicine* 24, no. 2 (2022): 183-194.
- 28. Mohanbhai, Soni Jignesh, Mohammed Nadim Sardoiwala, Shiwangi Gupta, Nishith Shrimali, Subhasree Roy Choudhury, Shyam Sunder Sharma, Prasenjit Guchhait, and SurajitKarmakar. "Colon targeted chitosan-melatonin nanotherapy for preclinical Inflammatory Bowel Disease." *Biomaterials Advances* (2022): 212796.
- 29. Singla, Shivani, and Gopabandhu Jena. "Intervention of 3-aminobenzamide against Dextran Sulphate Sodium induced colitis in mice: Investigations on molecular mechanisms." *European Journal of Pharmacology* 920 **(2022)**: 174861.
- 30. Poleboina, Sumathi, Vaibhav G. Sheth, Nisha Sharma, PraveerSihota, Navin Kumar, and Kulbhushan Tikoo. "Selenium nanoparticles stimulate osteoblast differentiation via BMP-2/MAPKs/β-catenin pathway in diabetic osteoporosis." *Nanomedicine* 17, no. 9 (2022): 607-625.
- 31. Sahu, Chittaranjan, Shivani Singla, and Gopabandhu Jena. "Studies on male gonadal toxicity of bisphenol A in diabetic rats: An example of exacerbation effect." *Journal of Biochemical and Molecular Toxicology* 36, no. 4 **(2022)**: e22996.
- 32. Singh, Sneha, Paramdeep Kaur, Vinod Kumar, Kulbhushan Tikoo, and Sonal Singhal. "Facile integration of a novel Sm-doped CoFe2O4@ g-CN heterostructure to expedite PMS and H2O2 assisted degradation of pharmaceutical pollutants." *Applied Surface Science* 580 **(2022)**: 152254.
- 33. Sheoran, Ankush, Jaspreet Kaur, Paramdeep Kaur, Jyoti Agarwal, Vinod Kumar, S. Bansal, K. B. Tikoo, and Sonal Singhal. "Synthesis of Benzenesulfonamide Derivatives via Ring Opening of Aziridines in the Presence of Magnetically Retrievable Graphene Based (CoFe@ rGO) Nanohybrid." *Journal of Inorganic and Organometallic Polymers and Materials* 32, no. 3 **(2022)**: 814-830.
- 34. Vaidya, Bhupesh, Harpinder Kaur, Pavan Thapak, Shyam Sunder Sharma, and Jitendra Narain Singh. "Pharmacological modulation of TRPM2 channels via PARP pathway leads to neuroprotection in MPTP-induced Parkinson's disease in Sprague dawley rats." *Molecular Neurobiology* 59, no. 3 **(2022)**: 1528-1542.
- 35. Kaur, Paramdeep, Sneha Singh, Vinod Kumar, K. B. Tikoo, Anupama Kaushik, and Sonal Singhal. "Development of emphatic catalysts for waste water remediation via synchronized free radical and non-free radical routes with composites of strontium hexaferrite, graphene and multi-walled carbon nanotubes." *Ceramics International* 48, no. 4 **(2022)**: 4795-4811.
- 36. Kaur, Paramdeep, Sneha Singh, Diksha Aggarwal, Vinod Kumar, Kulbhushan Tikoo, Anupama Kaushik, and Sonal Singhal. "Synergizing hexagonal ferrite with

transition metals in core-shell-shell nanostructures (SrFe@ Dop@ M) as dualistic probe for detoxification and electrochemical detection of pharmaceutical drugs." *Ceramics International* **(2022)**.

- 37. Navik, Umashanker, Vaibhav G. Sheth, Nisha Sharma, and Kulbhushan Tikoo. "I-Methionine supplementation attenuates high-fat fructose diet-induced nonalcoholic steatohepatitis by modulating lipid metabolism, fibrosis, and inflammation in rats." *Food & Function* 13, no. 9 **(2022)**: 4941-4953.
- 38. Pant, Rajat, Nisha Sharma, ShaheenWasil Kabeer, Shivam Sharma, and Kulbhushan Tikoo. "Selenium-Enriched Probiotic Alleviates Western Diet-Induced Non-alcoholic Fatty Liver Disease in Rats via Modulation of Autophagy Through AMPK/SIRT-1 Pathway." *Biological Trace Element Research* (2022): 1-14.
- Navik, Umashanker, Kajal Rawat, and Kulbhushan Tikoo. "L-Methionine prevents β-cell damage by modulating the expression of Arx, MafA and regulation of FOXO1 in type 1 diabetic rats." *Acta Histochemica* 124, no. 1 (2022): 151820.
- 40. Rihan, Mohd, and Shyam Sunder Sharma. "Role of Pyruvate Kinase M2 (PKM2) in Cardiovascular Diseases." *Journal of Cardiovascular Translational Research* (2022): 1-21.
- 41. Kaundal, Ravinder K., Ashok Kumar Datusalia, and Shyam S. Sharma. "Posttranscriptional regulation of Nrf2 through miRNAs and their role in Alzheimer's disease." *Pharmacological Research* 175 **(2022)**: 106018.
- 42. Babu, Singothu Siva Nagendra, Shivani Singla, and Gopabandhu Jena. "Role of Combination Treatment of Aspirin and Zinc in DMH-DSS-induced Colon Inflammation, Oxidative Stress and Tumour Progression in Male BALB/c Mice." *Biological Trace Element Research* (2022): 1-17.
- 43. Charan, Harsh Vardhan, Durgesh Kumar Dwivedi, Sabbir Khan, and G. B. Jena. "Mechanisms of NLRP3 inflammasome-mediated hepatic stellate cell activation: therapeutic potential for liver fibrosis." *Genes & Diseases* (2022).

Pharmaceutical Analysis

- 44. Balhara, Ankit, Mayur K. Ladumor, Rakesh P. Nankar, SamiullaDodheri Syed, Sanjeev Giri, Bhagwat Prasad, and Saranjit Singh. "Exploration of the Plausible Mechanism of Ethambutol Induced Ocular Toxicity by Using Proteomics Informed Physiologically Based Pharmacokinetic (PBPK) Modeling." *Pharmaceutical Research* 39, no. 4 **(2022)**: 677-689.
- 45. Dhiman, Vivek, Saranjit Singh, Ankit Balhara, Bhoopendra Singh Kushwah, LaximanVelip, Vijaya MadhyanapuGolla, and GananadhamuSamanthula. "Stress degradation study on entrectinib and characterization of its degradation products using HRMS and NMR." *Journal of Pharmaceutical and Biomedical Analysis* 208 (2022): 114459.

Pharmacoinformatics

46. Sharma, Sanyog, Gurudutt Dubey, Balkaran Singh Sran, Mansi Sharma, Varinder Kaur, Sukhraj Kaur, Prasad V. Bharatam, and Geeta Hundal. "Microwave-Induced Synthesis of Pyridine Based Schiff Bases and Their Applications as Efficient Antimicrobial Textile Dyeing Agents: Experimental and Theoretical Approach." *ChemistrySelect* 7, no. 45 **(2022)**: e202203109.

- 47. Ovais Dar, Mohammad, Rahul Y. Kapse, Gurudutt Dubey, Tejender Singh, Vijay Thiruvenkatam, and Prasad V. Bharatam. "Electronic Structure Analysis and Synthesis of Nitroso N-Heterocyclic Imines." *ChemistrySelect* 7, no. 43 **(2022)**: e202203613.
- 48. Dhumal, Tushar Tukaram, Rajender Kumar, Anindita Paul, Pradyot Kumar Roy, Prabha Garg, and Sushma Singh. "Molecular explorations of the *Leishmania donovani* 6-phosphogluconolactonase enzyme, a key player in the pentose phosphate pathway." *Biochimie* 202 (2022): 212-225.
- 49. Jahan, Kousar, Sumi Aisha Salim, and Prasad V. Bharatam. "Ruthenium (II) catalysed regioselective C-2'-alkenylation of 2-phenylimidazo [1, 2-a] pyridine-3-carbaldehydes." *Tetrahedron* 122 **(2022)**: 132956.
- 50. Paul, Stanly, Swathi Nadendla, and M. Elizabeth Sobhia. "Identification of potential ACE2-derived peptide mimetics in SARS-CoV-2 omicron variant therapeutics using computational approaches." *The Journal of Physical Chemistry Letters* 13, no. 32 **(2022)**: 7420-7428.
- 51. Sobhia, M.E., Ghosh, K., Kumar, G.S., Sivangula, S., Laddha, K., Kumari, S., Kumar, H. The Role of Water Network Chemistry in Proteins: A Structural Bioinformatics Perspective in Drug Discovery and Development **2022***Current Topics in Medicinal Chemistry* 22(20): 1636-1653
- 52. Nel, Marizé, AnalikeBlom van Staden, Danielle Twilley, Carel B. Oosthuizen, Debra Meyer, Siva Kumar, Masilamani E. Sobhia, Judey Pretorius, and NamritaLall. "Potential of succulents for eczema-associated symptoms." *South African Journal of Botany* **(2022)**.
- 53. Kaur, Amanpreet, Gurudutt Dubey, Nisha Sharma, Rajat Pant, Prasad V. Bharatam, Kulbhushan Tikoo, and Arvind K. Bansal. "High dose nanocrystalline solid dispersion powder of voriconazole for inhalation." *International Journal of Pharmaceutics* (2022): 121827.
- 54. Sathe, Rohit Y., and Prasad V. Bharatam. "Drug-dendrimer complexes and conjugates: Detailed furtherance through theory and experiments." *Advances in Colloid and Interface Science* **(2022)**: 102639.
- 55. Jahan, Kousar, Firdoos Ahmad Sofi, Sumi Aisha Salim, and Prasad V. Bharatam. "NIS mediated dehydrogenative-cyclocondensation in aqueous medium towards the synthesis of 2-arylimidazo [1, 2-a] pyridines and their 3-formylated derivatives." *Tetrahedron* 112 **(2022)**: 132715.
- 56. Kaur, Amanpreet, Jay Prakash Yadav, Rohit Y. Sathe, Vibha Puri, Prasad V. Bharatam, and Arvind Kumar Bansal. "Understanding Poor Milling Behavior of Voriconazole from Crystal Structure and Intermolecular Interactions." *Molecular Pharmaceutics* 19, no. 3 (2022): 985-997.
- 57. Kumar, Navneet, and Prabha Garg. "Probing the Molecular Basis of Cofactor Affinity and Conformational Dynamics of Mycobacterium tuberculosis Elongation Factor Tu: An Integrated Approach Employing Steered Molecular Dynamics and Umbrella Sampling Simulations." *The Journal of Physical Chemistry B* 126, no. 7 (2022): 1447-1461.
- 58. Joseph, Athira, Gangasani Jagadeesh Kumar, Sachin Dattram Pawar, Bhakti Umesh Hirlekar, Prasad V. Bharatam, Satyanand Konda, Mohana Krishna Reddy Mudiam et al. "Analytical developments of p-hydroxy prenylamine reference material for dope control research: Characterization and purity assessment." *Drug Testing and Analysis* 14, no. 2 **(2022)**: 224-232.

- 59. Dubey, Gurudutt, NutanMahawar, Tejender Singh, NirjharSaha, Subash C. Sahoo, and Prasad V. Bharatam. "Thiazetidin-2-ylidenes as four membered N-heterocyclic carbenes: theoretical studies and the generation of complexes with N+ center." *Physical Chemistry Chemical Physics* 24, no. 2 (2022): 629-633.
- 60. Wanjari, Pravin J., NirjharSaha, Gurudutt Dubey, and Prasad V. Bharatam. "Metalfree methods for the generation of benzimidazoles and 2aminobenzimidazoles." *Tetrahedron* **(2022)**: 133143.
- 61. Dubey, Gurudutt, Tejender Singh, and Prasad V. Bharatam. "The importance of four-membered NHCs in stabilizing Breslow intermediates on benzoin condensation pathway." *Journal of Computational Chemistry*.
- 62. Kapoor, Saumya, Gurudutt Dubey, Samima Khatun, and Prasad V. Bharatam. "Remdesivir: Mechanism of Metabolic Conversion from Prodrug to Drug." *Current Drug Metabolism* 23, no. 1 **(2022)**: 73-81.
- 63. Roy, Himadri Shekhar, Gurudutt Dubey, Vishnu Kumar Sharma, Prasad V. Bharatam, and Deepa Ghosh. "Molecular docking and molecular dynamics to identify collagenase inhibitors as lead compounds to address osteoarthritis." *Journal of Biomolecular Structure and Dynamics* 40, no. 5 (2022): 2339-2351.
- 64. Bhattu, Monika, Aabid A. Wani, Meenakshi Verma, P. V. Bharatam, Deepika Kathuria, and Jesus Simal-Gandara. "A Selective Turn-On Fluorescent Chemosensor 1, 1-diaminoazine For Azinphos-methyl." *Journal of Photochemistry and Photobiology A: Chemistry* **(2022)**: 114476.
- 65. Sharma VK, Dobariya PK, Kawathe P, Pande AH, Jachak SM, Bharatam PV, "Pharmacoinformatics Studies to Identify Potential Inhibitors of Key SARS-CoV Enzymes among the Phytochemicals from *MurrayaKoenigii* and *Vitex nugundo.*",*CRIPS* 2022.
- 66. Sharma, Sanyog, Gurudutt Dubey, Balkaran Singh Sran, Mansi Sharma, Varinder Kaur, Sukhraj Kaur, Prasad V. Bharatam, and Geeta Hundal. "Microwave-Induced Synthesis of Pyridine Based Schiff Bases and Their Applications as Efficient Antimicrobial Textile Dyeing Agents: Experimental and Theoretical Approach." *ChemistrySelect* 7, no. 45 **(2022)**: e202203109.
- 67. Wani, AA, Valanju O, Dhaked D, Bharatam PV "Tautomerism in drugs: A review" *Drug Discovery Today*2022
- 68. Sharma VK, Bharatam PV "Artificial Intelligence in Drug Discovery (AIDD)" *CRIPS*(2022) 16, 1-8.
- 69. Saha, Nirjhar, Pravin J. Wanjari, Gurudutt Dubey, NutanMahawar, and Prasad V. Bharatam. "Metal-free synthesis of Imidazoles and 2-aminoimidazoles." *Journal of Molecular Structure* (2022): 134092.
- 70. Dar, Mohammad Ovais, Gurudutt Dubey, Tejender Singh, and Prasad V. Bharatam. "N-heterocyclic carbene ligated oximes: Exploring the electronic structure and properties." *International Journal of Quantum Chemistry* 122, no. 13 **(2022)**: e26907.
- 71. Gayatri, ShenviKudchadker, Vaishnavi Chhabra, Harish Kumar, and M. Elizabeth Sobhia. "Identification of prospective covalent inhibitors for SARS-CoV-2 main protease using structure-based approach." *Journal of Biomolecular Structure and Dynamics* (2022): 1-18.
- 72. Singh, Ravi, Muhammed Shaheer, and M. Elizabeth Sobhia. "Molecular dynamic assisted investigation on impact of mutations in deazaflavin dependent

nitroreductase against pretomanid: a computational study." *Journal of Biomolecular Structure and Dynamics* **(2022)**: 1-23.

- 73. Kumar, G. Siva, M. Elizabeth Sobhia, and Ketan Ghosh. "Binding affinity analysis of quinolone and dione inhibitors with Mtb-DNA gyrase emphasising the crystal water molecular transfer energy to the protein–ligand association." *Molecular Simulation* 48, no. 7 (2022): 631-646.
- 74. Sandhu, Hardeep, Rajaram Naresh Kumar, and Prabha Garg. "Machine learningbased modeling to predict inhibitors of acetylcholinesterase." *Molecular Diversity* 26, no. 1 (2022): 331-340.
- 75. Kumar, Navneet, Anuj Gahlawat, Rajaram Naresh Kumar, Yash Pal Singh, Gyan Modi, and Prabha Garg. "Drug repurposing for Alzheimer's disease: in silico and in vitro investigation of FDA-approved drugs as acetylcholinesterase inhibitors." *Journal of Biomolecular Structure and Dynamics* 40, no. 7 (2022): 2878-2892.
- 76. Dhumal, Tushar Tukaram, Rajender Kumar, Anindita Paul, Pradyot Kumar Roy, Prabha Garg, and Sushma Singh. "Molecular explorations of the Leishmania donovani 6-phosphogluconolactonase enzyme, a key player in the pentose phosphate pathway." *Biochimie* 202 **(2022)**: 212-225
- 77. Kumar, Harish, Anju Goyal, Navneet Kumar, and Prabha Garg. "Design, Synthesis, and biological evaluation of pyrazolo-benzothiazole derivatives as a potential therapeutic agent for the treatment of Alzheimer's disease." **(2022)**.
- 78. Choudhary, Deepika, Isha Rani, Jyoti Monga, Rajat Goyal, Asif Husain, Prabha Garg, and Sukhbir Lal Khokra. "Pyrazole Based Furanone Hybrids as Novel Antimalarial: A Combined Experimental, Pharmacological and Computational Study." *Central Nervous System Agents in Medicinal Chemistry* **(2022)**.

Pharmaceutics

- 79. Joshi, Prachi, and Abhay T. Sangamwar. "Insights into the Role of Compendial/Biorelevant Media on the Supersaturation Behaviour of Drug Combination (Drug-Drug Interaction) and Precipitation Inhibition by Polymers." *AAPS PharmSciTech* 23, no. 8 **(2022)**: 1-17.
- 80. Katiyar, Sameer S., Ravindra Patil, Rohan Ghadi, Kaushik Kuche, Varun Kushwah, Chander Parkash Dora, and Sanyog Jain. "Lipid-and TPGS-Based core–shell-type nanocapsules endowed with high paclitaxel loading and enhanced anticancer potential." *AAPS PharmSciTech* 23, no. 7 **(2022)**: 1-12.
- 81. Kaur, Amanpreet, and Arvind K. Bansal. "Optimization of Particle Properties of Nanocrystalline Solid Dispersion Based Dry Powder for Inhalation of Voriconazole." *Journal of Pharmaceutical Sciences* 111, no. 9 **(2022)**: 2592-2605.
- 82. Chaudhari, Dasharath, Oly Katari, Rohan Ghadi, Kaushik Kuche, Tushar Date, Nallamothu Bhargavi, and Sanyog Jain. "Unfolding the Potency of Adenosine in Targeting Triple Negative Breast Cancer via Paclitaxel-Incorporated pH-Responsive Stealth Liposomes." *ACS Biomaterials Science & Engineering* 8, no. 8 (2022): 3473-3484.
- 83. Parmar, Prashantkumar K., Nisha Sharma, ShaheenWasil Kabeer, Aastha Rohit, and Arvind K. Bansal. "Nanocrystal-based gel of apremilast ameliorates imiquimod-induced psoriasis by suppressing inflammatory responses." *International Journal of Pharmaceutics* (2022): 121873.

- 84. Jain, Sanyog, Kiran Dongare, Bhargavi Nallamothu, Chander Parkash Dora, Varun Kushwah, Sameer S. Katiyar, and Reena Sharma. "Enhanced stability and oral bioavailability of erlotinib by solid self nano emulsifying drug delivery systems." *International Journal of Pharmaceutics* 622 **(2022)**: 121852.
- 85. Sharma, Reena, Kaushik Kuche, Pradip Thakor, Valamla Bhavana, Saurabh Srivastava, Neelesh Kumar Mehra, and Sanyog Jain. "Chondroitin Sulfate: Emerging biomaterial for biopharmaceutical purpose and tissue engineering." *Carbohydrate Polymers* **(2022)**: 119305.
- 86. Date, Tushar, Kaushik Kuche, Dasharath Chaudhari, Rohan Ghadi, Deepak Kumar Sahel, Deepak Chitkara, and Sanyog Jain. "Hitting Multiple Cellular Targets in Triple-Negative Breast Cancer Using Dual-Action Cisplatin (IV) Prodrugs for Safer Synergistic Chemotherapy." *ACS Biomaterials Science & Engineering* (2022).
- 87. Palanisamy, Vasanthi, Palash Sanphui, KandhanPalanisamy, Muthuramalingam Prakash, and Arvind Kumar Bansal. "Design of Ascorbic Acid Eutectic Mixtures With Sugars to Inhibit Oxidative Degradation." *Frontiers in chemistry* 10 **(2022)**.
- Date, Tushar, Kaushik Kuche, Rohan Ghadi, Pradeep Kumar, and Sanyog Jain. "Understanding the Role of Axial Ligands in Modulating the Biopharmaceutical Outcomes of Cisplatin (IV) Derivatives." *Molecular Pharmaceutics* 19, no. 5 (2022): 1325-1337.
- 89. Kumari, Nimmy, Parag Roy, Sukanta Roy, Prashantkumar K. Parmar, Soumalya Chakraborty, Sourav Das, Noopur Pandey, Anirbandeep Bose, Arvind Kumar Bansal, and Animesh Ghosh. "Investigating the Role of the Reduced Solubility of the Pirfenidone–Fumaric Acid Cocrystal in Sustaining the Release Rate from Its Tablet Dosage Form by Conducting Comparative Bioavailability Study in Healthy Human Volunteers." *Molecular Pharmaceutics* (2022).
- 90. Sirvi, Arvind, Kaushik Kuche, Dasharath Chaudhari, Rohan Ghadi, Tushar Date, Sameer S. Katiyar, and Sanyog Jain. "Supersaturable self-emulsifying drug delivery system: A strategy for improving the loading and oral bioavailability of quercetin." *Journal of Drug Delivery Science and Technology* 71 **(2022)**: 103289.
- 91. Jain, Sanyog, Mahesh R. Desai, Bhargavi Nallamothu, Kaushik Kuche, Dasharath Chaudhari, and Sameer S. Katiyar. "Partial inclusion complex assisted crosslinked β-cyclodextrin nanoparticles for improving therapeutic potential of docetaxel against breast cancer." *Drug Delivery and Translational Research* 12, no. 3 (2022): 562-576.
- 92. Aggarwal, Kanika, Jyoti Gupta, Rose Kanwaljeet Kaur, Dipika Bansal, and Ashish Jain. "Effect of anxiety and psychologic stress on periodontal health: a systematic review and meta-analysis." *Quintessence International* 53, no. 2 **(2022)**.
- 93. Thakore, Samarth D., KatangurVishruth Reddy, Ajay K. Dantuluri, Deepika Patel, AkshantKumawat, Vaibhav Sihorkar, Chinmay Ghoroi, and Arvind K. Bansal. "Application of twin-screw melt granulation to overcome the poor tabletability of a high dose drug." *Pharmaceutical Research* **(2022)**: 1-17.
- 94. Kaur, Amanpreet, PrashantkumarKhodabhai Parmar, Sanika Jadhav, and Arvind Kumar Bansal. "Advances in nanocrystals as drug delivery systems." In *Nanoparticle Therapeutics*, pp. 413-454. Academic Press, 2022.
- 95. Ghai, Babita, Anudeep Jafra, Nidhi Bhatia, Neha Chanana, Dipika Bansal, and Vivek Mehta. "Opioid sparing strategies for perioperative pain management other than regional anaesthesia: A narrative review." *Journal of Anaesthesiology Clinical Pharmacology* 38, no. 1 **(2022)**: 3-10.

- 96. Kaur, Gurwinder, Barinderjit Singh, Anil Kumar Angrish, and Sanjeev K. Bansal. "Artificial Intelligence (AI) Based Smart Agriculture for Sustainable Development." *The Management Accountant Journal* 57, no. 6 **(2022)**: 54-57.
- 97. Anil Kumar Angrish and Sanjeev Kumar Bansal. Amway: When the going gets tough in India. A case study published. *DogoRangsang Research Journal***2022**. 12(9).
- 98. Jagia, Moksh, Dnyaneshwar P. Kale, Arvind Kumar Bansal, and Sarsvatkumar Patel. "Novel Co-crystals and Eutectics of Febuxostat: Characterization, Mechanism of Formation, and Improved Dissolution." *AAPS PharmSciTech* 23, no. 1 (2022): 1-17.
- 99. Palanisamy, Vasanthi, Palash Sanphui, KandhanPalanisamy, Muthuramalingam Prakash, and Arvind Kumar Bansal. "Design of Ascorbic Acid Eutectic Mixtures With Sugars to Inhibit Oxidative Degradation." *Frontiers in chemistry* 10 **(2022)**.
- 100. Chakraborty S, Bansal AK. "Current updates on in vitro release testing of long acting injectables". *American Pharmaceutical Review*(**2022**) 3:1-5.
- 101. Devi, Nagita, Priyanka Madaan, Jitendra Kumar Sahu, Bhavneet Bharti, and Dipika Bansal. "Translation, Adaptation, and Validation of Hindi version of Quality of Life of the Infant (QUALIN) for Use in Infants and Toddlers." *Indian Journal of Pediatrics* (2022): 1-7.

Natural Products

- 102. Mohi-Ud-Din, Roohi, Reyaz Hassan Mir, Saba Sabreen, Rafia Jan, Faheem HyderPottoo, and Inder Pal Singh. "Recent Insights into Therapeutic Potential of Plant-Derived Flavonoids against Cancer." *Anti-cancer agents in medicinal chemistry*.
- 103. Ambati, Goutami G., Kamalender Yadav, Ruchika Maurya, K. K. Kondepudi, Mahendra Bishnoi, and Sanjay M. Jachak. "Evaluation of the in vitro and in vivo anti-inflammatory activity of Gymnosporiamontana (Roth). Benth leaves." *Journal of Ethnopharmacology* 297 **(2022)**: 115539.
- 104. Lone, Nazir Ahmad, Tanveer Ahmad Malik, Raghu Rai Sharma, Reyaz Hassan Mir, Tasduq S. Abdullah, Inder Pal Singh, and Zulfiqar Ali Bhat. "Bioactivity guided isolation and characterization of anti-hepatotoxic markers from Berberis pachyacanthaKoehne." *Pharmacological Research-Modern Chinese Medicine* 4 (2022): 100144.
- 105. Beale, Phillipa K., William J. Foley, Isha Saraf, Inder Pal Singh, and Karen J. Marsh. "Common ringtail possums (Pseudocheirus peregrinus) tolerate high concentrations of unsubstituted B-ring flavanones in their diet." *Australian Mammalogy* 44, no. 3 (2022): 347-351.
- 106. Ranjana, Soni, Amit Srivastava, Alok Goyal, Inder Pal Singh, and Sanjay M. Jachak. "Quantitative analysis of tiliroside and other flavonoid glycosides in Hippophaesalicifolia D. Don leaves by HPLC-PDA." *Natural Product Research* (2022): 1-6.
- 107. Kumar, Sanjay, Purvi Shah, Siddharth K. Tripathi, Shabana I. Khan, and Inder Pal Singh. "Synthesis and In Vitro Evaluation of Hydrazonomethyl-Quinolin-8-ol and Pyrazol-3-yl-Quinolin-8-ol Derivatives for Antimicrobial and Antimalarial Potential." *Medicinal Chemistry (Shariqah (United Arab Emirates))* (2022).
- 108. Saraf, Isha, Karen J. Marsh, Vineet Kumar, William J. Foley, and Inder Pal Singh. "Correction to: Comparative qualitative analysis of different classes of

compounds in selected Australian and Indian Eucalyptus and Corymbia species: a convenient de-replication method for the eucalypts." *JPC–Journal of Planar Chromatography–Modern TLC* **(2022)**: 1-1.

- 109. Ahirrao, Pallavi, Ritu Kalia, and Sanjay M. Jachak. "Natural Product as Efflux Pump Inhibitors Against MRSA Efflux Pumps: An Update." In *Antimicrobial Resistance*, pp. 577-605. Springer, Singapore, 2022.
- 110. Ranjana S, Goyal A, Jena G, Tikoo K, Bansal AK, Singh IP, Jachak SM. HippophaesalicifoliaD.Don, a fascinating medicinal plant: An update on its traditional medicinal uses, ethnopharmacology and Phytochemistry. *Current traditional Medicine.* **(2022)** doi: 10.2174/2215083808666220527144311.
- 111. Kalia R, Srivastava A, Jachak SM. Analysis of phenolics in *Clematis gouriana* aerial parts by HPLC and method validation. *The Indian Forester*. **(2022)**.
- 112. Muley MM, Doshi SM, Goyal A, Jachak SM. Ethnopharmacology and Phytochemistry of Selected Species of Boerhavia Occurring in India: A Review. *Current traditional Medicine.* (2022).
- 113. Ranjana S, Srivastava A, Goyal A, Singh IP, Jachak SM Quantitative analysis of tiliroside and other flavonoid glycosides in HippophaesalicifoliaD.Don leaves by HPLC-PDA. *Natural products Research*.(2022).
- 114. Kalia R and Jachak SM. Anti-inflammatory Activity Guided Fractionation of Aerial Parts of Clematis gourianaRoxb. ex DC. *Journal of Biologically Active Products*. 12(5) (2022): 378-391
- 115. Kaur, Mandeep, Alka Choudhary, Isha Saraf, Inder P. Singh, and Sanehdeep Kaur.
 "Efficacy of Moringa oleifera (Lam.) extract against Spodoptera litura (Fabricius), (Lepidoptera: Noctuidae)." *International Journal of Tropical Insect Science* 42, no. 1 (2022): 103-108.

Medicinal Chemistry

- 116. Rathod, Gajanan K., Meenakshi Jain, Krishna K. Sharma, Samarpita Das, AhanaBasak, and Rahul Jain. "New structural classes of antimalarials." *European Journal of Medicinal Chemistry* **(2022)**: 114653.
- Sisodiya, S., Acharya, A., Nagpure, M., Roy, N., Giri, S. K., Yadav, H. R., ... &Guchhait, S. K. (2022). A cascade reaction of indolyl-migratory isocyanide insertion, scaffold rearrangement and redox-neutral event with isocyanide as a C (sp3) H–N synthon efficiently constructs indolylisoindolinones. *Chemical Communications*, 58(84), 11827-11830.
- 118. Katiyar, Madhurendra K., Govind Kumar Dhakad, Sahil Arora, Srikant Bhagat, Taruna Katyal, and Raj Kumar. "Synthetic Strategies and Pharmacological Activities of Chromene and Its Derivatives: An Overview." *Journal of Molecular Structure* (2022): 133012.
- 119. Kumar, Gulshan, Chinmay Das, Ayan Acharya, SubhasmitaBhal, Mayank Joshi, Chanakya Nath Kundu, Angshuman Roy Choudhury, and Sankar K. Guchhait. "Organocatalyzed umpolung addition for synthesis of heterocyclic-fused arylidene-imidazolones as anticancer agents." *Bioorganic & Medicinal Chemistry* (2022): 116835.
- 120. Sarotra, Pooja, Usha Dutta, Hina Gupta, KP RavindranathanKartha, Rakesh Kochhar, Ajay Prakash, PhulenSarma, Jimil Shah, and Bikash Medhi. "Simultaneous determination of lactulose, sucrose, sucralose, and mannitol using high-performance liquid chromatography-refractive index to estimate intestinal

permeability in patients with active ulcerative colitis." *Indian Journal of Pharmacology* 54, no. 4 **(2022)**: 270.

- 121. Rathod, Gajanan K., and Rahul Jain. "Palladium-CatalyzedAminocarbonylation of (Hetero) aryl Iodides with α-Amino Acid Esters as Nucleophiles." *The Journal of Organic Chemistry* (2022).
- 122. Chakraborti, Asit K., NirjharSaha, Asim Kumar, and AntarlinaMaulik. "Magnetic nanocomposite-catalyzed Suzuki cross-coupling reactions." In *Volume 1 Synthetic Applications*, pp. 241-308. De Gruyter, 2022.
- 123. Kumar, Gulshan, MithileshNagpure, Vajja Krishna Rao, and Sankar K. Guchhait. "Synthesis of Heterocyclic-Fused Furans and Dihydrofurans via (4+ 1)-Annulation with Ylide: Exploration of Unique Reactivity Behavior of α-Carbonyl Sulfoxonium Ylide." *European Journal of Organic Chemistry* 2022, no. 16 (2022): e202200193.
- 124. Bajpayee, Nikhil, ThangavelVijayakanth, SigalRencus-Lazar, Sneha Dasgupta, Aamod V. Desai, Rahul Jain, Ehud Gazit, and Rajkumar Misra. "Exploring Helical Peptides and Foldamers for the Design of Metal Helix Frameworks: Current Trends and Future Perspectives." *AngewandteChemie* (2022).

Pharmacy Practice

- 125. Bashir, Aamir, Ajay Duseja, Ashish Verma, Arka De, and Pramil Tiwari. "Lysosomal acid lipase activity in non-alcoholic fatty liver disease as a novel diagnostic and therapeutic target: A systematic literature review of current evidence and future directions." *Journal of Clinical and Experimental Hepatology* (2022).
- 126. Bashir, Aamir, Gautam Sahu, Ishfaq Rashid, and Pramil Tiwari. "Efficacy and safety of pharmacotherapeutic interventions used in visceral leishmaniasis clinical trials: A systematic review and network meta-analysis." *Asian Pacific Journal of Tropical Medicine* 15, no. 8 **(2022)**: 343.
- 127. Bashir, Aamir, Ashish Verma, Ajay Duseja, Arka De, and Pramil Tiwari. "Adjuvant use of ribavirin with treatment of hepatitis C virus in kidney transplant recipients: A systematic review and meta-analysis of real-world data." *Indian Journal of Transplantation* 16, no. 3 **(2022)**: 243.
- 128. Rashid, Ishfaq, Ashish Verma, Pramil Tiwari, and Sanjay D'Cruz. "Adenine phosphoribosyl transferase deficiency leads to renal allograft dysfunction in kidney transplant recipients: a systematic review." *Brazilian Journal of Nephrology* (2022).
- 129. Devi, Nagita, Priyanka Madaan, Rizwan Ameen, Jitendra Kumar Sahu, and Dipika Bansal. "Short-term and long-term efficacy and safety of antiseizure medications in Lennox Gastaut syndrome: A network meta-analysis." *Seizure* (2022).
- 130. Bashir, Aamir, Ajay Duseja, Arka De, Manu Mehta, and Pramil Tiwari. "Nonalcoholic fatty liver disease development: A multifactorial pathogenic phenomena." *Liver Research* (2022).

Process Chemistry

131. Laha, Joydev K., and Pankaj Gupta. "Sulfoxylate Anion Radical-Induced Aryl Radical Generation and Intramolecular Arylation for the Synthesis of Biarylsultams." *The Journal of Organic Chemistry* 87, no. 6 **(2022)**: 4204-4214.

- 132. Laha, Joydev K., and Mandeep Kaur Hunjan. "Diversity in Heterocycle Synthesis Using α-Iminocarboxylic Acids: Decarboxylation Dichotomy." *The Journal of Organic Chemistry* 87, no. 5 **(2022)**: 2315-2323.
- 133. Laha, Joydev K., Upma Gulati, Saima, Tim Schulte, and Martin Breugst. "pH-Controlled Intramolecular Decarboxylative Cyclization of Biarylacetic Acids: Implication on Umpolung Reactivity of Aroyl Radicals." *The Journal of Organic Chemistry* (2022).
- 134. Laha, Joydev K., Anjali Gupta, Upma Gulati, Mandeep Kaur Hunjan, J. Patrick Weber, and Martin Breugst. "TBHP-mediated denitrogenative synthesis of pyridine carboxamides from pyridine carbohydrazides and amines in water." *Organic Chemistry Frontiers* 9, no. 24 **(2022)**: 6902-6908.

BOOK CHAPTERS:

- 1. Anil Kumar Angrish and Sanjeev Kumar Bansal Cooperative Banks in India: Tracing, Tracking and Treating the Failures in: Cooperatives as a Catalyst for Sustainability: Lessons Learned from Asian Models. Asia-Pacific Business Series, World Scientific. ISBN: 978-981- 125-378-2 (hardcover).
- 2. Amol Adkonkar, Anil Kumar Angrish, Vishal, Anand Sharma and Sanjeev Kumar Bansal A Paradigm Shift in Pharmaceutical Marketing In: Paradigm Shift in Marketing and Finance, Eds. Dr. Shikha Gupta and Dr. Pooja Goel, Bharti Publications, New Delhi. ISBN 978-93-91681-30-2.
- 3. Anil Kumar Angrish and Sanjeev Kumar Bansal. Strategic Sale of a PSU by the Government: A Case Study of Bharat Petroleum Corporation Limited (BPCL) In: Innovations in Finance, Business Processes and Technology during Crisis. Edition-I by Weser Books, No. 79737, AussereWeberstr. 57 02763 Zittau, Germany. ISBN No.: 978-3-96492-353-0. p.112-121.
- 4. Anil Kumar Angrish, Dr. Sanjeev Kumar Bansal and Rohit Tandon. "Anti-Profiteering" Mechanism under the Goods and Services Tax (GST): A Review. In: Embracing Change in Business, Management and Social Sciences **(2022)**. National Press Associates (ISBN: 978-93-90863-09-9) pp. 6-10.
- 5. Shruti, Dr. Anil Kumar Angrish, Anand Sharma, Sanjeev Kumar Bansal. Corporate Social Innovation – A Study of select Healthcare Organizations. In: Recent Trends in Finance & Accounting **(2022)**. Weser Books, Zittau, Germany (ISBN: 978-3-96492-413-1). pp. 20-27.
- 6. Sanjeev Kumar Bansal and Anil Kumar Angrish. Application of Artificial Intelligence in Accounting: A Perspective. In: Recent Trends in Finance & Accounting **(2022)**. Weser Books, Zittau, Germany (ISBN: 978-3-96492-413-1). pp. 50-54.
- 7. Sanjeev Kumar Bansal and Anil Kumar Angrish. New Frontiers in Accounting Profession. In: Recent Trends in Finance & Accounting. **(2022)**. Weser Books, Zittau, Germany (ISBN: 978-3-96492-413-1). pp. 67-71.
- 8. Amanpreet Kaur, Prashant K Parmar, Sanika Jadhav, Arvind K Bansal. Advances in nanocrystals as drug delivery system. In: Nanoparticle Therapeutics, Academic Press. ISBN: 9780128207574. pp-413-454.
- 9. Sankar K Guchhait, Krishna V Rao, Ayan Acharya, Late-Stage C-H Activation– Functionalization of Drugs, Natural Products, and Biomolecules: In View of Molecular Property and Mechanistic Pathway. In: Handbook of CH-

Functionalization, John Wiley & Sons, Ltd, Chichester, UK, **(2022)**, ISBN: 9783527834242, pp.1-38.

- 10. Ghai B, Bansal D, Varun Singla. Back Care Book: All You Need for Healthy Back. 1 ed: Notion Press; **(2022)** 12/10/**(2022)**. 90 p. (English edition), ISBN No. 979-8-88833-306-8
- 11. Ghai B, Bansal D, Varun Singla. Back Care Book: All You Need for Healthy Back. 1 ed: Notion Press; **(2022)** 12/10/**(2022)**. 90 p. (Hindi edition), ISBN No. 979-8-88833-306-8
- 12. Anuj Gahlawat, Rajkumar R, Tanmaykumar Varma, PradnyaKamble, Aritra Banerjee, Hardeep Sandhu, Prabha Garg. Bioinformatics: Theory and Application. In: Biomedical and clinical science research: From philosophy and methods to publication, Springer Nature. accepted.
- 13. Iyengar, A.R.S., Dobariya, P., Pande, A.H. Paraoxonase 1 as a potential prophylactic against nerve agent poisoning In: Sensing of Deadly Toxic Chemical Warfare Agents, Nerve Agent Simulants, and their Toxicological Aspects, Elsevier publishers **(2022)**. 529-537

PATENTS:

- 1. Nandanwar Hemraj S.; Jachak Sanjay M.; TambatRushikesh R.; Chandal N.; Mahey N.; kalia R.; IngawaleRajnita R (2022). Use of novel pyrole derivatives as inhibitors of resistance-nodulation cell division (RND) efflux system. Indian Patent 202011054425.
- 2. Jain S, Pohekar M, Jain AK. Self Emulsifying Pharmaceutical Composition For Oral Delivery Of Quercetin. Patent No. 413857; Granted on December 07, **2022**
- 3. Chakraborti AK, Tanwar B. Novel 2-Biarylbenzoxazole Compounds and the Process of Preparation Thereof. Patent No. 413619; Granted on December 05, **2022**
- 4. Jain S, Thanki K. Novel Lipid Drug Conjugates for Improved Oral Delivery of Amphotericin B and Nanoformulations Thereof. Patent No. 411678; Granted on November 17, **2022**
- 5. Chakraborti AK, Tanwar B. Alkyl 1,2-Diamines and its Bioisoster ß-Aryloxyamines as Potential Anti-Tubercular Agents and Preparation Thereof. Patent No. 399880; Granted on June 22, **2022**
- 6. Tanwar DK, Ratan A, Gill MS One Pot Process for Preparation of Substituted Hydantoins. Patent No. 395046; Granted on April 20, **2022**.
- 7. Jain S, Katariya MK, Harde H, Arora S High Permeation Vesicles for Transdermal Drug Delivery System and Process of Preparation Thereof. Patent No. 391633; Granted on March 10, **2022**
- Chakraborti AK, Purohit P, Sharma SS, Seth K, Kharatmal SB, Singh M, Kumar G. 2-(2-Aryl/Alkyl Phenyl) Benzazoles as Selective COX-2 Inhibitors. Patent No. 387998; Granted on January 31, 2022